2021990
D002927_D007022 CID cimetidine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) hypotension/NN -PUNC- cimetidine/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubjpass) mediated/VBN (r_advcl) be/VB (l_acomp) useful/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) hypotension/NN
15627798
D005839_D009395 CID gentamicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) nephritis/NN -PUNC- gentamicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) attenuates/VBZ (l_dobj) nephritis/NN
D005839_D005355 NONE gentamicin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) Animals/NNS (r_nsubj) show/VB (l_dobj) areas/NNS (l_prep) of/IN (l_pobj) fibrosis/NN
19108278
D010042_D017180 CID ouabain/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) tachycardia/NN
D011433_D001145 NONE propranolol/NN (r_pobj) of/IN (r_prep) isomers/NNS (l_conj) effects/NNS (l_prep) on/IN (l_pobj) arrhythmias/NNS -PUNC- propranolol/NN (r_pobj) of/IN (r_prep) isomers/NNS (r_nsubj) were/VBD (l_acomp) capable/JJ (l_prep) of/IN (l_pcomp) preventing/VBG (l_dobj) arrhythmias/NNS -PUNC- -)-propranolol/, (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) was/VBD (r_conj) were/VBD (l_acomp) capable/JJ (l_prep) of/IN (l_pcomp) preventing/VBG (l_dobj) arrhythmias/NNS -PUNC- -propranolol/, (r_conj) of/IN (r_prep) that/DT (r_nsubj) was/VBD (r_advcl) was/VBD (r_conj) were/VBD (l_acomp) capable/JJ (l_prep) of/IN (l_pcomp) preventing/VBG (l_dobj) arrhythmias/NNS
D011433_D017180 NONE propranolol/NN (r_pobj) of/IN (r_prep) isomers/NNS (r_nsubj) were/VBD (l_acomp) capable/JJ (l_prep) of/IN (l_pcomp) reversing/VBG (l_dobj) tachycardia/NN
D004837_D001145 CID adrenaline/RB (r_advmod) induced/VBN (r_amod) arrhythmias/NNS -PUNC- adrenaline.7/NNS (r_pobj) of/IN (r_prep) dose/NN (r_dobj) increasing/VBG (r_pcomp) by/IN (r_prep) was/VBD (l_nsubj) Blockade/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS
D006221_D001145 CID halothane/NN (r_pobj) with/IN (r_prep) anaesthetized/VBN (r_acl) cats/NNS (r_pobj) in/IN (r_prep) arrhythmias/NNS
16801510
D008691_D008133 CID methadone/NN (r_dobj) receiving/VBG (r_acl) users/NNS (r_pobj) in/IN (r_prep) syndrome/NN -PUNC- methadone/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) prolongation/NN -PUNC- methadone/NN (r_compound) dose/NN (r_pobj) to/IN (r_prep) addition/NN (r_pobj) In/IN (r_prep) considered/VBN (l_prep) as/IN (l_pobj) factors/NNS (l_prep) for/IN (l_pobj) prolongation/NN -PUNC- methadone/NN (r_compound) patients/NNS (r_pobj) in/IN (r_prep) prolongation/NN -PUNC- methadone/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) occur/VB (l_nsubj) syndrome/NN
D011188_D008133 NONE potassium/NN (r_compound) level/NN (r_conj) inhibitors/NNS (r_nsubj) contribute/VBP (l_prep) to/IN (l_pobj) prolongation/NN
D008691_D007008 NONE methadone/NN (r_compound) dose/NN (r_pobj) to/IN (r_prep) attribution/NN (r_dobj) allowed/VBD (l_conj) cytochrome/NN (l_dobj) interactions/NNS (l_appos) hypokalemia/NN
D008691_D016171 NONE methadone/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) patients/NNS (r_nsubj) presented/VBD (l_dobj) pointes/FW
23871786
C006780_D001008 CID A/DT (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) increases/VBZ (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN -PUNC- BPA/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) mice/NNS (r_pobj) in/IN (r_prep) increased/VBN (l_nsubjpass) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN -PUNC- BPA/NNP (r_compound) exposure/NN (r_nsubj) increased/VBN (l_dobj) behavior/NN (l_amod) like/JJ (l_npadvmod) anxiety/NN
24653743
C042288_D016757 CID Pilsicainide/NNP (r_npadvmod) Induced/VBN (r_amod) Pointes/NNP (r_pobj) due/IN (r_amod) Case/NN (l_prep) of/IN (l_pobj) Death/NNP -PUNC- pilsicainide/NN (r_dobj) received/VBD (r_ccomp) developed/VBD (l_dobj) death/NN
C042288_D001281 NONE pilsicainide/NN (r_dobj) received/VBD (l_advcl) convert/VB (l_dobj) fibrillation/NN -PUNC- pilsicainide/NN (r_pobj) including/VBG (r_prep) administration/NN (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_xcomp) terminate/VB (l_dobj) fibrillation/NN
D012964_D016757 NONE sodium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_appos) pilsicainide/NN (r_dobj) received/VBD (r_ccomp) developed/VBD (l_dobj) death/NN
D012964_D001281 NONE sodium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_appos) pilsicainide/NN (r_dobj) received/VBD (l_advcl) convert/VB (l_dobj) fibrillation/NN
C042288_D016171 CID Pilsicainide/NNP (r_npadvmod) Induced/VBN (r_amod) Pointes/NNP -PUNC- pilsicainide/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) was/VBD (r_conj) was/VBD (r_advcl) been/VBN (l_advcl) produce/VB (l_dobj) pointes/FW -PUNC- pilsicainide/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) been/VBN (l_advcl) produce/VB (l_dobj) pointes/FW
24535067
D005283_D009207 NONE Fentanyl/NN (r_appos) myoclonus/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_conj) combination/NN (l_relcl) prevent/VB (l_dobj) myoclonus/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) combination/NN (l_relcl) prevent/VB (l_dobj) myoclonus/NN -PUNC- fentanyl/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) myoclonus/NN -PUNC- fentanyl/NN (r_pobj) of/IN (r_prep) fentanyl/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) myoclonus/NN
D005045_D010146 NONE etomidate/NN (r_xcomp) due/IN (r_prep) severity/NN (l_prep) of/IN (l_pobj) pain/NN
D008874_D009207 NONE midazolam/NN (r_appos) Fentanyl/NN (r_appos) myoclonus/NN -PUNC- midazolam/NN (r_conj) fentanyl/NN (r_pobj) of/IN (r_prep) effectiveness/NN (l_conj) combination/NN (l_relcl) prevent/VB (l_dobj) myoclonus/NN -PUNC- midazolam/NN (r_conj) fentanyl/NN (r_pobj) of/IN (r_prep) combination/NN (l_relcl) prevent/VB (l_dobj) myoclonus/NN -PUNC- midazolam/NN (r_conj) fentanyl/NN (r_pobj) of/IN (r_prep) fentanyl/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) preventing/VBG (l_dobj) myoclonus/NN
D005045_D009069 NONE etomidate/NN (r_advcl) graded/VBN (r_conj) observed/VBN (r_advcl) evaluated/VBN (l_nsubjpass) movements/NNS
D005045_D009207 CID etomidate/NN (r_npadvmod) induced/VBN (r_amod) myoclonus/NN -PUNC- etomidate/NN (r_npadvmod) induced/VBN (r_amod) myoclonus/NN -PUNC- etomidate/NN (r_npadvmod) induced/VBN (r_amod) myoclonus/NN
2904523
D004837_D006973 CID adrenaline/NN (r_compound) hypertension/NN -PUNC- adrenaline/NN (r_compound) infusion/NN (r_pobj) after/IN (r_prep) effect/NN (r_appos) Support/NN (l_prep) for/IN (l_pobj) hypothesis/NN (l_compound) hypertension/NN -PUNC- adrenaline/NN (r_compound) hypertension/NN
12452552
D018967_D009459 CID risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN (l_appos) NMS/NNP
D008728_D009459 CID levomepromazine/NN (r_conj) risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN -PUNC- levomepromazine/NN (r_conj) risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN (l_appos) NMS/NNP
D008728_D007676 NONE levomepromazine/NN (r_conj) risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) failure/NN -PUNC- levomepromazine/NN (r_conj) risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) failure/NN (l_appos) CRF/NNP
D018967_D007676 NONE risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) failure/NN -PUNC- risperidone/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) syndrome/NN (r_dobj) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) failure/NN (l_appos) CRF/NNP
2767010
D013327_D001145 CID strophanthidin/NN (r_npadvmod) induced/VBN (r_amod) arrhythmias/NNS
C043114_D017180 NONE sodium/NN (r_nsubj) have/VBP (l_dobj) activity/NN (l_prep) against/IN (l_pobj) tachycardia/NN
D010042_D017180 CID ouabain/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN
C043114_D012640 NONE ACC-9653/NN (l_conj) have/VBP (l_dobj) activity/NN (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- sodium/NN (r_nsubj) have/VBP (l_dobj) activity/NN (l_prep) against/IN (l_pobj) seizures/NNS
C043114_D064420 NONE ACC-9653/NNP (r_nmod) sodium/NN (r_pobj) of/IN (r_prep) studies/NNS (l_compound) toxicity/NN -PUNC- sodium/NN (r_pobj) of/IN (r_prep) studies/NNS (l_compound) toxicity/NN
C043114_D001145 NONE ACC-9653/NN (r_nmod) sodium/NN (l_amod) necessary/JJ (l_xcomp) convert/VB (l_dobj) arrhythmia/NN -PUNC- sodium/NN (l_amod) necessary/JJ (l_xcomp) convert/VB (l_dobj) arrhythmia/NN -PUNC- sodium/NN (r_nsubj) displayed/VBD (l_prep) in/IN (l_pobj) activity/NN (l_prep) against/IN (l_pobj) arrhythmias/NNS
2818777
D010672_D017093 CID phenytoin/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) failure/NN
D010672_D056486 NONE Phenytoin/NNP (r_nsubj) induced/VBD (l_dobj) injury/NN
19515070
D019343_D017114 NONE citrate/NN (r_compound) dialysate/NN (r_pobj) with/IN (r_prep) anticoagulated/VBN (r_acl) transplantation/NN (r_pobj) during/IN (r_prep) underwent/VBD (r_relcl) AKI/NNP (r_pobj) with/IN (r_prep) failure/NN -PUNC- Citrate/NNP (r_compound) dialysate/NN (r_nsubj) is/VBZ (l_attr) alternative/NN (l_prep) for/IN (l_pobj) support/NN (l_prep) in/IN (l_pobj) failure/NN
D000082_D058186 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) failure/NN (l_prep) with/IN (l_pobj) AKI/NNP
D000082_D017114 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) failure/NN
D019343_D064420 NONE citrate/NN (r_compound) anticoagulation/NN (r_attr) is/VBZ (l_conj) carries/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- citrate/JJ (r_compound) toxicity/NN -PUNC- citrate/JJ (r_compound) toxicity/NN
D019343_D058186 NONE citrate/NN (r_compound) dialysate/NN (r_pobj) with/IN (r_prep) anticoagulated/VBN (r_acl) transplantation/NN (r_pobj) during/IN (r_prep) underwent/VBD (r_relcl) AKI/NNP
24333387
D013311_D064420 NONE Streptozotocin/NNP (r_pobj) in/IN (r_prep) activation/NN (l_conj) toxicity/NN -PUNC- STZ/NNP (r_appos) Streptozotocin/NNP (r_pobj) in/IN (r_prep) activation/NN (l_conj) toxicity/NN -PUNC- STZ/NNP (r_nsubj) increased/VBD (l_conj) reduced/VBD (l_dobj) activity/NN (l_prep) in/IN (l_pobj) preparation/NN (l_acl) illustrating/VBG (l_dobj) generation/NN (l_conj) excitotoxicity/NN
D013311_D020258 NONE Streptozotocin/NNP (r_pobj) in/IN (r_prep) events/NNS (r_nsubj) induced/VBN (r_acl) activation/NN (l_conj) neurotoxicity/NN -PUNC- STZ/NNP (r_compound) treatment/NN (r_nsubj) showed/VBD (l_conj) remains/VBZ (l_nsubj) neurotoxicity/NN -PUNC- STZ/NNP (r_nsubj) induced/VBN (l_dobj) activation/NN (l_conj) death/NN (l_conj) post/VB (l_dobj) neurotoxicity/NN -PUNC- STZ/NNP (r_pobj) in/IN (r_prep) factors/NNS (r_attr) are/VBP (l_nsubj) activation/NN (l_conj) post/VB (l_dobj) neurotoxicity/NN
D002118_D064420 NONE Ca(2/NNP (r_conj) nitrite/NN (r_appos) ROS/NNP (r_pobj) of/IN (r_prep) level/NN (r_dobj) increased/VBD (l_conj) reduced/VBD (l_dobj) activity/NN (l_prep) in/IN (l_pobj) preparation/NN (l_acl) illustrating/VBG (l_dobj) generation/NN (l_conj) excitotoxicity/NN
D013311_D008569 CID Streptozotocin/NNP (r_pobj) in/IN (r_prep) events/NNS (r_nsubj) induced/VBN (l_dobj) impairment/NN -PUNC- Streptozotocin/NNP (r_pobj) in/IN (r_prep) activation/NN (r_pobj) of/IN (r_prep) role/NN (r_dobj) study/NN (r_pobj) In/IN (r_prep) induced/VBN (l_ccomp) explored/VBN (l_nsubjpass) rats/NNS (l_amod) impaired/VBN -PUNC- STZ/NNP (r_appos) Streptozotocin/NNP (r_pobj) in/IN (r_prep) activation/NN (r_pobj) of/IN (r_prep) role/NN (r_dobj) study/NN (r_pobj) In/IN (r_prep) induced/VBN (l_ccomp) explored/VBN (l_nsubjpass) rats/NNS (l_amod) impaired/VBN -PUNC- STZ/NNP (r_pobj) after/IN (r_prep) found/VBN (l_nsubjpass) deficit/NN -PUNC- STZ/NNP (r_pobj) in/IN (r_prep) factors/NNS (l_acl) induced/VBN (l_dobj) impairment/NN
D009573_D064420 NONE nitrite/NN (r_appos) ROS/NNP (r_pobj) of/IN (r_prep) level/NN (r_dobj) increased/VBD (l_conj) reduced/VBD (l_dobj) activity/NN (l_prep) in/IN (l_pobj) preparation/NN (l_acl) illustrating/VBG (l_dobj) generation/NN (l_conj) excitotoxicity/NN
D013311_D007249 CID STZ/NN (r_nsubj) causes/VBZ (l_dobj) expression/NN (l_prep) of/IN (l_pobj) GFAP/NNP (l_appos) activation/NN (l_conj) neuroinflammation/NN
6985498
D008733_D056486 CID methoxyflurane/NN (r_pobj) with/IN (r_prep) anesthesia/NN (r_pobj) after/IN (r_prep) acidosis/NN (r_conj) Hepatitis/NNP
D008733_D041881 NONE methoxyflurane/NN (r_compound) anesthesia/NN (r_pobj) under/IN (r_prep) operated/VBN (l_prep) for/IN (l_pobj) cholecystitis/NN
D008733_D048550 NONE methoxyflurane/NN (r_compound) anesthesia/NN (l_acl) developed/VBD (l_dobj) syndrome/NN
D008733_D000141 CID methoxyflurane/NN (r_pobj) with/IN (r_prep) anesthesia/NN (r_pobj) after/IN (r_prep) acidosis/NN -PUNC- methoxyflurane/NN (r_compound) anesthesia/NN (l_acl) developed/VBD (l_dobj) syndrome/NN (l_conj) acidosis/NN
9323412
D015742_D009325 NONE propofol/JJ (r_amod) infusion/NN (r_pobj) with/IN (r_prep) Anaesthesia/NNP (r_nsubj) provided/VBD (l_dobj) course/NN (l_amod) free/JJ (l_npadvmod) nausea/NN
D012701_D003866 NONE serotonin/NN (r_compound) antagonists/NNS (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) with/IN (r_prep) Anaesthesia/NNP (r_nsubj) provided/VBD (l_prep) without/IN (l_pobj) exacerbation/NN (l_prep) of/IN (l_pobj) disorder/NN
D012701_D009325 NONE serotonin/NN (r_compound) antagonists/NNS (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) with/IN (r_prep) Anaesthesia/NNP (r_nsubj) provided/VBD (l_dobj) course/NN (l_amod) free/JJ (l_npadvmod) nausea/NN
D017294_D020250 NONE ondansetron/NN (r_compound) prophylaxis/NN (r_nsubjpass) used/VBN (r_relcl) anaesthetic/NN (r_pobj) after/IN (r_prep) presented/VBN (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN
D012701_D003865 NONE serotonin/NN (r_compound) antagonist/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) to/IN (r_prep) related/VBN (r_advcl) developed/VBN (l_dobj) disorder/NN
D015742_D003866 NONE propofol/JJ (r_amod) infusion/NN (r_pobj) with/IN (r_prep) Anaesthesia/NNP (r_nsubj) provided/VBD (l_prep) without/IN (l_pobj) exacerbation/NN (l_prep) of/IN (l_pobj) disorder/NN
D017294_D003866 NONE ondansetron/NN (r_pobj) following/VBG (r_prep) depression/NN
8957205
D013972_D006935 NONE thyrotropin/NN (r_npadvmod) releasing/VBG (r_amod) hormone/NN (r_nsubj) modulate/VBP (l_dobj) response/NN (l_amod) hypercapnic/JJ
D000324_D006935 NONE corticotropin/NN (r_npadvmod) releasing/VBG (r_amod) hormone/NN (r_nmod) hormone/NN (r_nsubj) modulate/VBP (l_dobj) response/NN (l_amod) hypercapnic/JJ
2625524
D000661_D012640 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- amphetamine/NN (r_compound) exposure/NN (r_pobj) from/IN (r_prep) death/NN (r_pobj) against/IN (r_prep) blocker/NN (r_pobj) for/IN (r_prep) role/NN (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS
D004298_D012640 NONE dopamine/NN (r_compound) blocker/NN (r_pobj) for/IN (r_prep) role/NN (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS
D003042_D012640 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D006220_D012640 NONE Haloperidol/NNP (r_nsubj) failed/VBD (l_xcomp) prevent/VB (l_dobj) seizures/NNS -PUNC- Haloperidol/NN (r_nsubj) decreased/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- haloperidol/NN (r_appos) blocker/NN (r_pobj) for/IN (r_prep) role/NN (l_prep) without/IN (l_pcomp) reducing/VBG (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- haloperidol/NN (r_nsubj) demonstrated/VBD (l_dobj) ability/NN (l_acl) reduce/VB (l_dobj) seizures/NNS
3895875
D008012_D007238 NONE lidocaine/NN (r_compound) level/NN (r_nsubj) was/VBD (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN
D008012_D006323 NONE lidocaine/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_ccomp) occurred/VBD (l_conj) died/VBD (l_prep) from/IN (l_pobj) asystole/NN -PUNC- lidocaine/NN (r_dobj) received/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_conj) died/VBD (l_prep) from/IN (l_pobj) asystole/NN -PUNC- lidocaine/NN (r_dobj) had/VBN (r_conj) died/VBD (l_prep) from/IN (l_pobj) asystole/NN
D008012_D017180 NONE Lidocaine/NN (r_nsubj) prevent/VB (l_dobj) tachycardia/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) was/VBD (r_advcl) prevent/VB (l_dobj) tachycardia/NN
D008012_D001145 NONE Lidocaine/NN (r_nsubj) prevent/VB (l_advcl) was/VBD (l_attr) reduction/NN (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pcomp) warning/VBG (l_dobj) arrhythmias/NNS -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) was/VBD (l_attr) reduction/NN (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pcomp) warning/VBG (l_dobj) arrhythmias/NNS
D008012_D009203 NONE lidocaine/NN (l_prep) in/IN (l_pobj) phase/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) trial/NN (r_dobj) entered/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- lidocaine/NN (r_compound) level/NN (l_prep) after/IN (l_pobj) administration/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) infarction/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) advocate/VB (l_prep) in/IN (l_pobj) hours/NNS (l_prep) of/IN (l_pobj) infarction/NN
D008012_D007022 CID lidocaine/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_ccomp) occurred/VBD (l_nsubj) hypotension/NN -PUNC- lidocaine/NN (r_dobj) received/VBN (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) hypotension/NN -PUNC- lidocaine/NN (r_dobj) had/VBN (r_conj) died/VBD (r_conj) occurred/VBD (l_nsubj) hypotension/NN
7477981
D007980_D004409 NONE Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/JJ (r_npadvmod) responsive/JJ (r_amod) patients/NNS (r_pobj) in/IN (r_prep) dyskinesias/NNS -PUNC- levodopa-/JJ (r_nmod) dyskinesias/NNS
D001058_D004409 CID apomorphine/NN (r_appos) agonist/NN (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) severity/NN (l_conj) dyskinesias/NNS -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) improvement/NN (r_attr) was/VBD (l_advcl) induced/VBN (l_dobj) dyskinesias/NNS
D005473_D004409 CID fluoxetine/NN (r_pobj) by/IN (r_agent) improved/VBN (l_nsubjpass) dyskinesias/NNS -PUNC- fluoxetine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_conj) before/RB (r_prep) evaluated/VBD (l_dobj) severity/NN (l_conj) dyskinesias/NNS -PUNC- fluoxetine/NN (r_amod) treatment/NN (r_pobj) After/IN (r_prep) was/VBD (l_advcl) induced/VBN (l_dobj) dyskinesias/NNS -PUNC- fluoxetine/NN (r_pobj) with/IN (r_prep) transmission/NN (r_nsubj) reduce/VB (l_dobj) dyskinesias/NNS
D004298_D010300 NONE dopamine/NN (r_compound) agonist/NN (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) severity/NN (l_conj) dyskinesias/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dopamine/NN (r_conj) levodopa-/JJ (r_nmod) dyskinesias/NNS (r_dobj) reduce/VB (l_prep) without/IN (l_pobj) disability/NN (l_amod) parkinsonian/JJ
D005473_D009069 NONE fluoxetine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_conj) before/RB (r_prep) evaluated/VBD (l_dobj) severity/NN (l_prep) of/IN (l_pobj) disability/NN -PUNC- fluoxetine/NN (r_amod) treatment/NN (r_pobj) After/IN (r_prep) was/VBD (l_advcl) induced/VBN (l_prep) without/IN (l_pobj) modification/NN (l_prep) of/IN (l_pobj) disability/NN -PUNC- fluoxetine/NN (r_pobj) with/IN (r_prep) transmission/NN (r_nsubj) reduce/VB (l_prep) without/IN (l_pobj) disability/NN
D005473_D010300 NONE fluoxetine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_conj) before/RB (r_prep) evaluated/VBD (l_dobj) severity/NN (l_conj) dyskinesias/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- fluoxetine/NN (r_amod) treatment/NN (r_pobj) After/IN (r_prep) was/VBD (l_advcl) induced/VBN (l_prep) without/IN (l_pobj) modification/NN (l_prep) of/IN (l_pobj) disability/NN (l_amod) parkinsonian/JJ -PUNC- fluoxetine/NN (r_pobj) with/IN (r_prep) transmission/NN (r_nsubj) reduce/VB (l_prep) without/IN (l_pobj) disability/NN (l_amod) parkinsonian/JJ
D007980_D009069 NONE levodopa/JJ (r_npadvmod) responsive/JJ (r_amod) patients/NNS (r_pobj) in/IN (r_prep) dyskinesias/NNS (r_conj) severity/NN (l_prep) of/IN (l_pobj) disability/NN -PUNC- levodopa-/JJ (r_nmod) dyskinesias/NNS (r_dobj) reduce/VB (l_prep) without/IN (l_pobj) disability/NN
D001058_D009069 NONE apomorphine/NN (r_appos) agonist/NN (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) severity/NN (l_prep) of/IN (l_pobj) disability/NN -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) improvement/NN (r_attr) was/VBD (l_advcl) induced/VBN (l_prep) without/IN (l_pobj) modification/NN (l_prep) of/IN (l_pobj) disability/NN
D001058_D010300 NONE apomorphine/NN (r_appos) agonist/NN (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) severity/NN (l_conj) dyskinesias/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- apomorphine/NN (r_pobj) of/IN (r_prep) improvement/NN (r_attr) was/VBD (l_advcl) induced/VBN (l_prep) without/IN (l_pobj) modification/NN (l_prep) of/IN (l_pobj) disability/NN (l_amod) parkinsonian/JJ
D004298_D004409 NONE dopamine/NN (r_compound) agonist/NN (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) severity/NN (l_conj) dyskinesias/NNS -PUNC- dopamine/NN (r_conj) levodopa-/JJ (r_nmod) dyskinesias/NNS
D004298_D009069 NONE dopamine/NN (r_compound) agonist/NN (r_pobj) with/IN (r_prep) challenge/NN (r_pobj) after/IN (r_prep) evaluated/VBD (l_dobj) severity/NN (l_prep) of/IN (l_pobj) disability/NN -PUNC- dopamine/NN (r_conj) levodopa-/JJ (r_nmod) dyskinesias/NNS (r_dobj) reduce/VB (l_prep) without/IN (l_pobj) disability/NN
D007980_D010300 NONE levodopa/JJ (r_npadvmod) responsive/JJ (r_amod) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- levodopa-/JJ (r_nmod) dyskinesias/NNS (r_dobj) reduce/VB (l_prep) without/IN (l_pobj) disability/NN (l_amod) parkinsonian/JJ
24753331
C106487_D005317 CID S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) retardation/NN
C083440_D005317 CID S-23121/NN (r_conj) S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) retardation/NN
C083440_D064420 NONE S-23121/NN (r_conj) S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) retardation/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) in/IN (l_pobj) studies/NNS (l_compound) toxicity/NN
C106487_D064793 CID S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) teratogenicity/NN -PUNC- S-53482/NNS (r_nsubj) were/VBD (l_acomp) teratogenic/JJ
C106487_D064420 NONE S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) retardation/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) in/IN (l_pobj) studies/NNS (l_compound) toxicity/NN -PUNC- S-53482/NNS (r_pobj) to/IN (r_prep) exposure/NN (l_prep) at/IN (l_pobj) patterns/NNS (l_prep) of/IN (l_pobj) toxicity/NN
C106487_D006345 CID S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) teratogenicity/NN (l_conj) defects/NNS
C106487_D020964 CID S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) embryolethality/NN
C083440_D006345 CID S-23121/NN (r_conj) S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) teratogenicity/NN (l_conj) defects/NNS -PUNC- S-23121/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) death/NN (l_conj) defect/NN -PUNC- S-23121/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) following/VBG (r_advcl) observed/VBN (r_conj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) death/NN (l_conj) defect/NN
C083440_D020964 CID S-23121/NN (r_conj) S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) embryolethality/NN -PUNC- S-23121/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) death/NN -PUNC- S-23121/NN (r_pobj) to/IN (r_prep) exposure/NN (r_dobj) following/VBG (r_advcl) observed/VBN (r_conj) resulted/VBD (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) death/NN
C083440_D064793 CID S-23121/NN (r_conj) S-53482/NNS (r_nsubj) are/VBP (l_attr) herbicides/NNS (l_conj) teratogenicity/NN -PUNC- S-23121/NN (r_conj) S-53482/NNS (r_nsubj) were/VBD (l_acomp) teratogenic/JJ
17351238
D005996_D007022 CID GTN/NNP (r_compound) administration/NN (r_pobj) following/VBG (r_prep) drop/NN (l_prep) in/IN (l_pobj) pressure/NN -PUNC- GTN/NNP (r_nsubj) experienced/VBD (l_dobj) drop/NN (l_prep) in/IN (l_pobj) pressure/NN
D001285_D007022 NONE sulphate/NN (r_pobj) by/IN (r_agent) rectified/VBN (l_advcl) experienced/VBD (l_dobj) drop/NN (l_prep) in/IN (l_pobj) pressure/NN
24309294
D009020_D000647 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- morphine/NN (r_npadvmod) treated/VBN (r_amod) animals/NNS (r_pobj) in/IN (r_prep) region/NN (r_pobj) in/IN (r_prep) decreases/VBZ (r_conj) alleviated/VBN (l_dobj) amnesia/NN
D012844_D000647 NONE CCK-8/NNP (r_punct) alleviated/VBN (l_dobj) amnesia/NN
D009020_D008569 NONE morphine/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) attenuates/VBZ (l_conj) suggest/VBP (l_dobj) function/NN (l_prep) on/IN (l_pobj) impairment/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) impairment/NN
D012844_D008569 NONE CCK-8/NNP (r_nsubj) attenuates/VBZ (l_conj) suggest/VBP (l_dobj) function/NN (l_prep) on/IN (l_pobj) impairment/NN -PUNC- CCK-8/NNP (r_punct) on/IN (l_pobj) impairment/NN
89511
D011372_D004714 NONE progestagen/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_nsubj) seem/VB (l_xcomp) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperplasia/NN
D004967_D009369 NONE oestrogen/NN (r_compound) therapy/NN (l_conj) difficulty/NN (l_prep) in/IN (l_pcomp) distinguishing/VBG (l_prep) from/IN (l_pobj) malignancy/NN
D004967_D004714 NONE oestrogen/NN (r_compound) therapy/NN (r_nsubj) seem/VB (l_xcomp) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperplasia/NN
D004967_D014591 NONE oestrogen/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) women/NNS (r_pobj) in/IN (r_prep) Prevention/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- oestrogen/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) women/NNS (r_pobj) among/IN (r_prep) described/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D011372_D002277 NONE progestagen/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) with/IN (r_prep) therapy/NN (r_nsubj) seem/VB (l_xcomp) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperplasia/NN (l_conj) carcinoma/NN
D004967_D016889 NONE oestrogen/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) problems/NNS (r_dobj) demonstrated/VBD (l_csubj) referred/VBD (l_nsubj) cases/NNS (l_prep) of/IN (l_pobj) carcinoma/NN
D004967_D002277 NONE oestrogen/NN (r_compound) therapy/NN (r_nsubj) seem/VB (l_xcomp) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) hyperplasia/NN (l_conj) carcinoma/NN
D011372_D006965 NONE progestagen/NN (r_pobj) without/IN (r_prep) associated/VBN (l_nsubjpass) hyperplasia/NN
D004967_D006965 CID oestrogen/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) hyperplasia/NN -PUNC- oestrogen/NN (r_compound) therapy/NN (l_conj) difficulty/NN (l_prep) in/IN (l_pcomp) distinguishing/VBG (l_dobj) hyperplasia/NN
D009640_D006965 NONE norethisterone/NN (r_amod) mg/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) of/IN (r_prep) courses/NNS (r_nsubj) caused/VBN (l_dobj) reversion/NN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hyperplasia/NN -PUNC- norethisterone/NN (r_amod) mg/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) of/IN (r_prep) courses/NNS (r_nsubj) caused/VBN (l_conj) 6/CD (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hyperplasia/NN
16369751
C032348_D066126 NONE alanine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) cardiotoxicity/NN -PUNC- alanine/NN (r_pobj) of/IN (r_prep) level/NN (r_nsubjpass) observed/VBN (r_relcl) cardiotoxicity/NN -PUNC- FBAL/NNP (r_preconj) (/-LRB- (r_punct) observed/VBN (r_relcl) cardiotoxicity/NN -PUNC- FBAL/NNP (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) cardiotoxicity/NN
D005472_D009369 NONE 5-FU/CD (r_nummod) treatment/NN (l_prep) for/IN (l_pobj) malignancies/NNS
C032348_D002037 NONE FBAL/NNP (r_compound) concentration/NN (r_pobj) with/IN (r_prep) occurred/VBD (l_nsubj) pain/NN (l_prep) with/IN (l_pobj) block/NN
C032348_D002637 NONE FBAL/NNP (r_compound) concentration/NN (r_pobj) with/IN (r_prep) occurred/VBD (l_nsubj) pain/NN
D005472_D066126 NONE 5-Fluorouracil/CD (r_punct) cardiotoxicity/NN -PUNC- 5-fluorouracil/CD (r_punct) is/VBZ (l_nsubj) Cardiotoxicity/NNP -PUNC- 5-FU/CD (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- 5-FU/CD (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) abandoned/VBN (l_advcl) considered/VBN (l_xcomp) been/VBN (l_acomp) due/JJ (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- 5-FU/CD (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN -PUNC- 5-FU/CD (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
D005472_D002637 CID 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (l_relcl) occurred/VBD (l_nsubj) pain/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) after/IN (r_prep) disappeared/VBD (l_nsubj) pain/NN -PUNC- 5-FU/CD (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) been/VBN (r_xcomp) considered/VBN (l_nsubjpass) pain/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) abandoned/VBN (l_advcl) considered/VBN (l_nsubjpass) pain/NN
D005472_D002037 CID 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (l_relcl) occurred/VBD (l_nsubj) pain/NN (l_prep) with/IN (l_pobj) block/NN
7378868
D013390_D014313 CID Suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) stiffness/NN -PUNC- suxamethonium/NN (r_pobj) after/IN (r_prep) occur/VB (l_nsubj) rigidity/NN
D013390_D063806 CID Suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) stiffness/NN (l_conj) myalgia/NN -PUNC- suxamethonium/NN (r_pobj) after/IN (r_prep) occur/VB (l_nsubj) rigidity/NN (l_conj) myalgia/NN
D010197_D014313 NONE pancuronium/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) despite/IN (r_prep) suxamethonium/NN (r_pobj) after/IN (r_prep) occur/VB (l_nsubj) rigidity/NN
D010197_D063806 NONE pancuronium/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) despite/IN (r_prep) suxamethonium/NN (r_pobj) after/IN (r_prep) occur/VB (l_nsubj) rigidity/NN (l_conj) myalgia/NN
19184102
D014635_D009765 CID VPA/NNP (r_compound) treatment/NN (r_pobj) during/IN (r_prep) developed/VBD (l_dobj) obesity/NN -PUNC- VPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_conj) resistance/NN (r_conj) hyperinsulinemia/NN (r_conj) obesity/NN -PUNC- VPA/NNP (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) is/VBZ (l_ccomp) suggests/VBZ (l_ccomp) associated/VBN (l_nsubjpass) obesity/NN
D014635_D007333 CID VPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_conj) resistance/NN -PUNC- VPA/NNP (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) is/VBZ (l_ccomp) suggests/VBZ (l_ccomp) associated/VBN (l_nsubjpass) obesity/NN (l_conj) hyperinsulinemia/NN (l_conj) resistance/NN
D014635_D015431 NONE VPA/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) After/IN (r_prep) showed/VBD (l_dobj) loss/NN
D014635_D065626 CID valproate/NN (r_amod) therapy/NN (r_pobj) during/IN (r_prep) disease/NN -PUNC- VPA/NNP (r_compound) treatment/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) child/NN (r_pobj) in/IN (r_prep) arising/VBG (r_acl) disease/NN -PUNC- VPA/NNP (r_compound) treatment/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) child/NN (r_pobj) in/IN (r_prep) arising/VBG (r_acl) disease/NN (l_appos) NAFLD/NNP -PUNC- VPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_conj) resistance/NN (r_conj) hyperinsulinemia/NN (r_conj) obesity/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) NAFLD/NNP -PUNC- VPA/NNP (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) is/VBZ (l_ccomp) suggests/VBZ (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) NAFLD/NNP
D014635_D006946 CID VPA/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_conj) resistance/NN (r_conj) hyperinsulinemia/NN -PUNC- VPA/NNP (r_compound) withdrawal/NN (r_pobj) after/IN (r_prep) is/VBZ (l_ccomp) suggests/VBZ (l_ccomp) associated/VBN (l_nsubjpass) obesity/NN (l_conj) hyperinsulinemia/NN
D014635_D004827 NONE acid/NN (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) epilepsy/NN -PUNC- VPA/NNP (r_appos) acid/NN (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) epilepsy/NN
11439380
D000728_D011471 NONE androgen/JJ (r_npadvmod) independent/JJ (r_amod) cancer/NN
D013792_D009422 NONE Thalidomide/NNP (r_compound) neuropathy/NN -PUNC- thalidomide/NN (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) be/VB (l_nsubj) Neuropathy/NNP
D013792_D011471 NONE Thalidomide/NNP (r_compound) neuropathy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) treated/VBN (l_prep) for/IN (l_pobj) cancer/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) trial/NN (r_pobj) in/IN (r_prep) men/NNS (l_prep) with/IN (l_pobj) cancer/NN
19967075
D011188_D007674 NONE K/NNP (r_compound) ATPase/NNP (l_prep) in/IN (l_pobj) Nephropathy/NNP -PUNC- Na(+)/K(+)-ATPase/NNP (r_pobj) of/IN (r_prep) expression/NN (r_pobj) with/IN (r_prep) related/VBN (l_nsubjpass) nephropathy/NN
D005839_D007674 CID Gentamicin/NNP (r_npadvmod) induced/VBN (r_amod) Nephropathy/NNP -PUNC- gentamicin/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- Gentamicin/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D012964_D007674 NONE Na/NNP (r_nmod) ATPase/NNP (l_prep) in/IN (l_pobj) Nephropathy/NNP -PUNC- Na(+)/K(+)-ATPase/NNP (r_pobj) of/IN (r_prep) expression/NN (r_pobj) with/IN (r_prep) related/VBN (l_nsubjpass) nephropathy/NN
25096313
D013256_D013716 NONE steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_advcl) treat/VB (l_dobj) epicondylitis/NN -PUNC- steroid/NN (r_compound) injection/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) epicondylitis/NN
D013256_D009422 NONE steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) neuropathy/NN -PUNC- steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) occurred/VBD (r_relcl) neuropathy/NN
D013256_D010292 CID steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) occurred/VBN (l_ccomp) presented/VBN (l_prep) with/IN (l_pobj) sensation/NN (l_conj) paresthesia/NN -PUNC- steroid/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) occurred/VBN (l_nsubj) paresthesia/NN
12559315
D007213_D008415 CID Indomethacin/NNP (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) findings/NNS (l_amod) typical/JJ (l_prep) of/IN (l_pobj) cystitis/NN (l_prep) as/IN (l_pobj) epithelium/NN (l_conj) mastocytosis/NN
D007213_D018856 CID Indomethacin/NNP (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) findings/NNS (l_amod) typical/JJ (l_prep) of/IN (l_pobj) cystitis/NN
8318674
D003561_D011654 CID C/NN (r_pobj) after/IN (r_prep) edema/NN
D003561_D012769 CID C/NN (r_pobj) after/IN (r_prep) edema/NN (l_conj) shock/NN -PUNC- C/NNP (r_nsubjpass) associated/VBN (r_ccomp) hypothesize/VBP (l_advcl) thought/VBN (l_xcomp) involved/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) shock/NN
D003561_D012128 NONE C/NNP (r_nsubjpass) associated/VBN (r_ccomp) hypothesize/VBP (l_advcl) thought/VBN (l_xcomp) involved/VBN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) shock/NN (l_conj) syndrome/NN
D003561_D008223 NONE C/NN (l_prep) for/IN (l_pobj) lymphoma/NN -PUNC- C/NNP (r_pobj) with/IN (r_prep) treated/VBN (l_prep) for/IN (l_pobj) lymphomas/NNS
16309808
D004294_D012148 NONE domperidone/NN (r_nsubj) potentiate/VB (l_dobj) syndrome/NN -PUNC- domperidone/NN (r_nsubj) induce/VB (l_conj) aggravate/VBP (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- domperidone/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) added/VBN (r_ccomp) report/VBP (l_dobj) comorbid/JJ (l_prep) with/IN (l_pobj) dyspepsia/NN (l_relcl) developed/VBD (l_dobj) RLS/NNP -PUNC- domperione/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) support/VB (l_nsubj) relationship/NN (l_prep) between/IN (l_pobj) use/NN (l_conj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- domperione/NN (l_prep) on/IN (l_pobj) RLS/NNP
D004298_D012148 NONE dopamine/NN (r_compound) agonists/NNS (r_pobj) by/IN (r_agent) improved/VBN (l_nsubjpass) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- dopamine/NN (r_compound) agonists/NNS (r_pobj) by/IN (r_agent) improved/VBN (l_advcl) induce/VB (l_conj) aggravate/VB (l_dobj) symptoms/NNS (l_compound) RLS/NNP -PUNC- dopamine/NN (r_compound) antagonists/NNS (r_nsubj) induce/VB (r_advcl) improved/VBN (l_nsubjpass) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- dopamine/NN (r_compound) antagonists/NNS (r_nsubj) induce/VB (l_conj) aggravate/VB (l_dobj) symptoms/NNS (l_compound) RLS/NNP -PUNC- dopamine/NN (r_compound) antagonist/NN (r_appos) domperidone/NN (r_nsubj) induce/VB (l_conj) aggravate/VBP (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- dopamine/NN (r_compound) antagonists/NNS (r_dobj) receiving/VBG (r_acl) those/DT (r_appos) possibility/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) RLS/NNP
D004294_D004415 NONE domperidone/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) added/VBN (r_ccomp) report/VBP (l_dobj) comorbid/JJ (l_prep) with/IN (l_pobj) dyspepsia/NN
D007980_D012148 NONE levodopa/NN (r_nmod) agonists/NNS (r_pobj) by/IN (r_agent) improved/VBN (l_nsubjpass) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- levodopa/NN (r_nmod) agonists/NNS (r_pobj) by/IN (r_agent) improved/VBN (l_advcl) induce/VB (l_conj) aggravate/VB (l_dobj) symptoms/NNS (l_compound) RLS/NNP
C035133_D004415 NONE mirtazapine/RB (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) dyspepsia/NN
C035133_D012148 CID mirtazapine/RB (r_advmod) associated/VBN (r_amod) syndrome/NN -PUNC- Mirtazapine/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) RLS/NNP -PUNC- mirtazapine/RB (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) RLS/NNP -PUNC- mirtazapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) have/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- mirtazapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) have/VB (r_xcomp) started/VBD (l_conj) resolved/VBD (l_nsubj) symptoms/NNS (l_compound) RLS/NNP -PUNC- mirtazapine/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) upon/IN (r_prep) resolved/VBD (r_conj) started/VBD (l_xcomp) have/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- mirtazapine/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) upon/IN (r_prep) resolved/VBD (l_nsubj) symptoms/NNS (l_compound) RLS/NNP -PUNC- mirtazapine/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- mirtazapine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) between/IN (r_prep) relationship/NN (r_nsubj) support/VB (l_dobj) effect/NN (l_prep) of/IN (l_pobj) domperione/NN (l_prep) on/IN (l_pobj) RLS/NNP -PUNC- mirtazapine/RB (r_npadvmod) associated/VBN (r_amod) RLS/NNP (r_pobj) on/IN (r_prep) domperione/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) support/VB (l_nsubj) relationship/NN (l_prep) between/IN (l_pobj) use/NN (l_conj) symptoms/NNS (l_prep) of/IN (l_pobj) RLS/NNP -PUNC- mirtazapine/RB (r_npadvmod) associated/VBN (r_amod) RLS/NNP -PUNC- mirtazapine/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) RLS/NNP
1564030
D005473_D011618 NONE fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (r_pobj) for/IN (r_prep) factors/NNS (l_appos) depression/NN (l_prep) with/IN (l_pobj) features/NNS (l_amod) psychotic/JJ
D012701_D003866 NONE serotonin/NN (r_compound) inhibitor/NN (r_appos) Fluoxetine/NNP (r_nsubj) gaining/VBG (l_dobj) acceptance/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) depression/NN
D005473_D001714 CID fluoxetine/NN (r_amod) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Mania/NNP -PUNC- fluoxetine/NN (r_nsubjpass) reported/VBN (l_xcomp) induce/VB (l_dobj) mania/NN -PUNC- fluoxetine/NN (r_pobj) with/IN (r_prep) pharmacotherapy/NN (r_pobj) during/IN (r_prep) developed/VBD (l_dobj) mania/NN -PUNC- fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (l_prep) of/IN (l_pobj) mania/NN -PUNC- fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN -PUNC- fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (r_pobj) for/IN (r_prep) factors/NNS (l_appos) depression/NN (l_conj) history/NN (l_prep) of/IN (l_pobj) disorder/NN (l_appos) disorder/NN -PUNC- fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (r_pobj) for/IN (r_prep) factors/NNS (l_appos) depression/NN (l_conj) history/NN (l_conj) diagnosis/NN (l_prep) of/IN (l_pobj) disorder/NN -PUNC- fluoxetine/VB (r_advmod) induced/VBN (r_amod) mania/NN
D005473_D003866 NONE Fluoxetine/NNP (r_nsubj) gaining/VBG (l_dobj) acceptance/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) depression/NN -PUNC- fluoxetine/NN (r_pobj) with/IN (r_prep) pharmacotherapy/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) cases/NNS (l_prep) of/IN (l_pobj) adolescents/NNS (l_amod) depressed/JJ -PUNC- fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (r_pobj) for/IN (r_prep) factors/NNS (l_appos) depression/NN
D005473_D019964 NONE fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (r_pobj) for/IN (r_prep) factors/NNS (l_appos) depression/NN (l_conj) history/NN (l_prep) of/IN (l_pobj) disorder/NN
D005473_D001289 NONE fluoxetine/NN (r_amod) pharmacotherapy/NN (r_pobj) during/IN (r_prep) hypomania/NN (r_conj) development/NN (r_pobj) for/IN (r_prep) factors/NNS (r_nsubj) were/VBD (l_attr) combination/NN (l_prep) of/IN (l_pobj) disorder/NN
15366550
D008094_D018500 CID Lithium/NN (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) DI/NNP -PUNC- Lithium/NN (r_nsubjpass) implicated/VBN (l_conj) changed/VBD (l_advcl) focus/VB (l_prep) on/IN (l_pobj) DI/NNP -PUNC- lithium/NN (r_dobj) received/VBN (r_advcl) changed/VBD (r_conj) implicated/VBN (l_prep) in/IN (l_pobj) DI/NNP -PUNC- lithium/NN (r_dobj) received/VBN (r_advcl) changed/VBD (l_advcl) focus/VB (l_prep) on/IN (l_pobj) DI/NNP -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) DI/NNP -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) DI/NNP (r_dobj) treating/VBG (l_conj) developed/VBN (l_dobj) DI/NNP
D008094_D059606 NONE lithium/NN (r_compound) use/NN (r_conj) polydipsia/NN
D008094_D001930 NONE lithium/NN (r_npadvmod) induced/VBN (r_amod) DI/NNP (r_dobj) treating/VBG (l_conj) developed/VBN (l_advcl) brain/NN (l_dobj) trauma/NN
1449452
D004077_D001281 NONE digoxin/NN (l_compound) fibrillation/NN
D004077_D009203 NONE digoxin/NN (r_nsubj) increase/VB (l_prep) after/IN (l_pobj) infarction/NN -PUNC- digoxin/NN (r_nsubj) increase/VB (l_prep) after/IN (l_pobj) infarction/NN (l_appos) MI/NNP
D004077_D001145 CID digoxin/NN (r_nsubj) has/VBZ (l_dobj) effects/NNS (l_prep) as/IN (l_pcomp) increasing/VBG (l_conj) causing/VBG (l_dobj) arrhythmias/NNS
24220752
-1_D006973 NONE bevacizumab/NN (r_amod) irinotecan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (l_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- bevacizumab/NN (r_amod) irinotecan/NN (r_pobj) of/IN (r_prep) combination/NN (r_conj) Hypertension/NN -PUNC- bevacizumab/NN (r_pobj) with/IN (r_prep) treatment/NN (r_conj) Hypertension/NN
D003287_D007674 CID contrast/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- contrast/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- Contrast/RB (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D003287_D009369 NONE contrast/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_pobj) of/IN (r_prep) Incidence/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- contrast/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN (r_pobj) to/IN (r_prep) related/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
C051890_D006973 NONE irinotecan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (l_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- irinotecan/NN (r_pobj) of/IN (r_prep) combination/NN (r_conj) Hypertension/NN
1655018
D000305_D008113 NONE corticosteroid/NN (r_npadvmod) treated/VBN (r_conj) androgen-/NN (r_amod) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) develop/VB (l_nsubj) neoplasms/NNS
D000305_D006528 CID corticosteroid/NN (r_conj) androgen/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) carcinoma/NN
D000728_D005199 NONE androgen/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) carcinoma/NN (l_prep) in/IN (l_pobj) anemia/NN -PUNC- androgens/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) known/VBN (l_xcomp) have/VB (l_dobj) anemia/NN -PUNC- androgen-/NN (r_amod) anemia/NN
D000728_D010382 CID androgen-/NN (r_amod) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) develop/VB (l_nsubj) neoplasms/NNS (l_conj) peliosis/NN
D000728_D008113 NONE androgen-/NN (r_amod) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) develop/VB (l_nsubj) neoplasms/NNS
D000305_D005199 NONE corticosteroid/NN (r_conj) androgen/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) carcinoma/NN (l_prep) in/IN (l_pobj) anemia/NN -PUNC- corticosteroids/NNS (r_conj) androgens/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_conj) known/VBN (l_xcomp) have/VB (l_dobj) anemia/NN -PUNC- corticosteroid/NN (r_npadvmod) treated/VBN (r_conj) androgen-/NN (r_amod) anemia/NN
D000305_D010382 CID corticosteroid/NN (r_npadvmod) treated/VBN (r_conj) androgen-/NN (r_amod) anemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) develop/VB (l_nsubj) neoplasms/NNS (l_conj) peliosis/NN
D000728_D006528 CID androgen/JJ (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) carcinoma/NN
24571687
D020927_D013575 NONE dexmedetomidine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_acl) girl/NN (r_pobj) in/IN (r_prep) bradycardia/NN (r_conj) syncope/NN
D020927_D001919 CID dexmedetomidine/NN (r_dobj) following/VBG (r_prep) bradycardia/NNS -PUNC- dexmedetomidine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_acl) girl/NN (r_pobj) in/IN (r_prep) bradycardia/NN
D020927_D019462 CID dexmedetomidine/NN (r_dobj) following/VBG (r_prep) bradycardia/NNS (r_conj) syncope/NN
23433219
D008694_D019964 NONE methamphetamine/NN (r_compound) use/NN (r_conj) personality/NN (r_conj) disorder/NN
D008694_D001714 CID methamphetamine/NN (r_compound) uses/NNS (r_conj) disorder/NN (r_appos) disorder/NN (l_appos) disorder/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) disorder/NN (l_appos) disorder/NN
D008694_D000987 CID methamphetamine/NN (r_compound) uses/NNS (r_conj) disorder/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) disorder/NN (l_appos) disorder/NN -PUNC- methamphetamine/NN (r_compound) use/NN (r_conj) personality/NN
D008694_D011605 CID methamphetamine/NN (r_compound) psychosis/NN -PUNC- methamphetamine/NN (r_npadvmod) dependent/JJ (r_amod) patients/NNS (r_pobj) in/IN (r_prep) psychosis/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN -PUNC- methamphetamine/NN (r_compound) dependence/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) lifetime/NN (l_conj) psychosis/NN -PUNC- methamphetamine/NN (r_punct) -/HYPH (r_punct) induced/VBN (r_amod) psychosis/NN -PUNC- methamphetamine/NN (r_pobj) of/IN (r_prep) diagnosis/NN (r_pobj) with/IN (r_prep) Patients/NNS (r_nsubjpass) interviewed/VBN (l_advcl) using/VBG (l_prep) for/IN (l_pobj) psychosis/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN -PUNC- methamphetamine/NN (r_compound) uses/NNS (r_conj) disorder/NN (r_appos) disorder/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) psychosis/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN -PUNC- methamphetamine/NN (r_compound) dependence/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) risk/NN (l_prep) of/IN (l_pobj) psychosis/NN -PUNC- methamphetamine/NN (r_compound) dependence/NN (r_pobj) of/IN (r_prep) cases/NNS (r_nsubjpass) screened/VBN (l_prep) for/IN (l_pobj) symptoms/NNS
D008694_D003866 NONE methamphetamine/NN (r_compound) uses/NNS (r_conj) disorder/NN (r_appos) disorder/NN -PUNC- methamphetamine/NN (r_npadvmod) induced/VBN (r_amod) psychosis/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) disorder/NN
10960401
D009020_D009759 CID morphine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) nystagmus/NN -PUNC- morphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_prep) with/IN (l_pobj) nystagmus/NN
D009020_D004244 CID morphine/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) dizziness/NN
24928523
D003907_D009101 NONE dexamethasone/NN (r_conj) thalidomide/NN (r_conj) Combination/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) after/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- dexamethasone/NN (r_conj) thalidomide/NN (r_conj) bortezomib/NNS (r_pobj) of/IN (r_prep) regimen/NNS (r_pobj) of/IN (r_prep) safety/NN (r_dobj) analyzed/VBD (l_prep) as/IN (l_pobj) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP
C400082_D009101 NONE bortezomib/NNS (r_pobj) of/IN (r_prep) Combination/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) after/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- bortezomib/NNS (r_pobj) of/IN (r_prep) regimen/NNS (r_pobj) of/IN (r_prep) safety/NN (r_dobj) analyzed/VBD (l_prep) as/IN (l_pobj) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP
D013792_D009101 NONE thalidomide/NN (r_conj) Combination/NN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) after/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- thalidomide/NN (r_conj) bortezomib/NNS (r_pobj) of/IN (r_prep) regimen/NNS (r_pobj) of/IN (r_prep) safety/NN (r_dobj) analyzed/VBD (l_prep) as/IN (l_pobj) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP
11135381
D008729_D006973 CID Methoxamine/NNP (r_nsubj) evoked/VBD (l_conj) caused/VBD (l_dobj) rise/NN (l_prep) in/IN (l_pobj) pressure/NN
D008729_D014550 NONE methoxamine/NN (l_prep) on/IN (l_pobj) pressure/NN (l_prep) with/IN (l_pobj) incontinence/NN -PUNC- methoxamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) log/NN (r_csubjpass) administered/VBN (l_prep) to/IN (l_pobj) group/NN (l_prep) with/IN (l_pobj) incontinence/NN
25041770
D017291_D012206 CID clarithromycin/NN (r_pobj) in/IN (r_prep) increment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) Rhabdomyolysis/NNP -PUNC- clarithromycin/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) after/IN (r_prep) occurred/VBD (r_advcl) is/VBZ (l_prep) of/IN (l_pobj) interest/NN (l_prep) as/IN (l_pobj) rhabdomyolysis/NN
D019821_D012206 CID simvastatin/NN (r_nmod) increment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) Rhabdomyolysis/NNP -PUNC- statin/NN (r_pobj) with/IN (r_prep) associated/VBN (l_conj) induced/VBN (l_dobj) rhabdomyolysis/NN
24923469
24459006
D015725_D001855 NONE fluconazole/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) to/IN (r_prep) relationship/NN (l_prep) of/IN (l_pobj) suppression/NN
D015725_D000380 CID Fluconazole/NNP (r_nsubj) associated/VBD (l_dobj) agranulocytosis/NN -PUNC- fluconazole/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) describe/VBP (l_dobj) agranulocytosis/NN -PUNC- fluconazole/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) occurred/VBD (l_nsubj) agranulocytosis/NN
D015725_D013921 CID Fluconazole/NNP (r_nsubj) associated/VBD (l_dobj) agranulocytosis/NN (l_conj) thrombocytopenia/NN -PUNC- fluconazole/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) describe/VBP (l_dobj) agranulocytosis/NN (l_prep) with/IN (l_pobj) thrombocytopenia/NN -PUNC- fluconazole/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) occurred/VBD (l_nsubj) agranulocytosis/NN (l_conj) thrombocytopenia/NN
24209900
D007069_D009369 NONE Ifosfamide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_amod) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) range/NN (l_prep) of/IN (l_pobj) cancers/NNS -PUNC- Ifosfamide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_amod) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) range/NN (l_prep) of/IN (l_pobj) cancers/NNS (l_prep) including/VBG (l_pobj) sarcomas/NNS (l_conj) cancers/NNS -PUNC- ifosfamide/RB (r_advmod) related/VBN (r_amod) encephalopathy/NN (r_dobj) developed/VBD (r_relcl) done/VBN (l_advcl) admitted/VBN (l_prep) to/IN (l_pobj) Center/NNP (l_compound) Cancer/NNP
D007069_D008223 NONE Ifosfamide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_amod) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) range/NN (l_prep) of/IN (l_pobj) cancers/NNS (l_prep) including/VBG (l_pobj) sarcomas/NNS (l_conj) cancers/NNS (l_nmod) lymphoma/NN
D007069_D012509 NONE Ifosfamide/NNP (r_nsubj) is/VBZ (l_attr) agent/NN (l_amod) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) range/NN (l_prep) of/IN (l_pobj) cancers/NNS (l_prep) including/VBG (l_pobj) sarcomas/NNS
D007069_D001927 NONE Ifosfamide/IN (r_nmod) encephalopathy/NN -PUNC- ifosfamide/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) Encephalopathy/NNP -PUNC- ifosfamide/JJ (r_advmod) related/VBN (r_amod) encephalopathy/NN -PUNC- ifosfamide/RB (r_advmod) related/VBN (r_amod) encephalopathy/NN -PUNC- ifosfamide/RB (r_advmod) receiving/VBG (r_advcl) experienced/VBD (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) encephalopathy/JJ -PUNC- ifosfamide/JJ (r_advmod) related/JJ (r_amod) encephalopathy/JJ -PUNC- ifosfamide/RB (l_relcl) develop/VBP (l_dobj) features/NNS (l_prep) of/IN (l_pobj) encephalopathy/NN
11423811
D003042_D002637 CID cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) pain/NN -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) dobutamine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) regarding/VBG (r_prep) concern/NN (r_pobj) Because/IN (r_prep) conducted/VBD (l_dobj) study/NN (l_relcl) assess/VB (l_dobj) safety/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_dobj) used/VBN (l_advcl) preceding/VBG (l_dobj) onset/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- cocaine/NN (r_npadvmod) related/VBN (r_amod) pain/NN
D004280_D007511 NONE Dobutamine/NNP (r_nsubj) stress/NN (r_nsubj) is/VBZ (l_attr) test/NN (l_prep) for/IN (l_pcomp) evaluating/VBG (l_dobj) ischemia/NN
D003042_D064420 NONE cocaine/NN (r_compound) toxicity/NN
D004280_D002637 NONE dobutamine/NN (r_compound) stress/NN (l_dobj) echocardiography/RB (l_prep) in/IN (l_pobj) evaluation/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- dobutamine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) regarding/VBG (r_prep) concern/NN (r_pobj) Because/IN (r_prep) conducted/VBD (l_dobj) study/NN (l_relcl) assess/VB (l_dobj) safety/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pain/NN -PUNC- dobutamine/NN (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pain/NN
24068571
D013874_D003693 CID thiopentone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) delirium/NN
D015742_D003693 NONE propofol/NN (r_pcomp) to/IN (r_prep) compared/VBN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) delirium/NN
2553470
D008094_D012640 NONE lithium/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_conj) models/NNS (l_compound) seizure/NN -PUNC- lithium/NN (r_compound) pilocarpine/NN (r_compound) model/NN (r_pobj) with/IN (r_prep) action/NN (r_dobj) produced/VBD (l_advcl) suggesting/VBG (l_dobj) seizures/NNS -PUNC- lithium/NN (r_compound) pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_prep) after/IN (l_pobj) periods/NNS (l_prep) of/IN (l_pobj) activity/NN (l_compound) seizure/NN -PUNC- lithium/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- lithium/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS (r_dobj) block/VB (r_xcomp) is/VBZ (r_advcl) is/VBZ (l_xcomp) ongoing/JJ (l_advmod) epilepticus/NN (l_conj) block/VB (l_dobj) lethality/NN (l_prep) of/IN (l_pobj) seizures/NNS
D010862_D001930 NONE pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) damage/NN
D016202_D012640 NONE aspartate/NNP (r_nmod) antagonist/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) effects/NNS (l_acl) using/VBG (l_dobj) models/NNS (l_compound) seizure/NN -PUNC- NMDA/NNP (r_nmod) antagonist/NN (r_nsubjpass) tested/VBN (l_prep) for/IN (l_pobj) effects/NNS (l_acl) using/VBG (l_dobj) models/NNS (l_compound) seizure/NN
D016291_D012640 NONE MK-801/NNP (r_punct) tested/VBN (l_prep) for/IN (l_pobj) effects/NNS (l_acl) using/VBG (l_dobj) models/NNS (l_compound) seizure/NN -PUNC- MK-801/NNP (r_punct) produced/VBD (l_advcl) suggesting/VBG (l_dobj) seizures/NNS -PUNC- MK-801/NNP (r_punct) in/IN (r_prep) occurred/VBD (l_prep) after/IN (l_pobj) periods/NNS (l_prep) of/IN (l_pobj) activity/NN (l_compound) seizure/NN -PUNC- MK-801/NNP (r_punct) 30/CD (r_nummod) min/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) reduced/VBD (l_dobj) activity/NN (l_compound) seizure/NN
D016202_D013226 NONE NMDA/NNP (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) activation/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) damage/NN (l_amod) epilepticus/NN -PUNC- NMDA/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) showing/VBG (r_acl) results/NNS (r_pobj) by/IN (r_agent) supported/VBN (l_conj) were/VBD (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) mortality/NN (l_amod) epilepticus/NN
D016202_D001930 NONE NMDA/NNP (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) activation/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) damage/NN
D010862_D013226 CID pilocarpine/NN (r_compound) model/NN (r_pobj) on/IN (r_prep) epilepticus/NN -PUNC- pilocarpine/NN (r_conj) lithium/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS (r_dobj) block/VB (r_xcomp) is/VBZ (r_advcl) is/VBZ (l_xcomp) ongoing/JJ (l_advmod) epilepticus/NN -PUNC- pilocarpine/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) induced/VBN (r_acl) seizures/NNS (r_dobj) block/VB (r_xcomp) is/VBZ (r_advcl) is/VBZ (l_xcomp) ongoing/JJ (l_advmod) epilepticus/NN -PUNC- pilocarpine/NN (r_pobj) after/IN (r_prep) min/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) reduced/VBD (l_prep) during/IN (l_pobj) epilepticus/NN -PUNC- pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) damage/NN (l_amod) epilepticus/NN -PUNC- pilocarpine/NN (r_conj) NMDA/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) showing/VBG (r_acl) results/NNS (r_pobj) by/IN (r_agent) supported/VBN (l_conj) were/VBD (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) mortality/NN (l_amod) epilepticus/NN
D010862_D012640 NONE pilocarpine/NN (r_conj) lithium/NN (r_pobj) of/IN (r_prep) coadministration/NN (r_conj) models/NNS (l_compound) seizure/NN -PUNC- pilocarpine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) models/NNS (l_compound) seizure/NN -PUNC- pilocarpine/NN (r_compound) model/NN (r_pobj) with/IN (r_prep) action/NN (r_dobj) produced/VBD (l_advcl) suggesting/VBG (l_dobj) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) rats/NNS (r_pobj) with/IN (r_conj) produced/VBD (l_advcl) suggesting/VBG (l_dobj) seizures/NNS -PUNC- pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_prep) after/IN (l_pobj) periods/NNS (l_prep) of/IN (l_pobj) activity/NN (l_compound) seizure/NN -PUNC- pilocarpine/NN (r_conj) lithium/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_conj) lithium/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS (r_dobj) block/VB (r_xcomp) is/VBZ (r_advcl) is/VBZ (l_xcomp) ongoing/JJ (l_advmod) epilepticus/NN (l_conj) block/VB (l_dobj) lethality/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) induced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) induced/VBN (r_acl) seizures/NNS (r_dobj) block/VB (r_xcomp) is/VBZ (r_advcl) is/VBZ (l_xcomp) ongoing/JJ (l_advmod) epilepticus/NN (l_conj) block/VB (l_dobj) lethality/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) after/IN (r_prep) min/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) reduced/VBD (l_dobj) activity/NN (l_compound) seizure/NN
D008094_D001930 NONE lithium/NN (r_compound) pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) damage/NN
D016291_D013226 NONE MK-801/NNP (r_punct) on/IN (r_prep) epilepticus/NN -PUNC- MK-801/NNP (r_punct) 30/CD (r_nummod) min/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) reduced/VBD (l_prep) during/IN (l_pobj) epilepticus/NN
D008094_D013226 CID lithium/NN (r_compound) pilocarpine/NN (r_compound) model/NN (r_pobj) on/IN (r_prep) epilepticus/NN -PUNC- lithium/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS (r_dobj) block/VB (r_xcomp) is/VBZ (r_advcl) is/VBZ (l_xcomp) ongoing/JJ (l_advmod) epilepticus/NN -PUNC- lithium/NN (r_compound) pilocarpine/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) damage/NN (l_amod) epilepticus/NN
3990093
D011692_D007674 NONE aminonucleoside/JJ (r_amod) nephrosis/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) sclerosis/NN -PUNC- aminonucleoside/NN (r_nmod) model/NN (r_advcl) studied/VBN (l_nsubjpass) relationship/NN (l_prep) between/IN (l_pobj) dysfunction/NN -PUNC- aminonucleoside/NN (r_nmod) model/NN (r_advcl) studied/VBN (l_nsubjpass) relationship/NN (l_prep) between/IN (l_pobj) dysfunction/NN (l_prep) of/IN (l_pobj) sclerosis/NN -PUNC- PAN/NNP (r_nmod) model/NN (r_advcl) studied/VBN (l_nsubjpass) relationship/NN (l_prep) between/IN (l_pobj) dysfunction/NN -PUNC- PAN/NNP (r_nmod) model/NN (r_advcl) studied/VBN (l_nsubjpass) relationship/NN (l_prep) between/IN (l_pobj) dysfunction/NN (l_prep) of/IN (l_pobj) sclerosis/NN -PUNC- PAN/NNP (r_compound) rats/NNS (r_pobj) of/IN (r_prep) glomeruli/NN (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) sclerosis/NN -PUNC- PAN/NNP (r_compound) nephrosis/NN (r_pobj) in/IN (r_prep) model/NN (r_pobj) to/IN (r_prep) Similar/JJ (r_nsubjpass) related/VBN (l_nsubjpass) development/NN (l_prep) of/IN (l_pobj) sclerosis/NN
D011692_D011507 CID PAN/NNP (r_compound) rats/NNS (r_nsubj) were/VBD (r_auxpass) proteinuric/JJ
D011692_D012598 NONE PAN/NNP (r_compound) treatment/NN (r_pobj) during/IN (r_prep) change/VB (r_advcl) conclude/VBP (l_ccomp) caused/VBN (l_agent) by/IN (l_pobj) uptake/NN (l_prep) after/IN (l_pobj) injection/NN (l_prep) in/IN (l_pobj) areas/NNS (l_relcl) develop/VB (l_nsubj) sclerosis/NN
D002244_D011507 NONE carbon/NN (r_dobj) given/VBN (r_conj) proteinuric/JJ
D011692_D009401 NONE aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- PAN/NNP (r_compound) nephrosis/NN
20034406
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (l_amod) epilepticus/NN -PUNC- pilocarpine/NN (r_amod) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) SE/NNP (l_nmod) epilepticus/NN -PUNC- pilocarpine/NN (r_amod) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) SE/NNP -PUNC- pilocarpine/NN (r_amod) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) SE/NNP -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) SE/NNP
3439580
D007099_D009447 NONE imipramine/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Hypertension/NN (l_prep) in/IN (l_pobj) neuroblastoma/NN -PUNC- Imipramine/NNP (r_dobj) given/VBN (r_relcl) neuroblastoma/NN
D007099_D006973 CID imipramine/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Hypertension/NN -PUNC- Imipramine/NNP (r_dobj) given/VBN (r_relcl) neuroblastoma/NN (r_pobj) with/IN (r_prep) girl/NN (r_pobj) in/IN (r_prep) pressure/NN (r_appos) hypertension/NN -PUNC- Imipramine/NNP (r_pobj) of/IN (r_prep) discontinuation/NN (r_dobj) following/VBG (r_acl) none/NN (r_conj) elevation/NN (r_dobj) had/VBD (r_advcl) believe/VBP (l_ccomp) caused/VBD (l_dobj) hypertension/NN
D007099_D002653 NONE Imipramine/NNP (r_dobj) given/VBN (l_advcl) control/VB (l_dobj) disorder/NN
7457821
15991002
D002110_D001008 CID caffeine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anxiety/NN -PUNC- caffeine-/NN (r_dobj) blocked/VBD (l_conj) anxiety/NN -PUNC- caffeine/NN (r_npadvmod) induced/VBN (r_amod) anxiety/NN -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) specific/JJ (r_acomp) is/VBZ (l_nsubj) effect/NN (l_prep) on/IN (l_pobj) anxiety/NN
D009538_D001008 NONE nicotine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) anxiety/NN -PUNC- Nicotine/NNP (r_nsubj) blocked/VBD (l_conj) anxiety/NN -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) anxiety/NN
D010433_D001008 CID pentylenetetrazole/NN (r_appos) drug/NN (r_conj) caffeine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anxiety/NN -PUNC- pentylenetetrazole/NN (r_advmod) induced/VBN (r_amod) anxiety/NN
4010471
D004229_D012640 NONE dithiothreitol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) by/IN (r_agent) affected/VBN (l_nsubjpass) sites/NNS (l_prep) from/IN (l_pobj) mice/NNS (l_amod) sensitive/JJ (l_npadvmod) seizure/NN
D009538_D012640 CID nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- nicotine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) sensitive/JJ (r_amod) Mice/NNS (r_nsubj) had/VBD (l_dobj) binding/NN (l_prep) than/IN (l_pobj) mice/NNS (l_nmod) seizure/NN
9831002
D008774_D009459 CID methylphenidate/NN (r_conj) syndrome/NN -PUNC- methylphenidate/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubj) presented/VBN (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- methylphenidate/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) patient/JJ (l_prep) with/IN (l_pobj) syndrome/NN
10672628
D009569_D002375 NONE oxide/NN (r_compound) synthesis/NN (r_pobj) of/IN (r_prep) inhibition/NN (r_nsubj) modifies/VBZ (l_dobj) catalepsy/NN -PUNC- oxide/NN (r_compound) synthase/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) arginine/NN (r_nsubj) induces/VBZ (l_dobj) catalepsy/NN
D019335_D002375 NONE arginine/NN (r_nsubj) induces/VBZ (l_dobj) catalepsy/NN -PUNC- NOARG/NNP (r_appos) arginine/NN (r_nsubj) induces/VBZ (l_dobj) catalepsy/NN -PUNC- NOARG/NNP (r_compound) treatment/NN (l_prep) in/IN (l_pobj) catalepsy/NN -PUNC- NOARG/NNP (r_nmod) administration/NN (r_nsubj) produced/VBD (l_dobj) tolerance/NN (l_prep) of/IN (l_conj) of/IN (l_pobj) catalepsy/NN -PUNC- NOARG/NNP (r_pobj) of/IN (l_conj) of/IN (l_pobj) catalepsy/NN
D009249_D002375 NONE NADPH/NNP (r_compound) diaphorase/NN (r_compound) neurons/NNS (r_pobj) of/IN (r_prep) number/NN (r_conj) catalepsy/NN
D004298_D002375 NONE dopamine/NN (r_compound) receptors/NNS (r_dobj) block/VBP (r_relcl) haloperidol/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_nsubj) cause/VBP (l_dobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_nsubj) cause/VBP (l_dobj) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN
10427794
C065757_D056486 CID Meloxicam/NNP (r_npadvmod) induced/VBN (r_amod) toxicity/NN -PUNC- meloxicam/NN (r_pobj) due/IN (r_prep) developed/VBD (l_dobj) hepatitis/NN -PUNC- meloxicam/NNP (r_compound) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_nsubj) hepatitis/NN -PUNC- meloxicam/NNP (r_nmod) toxicity/NN -PUNC- meloxicam/NNP (r_nmod) toxicity/NN (r_pobj) of/IN (r_prep) case/NN (r_nsubj) demonstrates/VBZ (l_xcomp) induce/VB (l_dobj) damage/NN
C065757_D004342 CID meloxicam/NNP (r_compound) administration/NN (r_pobj) after/IN (r_prep) occurred/VBD (l_conj) associated/VBN (l_advcl) suggesting/VBG (l_dobj) mechanism/NN (l_compound) hypersensitivity/NN
C065757_D001172 NONE meloxicam/NN (r_pobj) due/IN (r_prep) developed/VBD (r_relcl) arthritis/NN
11385188
D003042_D009202 CID cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) common/JJ (r_acomp) is/VBZ (l_nsubj) disease/NN
D003042_D006331 NONE cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) Prevalence/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) disease/NN -PUNC- cocaine/NN (r_compound) users/NNS (r_conj) prevalence/NN (l_prep) of/IN (l_pobj) disease/NN
D003042_D003324 CID cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) common/JJ (r_acomp) is/VBZ (l_nsubj) disease/NN
21195121
D001120_D012640 NONE arginine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) increased/VBD (l_dobj) incidence/NN (l_compound) convulsion/NN -PUNC- arginine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) increased/VBD (l_conj) shortened/VBN (l_prep) to/IN (l_pobj) convulsion/NN
D009569_D004827 NONE oxide/NN (r_nsubj) has/VBZ (l_conj) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) epilepsy/NN -PUNC- NO/NNP (r_intj) oxide/NN (r_nsubj) has/VBZ (l_conj) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) epilepsy/NN -PUNC- NO/DT (r_det) syntheses/NNS (r_pobj) of/IN (r_prep) precursor/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) due/IN (r_prep) has/VBZ (l_conj) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) epilepsy/NN -PUNC- NO/DT (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) characteristics/NNS (l_prep) of/IN (l_pobj) epilepsy/NN
D001556_D012640 CID lindane/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) role/NN (l_prep) in/IN (l_pobj) convulsions/NNS -PUNC- lindane/NN (r_compound) dose/NN (r_pobj) by/IN (r_agent) elicited/VBN (r_acl) convulsion/NN (r_pobj) to/IN (r_prep) shortened/VBN (r_conj) increased/VBD (l_dobj) incidence/NN (l_compound) convulsion/NN -PUNC- lindane/NN (r_compound) dose/NN (r_pobj) by/IN (r_agent) elicited/VBN (r_acl) convulsion/NN -PUNC- lindane/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) decreased/VBD (l_npadvmod) incidence/NN (l_compound) convulsion/NN -PUNC- lindane/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) with/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) decreased/VBD (l_npadvmod) incidence/NN (l_conj) time/NN (l_prep) to/IN (l_pobj) convulsion/NN -PUNC- lindane/NN (r_pobj) of/IN (r_prep) dose/NN (l_amod) convulsive/JJ -PUNC- lindane/NN (r_compound) seizures/NNS
D001556_D004827 NONE lindane/NN (r_npadvmod) induced/VBN (r_amod) epilepsy/NN
D019331_D004827 NONE NAME/NNP (r_nsubj) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) epilepsy/NN
D001120_D004827 NONE arginine/NN (r_nmod) precursor/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) due/IN (r_prep) has/VBZ (l_conj) observed/VBN (l_prep) in/IN (l_pobj) models/NNS (l_compound) epilepsy/NN
D005680_D012640 NONE GABA(A/NNP (r_nmod) receptors/NNS (r_pobj) of/IN (r_prep) blockage/NN (r_dobj) trough/VB (l_nsubj) convulsions/NNS
D019331_D012640 NONE NAME/NNP (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) decreased/VBD (l_npadvmod) incidence/NN (l_compound) convulsion/NN -PUNC- NAME/NNP (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) decreased/VBD (l_npadvmod) incidence/NN (l_conj) time/NN (l_prep) to/IN (l_pobj) convulsion/NN -PUNC- NAME/NNP (r_pobj) with/IN (r_prep) pretreatment/NN (r_nsubj) decreased/VBD (l_prep) following/VBG (l_pobj) injection/NN (l_prep) with/IN (l_pobj) dose/NN (l_amod) convulsive/JJ
D009569_D012640 NONE oxide/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) convulsions/NNS -PUNC- NO/DT (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) seizures/NNS
8603459
D004317_D066126 CID Doxorubicin/NNP (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
D064730_D066126 NONE ICRF-187/NNP (r_pobj) by/IN (r_agent) provided/VBN (r_acl) protection/NN (r_pobj) by/IN (r_agent) demonstrated/VBN (l_nsubj) testing/NN (l_prep) of/IN (l_pobj) protectors/NNS (l_prep) against/IN (l_pobj) cardiotoxicity/NN
D004317_D006984 NONE doxorubicin/RB (r_npadvmod) treated/VBN (r_amod) animals/NNS (r_pobj) of/IN (r_prep) hearts/NNS (r_dobj) sacrifice/NN (r_pcomp) After/IN (r_prep) enlarged/VBN (l_conj) were/VBD (l_acomp) hypertrophic/JJ
D004317_D064420 NONE doxorubicin/NN (r_punct) toxicity/NN (r_pobj) with/IN (r_prep) schedule/NN (r_dobj) using/VBG (r_xcomp) determined/VBN (l_advcl) exerted/VBD (l_dobj) toxicity/NN -PUNC- doxorubicin/NN (r_punct) toxicity/NN
D064730_D064420 NONE ICRF-187/NNP (r_pobj) of/IN (r_prep) protection/NN (r_nsubjpass) determined/VBN (l_advcl) exerted/VBD (l_dobj) toxicity/NN -PUNC- ICRF-187/NNP (r_pobj) of/IN (r_prep) protection/NN (r_nsubjpass) determined/VBN (l_xcomp) using/VBG (l_dobj) schedule/NN (l_prep) with/IN (l_pobj) toxicity/NN
2453942
D001556_D020258 NONE Lindane/NN (r_nsubj) is/VBZ (l_attr) insecticide/NN (l_prep) with/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ -PUNC- hexachlorocyclohexane/NN (r_appos) Lindane/NN (r_nsubj) is/VBZ (l_attr) insecticide/NN (l_prep) with/IN (l_pobj) effects/NNS (l_amod) neurotoxic/JJ
D001556_D012640 CID lindane/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) studied/VBD (l_prep) by/IN (l_pcomp) measuring/VBG (l_prep) at/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- lindane/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) min/NN (r_pobj) at/IN (r_prep) suffered/VBD (l_dobj) convulsions/NNS
D004298_D012640 NONE dopamine/NN (r_conj) GABA/NNP (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) measuring/VBG (l_prep) at/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS
D005680_D012640 NONE GABA/NNP (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) measuring/VBG (l_prep) at/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS
1615846
D015248_D002340 NONE gemfibrozil/NN (r_compound) lovastatin/NN (r_amod) treatment/NN (r_conj) safety/NN (l_relcl) had/VBD (l_dobj) disease/NN
D003401_D012206 NONE creatine/NN (r_compound) phosphokinase/NN (r_pobj) with/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) had/VBD (l_dobj) rhabdomyolysis/NN
D015248_D006951 NONE Gemfibrozil/NNP (r_compound) lovastatin/NN (r_amod) therapy/NN (l_prep) for/IN (l_pobj) hyperlipoproteinemias/NNS
D008148_D006949 NONE lovastatin/NN (r_amod) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hyperlipidemia/NN
D008148_D006951 NONE lovastatin/NN (r_amod) therapy/NN (l_prep) for/IN (l_pobj) hyperlipoproteinemias/NNS
D015248_D006949 NONE gemfibrozil/NN (r_compound) lovastatin/NN (r_amod) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hyperlipidemia/NN
D003401_D009212 NONE creatine/NN (r_compound) phosphokinase/NN (r_pobj) with/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) had/VBD (l_dobj) rhabdomyolysis/NN (l_conj) myoglobinuria/NNS
D008148_D002340 NONE lovastatin/NN (r_amod) treatment/NN (r_conj) safety/NN (l_relcl) had/VBD (l_dobj) disease/NN
D003401_D009220 NONE creatine/NN (r_compound) phosphokinase/NN (r_pobj) with/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) had/VBD (r_conj) occurred/VBD (l_nsubj) Myositis/NNP
24927617
C486464_D012206 CID telaprevir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_appos) Rhabdomyolysis/NNP
C486464_D006526 NONE telaprevir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (l_amod) infected/VBN -PUNC- telaprevir/NNS (r_conj) interferon/NN (r_dobj) pegylated/VBN (r_conj) received/VBD (l_nsubj) man/NN (l_prep) with/IN (l_pobj) infection/NN
D019821_D006526 NONE simvastatin/NN (r_conj) treated/VBN (r_acl) patient/NN (l_amod) infected/VBN
D019821_D009135 CID Simvastatin/NNP (r_compound) plasma/NN (r_compound) concentration/NN (r_nsubj) increased/VBD (l_advcl) induced/VBD (l_ccomp) related/VBN (l_nsubjpass) toxicity/NN -PUNC- statin/NN (r_conj) patient/NN (r_pobj) in/IN (r_prep) increased/VBD (l_advcl) induced/VBD (l_ccomp) related/VBN (l_nsubjpass) toxicity/NN -PUNC- statin/NN (r_pobj) of/IN (r_prep) concentration/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) toxicity/NN
C417083_D006526 NONE interferon/NN (r_dobj) pegylated/VBN (r_conj) received/VBD (l_nsubj) man/NN (l_prep) with/IN (l_pobj) infection/NN
D019821_D064420 NONE simvastatin/NN (l_conj) discontinued/VBN (l_advcl) suspected/VBN (l_nsubjpass) toxicity/NN
D012254_D006526 NONE ribavirin/RB (r_pobj) with/IN (r_prep) received/VBD (l_nsubj) man/NN (l_prep) with/IN (l_pobj) infection/NN
D019821_D012206 CID simvastatin/NN (r_conj) treated/VBN (r_acl) patient/NN (r_appos) Rhabdomyolysis/NNP
17384765
D004113_D003072 CID Succimer/NNP (r_compound) chelation/NN (r_nsubj) improves/VBZ (l_conj) produces/VBZ (l_dobj) impairment/NN -PUNC- succimer/JJ (r_amod) treatment/NN (r_nsubj) produced/VBD (l_dobj) dysfunction/NN
D007854_D007855 NONE Pb/NNP (r_compound) exposure/NN (l_appos) agent/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) poisoning/NN
D007854_D003072 NONE lead/NN (r_npadvmod) exposed/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) regulation/NN (r_conj) attention/NN (r_conj) learning/VBG (r_xcomp) improves/VBZ (l_conj) produces/VBZ (l_dobj) impairment/NN -PUNC- lead/JJ (r_amod) exposure/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) in/IN (r_prep) produces/VBZ (l_dobj) impairment/NN -PUNC- Pb/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) treatment/NN (r_nsubj) produced/VBD (l_dobj) dysfunction/NN -PUNC- Pb/NNP (r_compound) regimen/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) that/DT (r_pobj) to/IN (r_prep) magnitude/NN (r_pobj) in/IN (r_prep) comparable/JJ (r_amod) dysfunction/NN -PUNC- Pb/NNP (r_compound) exposure/NN (r_pobj) due/IN (r_prep) alleviate/VB (l_dobj) deficits/NNS
D007854_D019964 NONE Pb/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) treatment/NN (r_nsubj) produced/VBD (l_dobj) dysfunction/NN -PUNC- Pb/NNP (r_compound) regimen/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) that/DT (r_pobj) to/IN (r_prep) magnitude/NN (r_pobj) in/IN (r_prep) comparable/JJ (r_amod) dysfunction/NN
D004113_D019964 NONE succimer/JJ (r_amod) treatment/NN (r_nsubj) produced/VBD (l_dobj) dysfunction/NN
D004113_D007855 NONE succimer/NN (r_pobj) with/IN (r_prep) exposure/NN (l_appos) agent/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) poisoning/NN
D007854_D007859 CID Pb/NNP (r_amod) exposure/NN (r_nsubj) produced/VBD (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) attention/NN (l_conj) control/NN (l_conj) regulation/NN -PUNC- Pb/NNP (r_npadvmod) exposed/VBN (r_amod) children/NNS (r_pobj) in/IN (r_prep) seen/VBN (r_acl) dysfunction/NN (r_pobj) of/IN (r_prep) areas/NNS (r_dobj) paralleling/VBG (r_advcl) produced/VBD (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) attention/NN (l_conj) control/NN (l_conj) regulation/NN
D007854_D019958 CID Pb/NNP (r_amod) exposure/NN (r_nsubj) produced/VBD (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) attention/NN (l_conj) control/NN (l_conj) regulation/NN -PUNC- Pb/NNP (r_npadvmod) exposed/VBN (r_amod) children/NNS (r_pobj) in/IN (r_prep) seen/VBN (r_acl) dysfunction/NN (r_pobj) of/IN (r_prep) areas/NNS (r_dobj) paralleling/VBG (r_advcl) produced/VBD (l_dobj) impairments/NNS (l_prep) in/IN (l_pobj) learning/NN (l_conj) attention/NN (l_conj) control/NN (l_conj) regulation/NN
17445520
D002110_D003866 NONE Caffeine/NN (r_amod) test/NN (l_prep) in/IN (l_pobj) disorder/NN (l_conj) depression/NN
D002110_D001008 NONE caffeine/NN (r_nsubjpass) administered/VBN (l_prep) in/IN (l_pobj) scales/NNS (l_nmod) form/NN (l_conj) anxiety/NN -PUNC- caffeine/NN (r_npadvmod) free/JJ (r_amod) solution/NN (r_conj) caffeine/NN (r_nsubjpass) administered/VBN (l_prep) in/IN (l_pobj) scales/NNS (l_nmod) form/NN (l_conj) anxiety/NN
D002110_D003865 NONE caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) depression/NN -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) depression/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_appos) MDP/NNP -PUNC- caffeine/NN (r_compound) test/NN (r_pobj) after/IN (r_prep) had/VBD (l_nsubj) total/NN (l_prep) of/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MDP/NNP -PUNC- caffeine/NN (r_compound) test/NN (r_pobj) after/IN (r_prep) had/VBD (l_nsubj) total/NN (l_prep) of/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MD/NNP -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) were/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) PD/NNP (l_conj) MDP/NNP -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) sensitive/JJ (l_advcl) were/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) MD/NNP -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) to/IN (r_prep) hyperreactivity/NN (r_conj) is/VBZ (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) PD/NNP (l_conj) MDP/NNP
D002110_D016584 CID Caffeine/NN (r_amod) test/NN (l_prep) in/IN (l_pobj) disorder/NN -PUNC- Caffeine/NN (r_amod) test/NN (l_prep) in/IN (l_pobj) disorder/NN (l_conj) depression/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_appos) PD/NNP -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) depression/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) depression/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_appos) MDP/NNP -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS -PUNC- caffeine/NN (r_compound) test/NN (r_pobj) after/IN (r_prep) had/VBD (l_nsubj) total/NN (l_prep) of/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) PD/NNP -PUNC- caffeine/NN (r_compound) test/NN (r_pobj) after/IN (r_prep) had/VBD (l_nsubj) total/NN (l_prep) of/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MDP/NNP -PUNC- caffeine/NN (r_compound) test/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) attack/NN -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) were/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) PD/NNP -PUNC- caffeine/NN (r_pobj) to/IN (r_prep) sensitive/JJ (r_acomp) were/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) PD/NNP (l_conj) MDP/NNP -PUNC- caffeine/NN (r_npadvmod) free/JJ (r_amod) intake/NN (r_pobj) after/IN (r_prep) observed/VBN (l_nsubjpass) attack/NN -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) to/IN (r_prep) hyperreactivity/NN (r_conj) is/VBZ (l_attr) association/NN (l_prep) between/IN (l_pobj) attacks/NNS -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) to/IN (r_prep) hyperreactivity/NN (r_conj) is/VBZ (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) PD/NNP -PUNC- caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) to/IN (r_prep) hyperreactivity/NN (r_conj) is/VBZ (l_advcl) associated/VBN (l_prep) with/IN (l_pobj) PD/NNP (l_conj) MDP/NNP
D002110_D001523 NONE caffeine/NN (r_compound) challenge/NN (r_compound) test/NN (r_pobj) by/IN (r_prep) attacks/NNS (r_pobj) of/IN (r_prep) induction/NN (r_pobj) to/IN (r_prep) way/NN (r_pobj) in/IN (r_prep) respond/VBP (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_conj) patients/NNS (l_prep) with/IN (l_pobj) depression/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_appos) Diagnostic/NNP (l_conj) Manual/NNP (l_prep) of/IN (l_pobj) Disorders/NNP
1735570
D014294_D013610 CID trimethaphan/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubjpass) accompanied/VBN (l_agent) by/IN (l_pobj) bradycardia/NN (l_prep) in/IN (l_pobj) rats/NNS (l_appos) beats/NNS (l_conj) tachycardia/NN
D014294_D007022 CID trimethaphan/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN
D014294_D001919 NONE trimethaphan/RB (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_nsubjpass) accompanied/VBN (l_agent) by/IN (l_pobj) bradycardia/NN
12644816
D013792_D019337 NONE thalidomide/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) assessed/VBN (l_prep) in/IN (l_pobj) trials/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) malignancies/NNS
D013792_D010523 CID thalidomide/NN (r_pobj) on/IN (r_prep) completed/VBD (r_relcl) men/NNS (r_pobj) In/IN (r_prep) found/VBN (l_nsubjpass) evidence/NN (l_prep) of/IN (l_pobj) neuropathy/NN -PUNC- thalidomide/NN (r_nsubj) be/VB (r_ccomp) indicate/VBP (l_ccomp) provided/VBD (l_dobj) maintained/VBN (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) neuropathy/NN
D000728_D011471 NONE androgen/JJ (r_npadvmod) independent/JJ (r_amod) cancer/NN -PUNC- androgen/JJ (r_npadvmod) independent/JJ (r_amod) cancer/NN
D013792_D011471 NONE thalidomide/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- thalidomide/NN (r_dobj) using/VBG (l_prep) for/IN (l_pobj) months/NNS (l_prep) in/IN (l_pobj) men/NNS (l_prep) with/IN (l_pobj) cancer/NN
24618873
D008614_D005128 NONE pethidine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) dysfunction/NN
D008614_D051437 NONE pethidine/NN (r_nsubj) cause/VB (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) function/NN
C002752_D020258 NONE norpethidine/NN (r_appos) metabolite/NN (l_amod) neurotoxic/JJ
C002752_D012640 CID norpethidine/NN (r_appos) metabolite/NN (r_pobj) through/IN (r_prep) effects/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) irritability/NN (l_conj) attack/NN (l_compound) seizure/NN
C002752_D017093 NONE norpethidine/NN (r_appos) metabolite/NN (r_pobj) through/IN (r_prep) effects/NNS (r_dobj) cause/VB (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) function/NN
D008614_D010146 NONE Pethidine/NNP (r_nsubj) is/VBZ (l_attr) opioid/NN (l_relcl) gains/VBZ (l_prep) for/IN (l_pobj) control/NN (l_compound) pain/NN -PUNC- pethidine/NN (r_nsubj) cause/VB (l_prep) In/IN (l_conj) those/DT (l_relcl) need/VBP (l_dobj) control/NN (l_compound) pain/NN
D008614_D020258 NONE pethidine/NN (r_nsubj) cause/VB (l_dobj) effects/NNS (l_prep) through/IN (l_pobj) metabolite/NN (l_amod) neurotoxic/JJ
C002752_D010146 NONE norpethidine/NN (r_appos) metabolite/NN (r_pobj) through/IN (r_prep) effects/NNS (r_dobj) cause/VB (l_prep) In/IN (l_conj) those/DT (l_relcl) need/VBP (l_dobj) control/NN (l_compound) pain/NN
C002752_D051437 NONE norpethidine/NN (r_appos) metabolite/NN (r_pobj) through/IN (r_prep) effects/NNS (r_dobj) cause/VB (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) function/NN
D008614_D012640 NONE pethidine/NN (r_nsubj) cause/VB (l_dobj) effects/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) irritability/NN (l_conj) attack/NN (l_compound) seizure/NN
D008614_D017093 NONE pethidine/NN (r_nsubj) cause/VB (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) function/NN
C002752_D001523 NONE norpethidine/NN (r_appos) metabolite/NN (r_pobj) through/IN (r_prep) effects/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) irritability/NN
D008614_D002526 NONE pethidine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) dysfunction/NN
D008614_D001523 NONE pethidine/NN (r_nsubj) cause/VB (l_dobj) effects/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) irritability/NN
9061777
D016291_D001930 NONE MK-801/NNP (r_punct) augments/VBZ (l_conj) protects/VBZ (l_prep) against/IN (l_pobj) damage/NN -PUNC- MK-801/NNP (r_punct) protected/VBD (l_dobj) damage/NN -PUNC- MK-801-treated/JJ (r_amod) group/NN (r_pobj) in/IN (r_prep) appeared/VBD (l_nsubj) Pentobarbital/JJ (l_appos) scopolamine/NN (l_conj) protected/VBD (l_dobj) damage/NN
D012601_D001930 NONE scopolamine/NN (l_conj) protected/VBD (l_dobj) damage/NN
D016291_D012640 CID MK-801/NNP (r_punct) augments/VBZ (l_dobj) seizure/NN -PUNC- MK-801/NNP (r_punct) on/IN (l_pobj) model/NN (l_compound) seizure/NN -PUNC- MK-801/NNP (r_punct) 0.5/CD (r_nummod) mg/kg/NN (r_conj) prevented/VBN (l_dobj) development/NN (l_prep) of/IN (l_pobj) seizure/NN -PUNC- MK-801/NNP (r_punct) treatment/NN (r_nsubj) augmented/VBD (r_conj) blocked/VBD (l_dobj) seizure/NN -PUNC- MK-801/NNP (r_punct) treatment/NN (r_nsubj) augmented/VBD (l_dobj) seizure/NN
D016202_D013226 NONE NMDA/NNP (r_compound) mechanism/NN (r_pobj) through/IN (r_prep) damage/NN (r_dobj) cause/VB (l_ccomp) indicate/VBP (l_ccomp) initiated/VBN (l_nsubjpass) status/NN (l_acl) induced/VBN (l_advmod) epilepticus/NN
D010424_D012640 NONE pentobarbital/NN (r_conj) Scopolamine/NNP (r_nsubj) prevented/VBN (l_dobj) development/NN (l_prep) of/IN (l_pobj) seizure/NN -PUNC- pentobarbital/NN (r_conj) Scopolamine/NNP (r_nsubj) blocked/VBD (l_dobj) seizure/NN -PUNC- pentobarbital/NN (r_conj) Scopolamine/NNP (r_nsubj) blocked/VBD (l_conj) augmented/VBD (l_dobj) seizure/NN
D016202_D001930 NONE NMDA/NNP (r_compound) mechanism/NN (r_pobj) through/IN (r_prep) damage/NN
D010424_D001930 NONE Pentobarbital/JJ (l_appos) scopolamine/NN (l_conj) protected/VBD (l_dobj) damage/NN
D012601_D012640 NONE Scopolamine/NNP (r_nsubj) prevented/VBN (l_dobj) development/NN (l_prep) of/IN (l_pobj) seizure/NN -PUNC- Scopolamine/NNP (r_nsubj) blocked/VBD (l_dobj) seizure/NN -PUNC- Scopolamine/NNP (r_nsubj) blocked/VBD (l_conj) augmented/VBD (l_dobj) seizure/NN
D010862_D001930 NONE pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN (r_dobj) augments/VBZ (l_conj) protects/VBZ (l_prep) against/IN (l_pobj) damage/NN -PUNC- pilocarpine/NN (r_pobj) by/IN (r_prep) damage/NN -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) status/NN (r_nsubjpass) initiated/VBN (r_ccomp) indicate/VBP (r_ccomp) cause/VB (l_dobj) damage/NN
D010862_D009410 CID Pilocarpine/NNP (r_nsubj) produced/VBD (l_dobj) death/NN
D010862_D013226 CID pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advmod) epilepticus/NN
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) seizure/NN -PUNC- pilocarpine/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) induced/VBN (l_dobj) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) treated/VBN (r_amod) group/NN (r_pobj) in/IN (r_prep) appeared/VBD (l_nsubj) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizure/NN (r_dobj) blocked/VBD (l_conj) augmented/VBD (l_dobj) seizure/NN -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizure/NN (r_dobj) augmented/VBD (r_conj) blocked/VBD (l_dobj) seizure/NN -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizure/NN
8996419
C033273_D054556 NONE gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- gestodene/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP
D011372_D054556 NONE progestagen/NN (r_nmod) OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_attr) were/VBD (r_relcl) VTE/NNP
D003276_D013927 NONE OCs/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) cases/NNS (r_pobj) Of/IN (r_prep) recorded/VBN (l_prep) as/IN (l_pobj) thrombosis/NN (l_appos) 35/CD (l_prep) as/IN (l_pobj) thrombosis/NN
D003276_D054556 CID contraceptives/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) thromboembolism/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) in/IN (r_prep) higher/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) in/IN (r_prep) higher/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OCs/NNP (r_appos) contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) in/IN (r_prep) higher/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- OCs/NNP (r_appos) contraceptives/NNS (r_dobj) used/VBD (r_relcl) women/NNS (r_pobj) in/IN (r_prep) higher/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- OC/NNP (r_conj) VTE/NNP -PUNC- OC/NNP (r_compound) preparations/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) compare/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OC/NNP (r_compound) preparations/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) compare/VB (r_conj) estimate/VB (r_relcl) analysis/NN (r_dobj) did/VBD (l_conj) study/NN (l_acl) calculate/VB (l_dobj) ratios/NNS (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OC/NNP (r_pobj) of/IN (r_prep) types/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) ratios/NNS (r_dobj) calculate/VB (r_acl) study/NN (r_conj) did/VBD (l_dobj) analysis/NN (l_relcl) estimate/VB (l_conj) compare/VB (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OC/NNP (r_pobj) of/IN (r_prep) types/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) ratios/NNS (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_attr) were/VBD (r_relcl) VTE/NNP -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) cases/NNS (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OC/NNP (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) 4.10/CD (r_attr) was/VBD (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) 3.10/CD (r_appos) 4.10/CD (r_attr) was/VBD (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OCs/NNS (r_pobj) to/IN (r_prep) relative/JJ (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) ratio/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) between/IN (r_prep) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- OCs/NNS (r_pobj) With/IN (r_prep) were/VBD (l_nsubj) ratios/NNS (l_prep) for/IN (l_pobj) VTE/NNP
D017135_D054556 NONE desogestrel/NN (r_conj) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- desogestrel/NN (r_conj) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- desogestrel/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- desogestrel/NN (r_conj) gestodene/NN (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- desogestrel/NN (r_pobj) for/IN (r_prep) 3.49/CD (r_attr) were/VBD (l_nsubj) ratios/NNS (l_prep) for/IN (l_pobj) VTE/NNP
D011374_D054556 NONE progestagens/NNS (r_compound) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- progestagens/NNS (r_compound) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- progestagens/NNS (r_dobj) containing/VBG (r_acl) OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN -PUNC- progestagens/NNS (r_dobj) containing/VBG (r_acl) OCs/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) gestodene/NN (r_dobj) containing/VBG (r_advcl) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) thromboembolism/NN (l_appos) VTE/NNP -PUNC- progestagens/NNS (r_pobj) of/IN (r_prep) users/NNS (r_pobj) Among/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- progestagens/NNS (r_pobj) for/IN (r_prep) were/VBD (l_nsubj) ratios/NNS (l_prep) for/IN (l_pobj) VTE/NNP
D004997_D054556 NONE ethinyloestradiol/NN (r_pobj) with/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- ethinyloestradiol/NN (r_pobj) with/IN (r_prep) users/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) VTE/NNP -PUNC- ethinyloestradiol/NN (r_appos) desogestrel/NN (r_pobj) for/IN (r_prep) 3.49/CD (r_attr) were/VBD (l_nsubj) ratios/NNS (l_prep) for/IN (l_pobj) VTE/NNP
D003276_D020246 NONE OCs/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) cases/NNS (r_pobj) Of/IN (r_prep) recorded/VBN (l_prep) as/IN (l_pobj) thrombosis/NN -PUNC- OCs/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) cases/NNS (r_pobj) Of/IN (r_prep) recorded/VBN (l_conj) five/CD (l_prep) as/IN (l_pobj) thrombosis/NN
9197951
D004053_D011681 NONE DEP/NNP (l_appos) changes/NNS (l_prep) in/IN (l_pobj) power/NN (l_prep) of/IN (l_pobj) oscillation/NN
D004053_D001714 CID diethylpropion/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) evaluating/VBG (r_acl) study/NN (r_pobj) in/IN (r_prep) subject/NN (r_attr) was/VBD (r_relcl) man/NN (r_nsubj) became/VBD (l_acomp) manic/JJ -PUNC- DEP/NNP (r_appos) diethylpropion/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) evaluating/VBG (r_acl) study/NN (r_pobj) in/IN (r_prep) subject/NN (r_attr) was/VBD (r_relcl) man/NN (r_nsubj) became/VBD (l_acomp) manic/JJ -PUNC- DEP/NNP (r_pobj) on/IN (r_prep) changes/NNS (r_nsubj) were/VBD (l_acomp) different/JJ (l_prep) than/IN (l_pobj) those/DT (l_acl) observed/VBN (l_prep) in/IN (l_pobj) subjects/NNS (l_relcl) become/VB (l_acomp) manic/JJ
D003042_D001714 NONE cocaine/NN (r_npadvmod) dependent/JJ (r_amod) man/NN (r_nsubj) became/VBD (l_acomp) manic/JJ
24055495
D005690_D008569 NONE galactose/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) induce/VBP (l_dobj) deterioration/NN -PUNC- galactose/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) tested/VBN (r_conj) induce/VBP (l_dobj) deterioration/NN
D013311_D003072 CID streptozotocin/NNS (r_pobj) with/IN (r_prep) treated/VBD (r_acl) deficits/NNS -PUNC- streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) model/NN (r_pobj) in/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) deficits/NNS -PUNC- STZ/NNP (r_nmod) icv/NN (r_nmod) model/NN (r_pobj) in/IN (r_prep) treatment/NN (l_prep) on/IN (l_pobj) deficits/NNS -PUNC- STZ/NNP (r_compound) icv/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) initiated/VBD (l_conj) prevented/VBN (l_dobj) development/NN (l_prep) of/IN (l_pobj) deficits/NNS -PUNC- STZ/NNP (r_compound) icv/NN (r_npadvmod) induced/VBN (r_amod) deficits/NNS
D005947_D003704 NONE glucose/NN (r_compound) transport/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) dementia/NN -PUNC- glucose/NN (r_compound) GLUT4/NNPS (r_pobj) via/IN (r_prep) transport/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) dementia/NN -PUNC- glucose/NN (r_compound) metabolism/NN (r_conj) transport/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) dementia/NN
D005947_D000544 CID glucose/NN (r_compound) transport/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) dementia/NN (l_prep) of/IN (l_pobj) type/NN (l_nmod) disease/NN -PUNC- glucose/NN (r_compound) GLUT4/NNPS (r_pobj) via/IN (r_prep) transport/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) dementia/NN (l_prep) of/IN (l_pobj) type/NN (l_nmod) disease/NN -PUNC- glucose/NN (r_compound) metabolism/NN (r_conj) transport/NN (r_pobj) by/IN (r_agent) followed/VBN (r_acl) dysfunction/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) dementia/NN (l_prep) of/IN (l_pobj) type/NN (l_nmod) disease/NN
D005690_D018149 NONE galactose/NN (r_compound) exposure/NN (r_nsubj) have/VB (l_conj) be/VB (l_acomp) worth/JJ (l_xcomp) investigating/VBG (l_prep) for/IN (l_pobj) improvement/NN (l_prep) of/IN (l_pobj) deficits/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hypometabolism/NN
D005690_D000544 NONE galactose/NN (r_compound) exposure/NN (r_nsubj) have/VB (l_conj) be/VB (l_acomp) worth/JJ (l_xcomp) investigating/VBG (l_prep) for/IN (l_pobj) improvement/NN (l_prep) of/IN (l_pobj) deficits/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) hypometabolism/NN (l_prep) in/IN (l_pobj) AD/NN
D005690_D003072 CID galactose/NN (r_compound) treatment/NN (r_nsubj) prevents/VBZ (l_dobj) deficits/NNS -PUNC- galactose/NN (l_appos) treatment/NN (l_prep) on/IN (l_pobj) deficits/NNS -PUNC- galactose/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) month/NN (r_nsubj) initiated/VBD (l_conj) prevented/VBN (l_dobj) development/NN (l_prep) of/IN (l_pobj) deficits/NNS -PUNC- galactose/NN (r_compound) exposure/NN (r_nsubj) have/VB (l_conj) be/VB (l_acomp) worth/JJ (l_xcomp) investigating/VBG (l_prep) for/IN (l_pobj) improvement/NN (l_prep) of/IN (l_pobj) deficits/NNS
2131034
D003561_D020258 CID arabinoside/NN (r_conj) methotrexate/NNP (r_pobj) with/IN (r_prep) described/VBN (l_nsubjpass) toxicities/NNS -PUNC- C/NN (r_conj) MTX/NNP (r_pobj) with/IN (r_prep) combination/NN (r_nsubj) cause/VB (l_dobj) neurotoxicity/NN
D008727_D020258 CID methotrexate/NNP (r_pobj) with/IN (r_prep) described/VBN (l_nsubjpass) toxicities/NNS -PUNC- MTX/NNP (r_pobj) with/IN (r_prep) combination/NN (r_nsubj) cause/VB (l_dobj) neurotoxicity/NN
D013852_D011115 CID thiotepa/NNS (r_compound) combination/NN (r_compound) chemotherapy/NN (r_pobj) after/IN (r_prep) polyneuropathy/NN
D013852_D020258 CID thiotepa/NNS (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) toxicity/NN -PUNC- TSPA/NNS (r_appos) thiotepa/NNS (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) toxicity/NN -PUNC- TSPA/NNP (r_conj) arabinoside/NN (r_conj) methotrexate/NNP (r_pobj) with/IN (r_prep) described/VBN (l_nsubjpass) toxicities/NNS -PUNC- TSPA/NNP (r_nsubj) is/VBZ (r_acl) fact/NN (r_pobj) of/IN (r_prep) spite/NN (r_pobj) In/IN (r_prep) cause/VB (l_dobj) neurotoxicity/NN
15482540
D012254_D000740 NONE ribavirin/RB (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- ribavirin/RB (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- Ribavirin/RB (r_npadvmod) induced/VBN (r_amod) anemia/NN
D016898_D019698 NONE Interferon/NNP (r_nmod) therapy/NN (l_prep) for/IN (l_pobj) C/NNP -PUNC- alpha-2b/NN (r_dobj) received/VBD (r_relcl) C/NNP
D012254_D019698 NONE ribavirin/RB (r_conj) Interferon/NNP (r_nmod) therapy/NN (l_prep) for/IN (l_pobj) C/NNP -PUNC- ribavirin/RB (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) administered/VBN (r_acl) dose/NN (r_pobj) at/IN (r_prep) received/VBD (r_relcl) C/NNP
D016898_D000743 CID Interferon/NNP (r_nmod) therapy/NN (r_nsubj) produces/VBZ (l_dobj) anemia/NN
D012254_D000743 CID ribavirin/RB (r_conj) Interferon/NNP (r_nmod) therapy/NN (r_nsubj) produces/VBZ (l_dobj) anemia/NN
11936424
D011692_D005921 NONE aminonucleoside/NN (r_nmod) PAN/NNP (r_npadvmod) prevented/VBN (l_dobj) glomerulosclerosis/NN -PUNC- PAN/NNP (r_npadvmod) prevented/VBN (l_dobj) glomerulosclerosis/NN -PUNC- PAN/NNP (r_compound) group/NN (r_pobj) in/IN (r_prep) weeks/NNS (r_pobj) at/IN (r_prep) was/VBD (l_nsubj) index/NN (l_compound) glomerulosclerosis/NN
D011692_D006984 NONE aminonucleoside/NN (r_nmod) PAN/NNP (r_npadvmod) prevented/VBN (r_conj) inhibited/VBD (l_dobj) hypertrophy/NN -PUNC- PAN/NNP (r_npadvmod) prevented/VBN (r_conj) inhibited/VBD (l_dobj) hypertrophy/NN
C055603_D007674 NONE Temocapril/NNP (r_nsubj) modulates/VBZ (l_dobj) injury/NN
D011692_D011507 CID aminonucleoside/NN (r_nmod) PAN/NNP (r_npadvmod) prevented/VBN (r_conj) inhibited/VBD (l_nsubj) administration/NN (l_appos) angiotensin/NN (l_acl) reduced/VBN (l_dobj) proteinuria/NN -PUNC- PAN/NNP (r_npadvmod) prevented/VBN (r_conj) inhibited/VBD (l_nsubj) administration/NN (l_appos) angiotensin/NN (l_acl) reduced/VBN (l_dobj) proteinuria/NN
C055603_D009404 NONE temocapril/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) inhibited/VBD (r_ccomp) determine/VB (r_xcomp) was/VBD (l_conj) induced/VBN (l_dobj) rats/NNS (l_amod) nephrotic/JJ
D000809_D007674 NONE angiotensin/NN (r_appos) Temocapril/NNP (r_nsubj) modulates/VBZ (l_dobj) injury/NN
D011692_D007674 NONE aminonucleoside/JJ (r_amod) nephrosis/NN (r_pobj) in/IN (r_prep) injury/NN
D011692_D009401 CID aminonucleoside/JJ (r_amod) nephrosis/NN -PUNC- PAN/NNP (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) Nephrosis/NNP -PUNC- PAN/NNP (r_compound) rats/NNS (l_amod) neprotic/JJ
D000809_D006984 NONE angiotensin/NN (r_appos) administration/NN (r_nsubj) inhibited/VBD (l_dobj) hypertrophy/NN
D000809_D005921 NONE angiotensin/NN (r_appos) administration/NN (r_nsubj) inhibited/VBD (l_conj) prevented/VBN (l_dobj) glomerulosclerosis/NN
D000809_D011507 NONE angiotensin/NN (l_acl) reduced/VBN (l_dobj) proteinuria/NN
D000809_D009401 NONE angiotensin/NN (r_appos) Temocapril/NNP (r_nsubj) modulates/VBZ (l_dobj) injury/NN (l_prep) in/IN (l_pobj) nephrosis/NN
C055603_D006984 NONE temocapril/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) inhibited/VBD (l_dobj) hypertrophy/NN
C055603_D005921 NONE temocapril/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) inhibited/VBD (l_conj) prevented/VBN (l_dobj) glomerulosclerosis/NN
C055603_D011507 NONE temocapril/NN (r_pobj) of/IN (r_prep) administration/NN (l_appos) angiotensin/NN (l_acl) reduced/VBN (l_dobj) proteinuria/NN -PUNC- Temocapril/NNP (r_nsubj) attenuate/VB (l_dobj) proteinuria/NN
D011692_D009404 NONE aminonucleoside/NN (r_nmod) PAN/NNP (r_npadvmod) prevented/VBN (r_conj) inhibited/VBD (r_ccomp) determine/VB (r_xcomp) was/VBD (l_conj) induced/VBN (l_dobj) rats/NNS (l_amod) nephrotic/JJ -PUNC- PAN/NNP (r_npadvmod) prevented/VBN (r_conj) inhibited/VBD (r_ccomp) determine/VB (r_xcomp) was/VBD (l_conj) induced/VBN (l_dobj) rats/NNS (l_amod) nephrotic/JJ
C055603_D009401 NONE Temocapril/NNP (r_nsubj) modulates/VBZ (l_dobj) injury/NN (l_prep) in/IN (l_pobj) nephrosis/NN -PUNC- temocapril/NN (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) retarding/VBG (l_conj) protected/VBD (l_dobj) function/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) neprotic/JJ
D000809_D009404 NONE angiotensin/NN (r_appos) administration/NN (r_nsubj) inhibited/VBD (r_ccomp) determine/VB (r_xcomp) was/VBD (l_conj) induced/VBN (l_dobj) rats/NNS (l_amod) nephrotic/JJ
24100257
C089750_D054549 CID Zolmitriptan/NNP (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) syndrome/NN (r_conj) syndrome/NN -PUNC- Zolmitriptan/NNP (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) syndrome/NN -PUNC- zolmitriptan/NN (r_advcl) vasospasm/NN (r_pobj) of/IN (r_prep) cases/NNS (r_dobj) revealed/VBD (l_conj) associated/VBN (l_prep) with/IN (l_pobj) TS/NNP
C089750_D003329 CID zolmitriptan/NN (r_advcl) vasospasm/NN
C089750_D008881 NONE zolmitriptan/NN (r_dobj) took/VBD (l_advcl) had/VBD (l_dobj) migraines/NNS -PUNC- zolmitriptan/JJ (r_dobj) taking/VBG (l_prep) because/IN (l_pobj) headache/NN
8667442
D009853_D051437 NONE omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (r_ccomp) remains/VBZ (l_nsubj) triad/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN (l_conj) alkalosis/NN (l_conj) impairment/NN
D009853_D014456 NONE omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (l_compound) ulcer/NN
C019248_D006934 NONE pamidronate/NN (l_advcl) presents/VBZ (l_nsubj) syndrome/NN -PUNC- pamidronate/NN (l_advcl) presents/VBZ (l_prep) as/IN (l_pobj) emergency/NN
D002118_D006934 CID calcium/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) context/NN (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) syndrome/NN
D013392_D014456 NONE sucralfate/JJ (r_conj) omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (l_compound) ulcer/NN
D002118_D010437 NONE calcium/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) with/IN (r_prep) treatment/NN (l_prep) of/IN (l_pobj) disease/NN
D000468_D010437 NONE alkali/NN (r_conj) calcium/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) with/IN (r_prep) treatment/NN (l_prep) of/IN (l_pobj) disease/NN
D000468_D006934 CID alkali/NN (r_conj) calcium/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) context/NN (r_pobj) in/IN (r_prep) described/VBN (l_nsubjpass) syndrome/NN
D009853_D000471 NONE omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (r_ccomp) remains/VBZ (l_nsubj) triad/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN (l_conj) alkalosis/NN
D013392_D000471 NONE sucralfate/JJ (r_conj) omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (r_ccomp) remains/VBZ (l_nsubj) triad/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN (l_conj) alkalosis/NN
D013392_D051437 NONE sucralfate/JJ (r_conj) omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (r_ccomp) remains/VBZ (l_nsubj) triad/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN (l_conj) alkalosis/NN (l_conj) impairment/NN
D002117_D007011 NONE 1,25(OH)2D/CD (r_pobj) by/IN (r_agent) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) hypoparathyroidism/NN -PUNC- calcitriol/NN (r_conj) carbonate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) hypoparathyroidism/NN
D009853_D006934 NONE omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (r_ccomp) remains/VBZ (l_nsubj) triad/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN
D002119_D007011 NONE carbonate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) hypoparathyroidism/NN
D002119_D006934 CID carbonate/NN (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) admissions/NNS (l_prep) for/IN (l_pobj) syndrome/NN
D013392_D006934 NONE sucralfate/JJ (r_conj) omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- sucralfate/JJ (r_conj) omeprazole/NN (r_conj) blockers/NNS (r_conj) therapy/NN (r_pobj) with/IN (r_advcl) decreased/VBN (r_ccomp) remains/VBZ (l_nsubj) triad/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN
D002117_D006934 CID 1,25(OH)2D/CD (r_pobj) by/IN (r_agent) induced/VBN (r_acl) syndrome/NN -PUNC- calcitriol/NN (r_conj) carbonate/NN (r_pobj) with/IN (r_prep) treated/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) admissions/NNS (l_prep) for/IN (l_pobj) syndrome/NN
25119790
C030272_D007674 CID maleate/NN (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- maleate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) injury/NN -PUNC- Maleate/NNP (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- Maleate/NNP (r_npadvmod) induced/VBN (r_amod) injury/NN (r_nsubj) included/VBD (l_conj) determined/VBN (l_nsubjpass) upregulation/NN (l_prep) of/IN (l_pobj) molecule/NN (l_compound) injury/NN -PUNC- maleate/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D005947_D009336 NONE glucose/NN (r_conj) protein/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) in/IN (r_conj) increase/NN (r_dobj) included/VBD (l_conj) determined/VBN (l_nsubjpass) upregulation/NN (l_parataxis) decrease/NN (l_prep) besides/IN (l_prep) of/IN (l_pobj) necrosis/NN
D012964_D007674 NONE sodium/NN (r_conj) glucose/NN (r_conj) protein/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) in/IN (r_conj) increase/NN (r_dobj) included/VBD (l_nsubj) injury/NN -PUNC- sodium/NN (r_conj) glucose/NN (r_conj) protein/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) in/IN (r_conj) increase/NN (r_dobj) included/VBD (l_conj) determined/VBN (l_nsubjpass) upregulation/NN (l_prep) of/IN (l_pobj) molecule/NN (l_compound) injury/NN
D010100_D007674 NONE oxygen/NN (r_compound) consumption/NN (r_conj) stress/NN (r_conj) alterations/NNS (r_pobj) to/IN (r_prep) relation/NN (r_appos) nephrotoxicity/NN
D012964_D009336 NONE sodium/NN (r_conj) glucose/NN (r_conj) protein/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) in/IN (r_conj) increase/NN (r_dobj) included/VBD (l_conj) determined/VBN (l_nsubjpass) upregulation/NN (l_parataxis) decrease/NN (l_prep) besides/IN (l_prep) of/IN (l_pobj) necrosis/NN
D005947_D007674 NONE glucose/NN (r_conj) protein/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) in/IN (r_conj) increase/NN (r_dobj) included/VBD (l_nsubj) injury/NN -PUNC- glucose/NN (r_conj) protein/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) in/IN (r_conj) increase/NN (r_dobj) included/VBD (l_conj) determined/VBN (l_nsubjpass) upregulation/NN (l_prep) of/IN (l_pobj) molecule/NN (l_compound) injury/NN
C030272_D011507 CID maleate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) proteinuria/NN
C030272_D009336 CID Maleate/NNP (r_npadvmod) induced/VBN (r_amod) injury/NN (r_nsubj) included/VBD (l_conj) determined/VBN (l_nsubjpass) upregulation/NN (l_parataxis) decrease/NN (l_prep) besides/IN (l_prep) of/IN (l_pobj) necrosis/NN
D003474_D007674 NONE Curcumin/NN (r_nsubj) prevents/VBZ (l_dobj) nephrotoxicity/NN -PUNC- curcumin/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) against/IN (l_pobj) injury/NN -PUNC- curcumin/NN (r_nsubj) is/VBZ (l_acomp) able/JJ (l_xcomp) attenuate/VB (l_prep) in/IN (l_pobj) nephropathy/NN
4082192
D000082_D007674 NONE acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (r_pobj) in/IN (r_prep) role/NN (l_appos) effect/NN (l_prep) of/IN (l_pobj) phosphate/NN (l_conj) nephrotoxicity/NN -PUNC- acetaminophen/NN (r_pobj) on/IN (r_prep) phosphate/NN (r_pobj) of/IN (r_prep) effect/NN (r_appos) role/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- acetaminophen/NN (r_pobj) on/IN (r_prep) phosphate/NN (l_conj) nephrotoxicity/NN -PUNC- APAP/NNP (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- APAP/NNP (l_conj) nephrotoxicity/NN -PUNC- APAP/NNP (r_pobj) to/IN (r_prep) prior/RB (r_advmod) Pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_appos) nephrotoxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- APAP/NNP (r_pobj) to/IN (r_prep) prior/RB (r_advmod) Pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_appos) nephrotoxicity/NN -PUNC- APAP/NNP (r_pobj) of/IN (r_prep) reduction/NN (l_appos) nephrotoxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- APAP/NNP (r_pobj) of/IN (r_prep) reduction/NN (l_appos) nephrotoxicity/NN -PUNC- APAP/NNP (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- APAP/NNP (r_compound) deacetylation/NN (r_pobj) of/IN (r_prep) inhibition/NN (r_pobj) due/JJ (r_acomp) be/VB (r_xcomp) appears/VBZ (l_nsubj) reduction/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN
D000082_D007683 CID Acetaminophen/NNP (r_nsubj) produces/VBZ (l_dobj) necrosis/NN -PUNC- APAP/NNP (r_appos) Acetaminophen/NNP (r_nsubj) produces/VBZ (l_dobj) necrosis/NN -PUNC- APAP/NNP (r_npadvmod) induced/VBN (r_amod) necrosis/NN
C002887_D007674 NONE phosphate/NN (r_pobj) of/IN (r_prep) effect/NN (r_appos) role/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- phosphate/NN (l_conj) nephrotoxicity/NN -PUNC- phosphate/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) APAP/NNP (l_conj) nephrotoxicity/NN -PUNC- BNPP/NNP (r_appos) phosphate/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) APAP/NNP (l_conj) nephrotoxicity/NN -PUNC- BNPP/NNP (r_pobj) with/IN (r_prep) animals/NNS (r_pobj) of/IN (r_prep) Pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_appos) nephrotoxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- BNPP/NNP (r_pobj) with/IN (r_prep) animals/NNS (r_pobj) of/IN (r_prep) Pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_appos) nephrotoxicity/NN -PUNC- BNPP/NNP (r_npadvmod) induced/VBN (r_amod) reduction/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN
C026729_D007674 NONE aminophenol/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- aminophenol/NN (r_pobj) of/IN (r_prep) role/NN (l_appos) effect/NN (l_prep) of/IN (l_pobj) phosphate/NN (l_conj) nephrotoxicity/NN -PUNC- aminophenol/NN (r_amod) nephrotoxicity/NN (r_conj) phosphate/NN (r_pobj) of/IN (r_prep) effect/NN (r_appos) role/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- aminophenol/NN (r_amod) nephrotoxicity/NN -PUNC- PAP/NNP (r_compound) formation/NN (r_nsubj) is/VBZ (l_attr) step/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- PAP/NNP (r_compound) nephrotoxicity/NN -PUNC- PAP/NNP (r_compound) administration/NN (r_conj) APAP/NNP (r_pobj) to/IN (r_prep) prior/RB (r_advmod) Pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_appos) nephrotoxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- PAP/NNP (r_compound) administration/NN (r_conj) APAP/NNP (r_pobj) to/IN (r_prep) prior/RB (r_advmod) Pretreatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) reduction/NN (l_appos) nephrotoxicity/NN -PUNC- PAP/NNP (r_compound) nephrotoxicity/NN (l_nmod) nephrotoxicity/NN -PUNC- PAP/NNP (r_compound) nephrotoxicity/NN
C026729_D007683 CID PAP/NNP (r_compound) formation/NN (r_nsubj) accounts/NNS (l_prep) for/IN (l_pobj) necrosis/NN
2933998
D017265_D001249 NONE Procaterol/NNP (l_conj) terbutaline/NN (l_prep) in/IN (l_pobj) asthma/NN -PUNC- Procaterol/NNP (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) trial/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) asthma/NN -PUNC- procaterol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) asthmatic/JJ
D017265_D014202 CID procaterol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) asthmatic/JJ (l_conj) tremorgenic/JJ
D013726_D001249 NONE terbutaline/NN (l_prep) in/IN (l_pobj) asthma/NN
11425091
D003042_D006470 NONE cocaine/NN (r_compound) exposure/NN (r_nsubjpass) linked/VBN (l_prep) with/IN (l_pobj) hemorrhage/NN
D003042_D007235 CID cocaine/NN (r_compound) exposure/NN (l_prep) in/IN (l_pobj) infants/NNS -PUNC- cocaine/NN (r_compound) exposure/NN (r_nsubj) increases/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) cysts/NNS (l_prep) in/IN (l_pobj) infants/NNS -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_relcl) infants/NNS
D003042_D019970 NONE cocaine/NN (r_npadvmod) exposed/VBN (r_amod) group/NN (r_pobj) to/IN (r_prep) assigned/VBN (l_advcl) was/VBD (l_attr) history/NN (l_prep) of/IN (l_pobj) abuse/NN
D003042_D003560 CID cocaine/NN (r_compound) exposure/NN (r_nsubjpass) linked/VBN (l_prep) with/IN (l_pobj) hemorrhage/NN (l_conj) formation/NN (l_prep) of/IN (l_pobj) cysts/NNS -PUNC- cocaine/NN (r_compound) exposure/NN (r_nsubj) increases/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) cysts/NNS -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) infants/NNS (r_pobj) in/IN (r_prep) cysts/NNS -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_relcl) infants/NNS (r_pobj) in/IN (r_prep) formation/NN (l_compound) cyst/NN
D003042_D001927 CID cocaine/NN (r_compound) exposure/NN (r_nsubj) increases/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) cysts/NNS -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) infants/NNS (r_pobj) in/IN (r_prep) cysts/NNS -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_relcl) infants/NNS (r_pobj) in/IN (r_prep) formation/NN (l_compound) cyst/NN
24842192
D008687_D009203 NONE metformin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) suppresses/VBZ (l_conj) left/VBN (l_dobj) dysfunction/NN (l_prep) following/VBG (l_pobj) infarction/NN -PUNC- metformin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) has/VBZ (l_dobj) effect/NN (l_prep) in/IN (l_pobj) infarction/NN -PUNC- metformin/NN (r_nmod) activities/NNS (l_acl) following/VBG (l_pobj) infarction/NN -PUNC- metformin/NN (r_nsubj) reduces/VBZ (l_dobj) dysfunction/NN (l_nmod) infarction/NN
D000667_D009203 NONE AMP/NNP (r_npadvmod) activated/VBN (r_amod) kinase/NN (r_pobj) of/IN (r_prep) activation/NN (r_pobj) due/JJ (r_prep) has/VBZ (l_dobj) effect/NN (l_prep) in/IN (l_pobj) infarction/NN
D008687_D006331 NONE metformin/NN (l_prep) on/IN (l_pobj) dysfunction/NN
D008687_D018487 NONE metformin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) suppresses/VBZ (l_conj) left/VBN (l_dobj) dysfunction/NN -PUNC- metformin/NN (r_pobj) of/IN (r_prep) kg/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) groups/NNS (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) dysfunction/NN
D007545_D009369 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) elevation/NN (r_dobj) lowered/VBD (l_advcl) myeloid/NN (l_dobj) protein/NN (l_appos) factor/NN (l_compound) necrosis/NN (l_compound) tumor/NN
D007545_D009336 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) elevation/NN (r_dobj) lowered/VBD (l_advcl) myeloid/NN (l_dobj) protein/NN (l_appos) factor/NN (l_compound) necrosis/NN
D007545_D009203 CID Isoproterenol/NNP (r_nsubjpass) injected/VBN (l_advcl) induce/VB (l_dobj) infarction/NN
3339945
D013806_D020258 NONE Theophylline/NNP (r_amod) neurotoxicity/NN -PUNC- theophylline/NN (r_pobj) of/IN (r_prep) neurotoxicity/NN -PUNC- theophylline/NN (r_pobj) to/IN (r_prep) response/NN (l_amod) neurotoxic/JJ
D000628_D012640 CID aminophylline/NN (r_pobj) of/IN (r_prep) infusions/NNS (r_dobj) received/VBD (l_prep) until/IN (l_pobj) onset/NN (l_prep) of/IN (l_pobj) seizures/NNS
9071336
D002955_D001943 NONE acid/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- acid/NN (r_nsubj) are/VBP (l_attr) therapies/NNS (l_prep) for/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- acid/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN
D005472_D064420 NONE 5-fluorouracil/CD (r_punct) have/VBP (l_dobj) cytotoxicity/NN
D016179_D009503 NONE factor/NN (r_dobj) required/VBN (l_ccomp) reported/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) hospitalization/NN (l_det) neutropenia/NN -PUNC- factor/NN (r_dobj) required/VBN (l_prep) due/JJ (l_pobj) neutropenia/NN
D017239_D064420 NONE Paclitaxel/NNP (r_nsubj) have/VBP (l_dobj) cytotoxicity/NN
D005472_D001943 NONE 5-fluorouracil/CD (r_punct) ,/, (r_punct) Paclitaxel/NNP (l_conj) acid/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- 5-fluorouracil/CD (r_punct) m2/NN (r_pobj) before/IN (r_prep) acid/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN
D017239_D001943 NONE Paclitaxel/NNP (l_conj) acid/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- paclitaxel/NN (r_conj) acid/NN (r_nsubj) are/VBP (l_attr) therapies/NNS (l_prep) for/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- Taxol/NNP (r_nsubj) are/VBP (l_attr) therapies/NNS (l_prep) for/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- paclitaxel/NN (r_pobj) of/IN (r_prep) trial/NN (r_dobj) performed/VBD (l_dobj) phase/NN (l_relcl) followed/VBD (l_agent) by/IN (l_pobj) acid/NN (l_prep) in/IN (l_pobj) women/NNS (l_prep) with/IN (l_pobj) cancer/NN
6316193
D002766_D012640 NONE cholecystokinin/NN (r_pobj) by/IN (r_prep) seizures/NNS -PUNC- cholecystokinin/NN (r_pobj) of/IN (r_prep) analogues/NNS (r_conj) fragments/NNS (r_conj) cholecystokinin/NN (r_pobj) by/IN (r_prep) seizures/NNS
D012844_D012640 NONE octapeptide/JJ (r_compound) ester/NN (r_appos) cholecystokinin/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) enhanced/VBD (l_dobj) latency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- CCK-8-SE/NNP (r_parataxis) administration/NN (r_nsubj) enhanced/VBD (l_dobj) latency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- octapeptide/RB (r_appos) cholecystokinin/NN (r_conj) administration/NN (r_nsubj) enhanced/VBD (l_dobj) latency/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- CCK-8-NS/NNP (r_appos) octapeptide/RB (r_appos) cholecystokinin/NN (r_conj) administration/NN (r_nsubj) enhanced/VBD (l_dobj) latency/NN (l_prep) of/IN (l_pobj) seizures/NNS
D010852_D012640 CID picrotoxin/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- picrotoxin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- picrotoxin/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
D003975_D012640 NONE diazepam/NN (r_preconj) ,/, (r_punct) prevented/VBD (l_dobj) seizures/NNS
2765447
D019793_D004830 CID fluorescein/NN (r_amod) injection/NN (r_dobj) followed/VBD (l_nsubj) seizures/NNS
D019793_D012640 NONE fluorescein/NN (r_amod) angiography/NN (r_dobj) following/VBG (r_prep) Convulsion/NNP
895432
D007545_D007238 NONE isoproterenol/NN (r_pobj) of/IN (r_prep) dosages/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) mortality/NN (r_dobj) reduced/VBD (l_conj) had/VBD (l_prep) on/IN (l_pobj) severity/NN (l_prep) of/IN (l_pobj) infarction/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
1158089
D014280_D005234 NONE triglyceride/NN (r_pobj) of/IN (r_prep) secretion/NN (r_nsubj) accounted/VBD (l_advcl) indicating/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) production/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- triglyceride/NN (r_pobj) of/IN (r_prep) %/NN (r_dobj) accounted/VBD (l_advcl) indicating/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) production/NN (l_prep) of/IN (l_pobj) liver/NN -PUNC- triglyceride/NN (r_npadvmod) rich/JJ (r_amod) liver/NN
D013752_D005234 CID tetracycline/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) liver/NN -PUNC- tetracycline/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) relationships/NNS (l_conj) mechanisms/NNS (l_conj) differences/NNS (l_prep) in/IN (l_pobj) liver/NN -PUNC- tetracycline/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) production/NN (l_prep) of/IN (l_pobj) liver/NN
D013752_D003866 NONE tetracycline/NN (r_pobj) of/IN (r_prep) dose/NN (l_conj) accumulation/NN (l_prep) of/IN (l_pobj) triglyceride/NN (l_prep) in/IN (l_pobj) liver/NN (l_conj) depression/NN -PUNC- tetracycline/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) depression/NN
D019301_D003866 NONE acid/NN (r_pobj) of/IN (r_prep) provision/NN (r_pobj) With/IN (r_prep) observed/VBN (l_prep) between/IN (l_pobj) dose/NN (l_conj) accumulation/NN (l_prep) of/IN (l_pobj) triglyceride/NN (l_prep) in/IN (l_pobj) liver/NN (l_conj) depression/NN
D014280_D003866 NONE triglyceride/NN (l_prep) in/IN (l_pobj) liver/NN (l_conj) depression/NN -PUNC- triglyceride/NN (r_pobj) of/IN (r_prep) output/NN (r_pobj) of/IN (r_prep) liver/NN (l_conj) depression/NN -PUNC- triglyceride/NN (r_pobj) of/IN (r_prep) output/NN (r_pobj) of/IN (r_prep) depression/NN
24664478
C104457_D020258 NONE Nelarabine/JJ (r_compound) neurotoxicity/NN -PUNC- nelarabine/JJ (r_compound) neurotoxicity/NN -PUNC- nelarabine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) neurotoxicity/NN
2383364
D012837_D010146 NONE AgSD/NNP (r_pobj) to/IN (r_prep) closest/JJS (r_acomp) was/VBD (l_prep) in/IN (l_pobj) tolerance/NN (l_compound) pain/NN -PUNC- AgSD/NNP (r_pobj) from/IN (r_prep) differed/VBD (l_ccomp) was/VBD (l_prep) in/IN (l_pobj) tolerance/NN (l_compound) pain/NN
C048279_D010146 CID CHP/NNP (r_compound) concentration/NN (l_conj) ratings/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- CHP/NNP (r_compound) cream/NN (r_nsubj) was/VBD (l_prep) in/IN (l_pobj) tolerance/NN (l_compound) pain/NN
D012837_D002056 NONE sulphadiazine/NN (r_nmod) cream/NN (r_conj) vehicle/NN (r_dobj) treated/VBN (l_nsubjpass) site/NN (l_compound) burn/NN -PUNC- sulphadiazine/NN (r_nmod) cream/NN (l_appos) agent/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) wounds/NNS (l_compound) burn/NN -PUNC- AgSD/NNP (r_nmod) cream/NN (r_conj) vehicle/NN (r_dobj) treated/VBN (l_nsubjpass) site/NN (l_compound) burn/NN -PUNC- AgSD/NNP (r_nmod) cream/NN (l_appos) agent/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) wounds/NNS (l_compound) burn/NN
C048279_D002056 NONE diphosphanilate/NN (r_pobj) of/IN (r_prep) study/NN (l_appos) agent/NN (l_prep) for/IN (l_pobj) burns/NNS -PUNC- phosphanilate/NN (r_nsubjpass) evaluated/VBN (l_prep) as/IN (l_pobj) wound/NN (l_compound) burn/NN -PUNC- CHP/NNP (r_appos) phosphanilate/NN (r_nsubjpass) evaluated/VBN (l_prep) as/IN (l_pobj) wound/NN (l_compound) burn/NN -PUNC- CHP/NNP (r_compound) concentrations/NNS (r_pobj) of/IN (r_prep) each/DT (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) site/NN (l_compound) burn/NN -PUNC- CHP/NNP (r_compound) concentrations/NNS (r_pobj) of/IN (r_prep) each/DT (r_pobj) with/IN (r_prep) treated/VBN (l_dobj) vehicle/NN (l_conj) cream/NN (l_appos) agent/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) wounds/NNS (l_compound) burn/NN
1360900
D004976_D012640 CID acid/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- acid/NN (l_appos) dose/NN (l_amod) convulsive/JJ -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS
D000109_D012640 NONE acetylcholine/NN (r_conj) acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_dobj) suppressed/VBD (r_conj) accelerated/VBD (l_nsubj) injection/NN (l_prep) of/IN (l_pobj) acid/NN (l_appos) dose/NN (l_amod) convulsive/JJ
D005680_D012640 NONE acid/NN (r_pobj) of/IN (r_prep) synthesis/NN (r_dobj) suppressed/VBD (r_conj) accelerated/VBD (l_nsubj) injection/NN (l_prep) of/IN (l_pobj) acid/NN (l_appos) dose/NN (l_amod) convulsive/JJ
D012701_D012640 NONE 5-hydroxytryptamine/CD (r_pobj) of/IN (r_prep) turnover/NN (r_dobj) accelerated/VBD (l_nsubj) injection/NN (l_prep) of/IN (l_pobj) acid/NN (l_appos) dose/NN (l_amod) convulsive/JJ -PUNC- 5-HT/CD (r_appos) 5-hydroxytryptamine/CD (r_pobj) of/IN (r_prep) turnover/NN (r_dobj) accelerated/VBD (l_nsubj) injection/NN (l_prep) of/IN (l_pobj) acid/NN (l_appos) dose/NN (l_amod) convulsive/JJ
3925479
D000109_D002375 NONE acetylcholine/NN (r_compound) synthesis/NN (r_compound) inhibitor/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) prevented/VBD (l_dobj) catalepsy/NN
D001285_D002375 NONE atropine/NN (r_preconj) ,/, (r_punct) disrupted/VBD (l_dobj) catalepsy/NN
D010862_D002375 CID pilocarpine/NN (r_appos) doses/NNS (r_nsubj) induce/VB (l_dobj) catalepsy/NN -PUNC- pilocarpine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) caused/VBD (l_dobj) enhancement/NN (l_prep) of/IN (l_pobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_appos) blocker/NN (r_pobj) by/IN (r_agent) induced/VBN (r_relcl) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) catalepsy/NN -PUNC- haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_relcl) catalepsy/NN -PUNC- haloperidol/NN (r_pobj) as/IN (r_prep) neuroleptics/NNS (r_pobj) by/IN (r_agent) produced/VBN (r_relcl) catalepsy/NN
D006426_D002375 NONE hemicholinium/NN (r_appos) inhibitor/NN (r_pobj) of/IN (r_prep) injection/NN (r_nsubj) prevented/VBD (l_dobj) catalepsy/NN
D014150_D002375 NONE neuroleptic/RB (r_amod) induced/VBN (r_amod) catalepsy/NN (r_pobj) of/IN (r_prep) expression/NN (r_pobj) for/IN (r_prep) be/VB (r_xcomp) need/VBP (r_conj) promotes/VBZ (l_dobj) catalepsy/NN -PUNC- neuroleptic/RB (r_amod) induced/VBN (r_amod) catalepsy/NN -PUNC- neuroleptics/NNS (r_pobj) by/IN (r_agent) produced/VBN (r_relcl) catalepsy/NN
3423103
D012701_D001919 NONE 5-HT/CD (r_nummod) nerves/NNS (r_pobj) of/IN (r_prep) destruction/NN (r_nsubj) reduced/VBD (l_dobj) magnitude/NN (l_prep) of/IN (l_pobj) vasodepressor/NN (l_conj) responses/NNS (l_compound) bradycardiac/NN
D003000_D001919 CID clonidine/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_conj) bradycardia/NN -PUNC- clonidine/NN (r_npadvmod) induced/VBN (r_amod) bradycardia/NN -PUNC- clonidine/NN (r_advcl) reduced/VBD (l_dobj) magnitude/NN (l_prep) of/IN (l_pobj) vasodepressor/NN (l_conj) responses/NNS (l_compound) bradycardiac/NN -PUNC- clonidine/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (l_conj) bradycardia/NN
D015116_D001919 NONE 5,7-dihydroxytryptamine/CD (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) nerves/NNS (r_pobj) of/IN (r_prep) destruction/NN (r_nsubj) reduced/VBD (l_dobj) magnitude/NN (l_prep) of/IN (l_pobj) vasodepressor/NN (l_conj) responses/NNS (l_compound) bradycardiac/NN
D003000_D007022 CID clonidine/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- clonidine/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- clonidine/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN
9881641
C040442_D007022 CID helodermin/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) hypotension/NN -PUNC- Helodermin/NNP (r_nsubj) produced/VBD (l_dobj) hypotension/NN -PUNC- helodermin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN -PUNC- helodermin/NN (r_npadvmod) induced/VBN (r_amod) hypotension/NN (r_dobj) affect/VB (l_advcl) shortened/VBD (l_dobj) duration/NN (l_prep) of/IN (l_pobj) acetylcholine/NN (l_appos) hypotension/NN -PUNC- helodermin/NN (r_npadvmod) produced/VBN (r_amod) hypotension/NN
D000109_D007022 CID acetylcholine/NN (r_pobj) of/IN (r_prep) duration/NN (r_dobj) shortened/VBD (r_advcl) affect/VB (l_dobj) hypotension/NN -PUNC- acetylcholine/NN (l_appos) hypotension/NN -PUNC- ACh)-produced/JJ (r_amod) hypotension/NN (r_appos) acetylcholine/NN (r_pobj) of/IN (r_prep) duration/NN (r_dobj) shortened/VBD (r_advcl) affect/VB (l_dobj) hypotension/NN -PUNC- ACh)-produced/JJ (r_amod) hypotension/NN
D011188_D007022 NONE K+/NNP (r_amod) channels/NNS (r_pobj) of/IN (r_prep) activation/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_acomp) is/VBZ (l_nsubj) hypotension/NN -PUNC- K(ATP/NNP (r_nmod) channels/NNS (r_appos) channels/NNS (r_pobj) of/IN (r_prep) activation/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_acomp) is/VBZ (l_nsubj) hypotension/NN
D019806_D007022 CID levcromakalim/RB (r_npadvmod) produced/VBN (r_amod) decrease/NN (r_dobj) abolished/VBD (r_relcl) glibenclamide/NN (r_pobj) by/IN (r_agent) attenuated/VBN (l_nsubjpass) Hypotension/NN
D009569_D007022 NONE oxide/NN (r_dobj) relaxing/VBG (r_xcomp) derived/VBN (r_acl) EDRF/NN (r_nsubj) seem/VB (l_xcomp) play/VB (l_dobj) role/NN (l_prep) in/IN (l_pobj) hypotension/NN
D005905_D007022 NONE Glibenclamide/NN (r_npadvmod) sensitive/JJ (r_amod) hypotension/NN -PUNC- glibenclamide/NN (r_pobj) by/IN (r_agent) attenuated/VBN (l_nsubjpass) Hypotension/NN -PUNC- glibenclamide/NN (r_npadvmod) sensitive/JJ (r_amod) channels/NNS (r_pobj) of/IN (r_prep) activation/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_acomp) is/VBZ (l_nsubj) hypotension/NN
D000255_D007022 NONE K(ATP/NNP (r_nmod) channels/NNS (r_appos) channels/NNS (r_pobj) of/IN (r_prep) activation/NN (r_pobj) to/IN (r_prep) attributable/JJ (r_acomp) is/VBZ (l_nsubj) hypotension/NN
11366874
D019888_D001919 CID Viracept/NNP (r_nsubj) cause/VB (l_ccomp) beat/VBD (l_advcl) known/VBN (l_prep) as/IN (l_pobj) bradycardia/NNP -PUNC- Viracept/NNP (r_attr) was/VBD (r_relcl) patient/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) Bradycardia/NNS
D019888_D001145 NONE Viracept/NNP (r_amod) warning/NN (l_compound) heartbeat/NN -PUNC- Viracept/NNP (r_nsubj) cause/VB (l_ccomp) beat/VBD
8985298
D019259_D006509 NONE Lamivudine/NNP (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) suppressing/VBG (l_dobj) DNA/NN (l_compound) virus/NN (l_compound) B/NNP -PUNC- Lamivudine/NNP (r_nsubj) is/VBZ (l_attr) analogue/NN (l_relcl) has/VBZ (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) replication/NN (l_compound) virus/NN (l_compound) B/NN -PUNC- cytosine/NN (r_compound) analogue/NN (l_relcl) has/VBZ (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) replication/NN (l_compound) virus/NN (l_compound) B/NN -PUNC- lamivudine/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_nsubj) had/VBD (l_dobj) decrease/NN (l_prep) in/IN (l_pobj) virus/NN (l_compound) B/NN
D006514_D006509 CID antigen/NN (r_compound) carriers/NNS (r_pobj) in/IN (r_prep) DNA/NN (l_compound) virus/NN (l_compound) B/NNP
20408947
D000082_D017114 CID acetaminophen/RB (r_advmod) induced/VBN (r_amod) failure/NN -PUNC- Acetaminophen/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_nsubj) is/VBZ (l_attr) cause/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- Acetaminophen/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_nsubj) is/VBZ (l_attr) cause/NN (l_prep) of/IN (l_pobj) failure/NN (l_appos) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (l_appos) n=36/NNP (l_prep) with/IN (l_pobj) patients/NNS (l_acl) undergoing/VBG (l_dobj) LT/NN (l_prep) for/IN (l_pobj) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_pobj) for/IN (r_prep) LT/NN (r_dobj) undergoing/VBG (r_acl) patients/NNS (r_pobj) with/IN (r_prep) n=36/NNP (r_appos) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP -PUNC- Acetaminophen/NNP (r_npadvmod) induced/VBN (r_amod) patients/NNS (l_compound) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) patients/NNS (l_compound) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) patients/NNS (r_nsubj) had/VBD (l_prep) before/IN (l_pobj) LT/NNP (l_appos) ALF=0/35/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF=0/35/NNP (r_appos) LT/NNP (r_pobj) before/IN (r_prep) had/VBD (l_nsubj) patients/NNS (l_compound) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF=0/35/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_appos) groups/NNS (l_appos) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_acomp) non/AFX (r_nmod) ALF/NNP (r_appos) groups/NNS (l_appos) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_acomp) non/AFX (r_nmod) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) patients/NNS (l_compound) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_pobj) for/IN (r_prep) transplanted/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) outcomes/NNS (r_nsubj) were/VBD (l_acomp) comparable/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) transplanted/VBN (l_prep) for/IN (l_pobj) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_pobj) for/IN (r_prep) transplanted/VBN (r_acl) those/DT (r_pobj) to/IN (r_prep) comparable/JJ (r_acomp) were/VBD (l_nsubj) outcomes/NNS (l_prep) for/IN (l_pobj) patients/NNS (l_acl) transplanted/VBN (l_prep) for/IN (l_pobj) ALF/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP
D000082_D008107 NONE acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (l_appos) n=36/NNP (l_prep) with/IN (l_pobj) patients/NNS (l_acl) undergoing/VBG (l_dobj) LT/NN (l_prep) for/IN (l_pobj) ALF/NNP (l_conj) LT/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (l_appos) n=36/NNP (l_prep) with/IN (l_pobj) patients/NNS (l_acl) undergoing/VBG (l_dobj) LT/NN (l_prep) for/IN (l_pobj) ALF/NNP (l_conj) LT/NN (l_prep) for/IN (l_pobj) disease/NN (l_appos) CLD/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (l_conj) LT/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (l_conj) LT/NN (l_prep) for/IN (l_pobj) disease/NN (l_appos) CLD/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) patients/NNS (r_nsubj) had/VBD (l_prep) before/IN (l_pobj) LT/NNP (l_appos) ALF=0/35/NNP (l_appos) CLD=2/34/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF=0/35/NNP (l_appos) CLD=2/34/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_appos) groups/NNS (r_pobj) between/IN (r_prep) failure/NN (r_conj) differences/NNS (l_conj) CLD/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_acomp) non/AFX (r_nmod) ALF/NNP (r_appos) groups/NNS (r_pobj) between/IN (r_prep) failure/NN (r_conj) differences/NNS (l_conj) CLD/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_pobj) for/IN (r_prep) transplanted/VBN (r_acl) patients/NNS (r_pobj) for/IN (r_prep) outcomes/NNS (r_nsubj) were/VBD (l_acomp) comparable/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) transplanted/VBN (l_prep) for/IN (l_pobj) CLD/NNP -PUNC- acetaminophen/RB (r_advmod) induced/VBN (r_amod) ALF/NNP (r_pobj) for/IN (r_prep) transplanted/VBN (l_prep) for/IN (l_pobj) CLD/NNP
D000082_D056486 CID Acetaminophen/NNP (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN
11708428
D011241_D001008 CID Prednisone/NNP (r_nsubj) induces/VBZ (l_dobj) anxiety/NN -PUNC- prednisone/NNP (r_nsubj) produces/VBZ (l_dobj) anxiety/NN -PUNC- PDN/NNP (r_appos) prednisone/NNP (r_nsubj) produces/VBZ (l_dobj) anxiety/NN -PUNC- PDN/NNP (r_pobj) of/IN (r_prep) groups/NNS (r_pobj) in/IN (r_prep) documented/VBN (l_nsubjpass) Anxiety/NN -PUNC- PDN/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_nsubj) induced/VBD (l_dobj) anxiety/NN
3323259
C038806_D004487 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN
D009553_D008881 NONE nimodipine/RB (r_nsubj) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hemorrhage/NN (l_conj) headache/NN
D009553_D003704 NONE nimodipine/RB (r_nsubj) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hemorrhage/NN (l_conj) headache/NN (l_conj) dementia/NN
D009543_D000787 NONE nifedipine/NN (r_amod) controls/NNS (l_dobj) angina/NN
D002121_D004244 CID blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN (l_conj) nausea/NN (l_conj) anorexia/NN (l_conj) dizziness/NN
D009553_D013345 NONE nimodipine/RB (r_nsubj) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hemorrhage/NN
D015737_D000787 NONE nisoldipine/NN (r_pobj) of/IN (r_prep) properties/NNS (r_nsubj) led/VBN (l_prep) to/IN (l_pobj) investigation/NN (l_prep) for/IN (l_pobj) use/NN (l_prep) in/IN (l_pobj) angina/NN
D002121_D009325 CID blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN (l_conj) nausea/NN
D002121_D004487 CID blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN
D015737_D006973 NONE nisoldipine/NN (r_conj) nitrendipine/NN (r_pobj) with/IN (r_prep) dosage/NN (r_nsubj) offers/VBZ (l_dobj) schedule/NN (l_relcl) encourages/VBZ (l_dobj) compliance/NN (l_prep) in/IN (l_pobj) therapy/NN (l_prep) of/IN (l_pobj) hypertension/NN
C038806_D006973 NONE dihydropyridine/NN (r_advmod) available/JJ (r_advcl) controls/NNS (l_dobj) angina/NN (l_conj) hypertension/NN
D002121_D002318 NONE agents/NNS (r_dobj) blocking/VBG (r_acl) use/NN (r_pobj) into/IN (r_prep) stimulated/VBN (l_nsubj) recognition/NN (l_prep) of/IN (l_pobj) importance/NN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- agents/NNS (r_dobj) blocking/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) variety/NN (l_prep) of/IN (l_pobj) diseases/NNS
C038806_D004244 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN (l_conj) nausea/NN (l_conj) anorexia/NN (l_conj) dizziness/NN
D009568_D006973 NONE nitrendipine/NN (r_pobj) with/IN (r_prep) dosage/NN (r_nsubj) offers/VBZ (l_dobj) schedule/NN (l_relcl) encourages/VBZ (l_dobj) compliance/NN (l_prep) in/IN (l_pobj) therapy/NN (l_prep) of/IN (l_pobj) hypertension/NN
C038806_-1 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS
C038806_D006261 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN
D009543_D006973 NONE nifedipine/NN (r_amod) controls/NNS (l_dobj) angina/NN (l_conj) hypertension/NN
D009553_D020521 NONE nimodipine/RB (r_nsubj) useful/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hemorrhage/NN (l_conj) headache/NN (l_conj) dementia/NN (l_conj) stroke/NN
C038806_D009325 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN (l_conj) nausea/NN
D002118_D002318 NONE calcium/NN (r_pobj) of/IN (r_prep) importance/NN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- calcium/NN (r_pobj) of/IN (r_prep) importance/NN (r_pobj) of/IN (r_prep) recognition/NN (r_nsubj) stimulated/VBN (l_prep) into/IN (l_pobj) use/NN (l_acl) blocking/VBG (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) variety/NN (l_prep) of/IN (l_pobj) diseases/NNS
D002121_D000855 CID blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN (l_conj) nausea/NN (l_conj) anorexia/NN
D002121_D006261 CID blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN
C038806_D000787 NONE dihydropyridine/NN (r_advmod) available/JJ (r_advcl) controls/NNS (l_dobj) angina/NN
C038806_D005483 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN
D002121_-1 NONE blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS
C038806_D000855 NONE dihydropyridine/JJ (r_compound) calcium/NN (r_compound) channel/NN (r_compound) blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN (l_conj) palpitations/NNS (l_conj) edema/NN (l_conj) nausea/NN (l_conj) anorexia/NN
D002121_D005483 CID blockers/NNS (r_nsubjpass) tolerated/VBN (l_prep) with/IN (l_pobj) headache/NN (l_conj) flushing/NN
24126708
D007980_D004409 CID Levodopa/NNP (r_nsubj) is/VBZ (l_conj) lead/VB (l_prep) to/IN (l_pobj) outcomes/NNS (l_prep) as/IN (l_pobj) fluctuations/NNS (l_conj) dyskinesia/JJ
D007980_D010300 NONE levodopa/JJ (r_amod) effects/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN -PUNC- Levodopa/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) disease/NN
D007980_D006212 CID Levodopa/NNP (r_nsubj) is/VBZ (l_conj) lead/VB (l_prep) to/IN (l_pobj) outcomes/NNS (l_prep) as/IN (l_pobj) fluctuations/NNS (l_conj) dyskinesia/JJ (l_conj) hallucinations/NNS
24464946
D015251_D066126 CID epirubicine/NN (r_npadvmod) based/VBN (r_amod) chemotherapy/NN (r_pobj) during/IN (r_prep) detection/NN (l_conj) prediction/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN
D015251_D006331 NONE epirubicin/NNS (r_compound) exposure/NN (r_pobj) after/IN (r_prep) predict/VB (l_dobj) dysfunction/NN
D015251_D009202 NONE epirubicin/NNS (r_compound) exposure/NN (r_pobj) after/IN (r_prep) predict/VB (l_nsubj) alterations/NNS (l_prep) of/IN (l_pobj) strain/NN
D015251_D008228 NONE epirubicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) lymphoma/NN
D018943_D006331 NONE anthracycline/NN (r_advmod) based/VBN (r_amod) chemotherapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) dysfunction/NN
18987260
D019808_D011507 NONE losartan/NN (r_amod) treatment/NN (r_nsubj) improved/VBD (l_dobj) rate/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) proteinuria/NN -PUNC- losartan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) showed/VBD (l_advcl) preventing/VBG (l_dobj) proteinuria/NN
D019808_D001284 NONE losartan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) atrophy/NN -PUNC- losartan/NN (r_nsubj) prevent/VB (l_dobj) atrophy/NN
D019808_D014511 NONE Losartan/NNP (r_nsubj) reduced/VBD (l_dobj) uraemia/RB
D019808_D005921 NONE losartan/NN (r_amod) treatment/NN (r_nsubj) improved/VBD (l_dobj) rate/NN (l_conj) glomerulosclerosis/NN -PUNC- losartan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN
D004317_D001284 NONE ADR/NNP (r_compound) nephropathy/NN (r_pobj) in/IN (r_prep) atrophy/NN
D019808_D007676 NONE losartan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) showed/VBD (l_advcl) preventing/VBG (l_dobj) proteinuria/NN (l_conj) failure/NN -PUNC- Losartan/NNP (r_nsubj) reduces/VBZ (l_prep) to/IN (l_pobj) disease/NN
D019808_D006973 NONE losartan/NN (r_pobj) by/IN (r_agent) treated/VBN (r_acl) rats/NNS (l_amod) hypertensive/JJ -PUNC- losartan/NN (l_conj) potential/NN (l_prep) in/IN (l_pcomp) slowing/VBG (l_dobj) progression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D004317_D005923 CID ADR/NNP (r_npadvmod) induced/VBN (r_amod) glomerulosclerosis/NN
D019808_D005355 NONE losartan/NN (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) showed/VBD (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) atrophy/NN (l_conj) fibrosis/NN -PUNC- losartan/NN (r_nsubj) prevent/VB (l_dobj) atrophy/NN (l_conj) infiltration/NN (l_conj) fibrosis/NN
D004317_D007676 NONE ADR/NNP (r_npadvmod) induced/VBN (r_amod) glomerulosclerosis/NN (r_pobj) of/IN (r_prep) progression/NN (r_pobj) of/IN (r_prep) rate/NN (r_dobj) reduces/VBZ (l_prep) to/IN (l_pobj) disease/NN
D000804_D006973 NONE II/CD (r_compound) blocker/NN (l_conj) losartan/NN (l_conj) potential/NN (l_prep) in/IN (l_pcomp) slowing/VBG (l_dobj) progression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D019808_D007674 NONE losartan/NN (r_pobj) by/IN (r_agent) treated/VBN (r_acl) rats/NNS (r_pobj) in/IN (r_prep) progression/NN (l_prep) of/IN (l_pobj) nephropathy/NN -PUNC- losartan/NN (l_conj) potential/NN (l_prep) in/IN (l_pcomp) slowing/VBG (l_dobj) progression/NN (l_compound) disease/NN -PUNC- losartan/NN (l_conj) potential/NN (l_prep) in/IN (l_pcomp) slowing/VBG (l_dobj) progression/NN (l_prep) with/IN (l_pobj) nephropathy/NN -PUNC- Losartan/NNP (r_nsubj) reduced/VBD (l_conj) increased/VBN (l_dobj) clearance/NN (l_prep) in/IN (l_pobj) nephropathy/NN -PUNC- losartan/NN (r_nsubj) prevent/VB (l_dobj) atrophy/NN (l_prep) in/IN (l_pobj) nephropathy/NN
D004317_D014511 CID ADR/NNP (r_compound) nephropathy/NN (r_pobj) in/IN (r_prep) clearance/NN (r_dobj) increased/VBN (r_conj) reduced/VBD (l_dobj) uraemia/RB
D019808_D005923 NONE Losartan/NNP (r_nsubj) reduces/VBZ (l_dobj) rate/NN (l_prep) of/IN (l_pobj) progression/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN
D000804_D007674 NONE II/CD (r_compound) blocker/NN (l_conj) losartan/NN (l_conj) potential/NN (l_prep) in/IN (l_pcomp) slowing/VBG (l_dobj) progression/NN (l_compound) disease/NN -PUNC- II/CD (r_compound) blocker/NN (l_conj) losartan/NN (l_conj) potential/NN (l_prep) in/IN (l_pcomp) slowing/VBG (l_dobj) progression/NN (l_prep) with/IN (l_pobj) nephropathy/NN
D004317_D007674 NONE adriamycin/JJ (r_amod) nephropathy/NN -PUNC- adriamycin/NNS (r_nmod) nephropathy/NN (r_pobj) with/IN (r_prep) progression/NN (l_compound) disease/NN -PUNC- adriamycin/NNS (r_nmod) nephropathy/NN -PUNC- ADR/NNP (r_nmod) nephropathy/NN (r_pobj) with/IN (r_prep) progression/NN (l_compound) disease/NN -PUNC- ADR/NNP (r_nmod) nephropathy/NN -PUNC- ADR/NNP (r_compound) nephropathy/NN -PUNC- ADR/NNP (r_compound) nephropathy/NN
D004317_D006973 NONE adriamycin/JJ (r_amod) nephropathy/NN (r_pobj) of/IN (r_prep) progression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- adriamycin/NNS (r_nmod) nephropathy/NN (r_pobj) with/IN (r_prep) progression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- ADR/NNP (r_nmod) nephropathy/NN (r_pobj) with/IN (r_prep) progression/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D014508_D014511 NONE urea/NN (r_compound) clearance/NN (r_dobj) increased/VBN (r_conj) reduced/VBD (l_dobj) uraemia/RB
D014508_D007674 NONE urea/NN (r_compound) clearance/NN (l_prep) in/IN (l_pobj) nephropathy/NN
D004317_D005355 NONE ADR/NNP (r_compound) nephropathy/NN (r_pobj) in/IN (r_prep) atrophy/NN (l_conj) infiltration/NN (l_conj) fibrosis/NN
15625689
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- levodopa/NN (r_compound) dose/NN (r_pobj) of/IN (r_prep) basis/NN (r_pobj) on/IN (r_prep) explained/VBN (r_relcl) function/NN (r_pobj) in/IN (r_prep) performed/VBD (l_nsubj) patients/NNS (l_amod) dyskinetic/JJ
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) characterize/VB (l_dobj) dynamics/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP -PUNC- levodopa/NN (r_pobj) for/IN (r_prep) role/NN (r_dobj) suggest/VBP (l_conj) confirm/VB (l_ccomp) is/VBZ (l_attr) predictor/NN (l_prep) of/IN (l_pobj) alterations/NNS (l_prep) in/IN (l_pobj) PD/NNP
D007980_D003680 NONE levodopa/NN (r_pobj) for/IN (r_prep) role/NN (r_dobj) suggest/VBP (l_conj) confirm/VB (l_ccomp) is/VBZ (l_nsubj) dysphagia/NN
24675088
D004317_D066126 NONE doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
D005682_D018754 NONE gadolinium/NN (r_compound) enhancement/NN (l_conj) grading/NN (l_conj) dysfunction/NN
D004317_D064420 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (r_dobj) utilized/VBN (l_advcl) applying/VBG (l_conj) provide/VB (l_dobj) characterization/NN (l_prep) to/IN (l_pobj) date/NN (l_prep) of/IN (l_pobj) timecourse/NN (l_prep) of/IN (l_pobj) events/NNS (l_acl) underlying/VBG (l_dobj) toxicity/NN -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN (r_appos) doxorubicin/NN (r_pobj) of/IN (r_prep) model/NN (r_dobj) utilized/VBN (l_advcl) applying/VBG (l_conj) provide/VB (l_dobj) characterization/NN (l_prep) to/IN (l_pobj) date/NN (l_prep) of/IN (l_pobj) timecourse/NN (l_prep) of/IN (l_pobj) events/NNS (l_acl) underlying/VBG (l_dobj) toxicity/NN
D004317_D009202 CID doxorubicin/NN (l_appos) cardiomyopathy/NN -PUNC- DOX)-induced/VBN (r_amod) cardiomyopathy/NN
15229250
D008694_D003072 NONE MA/NNP (r_compound) abuse/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) alterations/NNS (r_pobj) of/IN (r_prep) pattern/NN (r_dobj) determined/VBD (l_conj) related/VBD (l_prep) to/IN (l_pobj) impairment/NN
D008694_D008659 NONE MA/NNP (r_dobj) used/VBN (r_relcl) subjects/NNS (r_pobj) of/IN (r_prep) Studies/NNS (r_nsubj) revealed/VBN (l_dobj) deficits/NNS (l_prep) in/IN (l_pobj) systems/NNS (l_conj) abnormalities/NNS
D008694_D006984 NONE MA/NNP (r_compound) abusers/NNS (r_nsubj) had/VBD (l_dobj) 0.05/CD (l_conj) hypertrophy/NN
D008694_D008569 CID methamphetamine/NN (r_compound) abuse/NN (r_nsubj) causes/VBZ (l_dobj) pattern/NN (l_prep) of/IN (l_pobj) deterioration/NN (l_relcl) contributes/VBZ (l_prep) to/IN (l_pobj) performance/NN
D008694_D001930 CID methamphetamine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) brain/NN -PUNC- MA/NNP (r_nmod) abuse/NN (r_appos) methamphetamine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) brain/NN -PUNC- MA/NNP (r_dobj) used/VBD (r_relcl) subjects/NNS (r_pobj) in/IN (r_prep) ventricles/NNS -PUNC- MA/NNP (r_compound) abuse/NN (r_pobj) of/IN (r_prep) symptoms/NNS (r_pobj) for/IN (r_prep) account/VB (r_xcomp) help/VB (l_advcl) providing/VBG (l_dobj) targets/NNS (l_prep) for/IN (l_pobj) injury/NN
11915580
D009569_D004412 NONE NO/JJ (r_det) donor/NN (r_appos) trinitrate/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) determine/VB (l_prep) in/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN
D005996_D004412 NONE trinitrate/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN -PUNC- trinitrate/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) determine/VB (l_prep) in/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN -PUNC- GTN/NNP (r_appos) trinitrate/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_dobj) determine/VB (l_prep) in/IN (l_pobj) resolution/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN -PUNC- GTN/NNP (r_nsubj) has/VBZ (l_prep) by/IN (l_pobj) comparison/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN
D005996_D017699 NONE GTN/NNP (r_compound) scores/NNS (r_nsubj) remained/VBD (r_advcl) continued/VBD (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) pain/NN -PUNC- GTN/NNP (r_npadvmod) remained/VBD (r_advcl) continued/VBD (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) pain/NN -PUNC- GTN/NNP (r_appos) GTN/NNP (r_npadvmod) remained/VBD (r_advcl) continued/VBD (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) pain/NN
D004008_D017699 NONE DCF/NNP (r_nsubj) continued/VBD (l_xcomp) be/VB (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) reducing/VBG (l_dobj) pain/NN
D004008_D004412 NONE diclofenac/NN (r_pobj) with/IN (r_prep) trinitrate/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN -PUNC- diclofenac/NNP (r_pobj) with/IN (r_prep) comparison/NN (r_pobj) in/IN (r_prep) resolution/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN -PUNC- DCF/NNP (r_appos) diclofenac/NNP (r_pobj) with/IN (r_prep) comparison/NN (r_pobj) in/IN (r_prep) resolution/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN -PUNC- DCF/NNP (r_pobj) with/IN (r_prep) comparison/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) dysmenorrhea/NN
D005996_D006261 CID GTN/NNP (r_pobj) by/IN (r_agent) increased/VBN (l_nsubjpass) Headache/NNP -PUNC- GTN/NNP (r_dobj) using/VBG (r_xcomp) stopped/VBD (l_advcl) became/VBD (l_nsubj) headache/NN
D004008_D006261 NONE DCF/NNP (r_pobj) by/IN (r_prep) increased/VBN (l_nsubjpass) Headache/NNP
D011453_D004412 NONE prostaglandins/NNS (r_pobj) of/IN (r_prep) hypersecretion/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) contractility/NN (r_pobj) by/IN (r_agent) characterized/VBN (r_acl) syndrome/NN (r_attr) is/VBZ (l_nsubj) dysmenorrhea/NN
18025637
D012701_D006973 NONE serotonin/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) Although/IN (r_prep) is/VBZ (l_ccomp) are/VBP (l_acomp) aware/JJ (l_ccomp) cause/VB (l_dobj) hypertension/NN
D005473_D012170 CID fluoxetine/NN (r_conj) occlusion/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) hypertension/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) occlusion/NN
D005473_D006973 CID fluoxetine/NN (r_advmod) induced/VBN (r_amod) hypertension/NN
15630069
C076029_D011618 NONE olanzapine/NN (r_conj) clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) matched/VBN (r_acl) subjects/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN (l_conj) disorder/NN
D003024_D012559 NONE clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) matched/VBN (r_acl) subjects/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
D018967_D007333 NONE risperidone/NNP (r_appos) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- risperidone/NNP (r_appos) P<.001/NNP (l_prep) with/IN (l_pobj) subjects/NNS (l_acl) exhibiting/VBG (l_dobj) resistance/NN -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) exhibiting/VBG (r_acl) subjects/NNS (r_pobj) with/IN (r_prep) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) exhibiting/VBG (l_dobj) resistance/NN -PUNC- risperidone/NN (r_pobj) vs/IN (r_prep) clozapine/NN (r_appos) risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) exhibiting/VBG (r_acl) subjects/NNS (r_pobj) with/IN (r_prep) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- risperidone/NN (r_pobj) vs/IN (r_prep) clozapine/NN (r_appos) risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) exhibiting/VBG (l_dobj) resistance/NN -PUNC- risperidone/NN (r_npadvmod) treated/VBN (r_amod) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) displayed/VBD (l_dobj) resistance/NN
C076029_D007333 CID olanzapine/RB (r_nmod) risperidone/NNP (r_appos) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- olanzapine/RB (r_nmod) risperidone/NNP (r_appos) P<.001/NNP (l_prep) with/IN (l_pobj) subjects/NNS (l_acl) exhibiting/VBG (l_dobj) resistance/NN -PUNC- olanzapine/RB (r_conj) clozapine/NN (r_dobj) received/VBD (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- olanzapine/RB (r_conj) clozapine/NN (r_dobj) received/VBD (r_relcl) subjects/NNS (l_acl) exhibiting/VBG (l_dobj) resistance/NN -PUNC- olanzapine/RB (r_npadvmod) treated/VBN (r_amod) groups/NNS (r_nsubj) displayed/VBD (l_dobj) resistance/NN -PUNC- olanzapine/NN (r_conj) taking/VBG (r_acl) Patients/NNS (r_nsubjpass) examined/VBN (l_prep) for/IN (l_pobj) resistance/NN
D018967_D011618 NONE risperidone/NN (r_conj) olanzapine/NN (r_conj) clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) matched/VBN (r_acl) subjects/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN (l_conj) disorder/NN
D005947_D003920 NONE glucose/NN (r_compound) metabolism/NN (r_dobj) affecting/VBG (r_ccomp) remains/VBZ (l_advcl) increasing/VBG (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) mellitus/NN -PUNC- glucose/NN (r_compound) metabolism/NN (r_dobj) affecting/VBG (l_conj) increasing/VBG (l_dobj) factors/NNS (l_prep) for/IN (l_pobj) diabetes/NNS
D003024_D011618 NONE clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) matched/VBN (r_acl) subjects/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN (l_conj) disorder/NN
D003024_D007333 CID clozapine/NN (r_nmod) risperidone/NNP (r_appos) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- clozapine/NN (r_nmod) risperidone/NNP (r_appos) P<.001/NNP (l_prep) with/IN (l_pobj) subjects/NNS (l_acl) exhibiting/VBG (l_dobj) resistance/NN -PUNC- clozapine/NN (r_dobj) received/VBD (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- clozapine/NN (r_dobj) received/VBD (r_relcl) subjects/NNS (l_acl) exhibiting/VBG (l_dobj) resistance/NN -PUNC- clozapine/NN (r_appos) risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) exhibiting/VBG (r_acl) subjects/NNS (r_pobj) with/IN (r_prep) P<.001/NNP (r_appos) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) index/NN (l_compound) sensitivity/NN -PUNC- clozapine/NN (r_appos) risperidone/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) subjects/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) exhibiting/VBG (l_dobj) resistance/NN -PUNC- clozapine-/NN (r_nmod) groups/NNS (r_nsubj) displayed/VBD (l_dobj) resistance/NN -PUNC- clozapine/NN (r_dobj) taking/VBG (r_acl) Patients/NNS (r_nsubjpass) examined/VBN (l_prep) for/IN (l_pobj) resistance/NN
D005947_D012559 NONE Glucose/NN (r_nsubj) metabolism/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN -PUNC- glucose/NN (r_compound) tolerance/NN (r_compound) test/NN (r_appos) metabolism/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN -PUNC- glucose/NN (r_compound) metabolism/NN (r_dobj) affecting/VBG (r_ccomp) remains/VBZ (l_advcl) increasing/VBG (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN -PUNC- glucose/NN (r_compound) tolerance/NN (r_compound) test/NN (r_dobj) using/VBG (r_advcl) evaluated/VBD (r_acl) schizophrenia/NN
D018967_D012559 NONE risperidone/NN (r_conj) olanzapine/NN (r_conj) clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) matched/VBN (r_acl) subjects/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
C076029_D012559 NONE olanzapine/NN (r_conj) clozapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) matched/VBN (r_acl) subjects/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
D005947_D007333 NONE glucose/NN (r_dobj) Fasting/VBG (l_conj) index/NN (l_compound) sensitivity/NN -PUNC- glucose/NN (r_dobj) Fasting/VBG (l_conj) index/NN (l_conj) assessment/NN (l_prep) of/IN (l_pobj) resistance/NN -PUNC- glucose/NN (r_compound) effectiveness/NN (r_conj) assessment/NN (r_conj) index/NN (l_compound) sensitivity/NN -PUNC- glucose/NN (r_compound) effectiveness/NN (r_conj) assessment/NN (l_prep) of/IN (l_pobj) resistance/NN -PUNC- glucose/NN (r_compound) effectiveness/NN (r_pobj) of/IN (r_prep) impairment/NN (r_conj) resistance/NN
19914299
D005472_D008569 CID 5-fluorouracil/CD (r_punct) improves/VBZ (l_dobj) deficits/NNS
D005473_D008569 NONE Fluoxetine/NNP (r_nsubj) improves/VBZ (l_dobj) deficits/NNS
7176945
D002712_D010146 NONE chloride/NN (r_oprd) used/VBN (r_acl) suxamethonium/NN (r_pobj) of/IN (r_prep) preparation/NN (r_conj) type/NN (r_nsubj) affected/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D000530_D010146 NONE Althesin/NNP (r_appos) agent/NN (r_pobj) of/IN (r_prep) type/NN (r_nsubj) affected/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
C084773_D010146 NONE Fazadinium/NNP (r_pobj) of/IN (r_prep) dose/NN (r_appos) abolition/NN (r_nsubj) influence/VB (l_dobj) occurrence/NN (l_prep) of/IN (l_pobj) pain/NN
D013874_D010146 NONE Thiopentone/NNP (r_conj) Althesin/NNP (r_appos) agent/NN (r_pobj) of/IN (r_prep) type/NN (r_nsubj) affected/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D013390_D010146 CID suxamethonium/NN (r_compound) pains/NNS -PUNC- scoline/JJ (r_amod) pain/NN -PUNC- scoline/JJ (r_amod) pain/NN -PUNC- scoline/JJ (r_amod) pain/NN -PUNC- suxamethonium/NN (r_pobj) of/IN (r_prep) preparation/NN (r_conj) type/NN (r_nsubj) affected/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN -PUNC- scoline/JJ (r_amod) pain/NN
D001965_D010146 NONE bromide/NN (r_conj) chloride/NN (r_oprd) used/VBN (r_acl) suxamethonium/NN (r_pobj) of/IN (r_prep) preparation/NN (r_conj) type/NN (r_nsubj) affected/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
D013390_D005207 CID scoline/JJ (r_amod) pain/NN (r_pobj) of/IN (r_prep) occurrence/NN (r_dobj) influence/VB (l_nsubj) abolition/NN (l_prep) of/IN (l_pobj) fasciculations/NNS
C084773_D005207 NONE Fazadinium/NNP (r_pobj) of/IN (r_prep) dose/NN (r_appos) abolition/NN (l_prep) of/IN (l_pobj) fasciculations/NNS
8755612
D004967_D010911 NONE estrogen/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induces/VBZ (l_dobj) growth/NN (l_prep) of/IN (l_pobj) tumors/NNS
D004054_D006470 NONE diethylstilbestrol/NN (r_nmod) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_nsubj) caused/VBD (l_ccomp) grow/VB (l_conj) become/VB (l_acomp) hemorrhagic/JJ -PUNC- DES/NNP (r_nmod) treatment/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_nsubj) caused/VBD (l_ccomp) grow/VB (l_conj) become/VB (l_acomp) hemorrhagic/JJ -PUNC- DES/NNP (r_npadvmod) induced/VBN (r_amod) growth/NN (r_nsubj) exhibited/VBD (r_advcl) exhibited/VBD (l_nsubj) phenotype/NN (l_amod) hemorrhagic/JJ
D004967_D009369 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) tumor/NN (r_pobj) in/IN (r_prep) separation/NN (l_prep) of/IN (l_pobj) growth/NN (l_compound) tumor/NN -PUNC- estrogen/NN (r_npadvmod) induced/VBN (r_amod) tumor/NN
D004967_D006470 NONE estrogen/NN (r_npadvmod) induced/VBN (r_amod) tumor/NN (r_pobj) in/IN (r_prep) separation/NN (l_prep) of/IN (l_pobj) growth/NN (l_conj) phenotypes/NNS (l_amod) hemorrhagic/JJ -PUNC- estrogen/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) induces/VBZ (l_dobj) growth/NN (l_prep) of/IN (l_pobj) tumors/NNS (l_amod) hemorrhagic/JJ
2173761
D020110_D007022 CID pinacidil/NN (r_conj) cromakalim/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Vasodilation/NN (l_prep) of/IN (l_pobj) vessels/NNS (l_conj) hypotension/NN
D020110_D013610 CID pinacidil/NN (r_conj) cromakalim/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Vasodilation/NN (r_nsubjpass) affected/VBN (l_agent) by/IN (l_pobj) blockade/VBP (l_conj) tachycardia/NN
D018727_D007022 NONE blockade/VBP (r_pobj) by/IN (r_agent) affected/VBN (l_nsubjpass) Vasodilation/NN (l_prep) of/IN (l_pobj) vessels/NNS (l_conj) hypotension/NN
D019806_D007022 CID cromakalim/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Vasodilation/NN (l_prep) of/IN (l_pobj) vessels/NNS (l_conj) hypotension/NN
D018727_D013610 NONE blockade/VBP (l_conj) tachycardia/NN
D000319_D013610 NONE blockade/VBP (l_conj) tachycardia/NN
D000319_D007022 NONE blockade/VBP (r_pobj) by/IN (r_agent) affected/VBN (l_nsubjpass) Vasodilation/NN (l_prep) of/IN (l_pobj) vessels/NNS (l_conj) hypotension/NN
D019806_D013610 CID cromakalim/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Vasodilation/NN (r_nsubjpass) affected/VBN (l_agent) by/IN (l_pobj) blockade/VBP (l_conj) tachycardia/NN
25054547
C049430_D001049 CID mivacurium/NN (r_conj) suxamethonium/NN (r_appos) relaxants/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) characterized/VBN (l_agent) by/IN (l_pobj) apnea/NN
C049430_C537417 CID mivacurium/NN (r_conj) suxamethonium/NN (r_appos) relaxants/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) characterized/VBN (l_nsubjpass) deficiency/NN
D013390_C537417 CID suxamethonium/NN (r_appos) relaxants/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) characterized/VBN (l_nsubjpass) deficiency/NN
D013390_D001049 CID suxamethonium/NN (r_pobj) with/IN (r_prep) apnea/NN -PUNC- suxamethonium/NN (r_appos) relaxants/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) characterized/VBN (l_agent) by/IN (l_pobj) apnea/NN
17554526
D018817_D001925 NONE ecstasy/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) by/IN (r_agent) explained/VBN (l_nsubjpass) deficit/NN (l_prep) in/IN (l_pobj) accuracy/NN (l_compound) recognition/NN
D003042_D001925 CID cocaine/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) recognition/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) by/IN (r_agent) explained/VBN (l_nsubjpass) deficit/NN (l_prep) in/IN (l_pobj) accuracy/NN (l_compound) recognition/NN
3533179
D003520_D064420 NONE CYA/NNP (r_pobj) of/IN (r_prep) dose/NN (r_dobj) calculated/VBD (l_advcl) correlates/VBZ (l_nsubj) toxicity/NN -PUNC- CYA/NNP (r_compound) cardiotoxicity/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) correlated/VBN (r_ccomp) determine/VB (r_advcl) calculated/VBD (l_advcl) correlates/VBZ (l_nsubj) toxicity/NN
D003520_D014923 NONE CYA/NNP (r_dobj) receive/VB (r_xcomp) were/VBD (r_relcl) patients/NNS (r_nsubj) underwent/VBD (l_conj) syndrome/NN
D003520_D000741 NONE CYA/NNP (r_dobj) receive/VB (r_xcomp) were/VBD (r_relcl) patients/NNS (r_nsubj) underwent/VBD (l_dobj) total/NN (l_prep) of/IN (l_pobj) transplants/NNS (l_prep) for/IN (l_pobj) anemia/NN -PUNC- CYA/NNP (r_compound) cardiotoxicity/NN (r_nsubj) correlates/VBZ (l_conj) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN -PUNC- CYA/NNP (r_compound) dosage/NN (r_pobj) with/IN (r_prep) correlates/VBZ (l_conj) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN -PUNC- CYA/NNP (r_compound) dose/NN (r_pobj) at/IN (r_prep) grafting/VBG (r_pobj) for/IN (r_prep) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN -PUNC- CYA/NNP (r_compound) dosage/NN (r_nsubjpass) calculated/VBN (r_relcl) patients/NNS (r_pobj) than/IN (r_prep) cardiotoxicity/NN (r_pobj) of/IN (r_prep) incidence/NN (r_pobj) with/IN (r_prep) grafting/VBG (r_pobj) for/IN (r_prep) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN
D003520_D066126 NONE Cyclophosphamide/NNP (r_compound) cardiotoxicity/NN -PUNC- CYA/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) At/IN (r_prep) occur/VB (l_nsubj) cardiotoxicity/NN -PUNC- CYA/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) At/IN (r_prep) occur/VB (l_conj) described/VBN (l_nsubjpass) factors/NNS (l_prep) for/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- CYA/NNP (r_pobj) of/IN (r_prep) dose/NN (r_dobj) calculated/VBD (l_advcl) determine/VB (l_ccomp) correlated/VBN (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) cardiotoxicity/NN -PUNC- CYA/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_pcomp) of/IN (r_prep) days/NNS (r_pobj) within/IN (r_prep) had/VBD (l_dobj) symptoms/NNS (l_amod) consistent/JJ (l_prep) with/IN (l_pobj) cardiotoxicity/NN -PUNC- CYA/NNP (r_pobj) to/IN (r_prep) related/VBN (r_xcomp) thought/VBN (r_relcl) Cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) cardiotoxicity/NN (r_nsubj) correlates/VBZ (l_conj) prepared/VBN (l_prep) for/IN (l_pobj) grafting/VBG (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) dosage/NN (r_pobj) with/IN (r_prep) correlates/VBZ (l_nsubj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) dosage/NN (r_pobj) with/IN (r_prep) correlates/VBZ (l_conj) prepared/VBN (l_prep) for/IN (l_pobj) grafting/VBG (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) dose/NN (r_pobj) at/IN (r_prep) grafting/VBG (r_pobj) for/IN (r_prep) prepared/VBN (r_conj) correlates/VBZ (l_nsubj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) dose/NN (r_pobj) at/IN (r_prep) grafting/VBG (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) dosage/NN (r_nsubjpass) calculated/VBN (r_relcl) patients/NNS (r_pobj) than/IN (r_prep) cardiotoxicity/NN (r_pobj) of/IN (r_prep) incidence/NN (r_pobj) with/IN (r_prep) grafting/VBG (r_pobj) for/IN (r_prep) prepared/VBN (r_conj) correlates/VBZ (l_nsubj) cardiotoxicity/NN -PUNC- CYA/NNP (r_compound) dosage/NN (r_nsubjpass) calculated/VBN (r_relcl) patients/NNS (r_pobj) than/IN (r_prep) cardiotoxicity/NN
D003520_D016511 NONE CYA/NNP (r_dobj) receive/VB (r_xcomp) were/VBD (r_relcl) patients/NNS (r_nsubj) underwent/VBD (l_conj) syndrome/NN (l_conj) syndrome/NN
D003520_D007153 NONE CYA/NNP (r_compound) cardiotoxicity/NN (r_nsubj) correlates/VBZ (l_conj) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN (l_conj) immunodeficiencies/NNS -PUNC- CYA/NNP (r_compound) dosage/NN (r_pobj) with/IN (r_prep) correlates/VBZ (l_conj) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN (l_conj) immunodeficiencies/NNS -PUNC- CYA/NNP (r_compound) dose/NN (r_pobj) at/IN (r_prep) grafting/VBG (r_pobj) for/IN (r_prep) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN (l_conj) immunodeficiencies/NNS -PUNC- CYA/NNP (r_compound) dosage/NN (r_nsubjpass) calculated/VBN (r_relcl) patients/NNS (r_pobj) than/IN (r_prep) cardiotoxicity/NN (r_pobj) of/IN (r_prep) incidence/NN (r_pobj) with/IN (r_prep) grafting/VBG (r_pobj) for/IN (r_prep) prepared/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) anemia/NN (l_conj) immunodeficiencies/NNS
733189
D010406_D015356 NONE penicillin/NN (r_conj) epinephrine/NN (r_conj) lidocaine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN (r_pobj) with/IN (r_prep) occlusions/NNS
D004837_D001766 NONE epinephrine/NN (r_conj) lidocaine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN
D004837_D015356 NONE epinephrine/NN (r_conj) lidocaine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN (r_pobj) with/IN (r_prep) occlusions/NNS
D010406_D001766 NONE penicillin/NN (r_conj) epinephrine/NN (r_conj) lidocaine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN
D008012_D001766 NONE lidocaine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN
C000873_D001766 NONE acetate/NN (r_pobj) with/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN
C000873_D015356 CID acetate/NN (r_pobj) with/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN (r_pobj) with/IN (r_prep) occlusions/NNS
D000305_D015356 NONE corticosteroid/NN (r_compound) suspensions/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) artery/NN (l_conj) occlusion/NN
D008012_D015356 NONE lidocaine/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) injection/NN (r_dobj) following/VBG (r_prep) blindness/NN (r_pobj) with/IN (r_prep) occlusions/NNS
6585590
D004317_D066126 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) nephrotoxicity/NN (r_conj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) nephrotoxicity/NN (r_conj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_pobj) of/IN (r_prep) dose/NN (r_pobj) at/IN (r_prep) observed/VBN (l_ccomp) scored/VBD (l_nsubj) evidence/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN
D004317_D009369 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) Animals/NNS (l_prep) with/IN (l_pobj) tumor/NN -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_pobj) with/IN (r_prep) observed/VBN (l_nsubjpass) regression/NN (l_compound) Tumor/NN -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_pobj) with/IN (r_prep) induced/VBN (l_nsubjpass) disappearance/NN (l_prep) of/IN (l_pobj) tumor/NN
D004317_-1 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) nephrotoxicity/NN (r_conj) cardiotoxicity/NN (l_prep) in/IN (l_pobj) rat/NN (l_amod) bearing/VBG (l_compound) immunocytoma/NN -PUNC- doxorubicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) nephrotoxicity/NN (r_conj) cardiotoxicity/NN (r_conj) activity/NN (r_nsubjpass) studied/VBN (l_advcl) bearing/VBG (l_dobj) immunocytoma/NN
D004317_D000419 CID doxorubicin/NN (r_nmod) kg/NNS (r_pobj) of/IN (r_prep) dose/NN (l_relcl) resulted/VBD (l_prep) in/IN (l_pobj) albuminuria/NN
D004317_D007674 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) nephrotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) nephrotoxicity/NN -PUNC- doxorubicin/NN (r_nmod) kg/NNS (r_pobj) of/IN (r_prep) dose/NN (r_pobj) above/IN (r_prep) seen/VBN (l_nsubjpass) evidence/NN (l_prep) of/IN (l_pobj) damage/NN
3832950
D002998_D004827 NONE Clonazepam/NNP (r_compound) monotherapy/NN (l_prep) for/IN (l_pobj) epilepsy/NN -PUNC- clonazepam/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) epilepsy/NN
D002998_D013036 NONE clonazepam/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) types/NNS (l_prep) than/IN (l_pobj) spasms/NNS
24067251
C418563_D005198 CID TDF/NNP (r_npadvmod) related/VBN (r_amod) disease/NN (r_pobj) for/IN (r_prep) criteria/NNS (r_dobj) analysed/VBN (r_acl) records/NNS (r_pobj) Of/IN (r_prep) had/VBD (l_conj) had/VBD (l_dobj) syndrome/NN -PUNC- TDF/NNP (r_compound) effects/NNS (r_pobj) for/IN (r_prep) hospitalisation/NN (r_pobj) of/IN (r_prep) incidence/NN (r_nsubj) was/VBD (l_prep) amongst/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) features/NNS (l_prep) of/IN (l_pobj) syndrome/NN
C418563_D007674 NONE fumarate/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) persons/NNS (r_pobj) in/IN (r_prep) injury/NN -PUNC- TDF/NNP (r_npadvmod) related/VBN (r_amod) disease/NN -PUNC- TDF/NNP (r_npadvmod) related/VBN (r_amod) disease/NN (r_pobj) for/IN (r_prep) criteria/NNS (r_dobj) analysed/VBN (r_acl) records/NNS (r_pobj) Of/IN (r_prep) had/VBD (l_dobj) features/NNS (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- TDF/NNP (r_npadvmod) related/VBN (r_amod) disease/NN (r_pobj) for/IN (r_prep) criteria/NNS (r_dobj) analysed/VBN (r_acl) records/NNS (r_pobj) Of/IN (r_prep) had/VBD (l_conj) found/VBN (l_advcl) have/VB (l_dobj) features/NNS (l_prep) of/IN (l_pobj) dysfunction/NN
23892921
D003907_D009101 NONE dexamethasone/NN (r_conj) lenalidomide/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) on/IN (r_prep) data/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- dexamethasone/NN (r_conj) lenalidomide/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) on/IN (r_prep) data/NNS (l_appos) study/NN (l_prep) of/IN (l_pobj) Group/NNP (l_compound) Myeloma/NNP -PUNC- dexamethasone/NN (r_conj) Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- dexamethasone/NN (r_conj) Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN (l_appos) RRMM/NNP -PUNC- RD/NNP (r_appos) dexamethasone/NN (r_conj) Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- RD/NNP (r_appos) dexamethasone/NN (r_conj) Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN (l_appos) RRMM/NNP -PUNC- RD/NNP (r_dobj) received/VBD (r_relcl) patients/NNS (l_compound) RRMM/NNP -PUNC- RD/NNP (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_conj) safe/JJ (l_prep) in/IN (l_pobj) RRMM/NNP
C467567_D009101 NONE lenalidomide/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) on/IN (r_prep) data/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- lenalidomide/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_pobj) on/IN (r_prep) data/NNS (l_appos) study/NN (l_prep) of/IN (l_pobj) Group/NNP (l_compound) Myeloma/NNP -PUNC- Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN (l_appos) RRMM/NNP -PUNC- RD/NNP (r_appos) dexamethasone/NN (r_conj) Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN -PUNC- RD/NNP (r_appos) dexamethasone/NN (r_conj) Lenalidomide/NNP (r_nsubj) is/VBZ (l_attr) standard/NN (l_prep) for/IN (l_pobj) myeloma/NN (l_appos) RRMM/NNP -PUNC- RD/NNP (r_dobj) received/VBD (r_relcl) patients/NNS (l_compound) RRMM/NNP -PUNC- RD/NNP (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_conj) safe/JJ (l_prep) in/IN (l_pobj) RRMM/NNP
448423
D000614_D007674 NONE acid/NN (r_compound) therapy/NN (l_conj) thrombosis/NN
D015119_D020767 CID EACA/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) syndromes/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) capillary/JJ (r_conj) arteriolar/JJ (r_conj) SAH/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) deterioration/NN (l_conj) thrombosis/NN
D015119_D013923 NONE EACA/NNP (l_conj) phenomena/NNS
D000614_D013345 NONE acid/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hemorrhage/NN
D015119_D013927 CID EACA/NNP (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complications/NNS (l_amod) thrombotic/JJ -PUNC- EACA/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) syndromes/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) capillary/JJ (l_dobj) thrombi/NN -PUNC- EACA/NNP (r_nsubjpass) implicated/VBN (l_advcl) observed/VBN (l_nsubjpass) thrombi/NN -PUNC- EACA/NNP (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) thrombi/NN
D015119_D013345 CID acid/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) rebleeding/NN (l_prep) with/IN (l_pobj) hemorrhage/NN -PUNC- acid/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) rebleeding/NN (l_prep) with/IN (l_pobj) hemorrhage/NN (l_appos) SAH/NNP -PUNC- EACA/NNP (r_appos) acid/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) rebleeding/NN (l_prep) with/IN (l_pobj) hemorrhage/NN -PUNC- EACA/NNP (r_appos) acid/NN (r_nsubjpass) used/VBN (l_xcomp) prevent/VB (l_dobj) rebleeding/NN (l_prep) with/IN (l_pobj) hemorrhage/NN (l_appos) SAH/NNP -PUNC- EACA/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) syndromes/NNS (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) capillary/JJ (r_conj) arteriolar/JJ (r_conj) SAH/NNP -PUNC- EACA/NNP (r_compound) therapy/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) SAH/NNP -PUNC- EACA/NNP (r_compound) therapy/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) documentation/NN (l_prep) of/IN (l_pobj) SAH/NNP
D015119_D004211 NONE EACA/NNP (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) thrombi/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) coagulation/NN -PUNC- EACA/NNP (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) thrombi/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) coagulation/NN (l_conj) coagulopathies/NNS
2884595
D006632_D014917 NONE histamine/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) Blockade/NN (r_nsubj) reduce/VB (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) encephalopathy/NN (l_compound) pertussis/NN
D006632_D001927 NONE histamine/NN (r_compound) receptors/NNS (r_pobj) of/IN (r_prep) Blockade/NN (r_nsubj) reduce/VB (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) encephalopathy/NN
24691439
D003907_D005901 CID dexamethasone/NN (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) led/VBN (l_advcl) resembling/VBG (l_dobj) glaucoma/NN
D003907_D009798 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- Dexamethasone/NN (r_nsubj) induced/VBD (l_conj) reduced/VBN (l_conj) prevented/VBN (l_dobj) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
D003907_D009410 CID dexamethasone/NN (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) led/VBN (l_prep) to/IN (l_pobj) elevation/NN (l_prep) of/IN (l_pobj) pressure/NN (l_appos) loss/NN (l_conj) degeneration/NN
C075773_D009798 NONE 4-phenylbutyrate/RB (r_pobj) with/IN (r_prep) reduction/NN (r_nsubj) prevented/VBN (l_dobj) hypertension/NN
D003907_D012173 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) led/VBN (l_prep) to/IN (l_pobj) elevation/NN (l_prep) of/IN (l_pobj) pressure/NN (l_appos) loss/NN (l_prep) of/IN (l_pobj) cells/NNS (l_compound) ganglion/NN
12948256
D004977_D014388 NONE ethambutol/NN (l_prep) for/IN (l_pobj) tuberculosis/NN (l_prep) of/IN (l_pobj) node/NN
D004977_D014397 NONE ethambutol/NN (l_prep) for/IN (l_pobj) tuberculosis/NN (l_prep) of/IN (l_pobj) node/NN
D004977_D009901 CID Ethambutol/NNP (r_nmod) neuropathy/NN -PUNC- ethambutol/NN (r_amod) neuropathy/NN -PUNC- ethambutol/NN (r_pobj) with/IN (r_prep) treated/VBN (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) neuropathy/NN -PUNC- ethambutol/NN (r_amod) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) had/VBD (l_dobj) neuropathy/NN -PUNC- ethambutol/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) considered/VBN (l_nsubjpass) recognition/NN (l_prep) of/IN (l_pobj) neuropathy/NN
7369302
D011803_D009120 NONE sulfate/NN (l_prep) for/IN (l_pobj) cramps/NNS
D011803_D015845 CID sulfate/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) developed/VBN (r_acl) potentials/NNS (r_conj) supersensitivity/NN (r_conj) response/NN (l_amod) pupillary/JJ -PUNC- quinine/NN (r_compound) toxicity/NN (r_pobj) in/IN (r_prep) potentials/NNS (r_conj) supersensitivity/NN (r_conj) response/NN (l_amod) pupillary/JJ
D011803_D000550 CID quinine/NN (r_compound) amblyopia/NN
D011803_D001766 CID sulfate/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) developed/VBN (r_acl) potentials/NNS (r_conj) supersensitivity/NN (r_conj) response/NN (r_pobj) with/IN (r_prep) blindness/NN
D011803_D064420 NONE quinine/NN (r_compound) toxicity/NN
20046642
D008315_D009369 NONE malondialdehyde/NN (r_conj) MT/NNP (r_appos) alpha/NN (r_appos) factor/NN (l_compound) necrosis/NN (l_compound) tumor/NN -PUNC- MDA/NNP (r_nmod) contents/NNS (l_nmod) factor/NN (l_compound) necrosis/NN (l_compound) tumor/NN
D002330_D064420 NONE BCNU/NNP (r_npadvmod) induced/VBN (r_amod) toxicity/NN
D002330_D009369 NONE BCNU/NNP (r_compound) administration/NN (r_nsubj) increased/VBD (l_dobj) contents/NNS (l_nmod) factor/NN (l_compound) necrosis/NN (l_compound) tumor/NN
D002330_D007859 CID BCNU/NNP (r_nsubj) revealed/VBD (l_ccomp) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- BCNU/NNP (r_compound) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D008668_D064420 NONE MT/NNP (r_compound) induction/NN (r_nsubj) halts/VBZ (l_dobj) toxicity/NN
D008668_D009336 NONE MT/NNP (r_appos) alpha/NN (r_appos) factor/NN (l_compound) necrosis/NN
D002330_D009336 NONE BCNU/NNP (r_compound) administration/NN (r_nsubj) increased/VBD (l_dobj) contents/NNS (l_nmod) factor/NN (l_compound) necrosis/NN
D005978_D064420 NONE GSH/NNP (r_compound) depletion/NN (r_conj) inhibition/NN (r_dobj) prevented/VBD (r_advcl) halts/VBZ (l_dobj) toxicity/NN
D008315_D009336 NONE malondialdehyde/NN (r_conj) MT/NNP (r_appos) alpha/NN (r_appos) factor/NN (l_compound) necrosis/NN -PUNC- MDA/NNP (r_nmod) contents/NNS (l_nmod) factor/NN (l_compound) necrosis/NN
D008668_D009369 NONE MT/NNP (r_appos) alpha/NN (r_appos) factor/NN (l_compound) necrosis/NN (l_compound) tumor/NN
D005978_D007859 NONE glutathione/NN (r_compound) reductase/NN (r_pobj) with/IN (r_prep) accompanied/VBN (r_conj) measured/VBN (r_advcl) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- glutathione/NN (r_nmod) content/NN (r_conj) activity/NN (r_appos) reductase/NN (r_pobj) with/IN (r_prep) accompanied/VBN (r_conj) measured/VBN (r_advcl) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- GSH/NNP (r_nmod) content/NN (r_conj) activity/NN (r_appos) reductase/NN (r_pobj) with/IN (r_prep) accompanied/VBN (r_conj) measured/VBN (r_advcl) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D002330_D003072 CID carmustine/NN (l_appos) dysfunction/NN -PUNC- BCNU)-induced/VBN (r_amod) dysfunction/NN
D008668_D003072 NONE MT/NNP (r_compound) induction/NN (l_prep) on/IN (l_pobj) carmustine/NN (l_appos) dysfunction/NN
D005978_D008569 NONE glutathione/NN (r_compound) reductase/NN (r_pobj) with/IN (r_prep) accompanied/VBN (r_conj) measured/VBN (r_advcl) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- glutathione/NN (r_nmod) content/NN (r_conj) activity/NN (r_appos) reductase/NN (r_pobj) with/IN (r_prep) accompanied/VBN (r_conj) measured/VBN (r_advcl) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- GSH/NNP (r_nmod) content/NN (r_conj) activity/NN (r_appos) reductase/NN (r_pobj) with/IN (r_prep) accompanied/VBN (r_conj) measured/VBN (r_advcl) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D002330_D008569 CID BCNU/NNP (r_nsubj) revealed/VBD (l_ccomp) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- BCNU/NNP (r_compound) administration/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) deterioration/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D008315_D064420 NONE MDA/NNP (r_conj) TNFalpha/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_dobj) counteracted/VBD (r_conj) prevented/VBD (r_advcl) halts/VBZ (l_dobj) toxicity/NN
9382023
D004280_D006973 CID dobutamine/NN (r_compound) stress/NN (r_compound) echocardiography/RB (r_pobj) during/IN (r_prep) response/NN (l_amod) Hypertensive/JJ -PUNC- dobutamine/NN (r_compound) stress/NN (r_compound) echocardiographic/JJ (r_amod) studies/NNS (r_pobj) Among/IN (r_prep) response/NN (l_amod) hypertensive/JJ -PUNC- dobutamine/NN (r_compound) infusion/NN (r_pobj) before/IN (r_prep) had/VBD (r_conj) had/VBD (l_dobj) history/NN (l_prep) of/IN (l_pobj) hypertension/NN
24665854
D014635_D022124 CID Valproate/NNP (r_npadvmod) induced/VBN (l_dobj) encephalopathy/NN (l_det) hyperammonemic/JJ -PUNC- Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (l_det) hyperammonemic/JJ -PUNC- valproate/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) encephalopathy/NN (l_det) hyperammonemic/JJ -PUNC- valproate/NN (l_conj) revealed/VBN (l_dobj) consciousness/NN (l_prep) with/IN (l_pobj) hyperammonemia/NN
D014635_D003244 CID valproate/NN (l_conj) revealed/VBN (l_dobj) consciousness/NN
D014635_D001927 NONE Valproate/NNP (r_npadvmod) induced/VBN (l_dobj) encephalopathy/NN -PUNC- Valproate/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- valproate/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) encephalopathy/NN
D014635_D004827 NONE valproate/NN (l_prep) due/JJ (l_prep) to/IN (l_pobj) epilepsy/NN
12677626
C476513_D012640 NONE levobupivacaine/PRP (r_nsubj) have/VB (r_advcl) result/VB (l_prep) in/IN (l_pobj) convulsions/NNS -PUNC- levobupivacaine/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_nsubj) reach/VBP (r_advcl) result/VB (l_prep) in/IN (l_pobj) convulsions/NNS
D013390_D012640 NONE succinylcholine/NN (r_pobj) to/IN (r_prep) addition/NN (r_pobj) in/IN (r_prep) treated/VBN (l_nsubjpass) seizures/NNS
C476513_D066126 NONE levobupivacaine/PRP (r_nsubj) have/VB (l_dobj) profile/NN (l_compound) toxicity/NN -PUNC- levobupivacaine/NN (r_pobj) of/IN (r_prep) amounts/NNS (r_nsubj) reach/VBP (r_advcl) result/VB (l_advcl) have/VB (l_dobj) profile/NN (l_compound) toxicity/NN
D004837_D004830 NONE epinephrine/NN (r_nmod) mL/NNP (r_pobj) with/IN (r_prep) %/NN (r_appos) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) seizures/NNS -PUNC- epinephrine/NN (r_compound) administration/NN (r_pobj) of/IN (r_prep) signs/NNS (r_conj) aspiration/NN (r_pobj) despite/IN (r_prep) developed/VBD (l_dobj) seizures/NNS
D002045_D012640 NONE bupivacaine/NN (r_pobj) than/IN (r_prep) profile/NN (r_dobj) have/VB (r_advcl) result/VB (l_prep) in/IN (l_pobj) convulsions/NNS
D013874_D012640 NONE thiopental/VBN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) seizures/NNS
C476513_D020258 NONE levobupivacaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_dobj) following/VBG (r_prep) toxicity/NN
C476513_D004830 CID levobupivacaine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) describe/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- levobupivacaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) seizures/NNS
D002045_D066126 NONE bupivacaine/NN (r_pobj) than/IN (r_prep) profile/NN (l_compound) toxicity/NN
8819482
D002118_D023921 NONE calcium/NN (r_compound) antagonist/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) ischemia/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN
D004110_D017202 NONE diltiazem/NN (r_conj) nifedipine/NN (r_pobj) for/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) studied/VBN (l_nsubjpass) ischemia/NN
D007545_D003251 NONE ISO/NN (r_compound) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- ISO/NN (r_compound) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- ISO/NN (r_compound) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- ISO/NN (r_compound) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN
D004110_D003251 NONE Diltiazem/NNP (r_nsubj) prevented/VBD (l_conj) elevation/NN (l_prep) from/IN (l_prep) at/IN (l_pobj) min/NN (l_prep) after/IN (l_pobj) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN
C082828_D003251 NONE CD-832/NNP (r_punct) performed/VBN (l_nsubjpass) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- CD-832/NNP (r_nsubj) prevented/VBD (l_conj) elevation/NN (l_prep) at/IN (l_pobj) min/NN (l_prep) after/IN (l_pobj) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- CD-832/NNP (r_nsubj) improves/VBZ (l_prep) during/IN (l_pobj) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- CD-832/NNP (r_punct) plays/VBZ (r_ccomp) suggest/VBP (r_conj) improves/VBZ (l_prep) during/IN (l_pobj) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- CD-832/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) in/IN (r_prep) plays/VBZ (r_ccomp) suggest/VBP (r_conj) improves/VBZ (l_prep) during/IN (l_pobj) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN
D004110_D023921 NONE diltiazem/NN (r_conj) nifedipine/NN (r_pobj) for/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) studied/VBN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN
D009543_D003251 NONE nifedipine/NN (r_pobj) to/IN (r_prep) contrast/NN (r_pobj) In/IN (r_prep) prevented/VBD (l_conj) elevation/NN (l_prep) at/IN (l_pobj) min/NN (l_prep) after/IN (l_pobj) infusion/NN (l_prep) with/IN (l_pobj) stenosis/NN
D009543_D017202 NONE nifedipine/NN (r_pobj) for/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) studied/VBN (l_nsubjpass) ischemia/NN
D007545_D023921 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- isoproterenol/NN (r_pobj) on/IN (r_prep) Effects/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- ISO)-induced/VBN (r_nmod) ischemia/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- ISO/NNP (r_compound) infusion/NN (r_pobj) of/IN (r_prep) periods/NNS (r_nsubj) increased/VBN (l_prep) In/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) stenosis/NN
D007545_D017202 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN -PUNC- isoproterenol/NN (r_pobj) on/IN (r_prep) Effects/NNS (r_nsubjpass) studied/VBN (l_nsubjpass) ischemia/NN -PUNC- ISO)-induced/VBN (r_nmod) ischemia/NN -PUNC- ISO/NN (r_compound) infusion/NN (r_pobj) during/IN (r_prep) improves/VBZ (l_dobj) ischemia/NN
D002118_D017202 NONE calcium/NN (r_compound) antagonist/NN (r_pobj) of/IN (r_prep) Effects/NNS (l_prep) on/IN (l_pobj) ischemia/NN
D009543_D023921 NONE nifedipine/NN (r_pobj) for/IN (r_prep) those/DT (r_pobj) with/IN (r_prep) compared/VBN (r_prep) studied/VBN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN
C082828_D017202 NONE CD-832/NNP (r_punct) ,/, (r_punct) Effects/NNS (l_prep) on/IN (l_pobj) ischemia/NN -PUNC- CD-832/NNP (r_pobj) of/IN (r_prep) Effects/NNS (r_nsubjpass) studied/VBN (l_nsubjpass) ischemia/NN -PUNC- CD-832/NNP (r_nsubj) improves/VBZ (l_dobj) ischemia/NN -PUNC- CD-832/NNP (r_punct) plays/VBZ (r_ccomp) suggest/VBP (r_conj) improves/VBZ (l_dobj) ischemia/NN -PUNC- CD-832/NNP (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) in/IN (r_prep) plays/VBZ (r_ccomp) suggest/VBP (r_conj) improves/VBZ (l_dobj) ischemia/NN
C082828_D023921 NONE CD-832/NNP (r_punct) ,/, (r_punct) Effects/NNS (l_prep) on/IN (l_pobj) ischemia/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN -PUNC- CD-832/NNP (r_pobj) of/IN (r_prep) Effects/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) stenosis/NN
9570197
D003042_D002637 NONE hydrochloride/NN (r_conj) subjects/NNS (r_appos) n=10/NNP (r_appos) volumes/NNS (r_conj) measured/VBD (l_ccomp) referred/VBD (l_prep) for/IN (l_pobj) catheterization/NN (l_prep) for/IN (l_pobj) evaluation/NN (l_prep) of/IN (l_pobj) pain/NN
D003042_D018487 CID cocaine/NN (r_pobj) of/IN (r_prep) amount/NN (r_nsubj) causes/VBZ (l_dobj) deterioration/NN (l_prep) of/IN (l_pobj) function/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) causes/VBZ (l_dobj) deterioration/NN (l_prep) of/IN (l_pobj) performance/NN
7727612
D008140_D009207 CID lorazepam/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) Myoclonus/NNP -PUNC- lorazepam/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) myoclonus/NN
2718706
D006221_D007022 CID halothane/NN (r_pobj) with/IN (r_prep) labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- halothane/NN (r_appos) anaesthetics/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) agent/NN (l_amod) hypotensive/JJ -PUNC- H/NN (r_compound) concentration/NN (l_prep) during/IN (l_pobj) hypotension/NN
D007741_D013610 NONE labetalol/NN (r_nsubj) induces/VBZ (l_dobj) hypotension/NN (l_prep) without/IN (l_pobj) tachycardia/NNS
D003404_D007022 NONE creatinine/NN (r_compound) concentration/NN (r_nsubj) rose/VBD (l_prep) During/IN (l_pobj) hypotension/NN -PUNC- creatinine/NN (r_compound) concentration/NN (r_nsubj) rose/VBD (l_prep) before/IN (l_pobj) hypotension/NN
D007741_D007022 CID labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- labetalol/NN (r_dobj) using/VBG (l_prep) as/IN (l_pobj) agent/NN (l_amod) hypotensive/JJ -PUNC- labetalol/NN (r_nsubj) induces/VBZ (l_dobj) hypotension/NN
D004737_D007022 CID enflurane/NN (r_conj) halothane/NN (r_pobj) with/IN (r_prep) labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- enflurane/NN (r_conj) halothane/NN (r_appos) anaesthetics/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) agent/NN (l_amod) hypotensive/JJ -PUNC- E/NN (r_compound) concentration/NN (r_appos) concentration/NN (l_prep) during/IN (l_pobj) hypotension/NN
D007530_D007022 CID isoflurane/RB (r_conj) enflurane/NN (r_conj) halothane/NN (r_pobj) with/IN (r_prep) labetalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hypotension/NN -PUNC- isoflurane/RB (r_conj) enflurane/NN (r_conj) halothane/NN (r_appos) anaesthetics/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) agent/NN (l_amod) hypotensive/JJ -PUNC- isoflurane/JJ (r_amod) group/NN (r_pobj) except/IN (r_prep) returned/VBD (r_conj) rose/VBD (l_prep) During/IN (l_pobj) hypotension/NN -PUNC- isoflurane/JJ (r_amod) group/NN (r_pobj) except/IN (r_prep) returned/VBD (r_conj) rose/VBD (l_prep) before/IN (l_pobj) hypotension/NN
D007741_D006973 NONE labetalol/NN (r_nsubj) induces/VBZ (l_dobj) hypotension/NN (l_conj) hypertension/NN
19655282
D003042_D017202 CID cocaine/NN (r_npadvmod) associated/VBN (r_amod) ischemia/NN -PUNC- cocaine/NN (r_pobj) with/IN (r_prep) patients/NNS (r_nsubjpass) discharged/VBN (r_acl) vasoconstriction/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) ischemia/NN
D003042_D002637 CID cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) ischemia/NN (r_nsubj) result/VB (l_prep) from/IN (l_pobj) vasoconstriction/NN (l_acl) discharged/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cocaine/NN (l_acl) associated/VBN (l_dobj) pain/NN -PUNC- cocaine/NN (l_acl) associated/VBN (l_dobj) pain/NN
D003042_D054058 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) with/IN (r_prep) presenting/VBG (r_acl) patients/NNS (r_nsubjpass) admitted/VBN (l_conj) receive/VB (l_dobj) protocol/NN (l_nmod) syndrome/NN
D003042_D003329 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) in/IN (r_prep) efficacious/JJ (r_acomp) be/VB (l_advcl) account/VB (l_nsubj) vasospasm/NN
D003042_D007511 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) in/IN (r_prep) efficacious/JJ (r_acomp) be/VB (l_advcl) account/VB (l_prep) for/IN (l_pobj) some/DT (l_prep) of/IN (l_pobj) ischemia/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) ischemia/NN (r_nsubj) result/VB (l_prep) from/IN (l_pobj) vasoconstriction/NN (l_acl) discharged/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cocaine/NN (l_acl) associated/VBN (l_dobj) pain/NN (l_conj) ECG/NNP (l_amod) ischemic/JJ -PUNC- cocaine/NN (l_acl) associated/VBN (l_dobj) pain/NN (l_conj) ECG/NNP (l_amod) ischemic/JJ
12119460
D002955_D013274 NONE acid/NN (l_prep) in/IN (l_pobj) combination/NN (l_prep) with/IN (l_pobj) C/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- acid/NN (r_nmod) FA/NNP (r_dobj) folinic/VB (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimens/NNS (l_prep) in/IN (l_pobj) cancer/NN -PUNC- acid/NN (r_nmod) FA/NNP (r_dobj) folinic/VB (r_conj) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_nsubj) AGC/NNP -PUNC- FA/NNP (r_dobj) folinic/VB (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimens/NNS (l_prep) in/IN (l_pobj) cancer/NN -PUNC- FA/NNP (r_dobj) folinic/VB (r_conj) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_nsubj) AGC/NNP -PUNC- FA/NNP (r_nmod) m(2/NN (r_punct) )/-RRB- (r_punct) patients/NNS (l_prep) with/IN (l_pobj) AGC/NNP -PUNC- FA/NNP (r_nmod) MMC/NNP (r_nsubj) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) AGC/NNP
D016685_D013274 NONE C/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- MMC/NNP (r_nsubj) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) AGC/NNP
D002955_D064420 NONE acid/NN (r_nmod) FA/NNP (r_dobj) folinic/VB (r_conj) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_xcomp) be/VB (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- FA/NNP (r_dobj) folinic/VB (r_conj) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_xcomp) be/VB (l_prep) with/IN (l_pobj) toxicity/NN
D002945_D006463 NONE cisplatin/NN (r_advmod) containing/VBG (r_amod) regimens/NNS (r_pobj) to/IN (r_prep) alternative/NN (r_pobj) as/IN (r_prep) serve/VB (r_ccomp) has/VBZ (l_xcomp) considered/VBN (l_ccomp) occur/VB (l_nsubj) HUS/NNP
D005472_D013274 NONE 5-fluorouracil/CD (r_punct) folinic/JJ (r_compound) acid/NN (l_prep) in/IN (l_pobj) combination/NN (l_prep) with/IN (l_pobj) C/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- 5-fluorouracil/CD (r_punct) (/-LRB- (r_punct) 5-FU/CD (l_conj) folinic/VB (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimens/NNS (l_prep) in/IN (l_pobj) cancer/NN -PUNC- 5-fluorouracil/CD (r_punct) (/-LRB- (r_punct) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_nsubj) AGC/NNP -PUNC- 5-FU/CD (l_conj) folinic/VB (l_prep) as/IN (l_pobj) part/NN (l_prep) of/IN (l_pobj) regimens/NNS (l_prep) in/IN (l_pobj) cancer/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_nsubj) AGC/NNP -PUNC- 5-FU/CD (r_dobj) receive/VB (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) AGC/NNP -PUNC- 5-FU/CD (r_nmod) MMC/NNP (r_nsubj) is/VBZ (l_attr) regimen/NN (l_prep) for/IN (l_pobj) AGC/NNP
D005472_D064420 NONE 5-fluorouracil/CD (r_punct) (/-LRB- (r_punct) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_xcomp) be/VB (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_nsubj) shown/VBN (l_xcomp) be/VB (l_prep) with/IN (l_pobj) toxicity/NN
9125676
D013015_D006331 NONE sotalol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) years/NNS (r_pobj) after/IN (r_prep) had/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) disease/NN
D013015_D016171 CID sotalol/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) pointes/FW (r_pobj) for/IN (r_prep) factors/NNS (r_conj) incidence/NN (l_prep) of/IN (l_pobj) pointes/FW -PUNC- sotalol/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) pointes/FW -PUNC- sotalol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) had/VBD (l_prep) from/IN (l_pobj) pointes/FW -PUNC- sotalol/NN (r_nsubj) was/VBD (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) pointes/FW -PUNC- sotalol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) years/NNS (r_pobj) after/IN (r_prep) had/VBD (l_dobj) pointes/NNS -PUNC- sotalol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) occurred/VBD (l_nsubj) pointes/NNS -PUNC- sotalol/NN (r_nsubj) identify/VB (l_dobj) subgroup/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) pointes/FW -PUNC- sotalol/NN (r_nsubj) identify/VB (l_prep) at/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) pointes/FW
D013015_D017180 NONE sotalol/NN (l_prep) for/IN (l_pobj) tachyarrhythmias/NNS -PUNC- sotalol/NN (l_prep) for/IN (l_pobj) tachyarrhythmias/NNS -PUNC- sotalol/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) tachycardia/NN -PUNC- sotalol/NN (r_dobj) received/VBD (l_advcl) prevent/VB (l_dobj) induction/NN (l_prep) of/IN (l_pobj) tachyarrhythmia/NN -PUNC- sotalol/NN (r_nsubj) prevented/VBN (l_dobj) induction/NN (l_prep) of/IN (l_pobj) tachycardia/NN -PUNC- sotalol/NN (r_dep) remained/VBD (r_conj) prevented/VBN (l_nsubjpass) Induction/NN (l_prep) of/IN (l_pobj) tachyarrhythmia/NN -PUNC- sotalol/NN (r_dep) remained/VBD (l_nsubj) tachyarrhythmia/NN -PUNC- sotalol/NN (r_pobj) of/IN (r_prep) mg/NN (r_dobj) tolerate/VB (r_conj) prevented/VBN (l_nsubjpass) Induction/NN (l_prep) of/IN (l_pobj) tachyarrhythmia/NN -PUNC- sotalol/NN (r_pobj) of/IN (r_prep) mg/NN (r_dobj) tolerate/VB (r_conj) prevented/VBN (l_conj) remained/VBD (l_nsubj) tachyarrhythmia/NN
D013015_-1 NONE sotalol/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) proarrhythmia/NN
D013015_D003324 NONE sotalol/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_appos) 54/CD (l_prep) with/IN (l_pobj) disease/NN
D013015_D014693 NONE sotalol/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) tachycardia/NN (l_conj) fibrillation/NN -PUNC- sotalol/NN (r_nsubj) prevented/VBN (l_dobj) induction/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_conj) fibrillation/NN
D013015_D002311 NONE sotalol/NN (r_dobj) received/VBD (l_nsubj) patients/NNS (l_appos) 54/CD (l_conj) 20/CD (l_prep) with/IN (l_pobj) cardiomyopathy/NN
25031906
D017311_D004408 CID Amlodipine/NNP (r_pobj) of/IN (r_prep) effect/NN (r_attr) be/VB (r_xcomp) Going/VBG (l_compound) Dysguesia/NNP -PUNC- amlodipine/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) is/VBZ (l_acomp) dysguesia/JJ -PUNC- amlodipine/NN (r_nsubj) cause/VB (l_dobj) dysguesia/NN -PUNC- amlodipine/NN (l_conj) dysguesia/NN
D017311_D012678 NONE amlodipine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_prep) hypertension/NN (r_pobj) with/IN (r_prep) female/NN (r_pobj) about/IN (r_prep) case/NN (r_dobj) report/VBP (l_dobj) loss/NN (l_prep) of/IN (l_pobj) sensation/NN
D017311_D006973 NONE amlodipine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_prep) hypertension/NN
9869655
D001647_D002780 NONE salt/NN (r_nmod) synthesis/NN (r_pobj) of/IN (r_prep) pathway/NN (r_pobj) of/IN (r_prep) inhibition/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) ethinylestradiol/NNP (l_appos) cholestasis/NN -PUNC- BS/NN (r_nmod) synthesis/NN (r_pobj) of/IN (r_prep) pathway/NN (r_pobj) of/IN (r_prep) inhibition/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) ethinylestradiol/NNP (l_appos) cholestasis/NN
D004997_D002780 CID ethinylestradiol/NNP (l_appos) cholestasis/NN -PUNC- EE)-induced/VBN (r_nmod) cholestasis/NN
12165618
D019469_D015658 NONE indinavir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) children/NNS (l_amod) 1-infected/VBN -PUNC- indinavir/NNS (r_npadvmod) related/VBN (r_amod) nephrotoxicity/NN (r_dobj) monitor/VB (l_prep) in/IN (l_pobj) cohort/NN (l_prep) of/IN (l_pobj) children/NNS (l_amod) 1-infected/VBN -PUNC- indinavir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) children/NNS (l_amod) 1-infected/VBN
D019469_D007674 CID indinavir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) children/NNS (r_dobj) associated/VBN (l_prep) with/IN (l_pobj) function/NN -PUNC- indinavir/NNS (r_npadvmod) related/VBN (r_amod) nephrotoxicity/NN -PUNC- indinavir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) children/NNS (r_pobj) of/IN (r_prep) cohort/NN (r_pobj) in/IN (r_prep) monitor/VB (l_dobj) nephrotoxicity/NN -PUNC- indinavir/NNS (r_nsubjpass) discontinued/VBN (l_prep) of/IN (l_pobj) nephrotoxicity/NN -PUNC- Indinavir/NNP (r_npadvmod) associated/VBN (r_amod) nephrotoxicity/NN -PUNC- indinavir/NNS (r_pobj) of/IN (r_prep) curve/NN (r_pobj) under/IN (r_prep) area/NN (r_appos) age/NN (r_appos) monitored/VBN (l_nsubjpass) nephrotoxicity/NN
D019469_-1 NONE indinavir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) children/NNS (r_dobj) associated/VBN (l_nsubjpass) leukocyturia/NN -PUNC- indinavir/NNS (r_pobj) of/IN (r_prep) level/NN (r_conj) L/NN (r_appos) >/XX (r_meta) found/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) leukocyturia/NN -PUNC- indinavir/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_csubj) have/VBP (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) leukocyturia/NN -PUNC- Indinavir/NNP (r_npadvmod) associated/VBN (r_amod) nephrotoxicity/NN (r_nsubjpass) monitored/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) factors/NNS (l_prep) as/IN (l_pobj) leukocyturia/NN -PUNC- indinavir/NNS (r_pobj) of/IN (r_prep) curve/NN (r_pobj) under/IN (r_prep) area/NN (r_appos) age/NN (r_appos) monitored/VBN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) factors/NNS (l_prep) as/IN (l_pobj) leukocyturia/NN
D003404_-1 NONE creatinine/NN (r_compound) ratio/NN (r_appos) urine/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) leukocyturia/NN -PUNC- creatinine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (l_nsubj) Children/NNS (l_prep) with/IN (l_pobj) leukocyturia/NN -PUNC- creatinine/JJ (r_compound) levels/NNS (r_dobj) had/VBD (l_prep) without/IN (l_pobj) leukocyturia/NN -PUNC- creatinine/NN (r_compound) levels/NNS (r_nsubj) decreased/VBD (l_conj) returned/VBD (l_conj) disappeared/VBD (l_nsubj) leukocyturia/NN -PUNC- creatinine/NN (r_compound) ratios/NNS (r_nsubj) returned/VBD (l_conj) disappeared/VBD (l_nsubj) leukocyturia/NN -PUNC- creatinine/NN (r_compound) levels/NNS (r_pobj) in/IN (r_prep) increase/NN (r_dobj) had/VBD (l_nsubj) Children/NNS (l_prep) with/IN (l_pobj) leukocyturia/NN
D003404_D006417 NONE creatinine/NN (r_compound) ratio/NN (r_appos) urine/NN (r_pobj) in/IN (l_conj) by/IN (l_pobj) hematuria/NN
20959502
D003404_D058186 NONE creatinine/JJ (r_appos) failure/NN
D008712_D008581 NONE methicillin/NN (r_npadvmod) sensitive/JJ (r_amod) aureus/NNP (l_appos) bacteremia/XX (l_prep) with/IN (l_pobj) meningitis/NN
D017576_D008581 NONE daptomycin/NN (l_prep) in/IN (l_pobj) meningitis/NN -PUNC- daptomycin/NN (r_pobj) with/IN (r_prep) treated/VBD (r_acl) meningitis/NN -PUNC- daptomycin/JJ (r_conj) discontinued/VBN (l_conj) initiated/VBN (l_prep) for/IN (l_pobj) meningitis/NN
D009254_D016470 NONE nafcillin/NN (r_npadvmod) induced/VBN (r_amod) nephritis/NN (l_conj) relapsing/VBG (l_dobj) bacteremia/NN
D009254_D009395 CID nafcillin/NN (r_npadvmod) induced/VBN (r_amod) nephritis/NN
D008712_D016470 NONE methicillin/NN (r_npadvmod) sensitive/JJ (r_amod) aureus/NNP (l_appos) bacteremia/XX
D017576_D016470 NONE daptomycin/NN (r_pobj) with/IN (r_prep) treated/VBD (r_acl) meningitis/NN (r_pobj) with/IN (r_prep) bacteremia/XX -PUNC- Daptomycin/NNP (r_nsubjpass) initiated/VBN (l_dobj) nephritis/NN (l_conj) relapsing/VBG (l_dobj) bacteremia/NN -PUNC- daptomycin/NN (r_nsubj) be/VB (l_attr) option/NN (l_prep) for/IN (l_pobj) bacteremia/VBG
D017576_D009395 NONE Daptomycin/NNP (r_nsubjpass) initiated/VBN (l_dobj) nephritis/NN
D009254_D008581 NONE Nafcillin/NNP (r_nsubjpass) discontinued/VBN (l_conj) initiated/VBN (l_prep) for/IN (l_pobj) meningitis/NN
7661171
D007213_D005355 NONE indomethacin/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (l_prep) in/IN (l_pobj) cirrhosis/NN -PUNC- indomethacin/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) cirrhotic/JJ -PUNC- indomethacin/NN (r_pobj) of/IN (r_prep) mg/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) after/IN (r_conj) before/RB (r_prep) assessed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) cirrhotic/JJ -PUNC- indomethacin/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) prevent/VB (r_acl) ability/NN (r_nsubjpass) confirmed/VBN (r_advcl) be/VB (l_xcomp) avoid/VB (l_dobj) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cirrhosis/NN
D012964_D005355 NONE sodium/NN (r_conj) hemodynamics/NNS (r_pobj) of/IN (r_prep) Parameters/NNS (r_nsubjpass) assessed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) cirrhotic/JJ
D016595_D007674 NONE misoprostol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) dysfunction/NN -PUNC- Misoprostol/NNP (r_nsubjpass) shown/VBN (l_xcomp) counteract/VB (l_dobj) dysfunction/NN
D016595_D005355 NONE misoprostol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) dysfunction/NN (l_prep) in/IN (l_pobj) cirrhosis/NN -PUNC- Misoprostol/NNP (r_nsubjpass) shown/VBN (l_xcomp) counteract/VB (l_dobj) dysfunction/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) cirrhotic/JJ -PUNC- misoprostol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_conj) mg/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) after/IN (r_conj) before/RB (r_prep) assessed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) cirrhotic/JJ -PUNC- misoprostol/NNP (r_pobj) of/IN (r_prep) micrograms/NNS (r_pobj) of/IN (r_prep) ability/NN (r_nsubjpass) confirmed/VBN (r_advcl) be/VB (l_xcomp) avoid/VB (l_dobj) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cirrhosis/NN
D007213_D007674 CID indomethacin/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN -PUNC- indomethacin/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN
12865514
D007980_D009127 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) rigidity/NN
D007980_D010300 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) rigidity/NN (r_conj) bradykinesia/JJ (r_conj) scale/NN (r_appos) patients/NNS (l_acl) suffering/VBG (l_prep) from/IN (l_pobj) disease/NN
D007980_D018476 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) rigidity/NN (r_conj) bradykinesia/JJ
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/JJ (r_compound) dose/NN (r_pobj) in/IN (r_prep) reduction/NN (r_nsubj) is/VBZ (l_acomp) useful/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) dyskinesias/NNS
15282950
D010936_D009202 NONE chebula/NN (l_prep) against/IN (l_pobj) injury/NN -PUNC- fruits/NNS (r_pobj) of/IN (r_prep) extract/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) examined/VBN (l_conj) induced/VBN (l_dobj) damage/NN
D007545_D009202 CID isoproterenol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_advcl) chebula/NN (l_prep) against/IN (l_pobj) injury/NN -PUNC- isoproterenol/NN (r_pobj) in/IN (r_prep) examined/VBN (l_conj) induced/VBN (l_dobj) damage/NN
24438483
D002045_D001145 NONE bupivacaine/NN (r_compound) consumption/NN (r_pobj) of/IN (r_prep) amount/NN (r_conj) time/NN (r_conj) pressure/NN (r_conj) times/NNS (r_npadvmod) recorded/VBD (l_prep) to/IN (l_pobj) occurrence/NN (l_amod) dysrhythmia/NN
D002045_D006323 CID bupivacaine/NN (r_compound) consumption/NN (r_pobj) of/IN (r_prep) amount/NN (r_conj) time/NN (l_relcl) asystole/NN
D015742_D002318 NONE propofol/NN (r_pobj) of/IN (r_prep) formulations/NNS (r_dobj) using/VBG (l_nsubj) treatment/NN (l_prep) of/IN (l_pobj) depression/NN
D015742_D066126 NONE propofol/NN (r_pobj) of/IN (r_prep) content/NN (r_nsubj) alleviate/VB (l_dobj) cardiotoxicity/NN -PUNC- propofol/NN (l_prep) in/IN (l_pobj) intralipid/NN (l_conj) emulsions/NNS (l_prep) on/IN (l_pobj) cardiotoxicity/NN -PUNC- propofol/NN (r_dobj) conclude/VBP (l_conj) induced/VBN (l_dobj) effects/NNS (l_amod) cardiotoxic/JJ -PUNC- propofol/NN (r_pcomp) with/IN (r_prep) compared/VBN (r_prep) propofol/NN (r_dobj) conclude/VBP (l_conj) induced/VBN (l_dobj) effects/NNS (l_amod) cardiotoxic/JJ
D002045_D002318 NONE bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) depression/NN
D002045_D066126 CID bupivacaine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) increase/VB (r_xcomp) shown/VBN (l_conj) alleviate/VB (l_dobj) cardiotoxicity/NN -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- bupivacaine/NN (r_npadvmod) induced/VBN (r_compound) cardiotoxicity/NN -PUNC- bupivacaine/NN (r_pobj) of/IN (r_prep) onset/NN (r_dobj) delayed/VBD (r_conj) conclude/VBP (l_conj) induced/VBN (l_dobj) effects/NNS (l_amod) cardiotoxic/JJ -PUNC- bupivacaine/NN (r_compound) levels/NNS (r_conj) effects/NNS (l_amod) cardiotoxic/JJ
12912689
D016190_D012175 NONE carboplatin/VBP (l_prep) for/IN (l_pobj) retinoblastoma/NN -PUNC- carboplatin/NN (l_ccomp) used/VBN (l_prep) as/IN (l_pobj) adjunct/NN (l_prep) to/IN (l_pobj) chemotherapy/NN (l_prep) for/IN (l_pobj) retinoblastoma/NN -PUNC- carboplatin/NN (r_ccomp) noted/VBD (l_dobj) motility/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) retinoblastoma/NN -PUNC- carboplatin/NN (r_advmod) detected/VBN (l_prep) in/IN (l_pobj) eyes/NNS (l_prep) of/IN (l_pobj) patients/NNS (l_acl) treated/VBN (l_prep) for/IN (l_pobj) retinoblastoma/NN
D016190_D064420 NONE carboplatin/NN (l_ccomp) used/VBN (l_prep) as/IN (l_pobj) adjunct/NN (l_amod) free/JJ (l_npadvmod) toxicity/NN -PUNC- carboplatin/NN (r_nsubj) is/VBZ (l_acomp) free/JJ (l_prep) of/IN (l_pobj) toxicity/NN
D016190_D005355 CID carboplatin/NN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) fibrosis/NN
D016190_D015835 CID carboplatin/NN (r_amod) chemotherapy/NN (r_dobj) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) motility/NN -PUNC- carboplatin/NN (r_ccomp) noted/VBD (l_dobj) motility/NN
20513036
C542870_D010243 NONE botox/JJ (r_compound) injection/NN (r_pobj) after/IN (r_prep) paralysis/NN -PUNC- Botox/NNP (r_compound) injections/NNS (r_pobj) following/VBG (r_prep) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) paralysis/NN -PUNC- Botox/NNP (r_compound) dose/NN (r_conj) sex/NN (r_conj) age/NN (r_conj) paralysis/NN -PUNC- Botox/NNP (r_compound) dose/NN (l_conj) dose/NN (l_conj) paralysis/NN -PUNC- Botox/NNP (r_compound) dose/NN (r_conj) dose/NN (r_conj) sex/NN (r_conj) age/NN (r_conj) paralysis/NN -PUNC- Botox/NNP (r_compound) dose/NN (l_conj) paralysis/NN -PUNC- Botox/NNP (r_compound) injection/NN (r_pobj) after/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) paralysis/NN -PUNC- Botox/NNP (r_compound) injections/NNS (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) paralysis/NN -PUNC- Botox/NNP (r_pobj) of/IN (r_prep) diffusion/NN (r_attr) is/VBZ (l_nsubj) mechanism/NN (l_prep) of/IN (l_pobj) paralysis/NN
C542870_D014826 CID botox/JJ (r_compound) injection/NN (l_prep) for/IN (l_pobj) dysphonia/NN -PUNC- Botox/NNP (r_appos) toxin/NN (r_nsubj) are/VBP (l_attr) standard/NN (l_prep) for/IN (l_pobj) dysphonia/NN -PUNC- Botox/NNP (r_appos) toxin/NN (r_nsubj) are/VBP (l_attr) standard/NN (l_prep) for/IN (l_pobj) dysphonia/NN (l_appos) ADSD/NNP -PUNC- Botox/NNP (r_compound) injections/NNS (l_prep) for/IN (l_pobj) ADSD/NNP -PUNC- Botox/NNP (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) of/IN (r_prep) database/NN (r_pobj) From/IN (r_prep) diagnosed/VBN (l_prep) with/IN (l_pobj) ADSD/NNP -PUNC- Botox/NNP (r_compound) injection/NN (l_prep) for/IN (l_pobj) ADSD/NNP -PUNC- Botox/NNP (r_compound) injections/NNS (l_prep) for/IN (l_pobj) ADSD/NNP
C542870_D055154 NONE Botox/NNP (r_compound) injections/NNS (r_dobj) received/VBD (l_prep) for/IN (l_pobj) dysphonia/NN
19447152
D010042_D001714 CID ouabain/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) model/NN (l_prep) of/IN (l_pobj) mania/NN -PUNC- ouabain/NN (r_pobj) of/IN (r_prep) administration/NN (r_appos) intracerebroventricular/JJ (r_nsubjpass) suggested/VBN (l_xcomp) mimic/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) mania/NN -PUNC- ouabain/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (l_nmod) mania/NN -PUNC- ouabain/NN (r_npadvmod) induced/VBN (r_amod) behavior/NN (r_nsubj) provide/VB (l_dobj) model/NN (l_relcl) test/VB (l_dobj) hypothesis/NN (l_prep) of/IN (l_pobj) involvement/NN (l_prep) of/IN (l_pobj) stress/NN (l_prep) in/IN (l_pobj) disorder/NN
D012964_D001714 NONE Na(+)/K(+)-ATPase/NNP (r_compound) inhibitor/NN (r_appos) administration/NN (r_appos) intracerebroventricular/JJ (r_nsubjpass) suggested/VBN (l_xcomp) mimic/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) mania/NN
D010042_D009069 NONE ouabain/NN (r_nsubj) induced/VBN (l_dobj) hyperlocomotion/NN
D011188_D001714 NONE Na(+)/K(+)-ATPase/NNP (r_compound) inhibitor/NN (r_appos) administration/NN (r_appos) intracerebroventricular/JJ (r_nsubjpass) suggested/VBN (l_xcomp) mimic/VB (l_dobj) symptoms/NNS (l_prep) of/IN (l_pobj) mania/NN
24902786
C067431_D008569 CID letrozole/NN (r_conj) Administration/NN (r_nsubj) impaired/VBD (l_dobj) memory/NN -PUNC- letrozole/NN (r_conj) Administration/NN (r_nsubj) impaired/VBD (l_conj) attenuated/VBD (l_dobj) replacement/NN (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) impairment/NN
D013739_D008569 NONE Testosterone/NN (r_nsubj) ameliorates/VBZ (l_dobj) impairment/NN -PUNC- testosterone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- testosterone/NN (r_compound) replacement/NN (r_dobj) attenuated/VBD (r_conj) impaired/VBD (l_dobj) memory/NN -PUNC- testosterone/NN (r_compound) replacement/NN (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) impairment/NN -PUNC- Testosterone/NN (r_compound) administration/NN (r_nsubj) ameliorates/VBZ (l_dobj) impairment/NN
D013311_D008569 CID streptozotocin/RB (r_npadvmod) induced/VBN (r_amod) impairment/NN -PUNC- streptozotocin/JJ (r_nmod) impairment/NN -PUNC- STZ)-induced/VBN (r_amod) memory/NN (r_compound) impairment/NN -PUNC- STZ-/NNP (r_nmod) impairment/NN (r_dobj) improving/VBG (r_pcomp) in/IN (r_prep) replacement/NN (r_dobj) attenuated/VBD (r_conj) impaired/VBD (l_dobj) memory/NN -PUNC- STZ-/NNP (r_nmod) impairment/NN -PUNC- STZ-/NNP (r_nmod) impairment/NN
D013629_D008569 CID tamoxifen/NN (r_conj) letrozole/NN (r_conj) Administration/NN (r_nsubj) impaired/VBD (l_dobj) memory/NN -PUNC- tamoxifen/NN (r_conj) letrozole/NN (r_conj) Administration/NN (r_nsubj) impaired/VBD (l_conj) attenuated/VBD (l_dobj) replacement/NN (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) impairment/NN
D005485_D008569 CID flutamide/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) impaired/VBD (l_dobj) memory/NN -PUNC- flutamide/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) impaired/VBD (l_conj) attenuated/VBD (l_dobj) replacement/NN (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) impairment/NN
8808730
D009569_D014570 NONE oxide/NN (r_compound) synthase/NN (r_pobj) of/IN (r_prep) expression/NN (r_pobj) in/IN (r_prep) alterations/NNS (l_prep) following/VBG (l_pobj) irritation/NN (l_prep) of/IN (l_pobj) tract/NN
D009569_D001745 NONE oxide/NN (r_compound) synthase/NN (r_pobj) of/IN (r_prep) expression/NN (l_prep) following/VBG (l_pobj) irritation/NN
D000171_D003556 NONE acrolein/NN (r_pobj) to/IN (r_prep) metabolized/VBN (r_relcl) CYP/NNP (r_appos) cyclophosphamide/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) cystitis/NN
D003520_D003556 CID cyclophosphamide/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) cystitis/NN -PUNC- CYP/NNP (r_appos) cyclophosphamide/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) cystitis/NN
10462057
C084325_D009336 NONE NCQ436/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cells/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) necrosis/NN -PUNC- NCQ436/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) cells/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_conj) had/VBD (l_advcl) inducing/VBG (l_advmod) apoptosis/NN (l_prep) at/IN (l_pobj) concentrations/NNS (l_conj) necrosis/NN
D001554_D000741 CID benzene/NN (r_conj) remoxipride/NN (r_nsubj) induce/VB (l_dobj) anemia/NN -PUNC- benzene/NN (r_conj) remoxipride/NN (r_nsubj) induce/VB (r_ccomp) propose/VBP (l_conj) contribute/VB (l_prep) to/IN (l_pobj) anemia/NN
C112341_D000741 NONE NCQ344/NNP (r_conj) NCQ436/NNP (r_pobj) of/IN (r_prep) ability/NN (r_nsubj) apoptosis/NN (r_conj) induce/VB (l_dobj) anemia/NN -PUNC- NCQ344/NNP (r_conj) NCQ436/NNP (r_pobj) of/IN (r_prep) ability/NN (r_nsubj) apoptosis/NN (r_conj) induce/VB (r_ccomp) propose/VBP (l_conj) contribute/VB (l_prep) to/IN (l_pobj) anemia/NN
D017330_D000741 CID remoxipride/NN (r_compound) metabolites/NNS (r_pobj) by/IN (r_agent) apoptosis/NN (r_pobj) of/IN (r_prep) Induction/NN (l_appos) relevance/NN (l_prep) to/IN (l_pobj) anemia/NN -PUNC- remoxipride/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- remoxipride/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anemia/NN -PUNC- amide/NN (r_appos) remoxipride/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) anemia/NN -PUNC- remoxipride/NN (r_nsubj) induce/VB (l_dobj) anemia/NN -PUNC- remoxipride/NN (r_nsubj) induce/VB (r_ccomp) propose/VBP (l_conj) contribute/VB (l_prep) to/IN (l_pobj) anemia/NN -PUNC- remoxipride/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) anemia/NN (r_pobj) to/IN (r_prep) contribute/VB (r_conj) propose/VBP (l_ccomp) induce/VB (l_dobj) anemia/NN -PUNC- remoxipride/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) anemia/NN
C112341_D009336 NONE NCQ344/NNP (r_nsubj) had/VBD (r_conj) observed/VBN (l_nsubjpass) necrosis/NN -PUNC- NCQ344/NNP (r_nsubj) had/VBD (l_advcl) inducing/VBG (l_advmod) apoptosis/NN (l_prep) at/IN (l_pobj) concentrations/NNS (l_conj) necrosis/NN
C084325_D000741 NONE NCQ436/NNP (r_pobj) of/IN (r_prep) ability/NN (r_nsubj) apoptosis/NN (r_conj) induce/VB (l_dobj) anemia/NN -PUNC- NCQ436/NNP (r_pobj) of/IN (r_prep) ability/NN (r_nsubj) apoptosis/NN (r_conj) induce/VB (r_ccomp) propose/VBP (l_conj) contribute/VB (l_prep) to/IN (l_pobj) anemia/NN
17159032
D006886_D014786 CID hydroxychloroquine/NN (r_dobj) taking/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) loss/NN -PUNC- hydroxychloroquine/JJ (r_compound) treatment/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_relcl) abnormalities/NNS
7739955
D002220_D009205 CID carbamazepine/NN (r_npadvmod) induced/VBN (r_amod) myocarditis/NN (r_dobj) had/VBD (l_ccomp) had/VBD (l_dobj) myocarditis/NN -PUNC- carbamazepine/NN (r_npadvmod) induced/VBN (r_amod) myocarditis/NN
D002220_D012770 NONE carbamazepine/NN (r_npadvmod) induced/VBN (r_amod) myocarditis/NN (r_dobj) had/VBD (l_conj) had/VBD (l_dobj) hemosiderosis/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) shock/NN
D002220_D004802 CID carbamazepine/NN (r_npadvmod) induced/VBN (r_amod) myocarditis/NN
8511251
D005996_D007511 NONE nitroglycerin/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) induced/VBN (l_nsubj) ischemia/NN
D002118_D007511 NONE calcium/NN (r_npadvmod) blocking/VBG (r_amod) agents/NNS (r_conj) nitroglycerin/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) induced/VBN (l_nsubj) ischemia/NN
D003042_D017202 CID Cocaine/NN (r_nsubj) induced/VBD (l_dobj) ischemia/NN -PUNC- cocaine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) ischemia/NN
D002118_D003329 NONE calcium/NN (r_npadvmod) blocking/VBG (r_amod) agents/NNS (r_conj) nitroglycerin/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) induced/VBN (l_agent) by/IN (l_pobj) spasm/NN
D005996_D003329 NONE nitroglycerin/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) induced/VBN (l_agent) by/IN (l_pobj) spasm/NN
3475563
D001507_D006685 CID dipropionate/NN (r_pobj) with/IN (r_prep) hoarseness/NN -PUNC- beclomethasone/NN (r_pobj) on/IN (r_prep) placed/VBN (r_relcl) patients/NNS (r_pobj) Of/IN (r_prep) developed/VBD (l_dobj) hoarseness/NN -PUNC- beclomethasone/NN (r_pobj) on/IN (r_prep) restarted/VBN (r_ccomp) conclude/VBP (r_ccomp) be/VB (l_prep) because/IN (l_pobj) rate/NN (l_appos) patients/NNS (l_relcl) develop/VBP (l_dobj) hoarseness/NN -PUNC- beclomethasone/NN (r_conj) prednisone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) hoarseness/NN
D011241_D002177 NONE prednisone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) hoarseness/NN (l_conj) candidiasis/NN
D011241_D006685 NONE prednisone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) hoarseness/NN
D001507_D002177 NONE beclomethasone/NN (r_conj) prednisone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) hoarseness/NN (l_conj) candidiasis/NN
D001507_D001249 NONE beclomethasone/NN (r_pobj) on/IN (r_prep) placed/VBN (r_relcl) patients/NNS (l_amod) asthmatic/JJ
D001507_D002180 CID dipropionate/NN (r_pobj) with/IN (r_prep) hoarseness/NN (r_conj) candidiasis/NN -PUNC- beclomethasone/NN (r_pobj) on/IN (r_prep) placed/VBN (r_relcl) patients/NNS (r_pobj) Of/IN (r_prep) developed/VBD (l_dobj) hoarseness/NN (l_appos) 8)/CD (l_appos) thrush/NN
8308951
D010894_D001778 NONE piroxicam/NN (r_pobj) with/IN (r_prep) interaction/NN (r_nsubj) exacerbated/VBN (l_dobj) coagulopathy/NN
D014859_D006406 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) coagulopathy/NN (r_pobj) due/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) hematoma/NN
D014859_D002543 CID warfarin/VB (r_npadvmod) like/JJ (r_amod) anticoagulant/NN (r_pobj) to/IN (r_prep) exposure/NN (l_acl) causing/VBG (l_dobj) hemorrhage/NN
D014859_D001778 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) coagulopathy/NN -PUNC- warfarin/JJ (r_pobj) of/IN (r_prep) absorption/NN (l_acl) causing/VBG (l_dobj) coagulopathy/NN
25006961
D008094_D011141 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) polyuria/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) NDI/NNP (r_pobj) in/IN (r_prep) preserves/VBZ (l_conj) prevents/VBZ (l_dobj) development/NN (l_prep) of/IN (l_pobj) polyuria/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) polyuria/NN
D008094_D018500 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN -PUNC- Lithium/NN (r_nsubj) induces/VBZ (l_dobj) insipidus/NN -PUNC- Lithium/NN (r_nsubj) induces/VBZ (l_dobj) insipidus/NN (l_appos) NDI/NNP -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_amod) NDI/NNP -PUNC- lithium/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) polyuria/NN (r_pobj) of/IN (r_prep) development/NN (r_dobj) prevents/VBZ (r_conj) preserves/VBZ (l_prep) in/IN (l_pobj) NDI/NNP
24283660
D001663_D012640 NONE bilirubin/NN (r_conj) score/NN (l_ccomp) showed/VBD (l_ccomp) included/VBD (l_nsubj) factors/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) seizures/NNS
D001663_D058625 NONE bilirubin/NN (r_conj) score/NN (l_ccomp) showed/VBD (l_ccomp) included/VBD (l_dobj) gender/NN (l_conj) score/NN (l_compound) disease/NN
D016559_D012640 CID Tacrolimus/NNP (r_npadvmod) related/VBN (r_amod) seizure/NN -PUNC- TAC/NNP (r_compound) level/NN (r_pobj) trough/NN (r_conj) bilirubin/NN (r_conj) score/NN (l_ccomp) showed/VBD (l_ccomp) included/VBD (l_nsubj) factors/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- TAC/NNP (r_compound) level/NN (r_nsubj) was/VBD (l_attr) factor/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- TAC/NNP (r_compound) level/NN (r_nsubj) was/VBD (l_attr) factor/NN (l_relcl) contributed/VBD (l_prep) to/IN (l_pobj) seizures/NNS -PUNC- TAC/NNP (r_npadvmod) related/VBN (r_amod) seizures/NNS
D016559_D058625 NONE TAC/NNP (r_compound) level/NN (r_pobj) trough/NN (r_conj) bilirubin/NN (r_conj) score/NN (l_ccomp) showed/VBD (l_ccomp) included/VBD (l_dobj) gender/NN (l_conj) score/NN (l_compound) disease/NN
2239937
D002119_D006934 CID carbonate/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) hypercalcemia/NN -PUNC- carbonate/NN (r_pobj) to/IN (r_prep) switching/VBG (r_pcomp) after/IN (r_prep) became/VBD (l_acomp) hypercalcemic/JJ
D002118_D007674 NONE calcium/NN (r_compound) reabsorption/NN (r_pobj) of/IN (r_prep) parameters/NNS (r_appos) factors/NNS (r_dobj) identify/VB (r_acl) order/NN (r_pobj) In/IN (r_prep) compared/VBN (l_prep) with/IN (l_pobj) results/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_acl) matched/VBN (l_prep) for/IN (l_pobj) age/NN (l_conj) sex/NN (l_conj) length/NN (l_conj) etiology/NN (l_prep) of/IN (l_pobj) disease/NN
D010710_D006934 NONE phosphate/NN (r_compound) binder/NN (r_pobj) as/IN (r_prep) switching/VBG (r_pcomp) after/IN (r_prep) became/VBD (l_acomp) hypercalcemic/JJ
D002118_D006934 NONE calcium/NN (r_compound) reabsorption/NN (r_pobj) of/IN (r_prep) parameters/NNS (r_appos) factors/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) hypercalcemia/NN -PUNC- calcium/NN (r_compound) values/NNS (r_pobj) with/IN (r_prep) episodes/NNS (l_amod) hypercalcemic/JJ -PUNC- calcium/NN (r_compound) values/NNS (r_pobj) with/IN (r_prep) episodes/NNS (r_dobj) experiencing/VBG (r_pcomp) to/IN (r_prep) addition/NN (r_pobj) In/IN (r_prep) exhibited/VBD (l_nsubj) patients/NNS (l_prep) in/IN (l_pobj) group/NN (l_amod) hypercalcemic/NN -PUNC- calcium/NN (r_compound) concentration/NN (r_pobj) in/IN (r_prep) increase/NN (r_dobj) exhibited/VBD (l_prep) In/IN (l_pobj) addition/NN (l_prep) to/IN (l_pcomp) experiencing/VBG (l_dobj) episodes/NNS (l_amod) hypercalcemic/JJ -PUNC- calcium/NN (r_compound) concentration/NN (r_pobj) in/IN (r_prep) increase/NN (r_dobj) exhibited/VBD (l_nsubj) patients/NNS (l_prep) in/IN (l_pobj) group/NN (l_amod) hypercalcemic/NN
24975837
D003404_D058186 NONE creatinine/NN (r_pobj) of/IN (r_prep) levels/NNS (r_dobj) augment/VBP (r_conj) induce/VB (l_dobj) injury/NN
D014508_D007683 NONE urea/NN (r_conj) creatinine/NN (r_pobj) of/IN (r_prep) levels/NNS (r_dobj) augment/VBP (l_conj) increase/VB (l_dobj) score/NN (l_compound) necrosis/NN
D002945_D009336 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) injury/NN (r_pobj) in/IN (r_prep) involved/VBN (l_prep) by/IN (l_pcomp) mediating/VBG (l_dobj) process/NN (l_amod) necrotic/JJ
D002945_D007683 CID Cisplatin/NNP (r_compound) treatment/NN (r_nsubjpass) adopted/VBN (r_ccomp) induce/VB (l_conj) augment/VBP (l_conj) increase/VB (l_dobj) score/NN (l_compound) necrosis/NN
D014508_D058186 NONE urea/NN (r_conj) creatinine/NN (r_pobj) of/IN (r_prep) levels/NNS (r_dobj) augment/VBP (r_conj) induce/VB (l_dobj) injury/NN
D003404_D007683 NONE creatinine/NN (r_pobj) of/IN (r_prep) levels/NNS (r_dobj) augment/VBP (l_conj) increase/VB (l_dobj) score/NN (l_compound) necrosis/NN
D002945_D007674 NONE cisplatin/NN (r_amod) therapy/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) nephrotoxicity/NN
D002945_D058186 CID cisplatin/RB (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- Cisplatin/NNP (r_compound) treatment/NN (r_nsubjpass) adopted/VBN (r_ccomp) induce/VB (l_dobj) injury/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) injury/NN -PUNC- cisplatin/NN (r_pobj) with/IN (r_prep) challenged/VBN (l_advcl) examine/VB (l_dobj) role/NN (l_prep) of/IN (l_pobj) kinin/NN (l_appos) receptor/NN (l_prep) in/IN (l_pobj) injury/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) injury/NN
9158667
D014212_D013923 NONE ATRA/NNP (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complications/NNS (l_compound) thromboembolic/JJ
D014148_D015473 NONE acid/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- acid/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN (l_appos) APL/NNP
D006493_D013927 NONE heparin/NN (r_dobj) using/VBG (r_pcomp) by/IN (r_prep) avoided/VBN (l_nsubjpass) events/NNS (l_amod) Thrombotic/JJ
D014148_-1 NONE acid/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) of/IN (l_pobj) vessels/NNS
D014212_D013927 CID acid/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) complications/NNS (l_amod) Thrombotic/JJ
D014212_D015473 NONE acid/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) complications/NNS (l_prep) in/IN (l_pobj) leukemia/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN (l_appos) APL/NNP -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN (l_appos) APL/NNP -PUNC- ATRA/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (l_compound) APL/NNP -PUNC- ATRA/NNP (r_compound) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) APL/NNP -PUNC- ATRA/NNP (r_pobj) with/IN (r_prep) protocol/NN (r_pobj) in/IN (r_prep) included/VBN (r_conj) presented/VBD (l_dobj) signs/NNS (l_prep) of/IN (l_pobj) APL/NNP -PUNC- ATRA/NNP (r_nsubj) is/VBZ (l_attr) choice/NN (l_prep) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) APL/NNP
D014212_D058186 CID acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- ATRA/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) failure/NN
D014212_-1 NONE acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) of/IN (l_pobj) vessels/NNS -PUNC- ATRA/NNP (r_appos) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_amod) due/IN (l_pobj) occlusion/NN (l_prep) of/IN (l_pobj) vessels/NNS
D014148_D058186 NONE acid/NN (r_conj) acid/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) failure/NN
23846525
C055162_D056486 CID clopidogrel/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) hepatitis/NN -PUNC- clopidogrel/RB (r_npadvmod) related/VBN (r_amod) hepatitis/NN -PUNC- clopidogrel/NN (r_pobj) due/JJ (r_amod) Reports/NNS (l_prep) about/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- clopidogrel/JJ (r_nsubjpass) prescribed/VBN (r_advcl) consider/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) injury/NN
7644931
D017239_D064420 NONE paclitaxel/NN (r_pobj) of/IN (r_prep) trial/NN (r_dobj) compared/VBN (l_nsubjpass) Toxicities/NNS
D017239_D002289 NONE Paclitaxel/NNP (r_nsubjpass) combined/VBN (l_prep) in/IN (l_pobj) phase/NN (l_acl) directed/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- Taxol/NNP (r_appos) Paclitaxel/NNP (r_nsubjpass) combined/VBN (l_prep) in/IN (l_pobj) phase/NN (l_acl) directed/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D016190_D006402 NONE Carboplatin/NNP (r_nsubj) appear/VB (l_xcomp) add/VB (l_prep) to/IN (l_pobj) toxicities/NNS -PUNC- carboplatin/NN (r_compound) combination/NN (r_nsubjpass) dosed/VBN (r_conj) appear/VB (l_xcomp) add/VB (l_prep) to/IN (l_pobj) toxicities/NNS
D016190_D002289 NONE carboplatin/NN (r_pobj) with/IN (r_prep) combined/VBN (l_prep) in/IN (l_pobj) phase/NN (l_acl) directed/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D017239_D006402 CID paclitaxel/NN (r_nmod) carboplatin/NN (r_compound) combination/NN (r_nsubjpass) dosed/VBN (r_conj) appear/VB (l_xcomp) add/VB (l_prep) to/IN (l_pobj) toxicities/NNS
256433
D014031_D009369 NONE tobramycin/NN (l_acl) combined/VBN (l_prep) with/IN (l_pobj) carbenicillin/NN (l_prep) for/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D014031_D009503 NONE tobramycin/JJ (r_nsubjpass) given/VBN (l_advcl) overcome/VB (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) neutropenia/NN
D014031_D053099 CID tobramycin/JJ (r_amod) concentration/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) to/IN (r_prep) related/VBN (l_nsubjpass) Azotemia/NNP
D014031_D007239 NONE tobramycin/NN (l_acl) combined/VBN (l_prep) with/IN (l_pobj) carbenicillin/NN (l_prep) for/IN (l_pobj) infections/NNS
D002228_D007239 NONE carbenicillin/NN (l_prep) for/IN (l_pobj) infections/NNS
D002228_D009369 NONE carbenicillin/NN (l_prep) for/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D002228_D009503 NONE carbenicillin/NN (r_pobj) with/IN (r_prep) combined/VBN (r_conj) given/VBN (l_advcl) overcome/VB (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) neutropenia/NN
D003404_D053099 NONE creatinine/NN (r_appos) azotemia/NN
19920070
D010634_D006529 CID phenobarbital/JJ (r_amod) administration/NN (r_pobj) after/IN (r_prep) hepatomegaly/NN
1756784
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) during/IN (r_prep) Damage/NN (r_nsubj) epilepticus/NN -PUNC- pilocarpine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) epilepticus/NN
D010862_D001930 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) during/IN (r_prep) Damage/NN (l_prep) of/IN (l_pobj) reticulata/NNS
D002118_D009422 NONE calcium/NN (r_npadvmod) binding/VBG (r_amod) protein/NN (r_pobj) against/IN (r_prep) staining/VBG (r_nsubj) served/VBD (l_xcomp) detect/VB (l_dobj) damage/NN
24554916
D010758_D002779 CID phosphorus/NN (r_compound) poisoning/NN (r_pobj) of/IN (r_prep) presentation/NN (l_amod) Cholestatic/JJ -PUNC- phosphorus/NN (r_compound) poisoning/NN (l_relcl) presented/VBN (l_prep) with/IN (l_pobj) features/NNS (l_prep) of/IN (l_pobj) cholestasis/NN -PUNC- phosphorus/NN (r_compound) poisoning/NN (l_relcl) presented/VBN (l_advcl) highlighting/VBG (l_dobj) fact/NN (l_acl) be/VB (l_nsubj) cholestasis/NN -PUNC- phosphorus/NN (r_compound) hepatotoxicity/NN (r_pobj) of/IN (r_prep) feature/NN (r_attr) be/VB (r_acl) fact/NN (r_dobj) highlighting/VBG (r_advcl) presented/VBN (l_prep) with/IN (l_pobj) features/NNS (l_prep) of/IN (l_pobj) cholestasis/NN -PUNC- phosphorus/NN (r_compound) hepatotoxicity/NN (r_pobj) of/IN (r_prep) feature/NN (r_attr) be/VB (l_nsubj) cholestasis/NN
D010758_D011041 NONE phosphorus/NN (r_compound) poisoning/NN -PUNC- phosphorus/NN (r_pobj) with/IN (r_prep) Poisoning/VBG -PUNC- phosphorus/NN (r_compound) poisoning/NN -PUNC- phosphorus/NN (r_compound) hepatotoxicity/NN (r_pobj) of/IN (r_prep) feature/NN (r_attr) be/VB (r_acl) fact/NN (r_dobj) highlighting/VBG (r_advcl) presented/VBN (r_relcl) poisoning/NN
D010758_D056486 NONE phosphorus/NN (r_nsubj) is/VBZ (l_acomp) known/JJ (l_xcomp) cause/VB (l_dobj) hepatotoxicity/NN -PUNC- phosphorus/NN (r_compound) poisoning/NN (l_relcl) presented/VBN (l_advcl) highlighting/VBG (l_dobj) fact/NN (l_acl) be/VB (l_attr) feature/NN (l_prep) of/IN (l_pobj) hepatotoxicity/NN -PUNC- phosphorus/NN (r_compound) hepatotoxicity/NN
D010758_D006505 CID phosphorus/NN (r_pobj) with/IN (r_prep) Poisoning/VBG (r_nsubj) manifests/VBZ (l_prep) with/IN (l_pobj) hepatitis/NN
D010758_D017114 CID phosphorus/NN (r_pobj) with/IN (r_prep) Poisoning/VBG (r_nsubj) manifests/VBZ (l_prep) with/IN (l_pobj) hepatitis/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) failure/NN
8312343
D004317_D006331 NONE doxorubicin/NN (r_conj) disease/NN
D004317_D006349 NONE doxorubicin/NN (r_conj) disease/NN (l_appos) disease/NN
D004317_D002311 NONE doxorubicin/NN (r_conj) disease/NN (r_appos) Indications/NNS (r_nsubj) were/VBD (l_attr) cardiomyopathy/NN
D004317_D002312 NONE doxorubicin/NN (r_conj) disease/NN (l_conj) cardiomyopathy/NN
D015774_D003586 NONE ganciclovir/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) infections/NNS
D004317_D009202 CID doxorubicin/NN (l_appos) cardiomyopathy/NN
11401944
C086123_D016171 NONE azimilide/NN (r_conj) sotalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prolongation/NN (r_pobj) with/IN (r_prep) initiate/VB (l_dobj) pointes/FW -PUNC- azimilide/NN (r_conj) sotalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prolongation/NN (r_pobj) with/IN (r_prep) initiate/VB (l_dobj) pointes/FW (l_appos) TdP/NN
D013015_D016171 CID sotalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prolongation/NN (r_pobj) with/IN (r_prep) initiate/VB (l_dobj) pointes/FW -PUNC- sotalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prolongation/NN (r_pobj) with/IN (r_prep) initiate/VB (l_dobj) pointes/FW (l_appos) TdP/NN -PUNC- sotalol/NN (r_pobj) by/IN (r_prep) increase/NN (r_nsubj) facilitated/VBN (l_dobj) propagation/NN (l_relcl) initiated/VBD (l_dobj) episodes/NNS (l_prep) of/IN (l_pobj) TdP/NN
D013015_D008133 CID sotalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prolongation/NN -PUNC- Sotalol/NNP (r_nsubj) prolonged/VBD (l_advcl) leading/VBG (l_prep) to/IN (l_pobj) prolongation/NN -PUNC- sotalol/NNS (r_nsubj) induced/VBD (r_advcl) produced/VBD (l_relcl) pronounced/VBN (l_ccomp) seen/VBN (l_nsubjpass) prolongation/NN
C086123_D008133 NONE azimilide/NN (r_conj) sotalol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prolongation/NN -PUNC- azimilide/NN (r_conj) sotalol/NNS (r_nsubj) induced/VBD (r_advcl) produced/VBD (l_relcl) pronounced/VBN (l_ccomp) seen/VBN (l_nsubjpass) prolongation/NN
8825380
D008315_D011507 NONE malondialdehyde/NN (r_compound) content/NN (r_conj) area/NN (r_conj) GFR/NNP (r_conj) proteinuria/NN
D011692_D007674 CID aminonucleoside/JJ (r_amod) nephropathy/NN -PUNC- aminonucleoside/NN (r_nmod) nephropathy/NN -PUNC- aminonucleoside/NN (r_nmod) nephropathy/NN (l_appos) model/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- PAN/NNP (r_nmod) nephropathy/NN -PUNC- PAN/NNP (r_nmod) nephropathy/NN (l_appos) model/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN -PUNC- PAN/NNP (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) glomerulopathy/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN -PUNC- PAN/NNP (r_compound) nephropathy/NN
D011692_D006130 NONE PAN/NNP (r_compound) nephropathy/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) failure/NN
D008315_D007674 NONE malondialdehyde/NN (r_compound) content/NN (r_conj) injury/NN (r_conj) glomerulosclerosis/NN (r_conj) hypertrophy/NN -PUNC- malondialdehyde/NN (r_compound) content/NN (l_conj) damage/NN
D008315_D005921 NONE malondialdehyde/NN (r_compound) content/NN (r_conj) injury/NN (r_conj) glomerulosclerosis/NN
D008315_-1 NONE malondialdehyde/NN (r_compound) content/NN (r_conj) injury/NN
19338378
C031942_D008107 NONE argatroban/JJ (r_amod) dose/NN (r_nsubj) is/VBZ (l_attr) min/NN (l_acl) reduced/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) impairment/NN
C031942_D013921 NONE argatroban/JJ (r_amod) therapy/NN (l_prep) in/IN (l_pobj) thrombocytopenia/NN -PUNC- Argatroban/NNP (r_nsubj) is/VBZ (l_attr) inhibitor/NN (l_acl) used/VBN (l_prep) in/IN (l_pobj) thrombocytopenia/NN -PUNC- Argatroban/NNP (r_nsubj) is/VBZ (l_attr) inhibitor/NN (l_acl) used/VBN (l_prep) in/IN (l_pobj) thrombocytopenia/NN (l_appos) HIT/NNP -PUNC- Argatroban/NNP (r_nsubj) is/VBZ (l_conj) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_conj) at/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) HIT/NNP -PUNC- argatroban/JJ (r_amod) therapy/NN (l_prep) in/IN (l_pobj) HIT/NNP -PUNC- argatroban/JJ (r_amod) dose/NN (l_prep) in/IN (l_pobj) HIT/NNP -PUNC- argatroban/JJ (r_amod) therapy/NN (l_prep) in/IN (l_pobj) HIT/NNP -PUNC- argatroban/JJ (r_amod) therapy/NN (r_pobj) with/IN (r_prep) familiarity/NN (r_nsubj) facilitate/VB (l_dobj) reduction/NN (l_prep) of/IN (l_pobj) harm/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) thromboses/NNS (l_nmod) HIT/NNP -PUNC- argatroban/JJ (r_amod) errors/NNS (r_appos) treatment/NN (r_conj) thromboses/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) harm/NN (r_pobj) of/IN (r_prep) reduction/NN (r_dobj) facilitate/VB (l_nsubj) familiarity/NN (l_prep) with/IN (l_pobj) therapy/NN (l_prep) in/IN (l_pobj) HIT/NNP -PUNC- argatroban/JJ (r_amod) errors/NNS (r_appos) treatment/NN (r_conj) thromboses/NNS (l_nmod) HIT/NNP
C031942_D009765 NONE argatroban/NN (r_advmod) investigated/VBN (r_ccomp) is/VBZ (l_acomp) unnecessary/JJ (l_prep) for/IN (l_pobj) age/NN (l_conj) sex/NN (l_conj) ethnicity/NN (l_conj) obesity/NN
D006493_D013921 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) HIT/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) in/IN (r_prep) used/VBN (r_acl) inhibitor/NN (r_attr) is/VBZ (l_conj) for/IN (l_pobj) patients/NNS (l_prep) with/IN (l_conj) at/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) HIT/NNP
D006493_D013927 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) in/IN (r_prep) used/VBN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_conj) treatment/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C031942_D013927 NONE Argatroban/NNP (r_nsubj) is/VBZ (l_attr) inhibitor/NN (l_acl) used/VBN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_conj) treatment/NN (l_prep) of/IN (l_pobj) thrombosis/NN
C031942_D006470 CID argatroban/NN (r_amod) with/IN (r_prep) bleeding/VBG
2358093
D003613_D054179 NONE danazol/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) with/IN (l_pobj) angioedema/NN -PUNC- danazol/NN (r_pobj) of/IN (r_prep) safety/NN (r_dobj) investigated/VBD (l_prep) by/IN (l_pcomp) performing/VBG (l_dobj) review/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angioedema/NN -PUNC- danazol/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) review/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) angioedema/NN
17042797
D010862_D004833 CID pilocarpine/NN (r_amod) model/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (l_acl) epilepticus/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_nsubj) epilepticus/NN
10390729
D011188_D006948 NONE K(+)-channel/NNP (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) neither/DT (r_nsubj) affected/VBD (l_conj) prevented/VBD (l_dobj) hyperactivity/NN -PUNC- K(+)-channel/NNP (r_compound) blockers/NNS (r_nsubj) prevented/VBD (l_dobj) hyperactivity/NN -PUNC- K(+)-channels/NNPS (r_pobj) of/IN (r_prep) blockade/NN (r_nsubj) is/VBZ (l_advcl) seems/VBZ (l_nsubj) hyperactivity/NN -PUNC- K(+)-channels/NNPS (r_pobj) to/IN (r_prep) connected/VBN (r_xcomp) seems/VBZ (l_nsubj) hyperactivity/NN
D009020_D009069 NONE morphine/NN (r_npadvmod) induced/VBN (r_amod) hypoactivity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_dobj) prevented/VBD (r_conj) affected/VBD (l_dobj) hypoactivity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hypoactivity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_nsubj) seems/VBZ (r_advcl) is/VBZ (l_acomp) sufficient/JJ (l_xcomp) prevent/VB (l_dobj) hypoactivity/NN
D015761_D006948 NONE 4-aminopyridine/CD (r_punct) -/HYPH (r_punct) sensitive/JJ (r_amod) K(+)-channels/NNPS (r_pobj) to/IN (r_prep) connected/VBN (r_xcomp) seems/VBZ (l_nsubj) hyperactivity/NN
D011803_D009069 NONE quinine-/JJ (r_npadvmod) sensitive/JJ (r_amod) K(+)-channels/NNPS (r_pobj) to/IN (r_prep) connected/VBN (r_xcomp) seems/VBZ (r_advcl) is/VBZ (l_acomp) sufficient/JJ (l_xcomp) prevent/VB (l_dobj) hypoactivity/NN
D015761_D009069 NONE 4-aminopyridine/CD (r_punct) -/HYPH (r_punct) sensitive/JJ (r_amod) K(+)-channels/NNPS (r_pobj) to/IN (r_prep) connected/VBN (r_xcomp) seems/VBZ (r_advcl) is/VBZ (l_acomp) sufficient/JJ (l_xcomp) prevent/VB (l_dobj) hypoactivity/NN
D011188_D009069 NONE K(+)-channel/NNP (r_compound) blockers/NNS (r_pobj) of/IN (r_prep) neither/DT (r_nsubj) affected/VBD (l_dobj) hypoactivity/NN -PUNC- K(+)-channel/NNP (r_compound) blockers/NNS (r_nsubj) prevented/VBD (r_conj) affected/VBD (l_dobj) hypoactivity/NN -PUNC- K(+)-channels/NNPS (r_pobj) of/IN (r_prep) blockade/NN (r_nsubj) is/VBZ (l_acomp) sufficient/JJ (l_xcomp) prevent/VB (l_dobj) hypoactivity/NN -PUNC- K(+)-channels/NNPS (r_pobj) to/IN (r_prep) connected/VBN (r_xcomp) seems/VBZ (r_advcl) is/VBZ (l_acomp) sufficient/JJ (l_xcomp) prevent/VB (l_dobj) hypoactivity/NN
D011803_D006948 NONE quinine-/JJ (r_npadvmod) sensitive/JJ (r_amod) K(+)-channels/NNPS (r_pobj) to/IN (r_prep) connected/VBN (r_xcomp) seems/VBZ (l_nsubj) hyperactivity/NN
D009020_D006948 CID morphine/NN (r_npadvmod) induced/VBN (r_amod) hypoactivity/NN (r_dobj) affected/VBD (l_conj) prevented/VBD (l_dobj) hyperactivity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hypoactivity/NN (r_dobj) prevent/VB (r_xcomp) sufficient/JJ (r_acomp) is/VBZ (l_advcl) seems/VBZ (l_nsubj) hyperactivity/NN -PUNC- morphine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
10770468
D008094_D001714 NONE lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patient/NN (l_amod) bipolar/JJ -PUNC- lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) findings/NNS (r_nsubj) prompted/VBD (l_xcomp) conduct/VB (l_dobj) study/NN (l_prep) of/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) study/NN (r_dobj) conduct/VB (r_xcomp) prompted/VBD (l_nsubj) findings/NNS (l_prep) in/IN (l_pobj) patient/NN (l_amod) bipolar/JJ -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) study/NN (l_prep) of/IN (l_pobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_dobj) included/VBD (r_relcl) C1/NN (l_conj) C2/NNP (l_relcl) included/VBD (l_dobj) patients/NNS (l_amod) bipolar/JJ -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) diseases/NNS (l_conj) patients/NNS (l_amod) bipolar/JJ
D008094_D006934 CID lithium/NN (r_compound) therapy/NN (l_relcl) developed/VBD (l_dobj) hypercalcemia/NN -PUNC- lithium/NN (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) findings/NNS (r_nsubj) prompted/VBD (l_xcomp) conduct/VB (l_dobj) study/NN (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) study/NN (r_dobj) conduct/VB (r_xcomp) prompted/VBD (l_nsubj) findings/NNS (l_prep) in/IN (l_pobj) patient/NN (l_acl) receiving/VBG (l_dobj) therapy/NN (l_relcl) developed/VBD (l_dobj) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_dobj) identified/VBD (l_prep) After/IN (l_pcomp) eliminating/VBG (l_dobj) hypercalcemias/NNS -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_prep) with/IN (l_pobj) hypercalcemias/NNS -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_conj) patients/NNS (l_prep) with/IN (l_pobj) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_conj) patients/NNS (r_dobj) identified/VBD (l_prep) After/IN (l_pcomp) eliminating/VBG (l_dobj) hypercalcemias/NNS -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_conj) patients/NNS (l_prep) with/IN (l_pobj) hypercalcemias/NNS -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) diseases/NNS (r_pobj) from/IN (r_prep) resulting/VBG (r_acl) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN
D008094_D001919 NONE lithium/NN (r_compound) therapy/NN (l_relcl) developed/VBD (l_dobj) hypercalcemia/NN (l_conj) bradyarrhythmia/NN -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) study/NN (r_dobj) conduct/VB (r_xcomp) prompted/VBD (l_nsubj) findings/NNS (l_prep) in/IN (l_pobj) patient/NN (l_acl) receiving/VBG (l_dobj) therapy/NN (l_relcl) developed/VBD (l_dobj) hypercalcemia/NN (l_conj) bradyarrhythmia/NN
D008094_D009369 NONE lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_prep) with/IN (l_pobj) hypercalcemias/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) malignancies/NNS -PUNC- lithium/NN (r_npadvmod) associated/VBN (r_amod) hypercalcemia/NN (r_pobj) with/IN (r_prep) patients/NNS (r_conj) patients/NNS (l_prep) with/IN (l_pobj) hypercalcemias/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) malignancies/NNS
15094729
D020888_D064420 NONE Vigabatrin/NNP (r_npadvmod) associated/VBN (r_amod) defects/NNS (r_pobj) of/IN (r_prep) pathogenesis/NN (r_nsubj) be/VB (l_attr) reaction/NN (l_cc) than/IN (l_pobj) toxicity/NN
D020888_D014786 CID Vigabatrin/NNP (r_pobj) of/IN (r_prep) history/NN (r_nsubj) associated/VBD (l_dobj) defects/NNS -PUNC- Vigabatrin/NN (r_npadvmod) associated/VBN (r_amod) changes/NNS (r_dobj) have/VB (r_xcomp) known/VBN (r_acl) patients/NNS (r_pobj) of/IN (r_prep) group/NN (r_pobj) in/IN (r_prep) defects/NNS -PUNC- Vigabatrin/NNP (r_compound) therapy/NN (r_pobj) to/IN (r_prep) due/JJ (r_acomp) be/VB (r_xcomp) presumed/VBN (l_nsubj) defects/NNS -PUNC- Vigabatrin/NNP (r_npadvmod) associated/VBN (r_amod) defects/NNS
D020888_D012640 NONE Vigabatrin/NN (r_npadvmod) associated/VBN (r_amod) changes/NNS (l_relcl) elected/VBD (l_xcomp) continue/VB (l_prep) because/IN (l_pobj) control/NN (l_compound) seizure/NN
24671324
C400082_D019115 CID bortezomib/NNS (r_amod) regimen/NN (r_pobj) after/IN (r_prep) fasciitis/NN -PUNC- bortezomib/NNS (r_amod) dexamethasone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (l_dobj) fasciitis/NN
D003907_D008258 NONE dexamethasone/NN (r_npadvmod) containing/VBG (r_amod) regimen/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) of/IN (l_pobj) macroglobulinaemia/NN -PUNC- dexamethasone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (r_relcl) man/NN (l_prep) with/IN (l_pobj) macroglobulinaemia/NN
C400082_D008258 NONE bortezomib/NNS (r_amod) regimen/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) of/IN (l_pobj) macroglobulinaemia/NN -PUNC- bortezomib/NNS (r_amod) dexamethasone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (r_relcl) man/NN (l_prep) with/IN (l_pobj) macroglobulinaemia/NN
C400082_D009503 NONE bortezomib/NNS (r_amod) dexamethasone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (l_prep) without/IN (l_pobj) neutropenia/NN
D003907_D001424 NONE dexamethasone/NN (r_npadvmod) containing/VBG (r_amod) regimens/NNS (r_conj) Bortezomib/NNP (r_nsubjpass) considered/VBN (l_xcomp) be/VB (l_acomp) tolerable/JJ (l_prep) with/IN (l_pobj) infections/NNS -PUNC- dexamethasone/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) infections/NNS
C400082_D009369 NONE Bortezomib/NNP (r_nsubjpass) considered/VBN (l_xcomp) be/VB (l_acomp) tolerable/JJ (l_prep) with/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) malignancies/NNS
D003907_D009503 NONE dexamethasone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (l_prep) without/IN (l_pobj) neutropenia/NN
D003907_D009369 NONE dexamethasone/NN (r_npadvmod) containing/VBG (r_amod) regimens/NNS (r_conj) Bortezomib/NNP (r_nsubjpass) considered/VBN (l_xcomp) be/VB (l_acomp) tolerable/JJ (l_prep) with/IN (l_pobj) infections/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) malignancies/NNS
D003907_D019115 CID dexamethasone/NN (r_npadvmod) containing/VBG (r_amod) regimen/NN (r_pobj) after/IN (r_prep) fasciitis/NN -PUNC- dexamethasone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) suffered/VBD (l_dobj) fasciitis/NN
C400082_D001424 NONE Bortezomib/NNP (r_nsubjpass) considered/VBN (l_xcomp) be/VB (l_acomp) tolerable/JJ (l_prep) with/IN (l_pobj) infections/NNS -PUNC- bortezomib/NNS (r_amod) dexamethasone/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) infections/NNS
3084231
D014635_D022124 CID acid/NN (r_pobj) of/IN (r_prep) effect/NN (r_appos) system/NN (l_appos) effect/NN (l_conj) effect/NN (l_acl) mediated/VBN (l_prep) through/IN (l_pobj) hyperammonemia/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) hyperammonemia/NN
D014635_D004827 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) dementia/NN (r_nsubjpass) documented/VBN (l_prep) in/IN (l_pobj) man/NN (l_prep) with/IN (l_pobj) epilepsy/NN
D014635_D003704 CID acid/NN (r_npadvmod) induced/VBN (r_amod) dementia/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) dementia/NN
19681452
D000431_D012131 NONE ethanol/NN (r_compound) use/NN (r_conj) cocaine/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) arrhythmia/NN (l_conj) dysfunction/NN
D000431_D002545 NONE alcohol/NN (r_pobj) after/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) man/NN (l_prep) with/IN (l_pobj) ischemia/NN (l_prep) of/IN (l_pobj) pallidus/NN
D003042_D002543 NONE cocaine/NN (r_nmod) intoxication/NN (r_pobj) after/IN (r_prep) pallidus/NN
D003042_D020521 NONE Cocaine/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) for/IN (l_pobj) stroke/NN
D000431_D002543 NONE alcohol/NN (r_conj) cocaine/NN (r_nmod) intoxication/NN (r_pobj) after/IN (r_prep) pallidus/NN
D000431_D020520 NONE alcohol/NN (r_conj) cocaine/NN (r_nmod) intoxication/NN (r_pobj) after/IN (r_prep) pallidus/NN
D003042_D012131 NONE cocaine/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) arrhythmia/NN (l_conj) dysfunction/NN
D003042_D002545 CID cocaine/NN (r_compound) use/NN (r_conj) alcohol/NN (r_pobj) after/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) man/NN (l_prep) with/IN (l_pobj) ischemia/NN (l_prep) of/IN (l_pobj) pallidus/NN
D000431_-1 NONE ethanol/NN (r_compound) use/NN (r_conj) cocaine/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) arrhythmia/NN (r_nsubj) were/VBD (l_attr) causes/NNS (l_prep) of/IN (l_pobj) hypoperfusion/NN
D003042_D001145 NONE cocaine/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) arrhythmia/NN
D003042_-1 NONE cocaine/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) arrhythmia/NN (r_nsubj) were/VBD (l_attr) causes/NNS (l_prep) of/IN (l_pobj) hypoperfusion/NN
D000431_D001145 NONE ethanol/NN (r_compound) use/NN (r_conj) cocaine/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) arrhythmia/NN
D003042_D002544 NONE Cocaine/NN (r_nsubj) is/VBZ (l_attr) factor/NN (l_prep) for/IN (l_pobj) stroke/NN
D003042_D020520 NONE cocaine/NN (r_nmod) intoxication/NN (r_pobj) after/IN (r_prep) pallidus/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) infarcts/NNS
D003932_D020520 CID heroin/NN (r_pobj) with/IN (r_prep) associated/VBN (l_nsubjpass) infarctions/NNS -PUNC- heroin/NN (r_compound) use/NN (r_pobj) without/IN (r_prep) infarcts/NNS
24658375
D014212_D009220 CID acid/NN (r_npadvmod) induced/VBN (r_amod) myositis/NN -PUNC- ATRA/NNP (r_npadvmod) induced/VBN (r_amod) myositis/NN
D014212_D015473 NONE acid/NN (r_npadvmod) induced/VBN (r_amod) myositis/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- acid/NN (l_appos) component/NN (l_prep) for/IN (l_pobj) leukemia/NN -PUNC- acid/NN (l_appos) component/NN (l_prep) for/IN (l_pobj) leukemia/NN (l_appos) APL/NNP -PUNC- ATRA/NNP (r_appos) acid/NN (l_appos) component/NN (l_prep) for/IN (l_pobj) leukemia/NN -PUNC- ATRA/NNP (r_appos) acid/NN (l_appos) component/NN (l_prep) for/IN (l_pobj) leukemia/NN (l_appos) APL/NNP
2484903
D011441_D056486 CID propylthiouracil/NN (r_npadvmod) associated/VBN (r_amod) hepatitis/NN -PUNC- propylthiouracil/NN (r_npadvmod) associated/VBN (r_amod) syndrome/NN (r_pobj) of/IN (r_prep) case/NN (r_conj) case/NN (r_appos) cases/NNS (l_prep) of/IN (l_pobj) hepatitis/NN
D011441_D008180 CID propylthiouracil/NN (r_npadvmod) associated/VBN (r_amod) hepatitis/NN (r_pobj) of/IN (r_prep) cases/NNS (l_appos) case/NN (l_conj) case/NN (l_prep) of/IN (l_pobj) syndrome/NN -PUNC- propylthiouracil/NN (r_npadvmod) associated/VBN (r_amod) syndrome/NN
D011441_D047508 NONE propylthiouracil/NN (r_npadvmod) associated/VBN (r_amod) hepatitis/NN (r_pobj) of/IN (r_prep) cases/NNS (l_appos) case/NN (l_prep) of/IN (l_pobj) necrosis/NN -PUNC- propylthiouracil/NN (r_npadvmod) associated/VBN (r_amod) syndrome/NN (r_pobj) of/IN (r_prep) case/NN (r_conj) case/NN (l_prep) of/IN (l_pobj) necrosis/NN
D008713_D056486 NONE methimazole/NN (r_npadvmod) associated/VBN (r_amod) necrosis/NN (r_pobj) of/IN (r_prep) case/NN (r_appos) cases/NNS (l_prep) of/IN (l_pobj) hepatitis/NN
D008713_D047508 CID methimazole/NN (r_npadvmod) associated/VBN (r_amod) necrosis/NN
D008713_D008180 NONE methimazole/NN (r_npadvmod) associated/VBN (r_amod) necrosis/NN (r_pobj) of/IN (r_prep) case/NN (l_conj) case/NN (l_prep) of/IN (l_pobj) syndrome/NN
18450790
D013792_D008178 NONE thalidomide/NN (r_pobj) with/IN (r_prep) treated/VBN (r_parataxis) were/VBD (l_punct) amplitude/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) erythematosus/NN -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) CLE/NNP -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) identify/VB (r_xcomp) use/VB (r_conj) treated/VBN (r_parataxis) were/VBD (l_punct) amplitude/VBP (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) erythematosus/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) potential/NN (r_dobj) identify/VB (r_xcomp) use/VB (r_conj) treated/VBN (l_nsubj) CLE/NNP -PUNC- thalidomide/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) data/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) CLE/NNP
D013792_D020258 NONE thalidomide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_conj) use/VB (l_xcomp) identify/VB (l_dobj) potential/NN (l_amod) neurotoxic/JJ -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) potential/NN (l_amod) neurotoxic/JJ -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) potential/NN (l_amod) neurotoxic/JJ
D013792_D010523 CID Thalidomide/NNP (l_conj) neurotoxicity/NN -PUNC- thalidomide/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (r_pobj) in/IN (r_prep) incidence/NN (l_prep) of/IN (l_pobj) neuropathy/NN
23535177
D007980_D004409 CID levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (l_appos) LIDs/NNPS
D007980_D010300 NONE levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) disease/NN -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) disease/NN (l_appos) PD/NNP
24727461
C005975_D028361 NONE Hydroxytyrosol/NNP (r_nsubj) ameliorates/VBZ (l_dobj) stress/NN (l_conj) dysfunction/NN
D004317_D001943 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- doxorubicin/RB (r_npadvmod) associated/VBN (r_amod) toxicity/NN (r_nsubjpass) ameliorated/VBN (l_prep) with/IN (l_pobj) hydroxytyrosol/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_appos) divided/VBN (l_csubjpass) induced/VBD (l_nsubj) rats/NNS (l_acl) bearing/VBG (l_dobj) tumors/NNS -PUNC- doxorubicin/NN (r_conj) doxorubicin/NN (r_appos) divided/VBN (l_csubjpass) induced/VBD (l_nsubj) rats/NNS (l_acl) bearing/VBG (l_dobj) tumors/NNS
D004317_D006331 CID doxorubicin/NN (r_pobj) by/IN (r_agent) enhanced/VBN (r_acl) disturbances/NNS -PUNC- doxorubicin/NN (r_nmod) decreasing/VBG (r_advcl) demonstrates/VBZ (l_ccomp) hydroxytyrosol/JJ (l_dobj) damage/NN
D004317_D002318 NONE doxorubicin/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_dobj) potentiate/VB (r_xcomp) shown/VBN (r_conj) involved/VBN (l_prep) in/IN (l_pobj) processes/NNS (l_prep) including/VBG (l_pobj) cancer/NN (l_conj) disease/NN
C005975_D066126 NONE Hydroxytyrosol/NNP (r_nsubj) ameliorates/VBZ (l_prep) in/IN (l_pobj) cardiotoxicity/NN -PUNC- hydroxytyrosol/NN (r_pobj) with/IN (r_prep) ameliorated/VBN (l_nsubjpass) toxicity/NN
D004317_D028361 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_pobj) in/IN (r_prep) ameliorates/VBZ (l_dobj) stress/NN (l_conj) dysfunction/NN -PUNC- Doxorubicin/NNP (r_nsubj) causes/VBZ (l_dobj) cardiotoxicity/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) increases/NNS (l_prep) in/IN (l_pobj) stress/NN (l_conj) dysfunction/NN
C005975_D006331 NONE Hydroxytyrosol/NNP (r_nsubj) improved/VBD (l_dobj) disturbances/NNS -PUNC- hydroxytyrosol/JJ (l_dobj) damage/NN
C005975_D001943 NONE Hydroxytyrosol/NNP (r_nsubj) ameliorates/VBZ (l_prep) in/IN (l_pobj) cardiotoxicity/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- hydroxytyrosol/NN (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- hydroxytyrosol/NN (r_conj) control/NN (r_appos) groups/NNS (r_pobj) into/IN (r_prep) divided/VBN (l_csubjpass) induced/VBD (l_nsubj) rats/NNS (l_acl) bearing/VBG (l_dobj) tumors/NNS -PUNC- hydroxytyrosol/NN (r_conj) doxorubicin/NN (r_conj) doxorubicin/NN (r_appos) divided/VBN (l_csubjpass) induced/VBD (l_nsubj) rats/NNS (l_acl) bearing/VBG (l_dobj) tumors/NNS
D004317_D066126 NONE doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- Doxorubicin/NNP (r_nsubj) causes/VBZ (l_dobj) cardiotoxicity/NN -PUNC- doxorubicin/RB (r_npadvmod) associated/VBN (r_amod) toxicity/NN
D004317_D009369 NONE doxorubicin/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_dobj) potentiate/VB (r_xcomp) shown/VBN (r_conj) involved/VBN (l_prep) in/IN (l_pobj) processes/NNS (l_prep) including/VBG (l_pobj) cancer/NN
1779253
D002211_D008413 CID capsaicin/NN (r_npadvmod) induced/VBN (r_amod) sensations/NNS (l_appos) 4/CD (l_conj) mastitis/NN
D002211_D051474 NONE capsaicin/NN (l_prep) in/IN (l_pobj) neuralgia/NN -PUNC- capsaicin/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) of/IN (r_prep) course/NN (r_nmod) patients/NNS (l_prep) with/IN (l_pobj) neuralgia/NN -PUNC- capsaicin/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) of/IN (r_prep) action/NN (r_pobj) of/IN (r_prep) course/NN (r_nmod) patients/NNS (l_prep) with/IN (l_pobj) neuralgia/NN (l_appos) PHN/NNP -PUNC- capsaicin/NN (r_compound) cream/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) neuralgia/NN -PUNC- capsaicin/NN (r_compound) cream/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) neuralgia/NN (l_appos) PHN/NNP -PUNC- capsaicin/NN (l_prep) in/IN (l_pobj) PHN/NNP
3125850
D013390_D005207 CID suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) fasciculations/NNS -PUNC- suxamethonium/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) fasciculations/NNS -PUNC- suxamethonium/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) fasciculations/NNS -PUNC- suxamethonium/NN (r_npadvmod) induced/VBN (r_amod) fasciculations/NNS
D015760_D005207 NONE alfentanil/NN (r_pobj) by/IN (r_prep) inhibition/NN (r_appos) fasciculations/NNS -PUNC- alfentanil/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) than/IN (r_prep) greater/JJR (r_acomp) were/VBD (l_nsubj) incidence/NN (l_conj) intensity/NN (l_prep) of/IN (l_pobj) fasciculations/NNS -PUNC- alfentanil/NN (r_compound) group/NN (r_pobj) in/IN (r_prep) than/IN (r_prep) was/VBD (l_nsubj) pressure/NN (l_prep) during/IN (l_pobj) fasciculations/NNS -PUNC- Alfentanil/NNP (r_dep) inhibits/VBZ (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) fasciculations/NNS
D014867_D005207 NONE H2O/NNP (r_appos) group/NN (r_pobj) in/IN (r_prep) was/VBD (l_nsubj) pressure/NN (l_prep) during/IN (l_pobj) fasciculations/NNS
10726030
D006493_D011317 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN (l_conj) hypoaldosteronism/NN (l_conj) priapism/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN (l_conj) hypoaldosteronism/NN (l_conj) priapism/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN (l_conj) hypoaldosteronism/NN (l_conj) priapism/NN
D006493_D000505 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN
D006493_D006994 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN (l_conj) hypoaldosteronism/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN (l_conj) hypoaldosteronism/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN (l_conj) hypoaldosteronism/NN
D006493_D004802 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN
D006493_D010024 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) given/VBN (r_prep) are/VBP (l_acomp) common/JJ (l_conj) HITT/NNP (l_conj) osteoporosis/NN
D006493_D013921 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) thrombosis/NN (r_conj) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (r_conj) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ -PUNC- heparin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) given/VBN (r_prep) are/VBP (l_acomp) common/JJ (l_conj) HITT/NNP
D006493_D013927 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) thrombosis/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) thrombosis/NN -PUNC- Heparin/NNP (r_nsubj) used/VBD (r_ccomp) used/VBN (l_xcomp) treat/VB (l_dobj) thrombosis/NN -PUNC- heparin/NN (r_nsubj) remains/VBZ (l_xcomp) treat/VB (l_dobj) episodes/NNS (l_amod) thrombotic/JJ -PUNC- heparin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) given/VBN (r_prep) are/VBP (l_acomp) common/JJ (l_conj) HITT/NNP
D006493_D004342 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS
D006493_D006470 NONE heparin/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) Bleeding/VBG -PUNC- heparin/JJ (r_compound) therapy/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) concern/NN (r_pobj) of/IN (r_prep) is/VBZ (l_nsubj) bleeding/NN
D006493_D012871 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS
D006493_D006947 CID heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN (l_conj) transaminasemia/NN (l_conj) hyperkalemia/NN
1760851
D004317_D066126 CID doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- DOX/NNP (r_appos) doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- DOX/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) deaths/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (r_ccomp) revealed/VBD (l_dobj) changes/NNS (l_relcl) were/VBD (l_acomp) consistent/JJ (l_prep) with/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_conj) copolymer/NN (r_pobj) of/IN (r_prep) mixture/NN (r_conj) DOX/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) deaths/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_conj) copolymer/NN (r_pobj) of/IN (r_prep) mixture/NN (r_conj) DOX/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (r_ccomp) revealed/VBD (l_dobj) changes/NNS (l_relcl) were/VBD (l_acomp) consistent/JJ (l_prep) with/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN (r_pobj) with/IN (r_prep) consistent/JJ (r_acomp) were/VBD (r_relcl) changes/NNS (r_dobj) revealed/VBD (l_ccomp) observed/VBN (l_nsubjpass) deaths/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
C032976_D066126 NONE N-(2-hydroxypropyl)methacrylamide/JJ (r_compound) conjugates/NNS (r_pobj) of/IN (r_prep) form/NN (r_pobj) in/IN (r_prep) given/VBN (r_acl) doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN -PUNC- N-(2-hydroxypropyl)methacrylamide/NN (r_nmod) conjugates/NNS (r_pobj) of/IN (r_prep) form/NN (r_pobj) in/IN (r_conj) as/IN (r_prep) given/VBN (r_prep) used/VBN (l_xcomp) evaluate/VB (l_dobj) toxicity/NN (l_conj) cardiotoxicity/NN -PUNC- HPMA/NNP (r_nmod) copolymer/NN (r_compound) conjugates/NNS (r_pobj) of/IN (r_prep) form/NN (r_pobj) in/IN (r_conj) as/IN (r_prep) given/VBN (r_prep) used/VBN (l_xcomp) evaluate/VB (l_dobj) toxicity/NN (l_conj) cardiotoxicity/NN -PUNC- HPMA/NNP (r_compound) copolymer/NN (r_pobj) of/IN (r_prep) mixture/NN (r_conj) DOX/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) deaths/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) cardiotoxicity/NN -PUNC- HPMA/NNP (r_compound) copolymer/NN (r_pobj) of/IN (r_prep) mixture/NN (r_conj) DOX/NNP (r_dobj) received/VBD (r_relcl) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (r_ccomp) revealed/VBD (l_dobj) changes/NNS (l_relcl) were/VBD (l_acomp) consistent/JJ (l_prep) with/IN (l_pobj) cardiotoxicity/NN
D004317_D064420 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN -PUNC- DOX/NNP (r_appos) doxorubicin/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN (r_conj) toxicity/NN
C032976_D064420 NONE N-(2-hydroxypropyl)methacrylamide/NN (r_nmod) conjugates/NNS (r_pobj) of/IN (r_prep) form/NN (r_pobj) in/IN (r_conj) as/IN (r_prep) given/VBN (r_prep) used/VBN (l_xcomp) evaluate/VB (l_dobj) toxicity/NN -PUNC- HPMA/NNP (r_nmod) copolymer/NN (r_compound) conjugates/NNS (r_pobj) of/IN (r_prep) form/NN (r_pobj) in/IN (r_conj) as/IN (r_prep) given/VBN (r_prep) used/VBN (l_xcomp) evaluate/VB (l_dobj) toxicity/NN
25006369
C061870_D063806 NONE rocuronium/NN (r_pobj) of/IN (r_prep) dose/NN (l_acl) decrease/VB (l_dobj) fasciculation/NN (l_conj) myalgia/NN -PUNC- rocuronium/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) identified/VBD (l_advcl) prevent/VB (l_dobj) fasciculation/NN (l_conj) myalgia/NN -PUNC- rocuronium/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) evaluated/VBD (r_conj) identified/VBD (l_advcl) prevent/VB (l_dobj) fasciculation/NN (l_conj) myalgia/NN -PUNC- rocuronium/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) precurarizing/VBG (r_pcomp) of/IN (r_prep) amount/NN (r_dobj) increasing/VBG (r_pcomp) to/IN (r_prep) according/VBG (r_prep) decrease/VB (r_xcomp) tend/VBP (l_nsubj) Those/DT (l_prep) of/IN (l_pobj) myalgia/NN -PUNC- rocuronium/NN (r_pobj) with/IN (r_prep) Precurarization/NN (r_nsubj) was/VBD (l_attr) dose/NN (l_acl) considering/VBG (l_dobj) reduction/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) fasciculation/NN (l_conj) myalgia/NN
C061870_D005207 NONE rocuronium/NN (r_pobj) of/IN (r_prep) dose/NN (l_acl) decrease/VB (l_dobj) fasciculation/NN -PUNC- rocuronium/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) identified/VBD (l_advcl) prevent/VB (l_dobj) fasciculation/NN -PUNC- rocuronium/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) evaluated/VBD (r_conj) identified/VBD (l_advcl) prevent/VB (l_dobj) fasciculation/NN -PUNC- rocuronium/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) precurarizing/VBG (r_pcomp) of/IN (r_prep) amount/NN (r_dobj) increasing/VBG (r_pcomp) with/IN (r_prep) less/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) fasciculation/NN -PUNC- rocuronium/NN (r_pobj) with/IN (r_prep) Precurarization/NN (r_nsubj) was/VBD (l_attr) dose/NN (l_acl) considering/VBG (l_dobj) reduction/NN (l_prep) in/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) fasciculation/NN
D013390_D063806 CID succinylcholine/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) decrease/VB (l_dobj) fasciculation/NN (l_conj) myalgia/NN -PUNC- Succinylcholine/NNP (r_nsubj) produces/VBZ (l_dobj) effects/NNS (l_prep) including/VBG (l_pobj) fasciculation/NN (l_conj) myalgia/NN -PUNC- succinylcholine/NN (r_npadvmod) induced/VBN (r_amod) fasciculation/NN (l_conj) myalgia/NN -PUNC- succinylcholine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) onset/NN (r_pobj) of/IN (r_prep) speed/NN (r_pobj) on/IN (r_prep) rocuronium/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) evaluated/VBD (r_conj) identified/VBD (l_advcl) prevent/VB (l_dobj) fasciculation/NN (l_conj) myalgia/NN -PUNC- succinylcholine/NN (r_dobj) received/VBD (l_conj) assessed/VBN (l_advcl) assessed/VBN (l_nsubjpass) myalgia/NN
D013390_D005207 CID succinylcholine/NN (r_compound) administration/NN (r_pobj) following/VBG (r_prep) decrease/VB (l_dobj) fasciculation/NN -PUNC- Succinylcholine/NNP (r_nsubj) produces/VBZ (l_dobj) effects/NNS (l_prep) including/VBG (l_pobj) fasciculation/NN -PUNC- succinylcholine/NN (r_npadvmod) induced/VBN (r_amod) fasciculation/NN -PUNC- succinylcholine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) onset/NN (r_pobj) of/IN (r_prep) speed/NN (r_pobj) on/IN (r_prep) rocuronium/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) evaluated/VBD (r_conj) identified/VBD (l_advcl) prevent/VB (l_dobj) fasciculation/NN -PUNC- succinylcholine/NN (r_dobj) received/VBD (l_conj) assessed/VBN (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) fasciculations/NNS
24341598
D003287_D007674 NONE contrast/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- Contrast/RB (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
D004110_D007674 NONE diltiazem/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D012965_D007674 NONE chloride/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) with/IN (l_pobj) diltiazem/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D003287_D058186 CID contrast/NN (r_amod) material/NN (r_nsubjpass) injected/VBN (r_advcl) developed/VBD (l_dobj) failure/NN -PUNC- contrast/NN (r_amod) material/NN (r_nsubjpass) injected/VBN (r_advcl) developed/VBD (l_dobj) failure/NN (l_appos) ARF/NNP
3831029
D010424_D006333 CID pentobarbital/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
C037293_D001145 NONE denopamine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) arrhythmias/NNS
C037293_D006333 NONE denopamine/NN (r_pobj) by/IN (r_prep) Improvement/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- TA-064/NNP (r_punct) )/-RRB- (r_punct) of/IN (l_pobj) failure/NN -PUNC- denopamine/NN (r_pobj) of/IN (r_prep) efficacy/NN (r_nsubjpass) assessed/VBN (l_prep) in/IN (l_pcomp) improving/VBG (l_dobj) failure/NN -PUNC- denopamine/NN (r_pobj) of/IN (r_prep) trials/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) failure/NN
9578276
16867246
D002746_D012559 NONE chlorpromazine/NN (r_npadvmod) induced/VBN (r_conj) polymorphisms/NNS (r_nmod) syndrome/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ -PUNC- chlorpromazine/NN (r_npadvmod) induced/VBN (r_amod) EPS/NNP (l_prep) in/IN (l_pobj) patients/NNS (l_amod) schizophrenic/JJ -PUNC- chlorpromazine/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) rs6275/ADD (l_prep) in/IN (l_pobj) gene/NN (l_prep) in/IN (l_pobj) inpatients/NNS (l_amod) schizophrenic/JJ -PUNC- chlorpromazine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effect/NN (r_pobj) in/IN (r_prep) plays/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) schizophrenia/NN
D002746_D001480 CID chlorpromazine/NN (r_npadvmod) induced/VBN (r_conj) polymorphisms/NNS (r_nmod) syndrome/NN -PUNC- chlorpromazine/NN (r_npadvmod) induced/VBN (r_amod) EPS/NNP -PUNC- chlorpromazine/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) rs6275/ADD (l_prep) in/IN (l_pobj) gene/NN (l_prep) in/IN (l_pobj) inpatients/NNS (l_appos) 59/CD (l_prep) with/IN (l_pobj) EPS/NNP -PUNC- chlorpromazine/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) rs6275/ADD (l_prep) in/IN (l_pobj) gene/NN (l_prep) in/IN (l_pobj) inpatients/NNS (l_appos) 59/CD (l_conj) 87/CD (l_prep) without/IN (l_pobj) EPS/NNP
2083961
D012293_D014839 NONE Rifampicin/NNP (r_nsubjpass) administered/VBN (l_conj) developed/VBD (l_dobj) effects/NNS (l_prep) like/IN (l_pobj) nausea/NN (l_conj) vomiting/NN
D012293_D005334 NONE Rifampicin/NNP (r_nsubjpass) administered/VBN (l_conj) developed/VBD (l_dobj) effects/NNS (l_prep) like/IN (l_pobj) nausea/NN (l_conj) vomiting/NN (l_conj) fever/NN
D012293_D058186 CID rifampicin/NNS (r_pobj) due/IN (r_prep) failure/NN
D012293_D009325 NONE Rifampicin/NNP (r_nsubjpass) administered/VBN (l_conj) developed/VBD (l_dobj) effects/NNS (l_prep) like/IN (l_pobj) nausea/NN
24072398
D012701_D003866 NONE serotonin/NN (r_conj) hydroxylase/NN (r_conj) DOPAC/NNP (r_conj) indicated/VBN (r_advcl) accompanied/VBN (l_nsubjpass) profile/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ
D004298_D003866 NONE dopamine/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) reduction/NN (r_pobj) by/IN (r_agent) indicated/VBN (r_advcl) accompanied/VBN (l_nsubjpass) profile/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ
D006719_D003866 NONE HVA/NNP (r_conj) DOPAC/NNP (r_conj) indicated/VBN (r_advcl) accompanied/VBN (l_nsubjpass) profile/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ
D015102_D003866 NONE DOPAC/NNP (r_conj) indicated/VBN (r_advcl) accompanied/VBN (l_nsubjpass) profile/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ
D008694_D020258 NONE methamphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (l_amod) neurotoxic/JJ
D014443_D003866 NONE tyrosine/JJ (r_compound) hydroxylase/NN (r_conj) DOPAC/NNP (r_conj) indicated/VBN (r_advcl) accompanied/VBN (l_nsubjpass) profile/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ
D008694_D003866 CID methamphetamine/NN (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) induces/VBZ (l_dobj) behaviour/NN (l_amod) like/JJ (l_amod) depressive/JJ -PUNC- Methamphetamine/NN (r_nsubj) triggers/VBZ (l_conj) leads/VBZ (l_prep) to/IN (l_pobj) states/NNS (l_prep) including/VBG (l_pobj) symptoms/NNS -PUNC- METH/NNP (r_appos) Methamphetamine/NN (r_nsubj) triggers/VBZ (l_conj) leads/VBZ (l_prep) to/IN (l_pobj) states/NNS (l_prep) including/VBG (l_pobj) symptoms/NNS -PUNC- METH/NNP (r_compound) abuse/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) states/NNS (l_prep) including/VBG (l_pobj) symptoms/NNS -PUNC- METH/NNP (r_pobj) of/IN (r_prep) dosage/NN (r_nsubj) causes/VBZ (l_dobj) phenotype/NN (l_amod) depressive/JJ -PUNC- METH/NNP (r_compound) dose/NN (r_pobj) following/VBG (r_prep) assessed/VBD (l_dobj) behaviour/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ -PUNC- METH/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) profile/NN (l_amod) like/JJ (l_npadvmod) depressive/JJ -PUNC- METH/NNP (r_pobj) of/IN (r_prep) dose/NN (r_nsubj) induces/VBZ (l_dobj) behaviour/NN (l_amod) like/JJ (l_amod) depressive/JJ
2614930
D009543_D001919 CID Nifedipine/NNP (r_nsubj) induced/VBD (l_dobj) bradycardia/NNP
D009543_D009422 NONE Nifedipine/NNP (r_nsubj) induced/VBD (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) neuropathy/NN
D009543_D013610 CID nifedipine/NN (r_nsubj) induces/VBZ (l_dobj) tachycardia/VBG
D009543_D001282 NONE nifedipine/NN (r_advcl) slowed/VBD (r_relcl) rate/NN (r_pobj) at/IN (r_prep) have/VB (l_dobj) flutter/NN
1858969
D004049_D004660 CID diethylcarbamazine/NN (r_pobj) with/IN (r_prep) loiasis/NN (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) cases/NNS (l_prep) of/IN (l_pobj) encephalitis/NN -PUNC- diethylcarbamazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_prep) cases/NNS (l_prep) of/IN (l_pobj) encephalitis/NN -PUNC- DEC/NNP (r_appos) diethylcarbamazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_prep) cases/NNS (l_prep) of/IN (l_pobj) encephalitis/NN
D004049_D005368 NONE diethylcarbamazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_prep) cases/NNS (r_nsubjpass) observed/VBN (l_prep) with/IN (l_pobj) filariasis/NN -PUNC- DEC/NNP (r_appos) diethylcarbamazine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) following/VBG (r_prep) cases/NNS (r_nsubjpass) observed/VBN (l_prep) with/IN (l_pobj) filariasis/NN
D004049_D008118 NONE diethylcarbamazine/NN (r_pobj) with/IN (r_prep) loiasis/NN
20566328
C476756_-1 NONE MitoQ/NNP (r_nsubjpass) shown/VBN (l_xcomp) prevent/VB (l_dobj) abnormalities/NNS (l_conj) dysfunction/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) dysfunction/NN
D003042_D028361 NONE cocaine/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (r_pobj) to/IN (r_prep) contributes/VBZ (l_nsubj) impairment/NN -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) was/VBD (l_advcl) suggesting/VBG (l_ccomp) were/VBD (l_nsubj) abnormalities/NNS -PUNC- cocaine/NN (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) event/NN (r_attr) were/VBD (l_nsubj) abnormalities/NNS -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN (r_nsubj) be/VB (l_acomp) due/JJ (l_prep) to/IN (l_pobj) defect/NN
C476756_D028361 NONE MitoQ./NNP (r_pobj) by/IN (r_prep) Prevention/NN (r_appos) impairment/NN -PUNC- MitoQ/NNP (r_nsubjpass) shown/VBN (l_xcomp) prevent/VB (l_dobj) abnormalities/NNS
C476756_D006331 NONE MitoQ./NNP (r_pobj) by/IN (r_prep) Prevention/NN (r_appos) impairment/NN (r_nsubj) contributes/VBZ (l_prep) to/IN (l_pobj) dysfunction/NN -PUNC- MitoQ/NNP (r_nsubjpass) shown/VBN (l_xcomp) prevent/VB (l_dobj) abnormalities/NNS (l_conj) dysfunction/NN
D003042_D006331 CID cocaine/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) dysfunction/NN
3074291
D013806_D009325 CID theophylline/NN (r_pobj) after/IN (r_prep) reporting/VBG (l_dobj) nausea/NN
C017590_D001249 NONE bromide/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) of/IN (r_prep) Comparison/NN (l_conj) of/IN (l_pobj) theophylline/NN (l_prep) on/IN (l_pobj) asthma/NN -PUNC- bromide/NN (r_appos) drug/NN (r_pobj) of/IN (l_conj) of/IN (l_pobj) preparation/NN (l_prep) upon/IN (l_pobj) asthma/NN -PUNC- Oxitropium/NNP (r_nsubj) proves/VBZ (l_xcomp) be/VB (l_attr) alternative/NN (l_prep) in/IN (l_pobj) asthma/NN
D013806_D014202 CID theophylline/NN (r_pobj) after/IN (r_prep) reporting/VBG (l_dobj) nausea/NN (l_conj) vomiting/VBG (l_conj) tremors/NNS
C017590_D014202 NONE oxitropium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) reported/VBN (l_advcl) compared/VBN (l_prep) to/IN (l_pobj) subjects/NNS (l_acl) reporting/VBG (l_dobj) nausea/NN (l_conj) vomiting/VBG (l_conj) tremors/NNS
C017590_D014839 NONE oxitropium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) reported/VBN (l_advcl) compared/VBN (l_prep) to/IN (l_pobj) subjects/NNS (l_acl) reporting/VBG (l_dobj) nausea/NN (l_conj) vomiting/VBG
D013806_D001249 NONE theophylline/NN (l_prep) on/IN (l_pobj) asthma/NN -PUNC- theophylline/NN (r_amod) preparation/NN (l_prep) upon/IN (l_pobj) asthma/NN -PUNC- theophylline/NN (r_pobj) to/IN (r_prep) alternative/NN (l_prep) in/IN (l_pobj) asthma/NN
C017590_D009325 NONE oxitropium/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) reported/VBN (l_advcl) compared/VBN (l_prep) to/IN (l_pobj) subjects/NNS (l_acl) reporting/VBG (l_dobj) nausea/NN
D013806_D014839 CID theophylline/NN (r_pobj) after/IN (r_prep) reporting/VBG (l_dobj) nausea/NN (l_conj) vomiting/VBG
10219427
20431083
D014859_D002546 NONE warfarin/NN (r_amod) users/NNS (r_pobj) in/IN (r_prep) range/NN (r_parataxis) 3.4/CD (r_appos) range/NN (r_pobj) to/IN (r_prep) ratio/NN (r_pobj) from/IN (r_prep) increased/VBD (r_conj) were/VBD (l_prep) vs/IN (l_pobj) TIA/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) excess/NN (r_attr) was/VBD (l_attr) none/NN (l_prep) in/IN (l_pobj) users/NNS (l_prep) with/IN (l_pobj) TIA/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (l_prep) with/IN (l_pobj) TIA/NNP
D014859_D002543 CID warfarin/NN (r_amod) users/NNS (r_pobj) in/IN (r_prep) range/NN (r_parataxis) 3.4/CD (r_appos) range/NN (r_pobj) to/IN (r_prep) ratio/NN (r_pobj) from/IN (r_prep) increased/VBD (r_conj) were/VBD (l_prep) in/IN (l_pobj) ICH/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (l_prep) vs/IN (l_pobj) nonusers/NNS (l_prep) with/IN (l_pobj) ICH/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) none/NN (r_attr) was/VBD (l_attr) excess/NN (l_prep) in/IN (l_pobj) users/NNS (l_prep) vs/IN (l_pobj) nonusers/NNS (l_prep) with/IN (l_pobj) ICH/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (l_prep) with/IN (l_pobj) ICH/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) excess/NN (r_nsubj) suggests/VBZ (l_ccomp) increase/VBP (l_dobj) risk/NN (l_prep) of/IN (l_pobj) ICH/NNP -PUNC- warfarin/NN (r_npadvmod) associated/VBN (r_amod) ICH/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) increase/VBP (r_ccomp) suggests/VBZ (l_nsubj) excess/NN (l_prep) in/IN (l_pobj) users/NNS (l_prep) with/IN (l_pobj) ICH/NNP -PUNC- warfarin/NN (r_npadvmod) associated/VBN (r_amod) ICH/NNP
D014859_-1 NONE warfarin/NN (r_amod) users/NNS (r_pobj) in/IN (r_prep) range/NN (r_parataxis) 3.4/CD (r_appos) range/NN (r_pobj) to/IN (r_prep) ratio/NN (r_pobj) from/IN (r_prep) increased/VBD (r_conj) were/VBD (l_nsubj) MB/NNS -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) excess/NN (l_prep) of/IN (l_pobj) MB/NN -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) none/NN (r_attr) was/VBD (l_attr) excess/NN (l_prep) of/IN (l_pobj) MB/NN -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) excess/NN (l_prep) of/IN (l_pobj) MB/NN -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) excess/NN (r_nsubj) suggests/VBZ (l_ccomp) increase/VBP (l_nsubj) MB/NN -PUNC- warfarin/NN (r_npadvmod) associated/VBN (r_amod) ICH/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) increase/VBP (r_ccomp) suggests/VBZ (l_nsubj) excess/NN (l_prep) of/IN (l_pobj) MB/NN -PUNC- warfarin/NN (r_npadvmod) associated/VBN (r_amod) ICH/NNP (r_pobj) of/IN (r_prep) risk/NN (r_dobj) increase/VBP (l_nsubj) MB/NN
D014859_D002544 NONE warfarin/NN (r_amod) users/NNS (r_pobj) in/IN (r_prep) range/NN (r_parataxis) 3.4/CD (r_appos) range/NN (r_pobj) to/IN (r_prep) ratio/NN (r_pobj) from/IN (r_prep) increased/VBD (r_conj) were/VBD (l_prep) vs/IN (l_pobj) TIA/NNP (l_nmod) IS/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (r_pobj) in/IN (r_prep) excess/NN (r_attr) was/VBD (l_attr) none/NN (l_prep) in/IN (l_pobj) users/NNS (l_prep) with/IN (l_pobj) TIA/NNP (l_nmod) IS/NNP -PUNC- warfarin/JJ (r_amod) users/NNS (l_prep) with/IN (l_pobj) TIA/NNP (l_nmod) IS/NNP
6631522
D004317_D066126 CID doxorubicin/NN (r_compound) cardiotoxicity/NN
C013102_D066126 NONE HA/NNP (r_nsubj) are/VBP (l_attr) factor/NN (l_prep) in/IN (l_pobj) cardiotoxicity/NN
20009434
D008727_D007674 NONE methotrexate/NN (r_nsubj) is/VBZ (l_conj) cause/VB (l_dobj) toxicity/NN -PUNC- MTX/NNP (r_appos) methotrexate/NN (r_nsubj) is/VBZ (l_conj) cause/VB (l_dobj) toxicity/NN
D008727_D058186 CID methotrexate/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) failure/NN -PUNC- MTX/NNP (r_compound) therapy/NN (r_pobj) after/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) failure/NN -PUNC- MTX/NNP (r_compound) therapy/NN (r_nsubj) caused/VBD (l_dobj) failure/NN
D008727_D056486 NONE methotrexate/NN (r_nsubj) is/VBZ (l_conj) cause/VB (l_dobj) toxicity/NN -PUNC- MTX/NNP (r_appos) methotrexate/NN (r_nsubj) is/VBZ (l_conj) cause/VB (l_dobj) toxicity/NN
D008727_D001656 NONE MTX/NNP (r_compound) therapy/NN (r_pobj) after/IN (r_prep) report/VBP (r_ccomp) was/VBD (l_attr) boy/NN (l_relcl) received/VBN (l_dobj) transplantation/NN (l_prep) for/IN (l_pobj) atresia/NN
D008727_D002051 NONE methotrexate/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) lymphoma/NN -PUNC- MTX/NNP (r_appos) methotrexate/NN (r_nsubj) is/VBZ (l_attr) treatment/NN (l_prep) for/IN (l_pobj) lymphoma/NN
17223814
D015251_D054537 CID epirubicin/NNS (r_pobj) with/IN (r_prep) chemotherapy/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) block/NN
D017239_D054537 CID paclitaxel/NN (r_conj) epirubicin/NNS (r_pobj) with/IN (r_prep) chemotherapy/NN (r_pobj) of/IN (r_prep) result/NN (r_pobj) as/IN (r_prep) block/NN
12372954
D009530_D009395 CID nicergoline/NN (r_pobj) due/IN (r_prep) nephritis/NN -PUNC- Sermion/NN (r_appos) nicergoline/NN (r_pobj) due/IN (r_prep) nephritis/NN -PUNC- nicergoline/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) nephritis/NN -PUNC- nicergoline/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) nephritis/NN (l_appos) AIN/NNP -PUNC- Sermion/NN (r_appos) nicergoline/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) nephritis/NN -PUNC- Sermion/NN (r_appos) nicergoline/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) nephritis/NN (l_appos) AIN/NNP -PUNC- nicergoline/NN (r_npadvmod) associated/VBN (r_amod) AIN/NNP
D009530_D012170 NONE nicergoline/NN (r_dobj) taking/VBG (l_conj) bendazac/VB (l_prep) due/IN (l_pobj) occlusion/NN
C036067_D012170 NONE lysine/NN (r_dobj) bendazac/VB (l_prep) due/IN (l_pobj) occlusion/NN
10985896
D004317_D010051 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) cancers/NNS -PUNC- doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) be/VB (l_attr) agent/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) be/VB (l_attr) agent/NN (l_prep) in/IN (l_pobj) cancer/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) cancers/NNS
D017239_D010534 NONE paclitaxel/NN (r_compound) refractory/JJ (r_amod) cancers/NNS (l_conj) carcinoma/NN (l_prep) of/IN (l_pobj) peritoneum/NN -PUNC- paclitaxel/NN (r_compound) refractory/JJ (r_amod) disease/NN (r_pobj) with/IN (r_prep) carcinoma/NN
D004317_D005185 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) cancers/NNS -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) cancers/NNS
D004317_D010534 NONE doxorubicin/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) cancers/NNS (l_conj) carcinoma/NN (l_prep) of/IN (l_pobj) peritoneum/NN -PUNC- doxorubicin/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) cancers/NNS (l_conj) carcinoma/NN
D010984_D010534 NONE platinum/NN (r_nmod) refractory/JJ (r_amod) cancers/NNS (l_conj) carcinoma/NN (l_prep) of/IN (l_pobj) peritoneum/NN -PUNC- platinum/NN (r_nmod) disease/NN (r_pobj) with/IN (r_prep) carcinoma/NN
D017239_D010051 NONE paclitaxel/NN (r_compound) refractory/JJ (r_amod) cancers/NNS -PUNC- paclitaxel/NN (r_compound) refractory/JJ (r_amod) disease/NN (r_pobj) with/IN (r_prep) carcinoma/NN (r_conj) cancers/NNS -PUNC- paclitaxel/NN (r_conj) platinum-/NN (r_nmod) cancer/NN
D004317_D013280 CID doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN (l_appos) syndrome/NN (l_conj) stomatitis/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN (l_appos) syndrome/NN (l_conj) stomatitis/NN -PUNC- doxorubicin/NN (r_compound) regimen/NN (r_compound) results/VBZ (l_prep) in/IN (l_pobj) toxicity/NN (l_appos) stomatitis/NN
D004317_D064420 NONE doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) be/VB (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) be/VB (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- doxorubicin/NN (r_compound) regimen/NN (r_compound) results/VBZ (l_prep) in/IN (l_pobj) toxicity/NN
D010984_D005185 NONE platinum/NN (r_nmod) refractory/JJ (r_amod) cancers/NNS -PUNC- platinum/NN (r_nmod) disease/NN (r_pobj) with/IN (r_prep) carcinoma/NN (r_conj) cancers/NNS
D010984_D064420 NONE platinum/NN (r_npadvmod) resistant/JJ (r_amod) cancer/NN (r_pobj) in/IN (r_prep) agent/NN (r_attr) be/VB (l_prep) with/IN (l_pobj) toxicity/NN
D017239_D005185 NONE paclitaxel/NN (r_compound) refractory/JJ (r_amod) cancers/NNS -PUNC- paclitaxel/NN (r_compound) refractory/JJ (r_amod) disease/NN (r_pobj) with/IN (r_prep) carcinoma/NN (r_conj) cancers/NNS
D004317_D060831 CID doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN -PUNC- doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN (l_appos) syndrome/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN (l_appos) syndrome/NN -PUNC- doxorubicin/NN (r_compound) regimen/NN (r_compound) results/VBZ (l_prep) in/IN (l_pobj) toxicity/NN (l_appos) stomatitis/NN (l_appos) syndrome/NN
D010984_D013280 NONE platinum/NN (r_npadvmod) resistant/JJ (r_amod) cancer/NN (r_pobj) in/IN (r_prep) agent/NN (r_attr) be/VB (r_advcl) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN (l_appos) syndrome/NN (l_conj) stomatitis/NN
D010984_D060831 NONE platinum/NN (r_npadvmod) resistant/JJ (r_amod) cancer/NN (r_pobj) in/IN (r_prep) agent/NN (r_attr) be/VB (r_advcl) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN -PUNC- platinum/NN (r_npadvmod) resistant/JJ (r_amod) cancer/NN (r_pobj) in/IN (r_prep) agent/NN (r_attr) be/VB (r_advcl) demonstrated/VBN (l_advcl) being/VBG (l_attr) erythrodysesthesia/NN (l_appos) syndrome/NN
D010984_D010051 NONE platinum/NN (r_nmod) refractory/JJ (r_amod) cancers/NNS -PUNC- platinum/NN (r_npadvmod) resistant/JJ (r_amod) cancer/NN -PUNC- platinum/NN (r_nmod) disease/NN (r_pobj) with/IN (r_prep) carcinoma/NN (r_conj) cancers/NNS -PUNC- platinum-/NN (r_nmod) cancer/NN
26002693
C031763_D015464 NONE 1,3-Butadiene/CD (l_conj) CML/NNP -PUNC- 1,3-butadiene/CD (r_pobj) of/IN (r_prep) studies/NNS (r_nsubj) suggest/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- 1,3-butadiene/CD (r_pobj) of/IN (r_prep) studies/NNS (r_nsubj) suggest/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) leukemia/NN (l_appos) CML/NNP
6321816
D008094_D003919 CID lithium/NN (r_npadvmod) treated/VBN (r_amod) diabetes/NN (r_compound) insipidus/NN
D014667_D006973 NONE Vasopressin/NNP (l_prep) as/IN (l_pobj) contributor/NN (l_prep) to/IN (l_pobj) hypertension/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) role/NN (l_prep) as/IN (l_pobj) agent/NN (l_prep) to/IN (l_pobj) process/NN (l_amod) hypertensive/JJ -PUNC- Vasopressin/NNP (r_nsubj) plays/VBZ (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) action/NN (r_nsubj) appears/VBZ (l_xcomp) be/VB (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) action/NN (r_nsubj) appears/VBZ (l_advcl) observed/VBN (l_prep) in/IN (l_pobj) stage/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) secretion/NN (r_nsubj) promotes/VBZ (l_dobj) function/NN (l_prep) as/IN (l_pobj) factor/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) role/NN (r_nsubj) remains/VBZ (l_xcomp) determined/VBN (l_prep) in/IN (l_pobj) hypertension/NN
D014667_D003919 NONE Vasopressin/NNP (r_nsubj) plays/VBZ (l_advcl) was/VBD (l_acomp) substantial/JJ (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) insipidus/NN
D008094_D006973 NONE lithium/NN (r_npadvmod) treated/VBN (r_amod) diabetes/NN (r_compound) insipidus/NN (r_pobj) with/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) substantial/JJ (r_acomp) was/VBD (r_advcl) plays/VBZ (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) hypertension/NN
D003900_D006973 CID DOCA/NNP (r_compound) salt/NN (r_compound) hypertension/NN -PUNC- DOCA/NNP (r_compound) salt/NN (r_compound) treatment/NN (r_pobj) after/IN (r_prep) was/VBD (r_advcl) plays/VBZ (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) hypertension/NN
D003900_D003919 NONE DOCA/NNP (r_compound) salt/NN (r_compound) hypertension/NN (r_pobj) of/IN (r_prep) pathogenesis/NN (r_pobj) in/IN (r_prep) plays/VBZ (l_advcl) was/VBD (l_acomp) substantial/JJ (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) insipidus/NN -PUNC- DOCA/NNP (r_compound) salt/NN (r_compound) treatment/NN (r_pobj) after/IN (r_prep) was/VBD (l_acomp) substantial/JJ (l_prep) in/IN (l_pobj) rats/NNS (l_prep) with/IN (l_pobj) insipidus/NN
753803
D008696_D009135 NONE Dianabol/NNP (r_appos) agent/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_xcomp) encouraged/VBN (l_nsubj) results/NNS (l_acl) obtained/VBN (l_prep) in/IN (l_pobj) departments/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_amod) myopathic/JJ -PUNC- Dianabol/NNP (r_appos) agent/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_acl) rendered/VBN (l_oprd) myopathic/JJ
-1_D009135 NONE CIBA/NNP (r_appos) Dianabol/NNP (r_appos) agent/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_xcomp) encouraged/VBN (l_nsubj) results/NNS (l_acl) obtained/VBN (l_prep) in/IN (l_pobj) departments/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_amod) myopathic/JJ -PUNC- CIBA/NNP (r_appos) Dianabol/NNP (r_appos) agent/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_acl) rendered/VBN (l_oprd) myopathic/JJ
D014810_D009135 NONE E/NNS (r_pobj) of/IN (r_prep) lack/NN (r_pobj) due/IN (r_amod) Myopathy/NNP -PUNC- E/NNS (l_conj) myopathy/NNS -PUNC- E./NNP (r_punct) encouraged/VBN (l_nsubj) results/NNS (l_acl) obtained/VBN (l_prep) in/IN (l_pobj) departments/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_amod) myopathic/JJ -PUNC- E./NNP (r_punct) encouraged/VBN (l_xcomp) investigate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_acl) rendered/VBN (l_oprd) myopathic/JJ -PUNC- E/NN (r_pobj) of/IN (r_prep) lack/NN (r_attr) is/VBZ (r_conj) occurs/VBZ (r_advcl) have/VBP (r_conj) conclude/VBP (l_prep) by/IN (l_pcomp) affirming/VBG (l_dobj) efficacy/NN (l_prep) in/IN (l_pobj) disease/NN
D013256_D009135 NONE steroids/NNS (r_dobj) using/VBG (r_pcomp) by/IN (r_prep) obtained/VBN (l_prep) in/IN (l_pobj) departments/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_amod) myopathic/JJ -PUNC- steroids/NNS (r_dobj) using/VBG (r_pcomp) by/IN (r_prep) obtained/VBN (r_acl) results/NNS (r_nsubj) encouraged/VBN (l_xcomp) investigate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_acl) rendered/VBN (l_oprd) myopathic/JJ -PUNC- steroids/NNS (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) in/IN (l_pobj) disease/NN
D014810_D009136 CID E./NNP (r_pobj) in/IN (r_prep) lacking/VBG (r_acl) diet/NN (r_dobj) giving/VBG (r_pcomp) by/IN (r_prep) induced/VBD (l_dobj) myodystrophy/NN
8160791
D006152_D007674 NONE monophosphate/NN (r_nmod) excretion/NN (r_appos) reduction/NN (r_nsubjpass) observed/VBN (l_prep) in/IN (l_pobj) nephropathy/NN -PUNC- cGMP/NN (r_nmod) excretion/NN (r_appos) reduction/NN (r_nsubjpass) observed/VBN (l_prep) in/IN (l_pobj) nephropathy/NN
C038983_D007674 NONE DMTU/NNP (r_nsubj) reduced/VBD (l_dobj) damage/NN -PUNC- DMTU/NNP (r_conj) SOD/NNP (r_nsubj) have/VBP (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) nephropathy/NN -PUNC- DMTU/NNP (r_conj) SOD/NNP (r_pobj) for/IN (r_prep) differ/VBP (r_conj) have/VBP (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) nephropathy/NN
D005839_D007674 CID gentamicin/NN (r_npadvmod) mediated/VBN (r_amod) nephropathy/NN -PUNC- gentamicin/NN (r_nmod) nephropathy/NN -PUNC- GM)-mediated/JJ (r_amod) nephropathy/NN -PUNC- GM/NNP (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) induced/VBD (l_dobj) damage/NN -PUNC- GM/NNP (r_npadvmod) mediated/VBN (r_amod) nephropathy/NN -PUNC- GM/NNP (r_npadvmod) mediated/VBN (r_amod) nephropathy/NN -PUNC- GM/NNP (r_npadvmod) induced/VBN (r_amod) vasoconstriction/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) play/VBP (r_conj) have/VBP (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) nephropathy/NN
D013481_D007674 NONE superoxide/JJ (r_amod) anions/NNS (r_conj) SOD/NNP (r_pobj) for/IN (r_prep) differ/VBP (r_conj) have/VBP (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) nephropathy/NN
19263707
D002231_D014657 NONE carbimazole/NN (r_dobj) developed/VBD (r_relcl) disease/NN (r_pobj) with/IN (r_prep) patient/NN (r_nsubj) induced/VBD (l_dobj) vasculitis/NN -PUNC- carbimazole/NN (l_acl) induced/VBD (l_dobj) case/NN (l_compound) vasculitis/JJ
D013956_D056648 CID antithyroidmedications/NNS (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) antibody/NN (l_appos) vasculitis/NN
D011441_D006980 NONE propylthiouracil/NN (r_conj) carbimazole/NN (r_pobj) like/IN (r_prep) drugs/NNS (r_nsubjpass) prescribed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN -PUNC- PTU/NNP (r_appos) carbimazole/NN (r_pobj) like/IN (r_prep) drugs/NNS (r_nsubjpass) prescribed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
D002231_D006111 NONE carbimazole/NN (r_dobj) developed/VBD (r_relcl) disease/NN
D013956_D006980 NONE drugs/NNS (r_nsubjpass) prescribed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
D002231_D056648 CID Carbimazole/NNS (r_nsubj) induced/VBD (l_dobj) vasculitis/NN
D002231_D006980 NONE carbimazole/NN (r_pobj) like/IN (r_prep) drugs/NNS (r_nsubjpass) prescribed/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hyperthyroidism/NN
11176729
D000806_D007674 NONE inhibitor/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) Of/IN (r_prep) titrated/VBN (l_conj) because/IN (l_pobj) dysfunction/NN
D000806_D006947 NONE inhibitor/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) Of/IN (r_prep) titrated/VBN (l_conj) because/IN (l_pobj) dysfunction/NN (l_conj) hyperkalemia/NN
D000806_D007022 NONE inhibitor/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) Of/IN (r_prep) titrated/VBN (l_prep) because/IN (l_pobj) symptoms/NNS (l_acl) related/VBD (l_prep) to/IN (l_pobj) hypotension/NN
D017706_D006333 NONE lisinopril/NN (l_prep) in/IN (l_pobj) CHF/NNP
D000806_D006333 NONE inhibitors/NNS (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) Toleration/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- inhibitors/NNS (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) reduces/VBZ (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- inhibitors/NNS (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) reduces/VBZ (l_dobj) mortality/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN (l_appos) CHF/NNP -PUNC- inhibitor/NN (r_compound) therapy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) CHF/NNP
3987172
D010665_D020521 NONE PPA/NNP (r_nsubj) increased/VBD (l_dobj) volume/NN (l_compound) stroke/NN
D010665_D006973 CID phenylpropanolamine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- Phenylpropanolamine/NNP (r_nmod) overdose/NN (r_nsubj) cause/VB (l_dobj) hypertension/NN -PUNC- PPA/NNP (r_nmod) overdose/NN (r_nsubj) cause/VB (l_dobj) hypertension/NN -PUNC- PPA/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
D010665_D062787 NONE Phenylpropanolamine/NNP (r_nmod) overdose/NN -PUNC- PPA/NNP (r_nmod) overdose/NN
D010665_D002543 NONE Phenylpropanolamine/NNP (r_nmod) overdose/NN (r_nsubj) cause/VB (l_dobj) hypertension/NN (l_conj) hemorrhage/NN -PUNC- PPA/NNP (r_nmod) overdose/NN (r_nsubj) cause/VB (l_dobj) hypertension/NN (l_conj) hemorrhage/NN
D011433_D006973 NONE Propranolol/NNP (r_compound) antagonism/NN (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- propranolol/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypertension/NN
24451297
D019161_D056486 NONE statins/NNS (r_nsubj) are/VBP (r_advcl) reported/VBN (l_nsubjpass) cases/NNS (l_prep) of/IN (l_pobj) injury/NN
C065180_D056486 CID Fluvastatin/NNP (r_compound) Therapy/NNP (r_pobj) After/IN (r_prep) Hours/NNS (r_pobj) Within/IN (r_prep) Injury/NN -PUNC- fluvastatin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) beginning/VBG (r_pcomp) after/IN (r_prep) appeared/VBD (r_relcl) damage/NN
2782734
D000420_D001249 NONE salbutamol/NN (r_dobj) inhaled/VBN (l_prep) in/IN (l_pobj) asthmatics/NNS -PUNC- salbutamol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) produce/VB (l_dobj) improvements/NNS (l_prep) in/IN (l_pobj) response/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) asthma/NN -PUNC- salbutamol/NN (r_appos) dose/NN (r_pobj) with/IN (r_prep) treatment/NN (r_dobj) given/VBN (l_nsubjpass) predicted/VBD (l_nsubj) patients/NNS (l_amod) asthmatic/JJ -PUNC- salbutamol/NN (r_dobj) given/VBN (l_nsubjpass) predicted/VBD (l_nsubj) patients/NNS (l_amod) asthmatic/JJ
7147232
D010100_D007022 NONE oxygen/NN (r_compound) consumption/NN (r_conj) resistance/NN (r_dobj) left/VBD (l_ccomp) accompanied/VBN (l_nsubjpass) Hypotension/NN -PUNC- oxygen/NN (r_compound) difference/NN (r_conj) product/NN (r_conj) resistance/NN (r_appos) observed/VBN (l_prep) During/IN (l_pobj) hypotension/NN
D009599_D007022 CID nitroprusside/NN (l_nsubj) effects/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- nitroprusside/NN (r_nsubjpass) administered/VBN (l_advcl) induce/VB (l_conj) control/VB (l_dobj) hypotension/NN -PUNC- SNP/NNP (r_appos) nitroprusside/NN (r_nsubjpass) administered/VBN (l_advcl) induce/VB (l_conj) control/VB (l_dobj) hypotension/NN -PUNC- SNP/NNP (r_nmod) decreases/NNS (r_pobj) by/IN (r_agent) produced/VBN (r_acl) hypotension/NN
D000255_D007022 CID triphosphate/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) effects/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- triphosphate/NN (r_nsubj) nitroprusside/NN (r_nsubjpass) administered/VBN (l_advcl) induce/VB (l_conj) control/VB (l_dobj) hypotension/NN -PUNC- ATP/NNP (r_appos) triphosphate/NN (r_nsubj) nitroprusside/NN (r_nsubjpass) administered/VBN (l_advcl) induce/VB (l_conj) control/VB (l_dobj) hypotension/NN -PUNC- ATP/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Hypotension/NN -PUNC- ATP/NNP (r_nsubjpass) stopped/VBN (r_advcl) returned/VBD (l_ccomp) left/VBD (l_ccomp) accompanied/VBN (l_nsubjpass) Hypotension/NN
10401555
C096012_D006930 NONE nociceptin/NN (r_amod) as/IN (l_pobj) allodynia/NN -PUNC- nociceptin/NN (r_amod) as/IN (l_pobj) allodynia/NN (l_conj) hyperalgesia/NN -PUNC- nociceptin/RB (r_advmod) induced/VBN (r_amod) allodynia/NN -PUNC- nociceptin/RB (r_advmod) induced/VBN (r_amod) allodynia/NN (l_conj) hyperalgesia/NN
C111148_D007859 NONE nocistatin/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- nocistatin/NN (r_conj) FQ/NNP (r_nsubj) modulate/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
C111148_D008569 NONE nocistatin/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- nocistatin/NN (r_conj) FQ/NNP (r_nsubj) modulate/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
C111148_D006930 NONE nocistatin/NN (r_advmod) isolated/VBN (l_prep) from/IN (l_pobj) precursor/NN (l_prep) as/IN (l_pobj) allodynia/NN -PUNC- nocistatin/NN (r_advmod) isolated/VBN (l_prep) from/IN (l_pobj) precursor/NN (l_prep) as/IN (l_pobj) allodynia/NN (l_conj) hyperalgesia/NN
D012601_D007859 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
C096012_D008569 NONE Nociceptin/NNP (r_nmod) orphanin/NN (r_compound) FQ/NNP (l_conj) nocistatin/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- FQ/NNP (l_conj) nocistatin/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- nociceptin/NN (r_nmod) orphanin/VB (r_compound) FQ/NNP (r_nsubj) modulate/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- FQ/NNP (r_nsubj) modulate/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
D012601_D008569 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN -PUNC- scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
C096012_D007859 NONE Nociceptin/NNP (r_nmod) orphanin/NN (r_compound) FQ/NNP (l_conj) nocistatin/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- FQ/NNP (l_conj) nocistatin/NNS (l_prep) on/IN (l_pobj) impairment/NN -PUNC- nociceptin/NN (r_nmod) orphanin/VB (r_compound) FQ/NNP (r_nsubj) modulate/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN -PUNC- FQ/NNP (r_nsubj) modulate/VB (l_dobj) impairment/NN (l_prep) of/IN (l_pobj) learning/NN (l_conj) memory/NN
7411769
D007213_D051437 CID indomethacin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (r_acl) patients/NNS (l_appos) hyperkalemia/NN (l_conj) insufficiency/NN
D007213_D007674 NONE indomethacin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) function/NN (r_pobj) to/IN (r_prep) attention/NN (r_nsubj) help/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) mellitus/NN (l_conj) disease/NN
D007213_D003920 NONE indomethacin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) function/NN (r_pobj) to/IN (r_prep) attention/NN (r_nsubj) help/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) mellitus/NN
D011453_D006994 NONE prostaglandin/JJ (r_amod) synthesis/NN (l_conj) hypoaidosteronism/NN
D011188_D007674 NONE potassium/NN (r_compound) balance/NN (r_conj) function/NN (r_pobj) to/IN (r_prep) attention/NN (r_nsubj) help/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) mellitus/NN (l_conj) disease/NN
D007213_D015210 NONE Indomethacin/NNP (r_npadvmod) induced/VBN (r_amod) hyperkalemia/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- indomethacin/NN (r_pobj) with/IN (r_prep) treatment/NN (l_prep) of/IN (l_pobj) arthritis/NN
D007213_D006947 CID Indomethacin/NNP (r_npadvmod) induced/VBN (r_amod) hyperkalemia/NN -PUNC- indomethacin/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (r_acl) patients/NNS (l_appos) hyperkalemia/NN
D011188_D003920 NONE potassium/NN (r_compound) balance/NN (r_conj) function/NN (r_pobj) to/IN (r_prep) attention/NN (r_nsubj) help/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) mellitus/NN
7492040
D003042_D017180 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS (l_conj) tachycardia/NN
D008012_D001919 NONE lidocaine/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) seizures/NNS (r_conj) bradydysrhythmias/NNS
D003042_D064420 NONE cocaine/NN (r_compound) toxicity/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) Despite/IN (l_pobj) concerns/NNS (l_acl) enhance/VB (l_dobj) toxicity/NN
D008012_D002318 NONE lidocaine/NN (r_nsubj) enhance/VB (r_acl) concerns/NNS (r_pobj) Despite/IN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D008012_D002493 NONE lidocaine/NN (r_nsubj) enhance/VB (r_acl) concerns/NNS (r_pobj) Despite/IN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D003042_D001919 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS
D003042_D014693 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS (l_conj) tachycardia/NN (l_conj) fibrillation/NN
D003042_D002318 NONE cocaine/NN (r_compound) toxicity/NN (r_dobj) enhance/VB (r_acl) concerns/NNS (r_pobj) Despite/IN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D008012_D014693 NONE lidocaine/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS (l_conj) tachycardia/NN (l_conj) fibrillation/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) seizures/NNS (r_conj) bradydysrhythmias/NNS (l_conj) tachycardia/NN (l_conj) fibrillation/NN
D008012_D017180 NONE lidocaine/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS (l_conj) tachycardia/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) seizures/NNS (r_conj) bradydysrhythmias/NNS (l_conj) tachycardia/NN
D008012_D064420 NONE lidocaine/NN (r_nsubj) enhance/VB (l_dobj) toxicity/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) Despite/IN (l_pobj) concerns/NNS (l_acl) enhance/VB (l_dobj) toxicity/NN
D003042_D002493 NONE cocaine/NN (r_compound) toxicity/NN (r_dobj) enhance/VB (r_acl) concerns/NNS (r_pobj) Despite/IN (r_prep) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D003042_D009203 CID cocaine/NN (r_npadvmod) associated/VBN (r_amod) infarction/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN (l_appos) MI/NNP -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP -PUNC- cocaine/NN (r_compound) toxicity/NN (r_dobj) enhance/VB (r_acl) concerns/NNS (r_pobj) Despite/IN (r_prep) associated/VBN (l_nsubjpass) use/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MI/NNP -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP
D008012_D009203 NONE lidocaine/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) setting/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) safety/NN (l_prep) in/IN (l_pobj) setting/NN (l_prep) of/IN (l_pobj) infarction/NN (l_appos) MI/NNP -PUNC- lidocaine/NN (r_dobj) received/VBD (r_relcl) Patients/NNS (l_prep) with/IN (l_pobj) MI/NNP -PUNC- lidocaine/NN (r_dobj) received/VBD (l_prep) in/IN (l_pobj) setting/NN (l_prep) of/IN (l_pobj) MI/NNP -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) seizures/NNS (r_conj) bradydysrhythmias/NNS (r_dobj) exhibited/VBN (l_ccomp) died/VBD (l_nsubj) patients/NNS (l_relcl) received/VBD (l_prep) in/IN (l_pobj) setting/NN (l_prep) of/IN (l_pobj) MI/NNP -PUNC- lidocaine/NN (r_nsubj) enhance/VB (r_acl) concerns/NNS (r_pobj) Despite/IN (r_prep) associated/VBN (l_nsubjpass) use/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MI/NNP -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MI/NNP
D003042_D012640 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) MI/NNP (r_pobj) of/IN (r_prep) setting/NN (r_pobj) in/IN (r_prep) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS (l_conj) seizures/NNS
D008012_D012640 NONE lidocaine/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_nsubj) died/VBD (r_ccomp) exhibited/VBN (l_dobj) bradydysrhythmias/NNS (l_conj) seizures/NNS -PUNC- lidocaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) seizures/NNS
8096565
D018170_D003027 NONE sumatriptan/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) infarction/NN (l_prep) for/IN (l_pobj) headache/NN
D018170_D009203 CID sumatriptan/NNP (r_pobj) with/IN (r_prep) infarction/NN -PUNC- sumatriptan/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) infarction/NN
24999722
D005446_C537630 NONE acetonide/NN (r_compound) implant/NN (l_prep) in/IN (l_pobj) retinochoroidopathy/JJ -PUNC- acetonide/NN (r_amod) implant/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) retinochoroidopathy/JJ -PUNC- acetonide/NN (r_compound) implant/NN (r_dobj) fluocinolone/NN (r_ccomp) suggest/VBP (l_ccomp) helps/VBZ (l_xcomp) control/VB (l_dobj) inflammation/NN (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) retinochoroidopathy/JJ
D005446_D007249 NONE acetonide/NN (r_compound) implant/NN (r_dobj) fluocinolone/NN (r_ccomp) suggest/VBP (l_ccomp) helps/VBZ (l_xcomp) control/VB (l_dobj) inflammation/NN
10677406
D004280_D017682 CID dobutamine/NN (r_nsubj) induced/VBN (l_conj) presumed/VBN (l_xcomp) be/VB (l_acomp) similar/JJ (l_amod) stunning/JJ
D004280_D007511 NONE dobutamine/NN (r_conj) exercise/NN (r_pobj) after/IN (r_prep) study/NN (r_nsubj) induced/VBN (l_dobj) ischaemia/NN -PUNC- dobutamine/NN (r_nsubj) induced/VBN (l_dobj) results/NNS (l_compound) ischaemia/NN -PUNC- Dobutamine/NNP (r_nsubj) induced/VBD (l_dobj) ischaemia/NN
D004280_D017202 NONE dobutamine/NN (r_pobj) after/IN (r_mark) induced/VBN (l_dobj) ischaemia/NN
D004280_D003324 NONE dobutamine/NN (r_pobj) after/IN (r_mark) induced/VBN (r_advcl) occurs/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dobutamine/NN (r_nsubj) induced/VBN (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- Dobutamine/NNP (r_nsubj) induced/VBD (r_csubjpass) used/VBN (l_xcomp) study/VB (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D004280_D018487 CID dobutamine/NN (r_pobj) after/IN (r_mark) induced/VBN (r_advcl) occurs/VBZ (l_nsubj) dysfunction/NN -PUNC- dobutamine/NN (r_nsubj) induced/VBN (l_prep) in/IN (l_pobj) dysfunction/NN
12487093
C009591_D006973 NONE triphenyltetrazolium/NN (r_dobj) using/VBG (r_advcl) evaluated/VBN (r_relcl) BBB/NN (r_dobj) destroy/VB (r_xcomp) used/VBN (l_nsubjpass) hypertension/NN -PUNC- TTC/NNP (r_appos) triphenyltetrazolium/NN (r_dobj) using/VBG (r_advcl) evaluated/VBN (r_relcl) BBB/NN (r_dobj) destroy/VB (r_xcomp) used/VBN (l_nsubjpass) hypertension/NN
D004837_D006973 CID Adrenaline/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- adrenaline/NN (r_dobj) giving/VBG (r_pcomp) after/IN (r_prep) staining/NN (r_appos) triphenyltetrazolium/NN (r_dobj) using/VBG (r_advcl) evaluated/VBN (r_relcl) BBB/NN (r_dobj) destroy/VB (r_xcomp) used/VBN (l_nsubjpass) hypertension/NN
12950111
D006024_D010612 CID glycopyrrolate/NN (r_appos) patients/NNS (r_pobj) in/IN (r_prep) throat/NN -PUNC- glycopyrrolate/NN (r_parataxis) headache/NN (r_appos) mouth/NN (l_conj) throat/NN
D006024_D014987 NONE glycopyrrolate/NN (r_appos) patients/NNS (r_pobj) in/IN (r_prep) throat/NN (r_conj) mouth/NN -PUNC- glycopyrrolate/NN (r_parataxis) headache/NN (r_appos) mouth/NN
D006024_D013547 NONE glycopyrrolate/NN (r_pobj) with/IN (r_prep) hyperhidrosis/NN -PUNC- glycopyrrolate/NN (r_dobj) applying/VBG (r_pcomp) After/IN (r_prep) was/VBD (l_parataxis) sweating/NN -PUNC- glycopyrrolate/NN (r_dobj) applying/VBG (r_pcomp) After/IN (r_prep) was/VBD (l_parataxis) sweating/NN (l_conj) sweating/NN -PUNC- glycopyrrolate/JJ (r_compound) pad/NN (r_pobj) of/IN (r_prep) application/NN (l_appos) method/NN (l_prep) to/TO (l_pobj) symptoms/NNS (l_prep) of/IN (l_pobj) hyperhidrosis/NN
D006024_D006261 CID glycopyrrolate/NN (r_appos) patients/NNS (r_pobj) in/IN (r_prep) throat/NN (r_conj) mouth/NN (l_appos) headache/NN -PUNC- glycopyrrolate/NN (r_parataxis) headache/NN
24040781
D016559_D011507 NONE tacrolimus/NN (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) proteinuria/NN
C107135_D000686 CID everolimus/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) diagnosis/NN (l_appos) amyloidosis/NN (l_compound) AL/NNP -PUNC- everolimus/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) diagnosis/NN (l_appos) amyloidosis/NN -PUNC- everolimus/NN (r_pobj) to/IN (r_prep) tacrolimus/NN (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) significance/NN (r_pobj) of/IN (r_prep) gammapathy/JJ (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) diagnosis/NN (l_prep) of/IN (l_pobj) amyloidosis/NN
D016559_D000686 NONE tacrolimus/NN (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) significance/NN (r_pobj) of/IN (r_prep) gammapathy/JJ (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) diagnosis/NN (l_prep) of/IN (l_pobj) amyloidosis/NN
C107135_D011507 CID everolimus/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) diagnosis/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) proteinuria/NN -PUNC- everolimus/NN (r_pobj) to/IN (r_prep) tacrolimus/NN (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) proteinuria/NN
D020123_D011507 NONE rapamycin/NNS (r_amod) inhibitors/NNS (r_pobj) of/IN (r_prep) target/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) complication/NN (r_attr) is/VBZ (l_nsubj) Proteinuria/NNP
16092435
D004317_D066126 NONE adriamycin/NNS (r_npadvmod) evoked/VBN (r_amod) cardiotoxicity/NN -PUNC- Adriamycin/NNP (r_cc) evoked/VBN (l_dobj) toxicity/NN -PUNC- ADR/NNP (r_compound) cardiotoxicity/NN
D012266_D009202 NONE ribose/NN (l_prep) on/IN (l_pobj) myocardiopathy/NN
D012266_D066126 NONE ribose/NN (l_prep) on/IN (l_pobj) cardiotoxicity/NN -PUNC- ribose/NN (r_nsubj) influence/VB (l_dobj) cardiotoxicity/NN
D004317_D009202 CID adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) myocardiopathy/NN
24587916
D003907_D006973 CID dexamethasone/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- Dexamethasone-/NNP (r_nsubj) induced/VBN (l_ccomp) associated/VBN (l_nsubjpass) hypertension/NN -PUNC- Dex-/NNP (r_appos) Dexamethasone-/NNP (r_nsubj) induced/VBN (l_ccomp) associated/VBN (l_nsubjpass) hypertension/NN -PUNC- Dex/NNP (r_compound) administration/NN (r_pobj) upon/IN (r_prep) stress/NN (l_conj) hypertension/NN -PUNC- Dex/NNP (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- Dex/NNP (r_npadvmod) induced/VBN (r_amod) hypertension/NN
D006861_D015431 NONE H2O2/NNP (r_dobj) reduced/VBD (r_conj) prevented/VBD (l_dobj) loss/NN
15696449
D003404_D058186 NONE creatinine/NN (r_compound) level/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) by/IN (r_agent) defined/VBN (l_nsubjpass) insufficiency/NN -PUNC- creatinine/NN (r_compound) level/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) by/IN (r_agent) defined/VBN (l_nsubjpass) insufficiency/NN (l_appos) ARI/NNP
D008558_C531616 NONE melphalan/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) amyloidosis/NN
D008558_-1 NONE melphalan/NN (r_pobj) by/IN (r_prep) injury/NN (r_pobj) for/IN (r_prep) prerequisite/NN (r_attr) be/VB (l_nsubj) injury/NN
D008558_D058186 CID melphalan/NN (r_pobj) after/IN (r_prep) insufficiency/NN -PUNC- melphalan/NN (r_compound) conditioning/NN (r_pobj) after/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) insufficiency/NN -PUNC- melphalan/NN (r_nsubjpass) defined/VBN (l_nsubjpass) insufficiency/NN -PUNC- melphalan/NN (r_nsubjpass) defined/VBN (l_nsubjpass) insufficiency/NN (l_appos) ARI/NNP -PUNC- melphalan/NN (r_pobj) after/IN (r_prep) developed/VBD (l_nsubj) ARI/NNP -PUNC- melphalan/NN (r_nsubj) underwent/VBD (l_nsubj) Patients/NNS (l_relcl) had/VBD (l_dobj) ARI/NNP -PUNC- melphalan/NN (r_dobj) suggests/VBZ (l_nsubj) timing/NN (l_prep) of/IN (l_pobj) injury/NN -PUNC- melphalan/NN (r_pobj) by/IN (r_prep) injury/NN
16034922
D004967_D005705 CID oestrogen/NN (r_compound) HT/NNP (r_nsubj) increased/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) disease/NN
D004967_D020521 CID oestrogen/NN (r_compound) HT/NNP (r_nsubj) increased/VBD (l_dobj) risk/NN (l_prep) of/IN (l_pobj) disease/NN (l_nmod) stroke/NN
7931490
D002945_D014839 CID cisplatin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prevention/NN (l_conj) vomiting/VBG -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nausea/NN (l_conj) vomiting/NN -PUNC- cisplatin/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) vomiting/NN -PUNC- cisplatin/NN (r_dobj) received/VBD (l_conj) prevented/VBN (l_dobj) vomiting/VBG
D012701_D009325 NONE 5-hydroxytryptamine-3/CD (r_nummod) antagonist/NN (r_appos) Efficacy/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) nausea/NN
D002945_D009325 CID cisplatin/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) prevention/NN (l_prep) of/IN (l_pobj) nausea/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nausea/NN
D012701_D014839 NONE 5-hydroxytryptamine-3/CD (r_nummod) antagonist/NN (r_appos) Efficacy/NN (l_prep) in/IN (l_pobj) prevention/NN (l_conj) vomiting/VBG
D017829_D009325 NONE granisetron/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) nausea/NN -PUNC- granisetron/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) profile/NN (r_conj) effects/NNS (r_dobj) assess/VB (l_advcl) administered/VBN (l_dobj) dose/NN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_prep) of/IN (l_pobj) nausea/NN -PUNC- Kytril/NNP (r_appos) doses/NNS (r_pobj) of/IN (r_prep) profile/NN (r_conj) effects/NNS (r_dobj) assess/VB (l_advcl) administered/VBN (l_dobj) dose/NN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_prep) of/IN (l_pobj) nausea/NN
D017829_D014839 NONE granisetron/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) prevention/NN (l_conj) vomiting/VBG -PUNC- granisetron/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) profile/NN (r_conj) effects/NNS (r_dobj) assess/VB (l_advcl) administered/VBN (l_dobj) dose/NN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- Kytril/NNP (r_appos) doses/NNS (r_pobj) of/IN (r_prep) profile/NN (r_conj) effects/NNS (r_dobj) assess/VB (l_advcl) administered/VBN (l_dobj) dose/NN (l_prep) for/IN (l_pobj) prophylaxis/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) vomiting/NN -PUNC- granisetron/NN (r_compound) doses/NNS (l_appos) 10/CD (l_conj) micrograms/NNS (l_appos) response/NN (l_acl) vomiting/NN -PUNC- granisetron/NN (r_compound) doses/NNS (r_pobj) After/IN (r_prep) recorded/VBN (l_conj) response/NN (l_appos) vomiting/NN -PUNC- granisetron/NN (r_pobj) of/IN (r_prep) dose/NN (r_conj) 20-/CD (r_conj) 10-/LS (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) vomiting/NN -PUNC- granisetron/NN (r_pobj) of/IN (r_prep) dose/NN (r_conj) 20-/CD (r_conj) 10-/LS (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) in/IN (l_pcomp) controlling/VBG (l_dobj) vomiting/NN (l_prep) in/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) patients/NNS (l_relcl) received/VBD (l_conj) prevented/VBN (l_dobj) vomiting/VBG
17721298
D016578_D003320 CID cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) ulcers/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) ulcers/NNS -PUNC- cocaine/NN (r_compound) use/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) ulcers/NNS
1117341
D005947_D006030 NONE glucose/NN (r_compound) tolerance/NN (r_compound) curve/NN (l_conj) glucosuria/NN
D015119_D006030 NONE amino/JJ (r_amod) derivatives/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) of/IN (r_prep) feeding/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) hyperglycemia/NN (l_appos) curve/NN (l_conj) glucosuria/NN
C037652_D006030 NONE caproate/NN (r_pobj) of/IN (r_prep) derivatives/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) of/IN (r_prep) feeding/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) hyperglycemia/NN (l_appos) curve/NN (l_conj) glucosuria/NN
D015119_D006943 CID amino/JJ (r_compound) compounds/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) Hyperglycemic/JJ -PUNC- amino/JJ (r_amod) derivatives/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) of/IN (r_prep) feeding/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) hyperglycemia/NN
D005947_D006943 NONE glucose/NN (r_compound) tolerance/NN (r_compound) curve/NN (r_appos) hyperglycemia/NN
C037652_D006943 NONE caproate/NN (r_xcomp) related/VBN (l_nsubj) effect/NN (l_amod) Hyperglycemic/JJ -PUNC- caproate/NN (r_pobj) of/IN (r_prep) derivatives/NNS (r_pobj) of/IN (r_prep) amounts/NNS (r_pobj) of/IN (r_prep) feeding/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) hyperglycemia/NN
6893265
D011441_D056486 CID Propylthiouracil/NNP (r_npadvmod) induced/VBN (r_amod) damage/NN -PUNC- propylthiouracil/NN (r_npadvmod) induced/VBN (r_amod) damage/NN
3383127
D005472_D007022 CID 5-fluorouracil/CD (r_punct) ./. (r_punct) Hypotension/NN -PUNC- 5-fluorouracil/CD (r_punct) 5-FU/CD (r_npadvmod) developed/VBN (l_nsubj) symptoms/NNS (l_prep) including/VBG (l_pobj) hypotension/NN -PUNC- 5-FU/CD (r_npadvmod) developed/VBN (l_nsubj) symptoms/NNS (l_prep) including/VBG (l_pobj) hypotension/NN
D002945_D015179 NONE cisplatin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- CDDP/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D005472_D015179 NONE 5-fluorouracil/CD (r_punct) 5-FU/CD (r_npadvmod) developed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- 5-FU/CD (r_npadvmod) developed/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D002945_D007022 CID cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) manifestation/NN (r_pobj) as/IN (r_prep) Hypotension/NN -PUNC- cisplatin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBN (l_nsubj) symptoms/NNS (l_prep) including/VBG (l_pobj) hypotension/NN -PUNC- CDDP/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBN (l_nsubj) symptoms/NNS (l_prep) including/VBG (l_pobj) hypotension/NN
D005472_D066126 NONE 5-fluorouracil/CD (r_punct) ./. (r_punct) Hypotension/NN (l_prep) as/IN (l_pobj) manifestation/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- 5-FU/CD (r_compound) cardiotoxicity/NN
D002945_D066126 NONE cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) manifestation/NN (l_prep) of/IN (l_pobj) cardiotoxicity/NN -PUNC- CDDP/NNP (r_pobj) by/IN (r_agent) influenced/VBN (r_relcl) manifestations/NNS (l_prep) of/IN (l_pobj) cardiotoxicity/NN
2931989
D015474_D000013 NONE Isotretinoin/NNP (r_nsubjpass) contraindicated/VBN (l_prep) because/IN (l_pobj) abnormalities/NNS
D015474_C563492 NONE Isotretinoin/NNP (r_nsubjpass) contraindicated/VBN (l_prep) because/IN (l_pobj) abnormalities/NNS (l_prep) after/IN (l_pobj) use/NN (l_prep) including/VBG (l_pobj) microphthalmos/NNS (l_conj) hypertelorism/NN (l_conj) hypoplasia/NN
D015474_D000152 NONE isotretinoin/JJ (r_dobj) received/VBD (r_relcl) patients/NNS (l_appos) drug/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) acne/NN
D015474_D006972 NONE Isotretinoin/NNP (r_nsubjpass) contraindicated/VBN (l_prep) because/IN (l_pobj) abnormalities/NNS (l_prep) after/IN (l_pobj) use/NN (l_prep) including/VBG (l_pobj) microphthalmos/NNS (l_conj) hypertelorism/NN
D015474_D008850 NONE Isotretinoin/NNP (r_nsubjpass) contraindicated/VBN (l_prep) because/IN (l_pobj) abnormalities/NNS (l_prep) after/IN (l_pobj) use/NN (l_prep) including/VBG (l_pobj) microphthalmos/NNS
12535818
D000638_D001919 CID Amiodarone/NN (l_conj) risk/NN (l_prep) of/IN (l_pobj) bradyarrhythmia/JJ -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) bradyarrhythmia/NNS -PUNC- amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) bradyarrhythmia/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pobj) bradyarrhythmia/NNS
D000638_D009203 NONE Amiodarone/NN (l_conj) risk/NN (l_acl) requiring/VBG (l_dobj) pacemaker/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fibrillation/NN (l_conj) infarction/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) use/NN (l_conj) MI/NNP
D000638_D001145 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) bradyarrhythmia/NN (r_pobj) of/IN (r_prep) Reports/NNS (r_nsubj) are/VBP (l_acomp) infrequent/JJ (l_conj) limited/VBN (l_prep) to/IN (l_pobj) studies/NNS (l_acl) assessing/VBG (l_dobj) use/NN (l_prep) in/IN (l_pobj) management/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) arrhythmias/NNS
D000638_D001281 NONE Amiodarone/NN (l_conj) risk/NN (l_acl) requiring/VBG (l_dobj) pacemaker/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fibrillation/NN -PUNC- amiodarone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fibrillation/NN -PUNC- amiodarone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) fibrillation/NN (l_appos) AF/NNP -PUNC- amiodarone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) AF/NNP
4631913
D014750_D007970 CID sulfate/NN (r_pobj) of/IN (r_prep) mg/NN (r_quantmod) 2.5/CD (r_pobj) of/IN (r_prep) inoculation/NN (r_conj) Intravenous/JJ (r_nsubjpass) followed/VBN (l_agent) by/IN (l_pobj) leukopenia/NN
D014750_D011552 CID sulfate/NN (l_prep) on/IN (l_pobj) infections/NNS
3191389
D008528_D012640 NONE acid/NN (r_conj) ibuprofen/NNP (r_conj) indomethacin/NN (r_conj) phenylbutazone/NN (r_appos) salicylate/NN (r_conj) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- acid/NN (r_nsubj) prevented/VBN (l_dobj) seizures/NNS -PUNC- acid/NN (r_nsubj) prevented/VBN (l_dobj) seizures/NNS (l_prep) from/IN (l_pobj) damage/NN (l_amod) related/VBN (l_npadvmod) seizure/NN
D010862_D001930 NONE pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) damage/NN
D008528_D001930 NONE acid/NN (r_nsubj) prevented/VBN (l_dobj) seizures/NNS (l_prep) from/IN (l_pobj) damage/NN
D007213_D012640 NONE indomethacin/NN (r_conj) phenylbutazone/NN (r_appos) salicylate/NN (r_conj) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- Indomethacin/NNP (r_nsubj) failed/VBD (l_xcomp) modulate/VB (l_dobj) seizures/NNS
D010862_D013226 CID pilocarpine/NN (r_nsubj) induces/VBZ (l_prep) in/IN (l_pobj) seizures/NNS (l_conj) epilepticus/NN
D012980_D012640 CID salicylate/NN (r_conj) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS
D010653_D012640 CID phenylbutazone/NN (r_appos) salicylate/NN (r_conj) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS
D007052_D012640 NONE ibuprofen/NNP (r_conj) indomethacin/NN (r_conj) phenylbutazone/NN (r_appos) salicylate/NN (r_conj) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- ibuprofen/NNP (r_conj) mg/kg/NN (r_conj) Indomethacin/NNP (r_nsubj) failed/VBD (l_xcomp) modulate/VB (l_dobj) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_nsubj) induces/VBZ (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) damage/NN (r_pobj) from/IN (r_prep) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) damage/NN (l_amod) related/VBN (l_npadvmod) seizure/NN -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
6884395
D003276_D011782 NONE contraceptives/NNS (r_conj) smoke/NN (r_conj) hypertension/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) artery/NN (r_pobj) of/IN (r_prep) aneurysm/NN (r_pobj) of/IN (r_prep) case/NN (r_nsubjpass) reported/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) syndrome/NN
D003276_D000784 CID contraceptives/NNS (r_conj) smoke/NN (r_conj) hypertension/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) artery/NN (r_pobj) of/IN (r_prep) aneurysm/NN
D003276_D006973 NONE contraceptives/NNS (r_conj) smoke/NN (r_conj) hypertension/NN
15882284
D001241_D007674 NONE aspirin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) risk/NN (r_nsubjpass) related/VBN (l_conj) was/VBD (l_acomp) high/JJ (l_prep) among/IN (l_pobj) subset/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) nephropathy/NN
D001241_D007676 CID aspirin/NN (l_conj) drugs/NNS (l_appos) NSAIDs/NNPS (l_conj) disease/NN -PUNC- aspirin/NN (l_conj) drugs/NNS (l_appos) NSAIDs/NNPS (l_conj) disease/NN (l_appos) ESRD/NNP -PUNC- aspirin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) risk/NN (l_prep) of/IN (l_pobj) ESRD/NNS -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) ESRD/NNP
6517710
D011796_D013927 NONE hydrochloride/NN (r_appos) quinacrine/NN (r_dobj) given/VBN (r_csubj) had/VBD (l_dobj) thrombosis/NN
D011796_D003328 CID hydrochloride/NN (r_dobj) ingesting/VBG (r_acl) rats/NNS (r_pobj) of/IN (r_prep) heart/NN (r_dobj) involving/VBG (r_acl) thrombosis/NN -PUNC- hydrochloride/NN (r_appos) quinacrine/NN (r_pobj) with/IN (r_prep) treated/VBD (l_conj) developed/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) thrombosis/NN -PUNC- hydrochloride/NN (r_appos) quinacrine/NN (r_dobj) given/VBN (r_csubj) had/VBD (l_advcl) have/VB (l_dobj) thrombosis/NN
D012977_D003328 NONE nitrite/NN (r_conj) hydrochloride/NN (r_appos) quinacrine/NN (r_dobj) given/VBN (r_csubj) had/VBD (l_advcl) have/VB (l_dobj) thrombosis/NN
D012977_D013927 NONE nitrite/NN (r_conj) hydrochloride/NN (r_appos) quinacrine/NN (r_dobj) given/VBN (r_csubj) had/VBD (l_dobj) thrombosis/NN
9646784
D006493_D000505 CID heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ (l_conj) alopecia/NN
D006493_D004802 CID heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN
D006493_D013923 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) thromboembolism/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) thromboembolism/NN
D006493_D013921 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effects/NNS (r_conj) thromboembolism/NN (r_conj) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN -PUNC- heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (r_conj) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS (l_amod) other/JJ (l_prep) than/IN (l_pobj) thrombocytopenia/JJ
D006493_D010024 CID heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN (l_conj) osteoporosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN
D006493_D004342 CID heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS (l_conj) reactions/NNS
D006493_D012871 CID heparin/JJ (r_compound) therapy/NN (l_prep) including/VBG (l_pobj) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_conj) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS -PUNC- heparin/NN (r_npadvmod) associated/VBN (r_amod) osteoporosis/NN (l_conj) eosinophilia/NN (l_conj) reactions/NNS
6673474
D014294_D007022 CID trimetaphan/NN (l_pobj) hypotension/NN -PUNC- TMP/NNP (r_nmod) hypotension/NN -PUNC- trimetaphan/NN (r_mark) decrease/NN (r_conj) decrease/NN (r_advcl) used/VBN (r_ccomp) confirm/VB (l_prep) Regarding/VBG (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- trimetaphan/NN (r_mark) decrease/NN (r_conj) decrease/NN (r_advcl) used/VBN (l_nsubjpass) hypotension/NN -PUNC- trimetaphan/NN (r_mark) decrease/NN (l_dep) hypotension/NN
D009599_D007022 CID nitroprusside/NN (r_amod) sodium/NN (r_pobj) under/IN (r_prep) dogs/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) trimetaphan/NN (l_pobj) hypotension/NN -PUNC- SNP/NNP (r_appos) nitroprusside/NN (r_amod) sodium/NN (r_pobj) under/IN (r_prep) dogs/NNS (r_pobj) in/IN (r_prep) studied/VBN (l_conj) trimetaphan/NN (l_pobj) hypotension/NN -PUNC- nitroprusside/JJ (r_amod) hypotension/NN (r_nsubjpass) used/VBN (r_ccomp) confirm/VB (l_prep) Regarding/VBG (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- nitroprusside/JJ (r_amod) hypotension/NN -PUNC- nitroprusside/JJ (r_amod) hypotension/NN (r_nsubjpass) used/VBN (l_advcl) decrease/NN (l_conj) decrease/NN (l_dep) hypotension/NN -PUNC- SNP/NNP (r_compound) hypotension/NN
3708328
D007538_D012640 NONE isoniazid/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_pobj) after/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) produced/VBN (r_acl) seizures/NNS -PUNC- isoniazid/NN (r_pobj) of/IN (r_prep) microinjections/NNS (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- isoniazid/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) augment/VB (l_dobj) seizures/NNS
D018698_D013226 NONE acid/NN (r_compound) decarboxylase/NN (r_appos) enzyme/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) micrograms/NNS (r_conj) microinjections/NNS (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS (l_conj) epilepticus/NN
D005680_D013226 NONE GABA/NNP (r_npadvmod) synthesizing/VBG (r_amod) enzyme/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) micrograms/NNS (r_conj) microinjections/NNS (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS (l_conj) epilepticus/NN
D020888_D012640 NONE GABA/NNP (r_conj) isoniazid/NN (r_pobj) of/IN (r_prep) microinjection/NN (r_pobj) after/IN (r_prep) rats/NNS (r_pobj) in/IN (r_prep) produced/VBN (r_acl) seizures/NNS -PUNC- acid/NN (r_appos) D/NNP (r_nsubj) suppressed/VBD (l_dobj) appearance/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- GABA/NNP (r_pobj) of/IN (r_prep) Microinjections/NNS (r_nsubj) failed/VBD (l_xcomp) prevent/VB (l_dobj) development/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D010862_D004833 NONE Pilocarpine/NNP (r_nsubj) reproduces/VBZ (l_dobj) sequelae/NNS (l_prep) of/IN (l_pobj) epilepsy/NN
D010862_D013226 NONE pilocarpine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS (l_conj) epilepticus/NN
D007538_D013226 NONE isoniazid/NN (r_pobj) of/IN (r_prep) microinjections/NNS (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS (l_conj) epilepticus/NN
D005680_D012640 NONE acid/NN (r_pobj) of/IN (r_prep) activity/NN (r_dobj) manipulating/VBG (r_pcomp) of/IN (r_prep) effects/NNS (l_appos) inhibition/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- GABA)-mediated/VBN (r_amod) inhibition/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- GABA/NNP (r_npadvmod) synthesizing/VBG (r_amod) enzyme/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) micrograms/NNS (r_conj) microinjections/NNS (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- GABA/NNP (r_npadvmod) mediated/VBN (r_amod) inhibition/NN (r_pobj) of/IN (r_prep) regulation/NN (r_pobj) to/IN (r_prep) subjected/VBN (l_nsubjpass) threshold/NN (l_prep) for/IN (l_pobj) seizures/NNS
D018698_D012640 NONE acid/NN (r_compound) decarboxylase/NN (r_appos) enzyme/NN (r_pobj) of/IN (r_prep) activity/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) micrograms/NNS (r_conj) microinjections/NNS (r_pobj) with/IN (r_prep) pretreated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- Pilocarpine/NNP (r_nsubj) reproduces/VBZ (l_conj) provides/VBZ (l_dobj) model/NN (l_prep) for/IN (l_pcomp) studying/VBG (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) buildup/NN (l_prep) of/IN (l_pobj) activity/NN (l_amod) convulsive/JJ -PUNC- Pilocarpine/NNP (r_nsubj) reproduces/VBZ (l_conj) provides/VBZ (l_dobj) model/NN (l_prep) for/IN (l_pcomp) studying/VBG (l_dobj) mechanisms/NNS (l_prep) of/IN (l_pobj) buildup/NN (l_prep) of/IN (l_pobj) activity/NN (l_amod) operative/JJ (l_prep) in/IN (l_pobj) generalization/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) convulsions/NNS -PUNC- pilocarpine/NN (r_pobj) with/IN (r_prep) observed/VBN (r_relcl) formation/NN (r_pobj) to/IN (r_prep) damage/NN (l_amod) related/VBN (l_npadvmod) seizure/NN -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) seizures/NNS -PUNC- pilocarpine/NN (r_pobj) by/IN (r_agent) produced/VBN (r_acl) convulsions/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
18189308
D014443_D003556 NONE tyrosine/NN (r_det) receptors/NNS (r_pobj) of/IN (r_prep) expression/NN (r_dobj) examined/VBN (l_prep) in/IN (l_pobj) reflexes/NNS (l_prep) with/IN (l_pobj) inflammation/NN
D003520_D003556 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) durations/NNS (l_prep) of/IN (l_pobj) inflammation/NN -PUNC- CYP/NNP (r_appos) cyclophosphamide/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) durations/NNS (l_prep) of/IN (l_pobj) inflammation/NN -PUNC- CYP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- CYP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- CYP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN
2983630
D002110_D009421 NONE caffeine/NN (r_nsubj) is/VBZ (r_advcl) suggest/VBP (l_ccomp) have/VB (l_dobj) abnormalities/NNS (l_prep) in/IN (l_pobj) systems/NNS
D002110_-1 NONE Caffeine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN (l_conj) nervousness/NN (l_conj) fear/NN (l_conj) nausea/NN (l_conj) palpitations/NNS
D008734_D016584 NONE 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_conj) disorder/NN -PUNC- MHPG/RB (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- MHPG/RB (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_conj) disorder/NN
D002110_D000379 NONE caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN
D002110_D001008 CID Caffeine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN -PUNC- caffeine/NN (r_npadvmod) containing/VBG (r_amod) foods/NNS (r_dobj) avoiding/VBG (r_pcomp) by/IN (r_prep) benefit/VB (l_nsubj) Patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS
D000241_D016584 NONE adenosine/NN (r_amod) antagonist/NN (r_attr) is/VBZ (r_advcl) suggest/VBP (l_ccomp) have/VB (l_nsubj) patients/NNS (l_compound) disorder/NN -PUNC- adenosine/NN (r_dobj) involving/VBG (r_acl) systems/NNS (r_pobj) in/IN (r_prep) abnormalities/NNS (r_dobj) have/VB (l_nsubj) patients/NNS (l_compound) disorder/NN
D000241_D009421 NONE adenosine/NN (r_amod) antagonist/NN (r_attr) is/VBZ (r_advcl) suggest/VBP (l_ccomp) have/VB (l_dobj) abnormalities/NNS (l_prep) in/IN (l_pobj) systems/NNS -PUNC- adenosine/NN (r_dobj) involving/VBG (r_acl) systems/NNS
D006854_D000379 NONE cortisol/NN (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN
D002110_D016584 NONE caffeine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) disorders/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_conj) disorder/NN -PUNC- caffeine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) were/VBD (l_acomp) similar/JJ (l_prep) to/IN (l_pobj) those/DT (l_acl) experienced/VBN (l_prep) during/IN (l_pobj) attacks/NNS -PUNC- caffeine/NN (r_nsubj) is/VBZ (r_advcl) suggest/VBP (l_ccomp) have/VB (l_nsubj) patients/NNS (l_compound) disorder/NN
D006854_D016584 NONE cortisol/NN (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS -PUNC- cortisol/NN (r_conj) 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN (l_prep) with/IN (l_pobj) attacks/NNS (l_conj) disorder/NN
D008734_D000379 NONE 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN -PUNC- MHPG/RB (r_appos) 3-methoxy-4-hydroxyphenethyleneglycol/CD (r_pobj) of/IN (r_prep) pressure/NN (r_conj) symptoms/NNS (r_conj) ratings/NNS (r_pobj) on/IN (r_prep) effects/NNS (r_nsubjpass) determined/VBN (l_advcl) meeting/VBG (l_dobj) criteria/NNS (l_prep) for/IN (l_pobj) agoraphobia/NN
D002110_D014202 CID Caffeine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN (l_conj) nervousness/NN (l_conj) fear/NN (l_conj) nausea/NN (l_conj) palpitations/NNS (l_conj) restlessness/NN (l_conj) tremors/NNS
D002110_D009325 CID Caffeine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN (l_conj) nervousness/NN (l_conj) fear/NN (l_conj) nausea/NN
D002110_D011595 NONE Caffeine/NN (r_nsubj) produced/VBD (l_dobj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN (l_conj) nervousness/NN (l_conj) fear/NN (l_conj) nausea/NN (l_conj) palpitations/NNS (l_conj) restlessness/NN
15609701
D013015_D003329 CID Sotalol/NNP (r_npadvmod) induced/VBN (l_dobj) spasm/NN -PUNC- sotalol/NN (r_pobj) of/IN (r_prep) properties/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) vasospasm/NN
D013015_D017180 NONE Sotalol/NNP (r_npadvmod) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cardiomyopathy/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) tachycardia/NN -PUNC- sotalol/NN (r_appos) agent/NN (r_nsubj) was/VBD (l_acomp) effective/JJ (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) VT/NNP
C076259_D017180 NONE hydrochloride/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) terminated/VBN (l_nsubjpass) VT/NNP
D013015_D002311 NONE Sotalol/NNP (r_npadvmod) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) cardiomyopathy/NN
10510854
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) reversal/NN (l_prep) of/IN (l_pobj) catalepsy/NN
8659767
D002045_D001145 NONE bupivacaine/NN (r_pobj) Since/IN (r_prep) potentiate/VB (l_nsubj) dysrhythmias/NNS -PUNC- bupivacaine/NN (r_appos) dysrhythmias/NNS -PUNC- Bupivacaine/NNP (r_nsubj) antagonizes/VBZ (l_dobj) dysrhythmogenicity/NN (l_prep) in/IN (l_conj) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) dysrhythmias/NNS
D002045_D009203 NONE bupivacaine/NN (r_nsubj) alters/VBZ (l_prep) in/IN (l_conj) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) infarction/NN
D004837_D017180 CID epinephrine/NN (r_dobj) received/VBD (l_advcl) appeared/VBD (l_nsubj) VT/NNP -PUNC- epinephrine/NN (r_amod) dysrhythmogenicity/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_amod) susceptible/JJ (l_prep) to/IN (l_pobj) VT/NNP
D004837_D009203 NONE epinephrine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) of/IN (r_prep) dysrhythmogenicity/NN (r_dobj) alters/VBZ (l_prep) in/IN (l_conj) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- epinephrine/NN (r_dobj) received/VBD (l_prep) after/IN (l_pobj) infarction/NN
D002045_D017180 NONE Bupivacaine/NNP (r_nsubj) antagonizes/VBZ (l_dobj) dysrhythmogenicity/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_amod) susceptible/JJ (l_prep) to/IN (l_pobj) VT/NNP
D006221_D017180 NONE halothane/NN (r_npadvmod) anesthetized/VBN (r_amod) dogs/NNS (r_nsubj) received/VBD (l_advcl) appeared/VBD (l_nsubj) VT/NNP
D004837_D001145 NONE epinephrine/NN (r_conj) bupivacaine/NN (r_pobj) Since/IN (r_prep) potentiate/VB (l_nsubj) dysrhythmias/NNS -PUNC- epinephrine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) potentiate/VB (l_nsubj) dysrhythmias/NNS -PUNC- epinephrine/NN (r_amod) dysrhythmogenicity/NN (l_prep) in/IN (l_conj) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) dysrhythmias/NNS
D006221_D009203 NONE halothane/NN (r_npadvmod) anesthetized/VBN (r_amod) dogs/NNS (r_nsubj) received/VBD (l_prep) after/IN (l_pobj) infarction/NN
12523489
D003042_D006948 NONE Cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- Cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_nsubjpass) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN -PUNC- cocaine/NN (r_nmod) hyperactivity/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_pobj) in/IN (r_prep) active/JJ (r_acomp) were/VBD (r_relcl) those/DT (r_pobj) than/IN (r_prep) doses/NNS (r_pobj) at/IN (r_conj) decreased/VBD (l_dobj) hyperactivity/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- cocaine-/JJ (r_dobj) reduce/VBP (l_conj) indicate/VBP (l_ccomp) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- cocaine-/JJ (r_dobj) reduce/VBP (l_conj) indicate/VBP (l_ccomp) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- cocaine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_nsubjpass) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN
D000241_D004409 NONE adenosine/NN (r_amod) agonists/NNS (r_nsubj) decreased/VBD (l_dobj) activity/NN
D000661_D006948 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_pobj) than/IN (r_prep) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_conj) cocaine/NN (r_nmod) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_dobj) decreased/VBD (l_conj) at/IN (l_pobj) doses/NNS (l_prep) than/IN (l_pobj) those/DT (l_relcl) were/VBD (l_acomp) active/JJ (l_prep) in/IN (l_pobj) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) activity/NN (r_dobj) reduce/VBP (l_conj) indicate/VBP (l_ccomp) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) activity/NN (r_dobj) reduce/VBP (l_conj) indicate/VBP (l_ccomp) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN (r_pobj) than/IN (r_prep) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- amphetamine/NN (r_npadvmod) induced/VBN (r_amod) hyperactivity/NN
D000241_D006948 NONE adenosine/NN (r_amod) agonists/NNS (r_pobj) by/IN (r_agent) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_pobj) by/IN (r_agent) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (l_conj) antagonists/NNS (l_prep) on/IN (l_pobj) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_nsubj) decreased/VBD (l_dobj) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_nsubj) decreased/VBD (l_conj) at/IN (l_pobj) doses/NNS (l_prep) than/IN (l_pobj) those/DT (l_relcl) were/VBD (l_acomp) active/JJ (l_prep) in/IN (l_pobj) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_nsubj) reduce/VBP (l_conj) indicate/VBP (l_ccomp) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_nsubj) reduce/VBP (l_conj) indicate/VBP (l_ccomp) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_pobj) by/IN (r_agent) influenced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- adenosine/NN (r_amod) agonists/NNS (r_pobj) by/IN (r_agent) influenced/VBN (l_prep) than/IN (l_pobj) hyperactivity/NN
611664
D011433_C544351 NONE propranolol/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypotension/NN -PUNC- propranolol/NN (r_nsubj) is/VBZ (l_attr) drug/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypotension/NN
D011433_D006973 CID propranolol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) hypertension/NN
D009638_D004342 NONE norepinephrine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/IN (r_prep) hypersensitivity/NN
D002395_D004342 NONE catecholamines/NNS (r_dobj) exhibited/VBD (l_conj) marked/VBN (l_dobj) hypersensitivity/NN
10713017
D005277_D006976 CID fenfluramines/NNS (r_nsubj) had/VBD (l_dobj) association/NN (l_prep) with/IN (l_pobj) PPH/NNP -PUNC- fenfluramines/NNS (r_pobj) for/IN (r_prep) specificity/NN (r_conj) association/NN (l_prep) with/IN (l_pobj) PPH/NNP -PUNC- fenfluramines/NNS (r_pobj) for/IN (r_prep) specificity/NN (r_conj) association/NN (r_pobj) of/IN (r_prep) magnitude/NN (r_nsubj) are/VBP (l_acomp) consistent/JJ (l_prep) with/IN (l_pobj) studies/NNS (l_acl) indicating/VBG (l_ccomp) related/VBN (l_prep) to/IN (l_pobj) PPH/NNP -PUNC- fenfluramines/NNS (r_nsubjpass) related/VBN (r_ccomp) indicating/VBG (r_acl) studies/NNS (r_pobj) with/IN (r_prep) consistent/JJ (r_acomp) are/VBP (l_nsubj) magnitude/NN (l_prep) of/IN (l_pobj) association/NN (l_prep) with/IN (l_pobj) PPH/NNP -PUNC- fenfluramines/NNS (r_nsubjpass) related/VBN (l_prep) to/IN (l_pobj) PPH/NNP
24595967
D018817_D008569 CID ecstasy/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) consolidation/NN (l_compound) memory/NN -PUNC- Ecstasy/NNP (r_compound) users/NNS (r_nsubj) demonstrated/VBD (l_dobj) consolidation/NN (l_compound) memory/NN -PUNC- ecstasy/NN (r_npadvmod) associated/VBN (r_amod) dysfunction/NN (r_nsubj) underlie/VB (l_dobj) impairments/NNS -PUNC- ecstasy/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) impairments/NNS
D018817_D012893 CID ecstasy/NN (r_compound) users/NNS (r_nsubj) marked/VBN (l_conj) impairments/NNS
20828385
C401859_D009336 CID temsirolimus/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) found/VBN (l_nsubjpass) areas/NNS (l_amod) compatible/JJ (l_prep) with/IN (l_pobj) repair/NN (l_amod) necrotic/JJ
C401859_D009369 NONE temsirolimus/NN (r_compound) treatment/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) regression/NN (l_compound) tumor/NN -PUNC- temsirolimus/NN (r_nsubj) inhibited/JJ (l_dobj) proliferation/NN (l_compound) cell/NN (l_compound) tumor/NN -PUNC- temsirolimus/NN (r_nsubj) inhibited/JJ (l_conj) induce/VB (l_dobj) change/NN (l_prep) in/IN (l_pobj) number/NN (l_prep) of/IN (l_pobj) cells/NNS (l_compound) tumor/NN -PUNC- temsirolimus/NNS (r_nsubj) had/VBD (l_dobj) effect/NN (l_prep) with/IN (l_pobj) decrease/NN (l_prep) of/IN (l_pobj) density/NN (l_compound) tumor/NN -PUNC- temsirolimus/NNS (r_nsubj) reduced/VBN (l_dobj) burden/NN (l_compound) tumor/NN -PUNC- temsirolimus/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) tissue/NN (l_compound) tumor/NN
C401859_D020522 NONE temsirolimus/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) lymphoma/NN -PUNC- temsirolimus/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) reported/VBN (l_prep) in/IN (l_pobj) MCL/NN -PUNC- temsirolimus/NN (r_compound) treatment/NN (r_pobj) after/IN (r_prep) had/VBD (r_relcl) MCL/NNP -PUNC- temsirolimus/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) contribute/VB (l_prep) to/IN (l_pobj) efficiency/NN (l_prep) in/IN (l_pobj) MCL/NN
12059909
D003520_D064420 NONE cyclophosphamide/NN (r_pobj) of/IN (r_prep) toxicity/NN -PUNC- CY/NNP (r_compound) toxicity/NN -PUNC- CY/NNP (r_pobj) of/IN (r_prep) toxicity/NN
D003520_D006470 CID CY/NNP (r_compound) toxicity/NN (r_nsubj) caused/VBD (l_dobj) cystitis/NN (l_amod) haemorrhagic/JJ
D003520_D003556 CID CY/NNP (r_compound) toxicity/NN (r_nsubj) caused/VBD (l_dobj) cystitis/NN -PUNC- CY/NNP (r_compound) injection/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) After/IN (r_prep) appeared/VBD (l_nsubj) forms/NNS (l_prep) of/IN (l_pobj) cystitis/NN
612112
D005045_D009207 CID etomidate/NN (r_nsubj) prove/VB (l_xcomp) be/VB (l_prep) because/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) myoclonia/NN
8392553
D004837_D005355 NONE epinephrine/NN (r_compound) infusion/NN (r_pobj) With/IN (r_prep) died/VBD (l_conj) observed/VBN (l_nsubjpass) lesions/NNS (l_conj) fibrosis/NN -PUNC- epinephrine/RB (r_npadvmod) induced/VBN (r_amod) death/NN (r_dobj) prevented/VBD (l_conj) attenuated/VBD (l_dobj) lesions/NNS (l_conj) fibrosis/NN
C056595_D005355 NONE clentiazem/NN (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) prevented/VBD (l_conj) attenuated/VBD (l_dobj) lesions/NNS (l_conj) fibrosis/NN
D004837_D007511 NONE epinephrine/NN (r_compound) infusion/NN (r_pobj) With/IN (r_prep) died/VBD (l_conj) observed/VBN (l_nsubjpass) lesions/NNS -PUNC- epinephrine/RB (r_npadvmod) induced/VBN (r_amod) death/NN (r_dobj) prevented/VBD (l_conj) attenuated/VBD (l_dobj) lesions/NNS
C056595_D009202 NONE clentiazem/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) cardiomyopathy/NN
D004837_D009202 CID epinephrine/NN (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN
D004837_D006331 NONE epinephrine/NN (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- epinephrine/NN (r_npadvmod) induced/VBN (r_amod) injury/NN
C106746_D009202 NONE 1,5-benzothiazepine/CD (r_amod) antagonist/NN (r_appos) effects/NNS (l_prep) on/IN (l_pobj) cardiomyopathy/NN
C056595_D007511 NONE clentiazem/NN (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) prevented/VBD (l_conj) attenuated/VBD (l_dobj) lesions/NNS
D002118_D009202 NONE calcium/NN (r_compound) antagonist/NN (r_appos) effects/NNS (l_prep) on/IN (l_pobj) cardiomyopathy/NN
C056595_D006331 NONE clentiazem/NN (l_prep) against/IN (l_pobj) injury/NN -PUNC- clentiazem/NN (r_npadvmod) attenuated/VBD (l_dobj) injury/NN
24971338
D016572_D007674 CID cyclosporine/NN (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- A/NNP (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) of/IN (r_prep) Protocols/NNS (r_nsubjpass) used/VBN (l_prep) after/IN (l_pobj) transplantation/NN (l_relcl) prevent/VB (l_dobj) nephropathy/NN -PUNC- CsA/NNP (r_appos) A/NNP (r_pobj) from/IN (r_prep) conversion/NN (r_pobj) of/IN (r_prep) Protocols/NNS (r_nsubjpass) used/VBN (l_prep) after/IN (l_pobj) transplantation/NN (l_relcl) prevent/VB (l_dobj) nephropathy/NN -PUNC- CsA/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- CsA/NNP (r_compound) treatment/NN (r_nsubj) presented/VBD (l_dobj) lesions/NNS -PUNC- CsA/NNP (r_compound) exposure/NN (r_nsubj) aggravated/VBD (l_dobj) damage/NN -PUNC- CsA/NNP (r_npadvmod) induced/VBN (r_amod) evolution/NN (l_compound) damage/NN -PUNC- CsA/NNP (r_compound) replacement/NN (r_pobj) of/IN (r_prep) biomarker/NN (r_attr) be/VB (r_xcomp) seems/VBZ (r_advcl) prevented/VBN (l_dobj) evolution/NN (l_compound) damage/NN
D006416_D007674 NONE hematoxylin/NN (r_pobj) in/IN (r_prep) analyzed/VBN (l_nsubjpass) lesions/NNS
D020123_D007674 NONE sirolimus/VB (r_relcl) Conversion/NN (r_nsubj) ameliorates/VBZ (l_dobj) nephropathy/NN -PUNC- sirolimus/VB (r_pobj) to/TO (r_prep) conversion/NN (r_pobj) of/IN (r_prep) Protocols/NNS (r_nsubjpass) used/VBN (l_prep) after/IN (l_pobj) transplantation/NN (l_relcl) prevent/VB (l_dobj) nephropathy/NN -PUNC- SRL/NN (r_nsubjpass) used/VBN (l_prep) after/IN (l_pobj) transplantation/NN (l_relcl) prevent/VB (l_dobj) nephropathy/NN -PUNC- SRL/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) presented/VBD (l_prep) as/IN (l_pobj) markers/NNS (l_prep) of/IN (l_pobj) impairment/NN -PUNC- SRL/NNP (r_pobj) to/IN (r_prep) Conversion/NN (r_nsubj) prevented/VBN (l_dobj) evolution/NN (l_compound) damage/NN -PUNC- SRL/NNP (r_pobj) to/IN (r_prep) replacement/NN (r_pobj) of/IN (r_prep) biomarker/NN (r_attr) be/VB (r_xcomp) seems/VBZ (r_advcl) prevented/VBN (l_dobj) evolution/NN (l_compound) damage/NN
D004801_D007674 NONE eosin/NN (r_conj) hematoxylin/NN (r_pobj) in/IN (r_prep) analyzed/VBN (l_nsubjpass) lesions/NNS
D020123_D011507 CID SRL/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_nsubj) presented/VBD (l_dobj) proteinuria/NN
24894748
D008790_D012804 NONE metoprolol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advcl) report/VB (l_dobj) bradycardia/NN -PUNC- metoprolol/NN (r_pobj) between/IN (r_prep) interaction/NN (r_conj) bradycardia/NNP -PUNC- metoprolol/NN (r_poss) clearance/NN (r_dobj) decreased/VBN (l_advcl) leading/VBG (l_prep) in/IN (l_pobj) accumulation/NN (l_relcl) resulted/VBN (l_prep) in/IN (l_pobj) bradycardia/NN -PUNC- metoprolol/NN (r_compound) accumulation/NN (l_relcl) resulted/VBN (l_prep) in/IN (l_pobj) bradycardia/NN
D008790_D003324 NONE metoprolol/NN (l_prep) for/IN (l_pobj) disease/NN
C041359_D003221 NONE terbinafine/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) day/NN (r_pobj) On/IN (r_prep) brought/VBN (l_prep) for/IN (l_pobj) decrease/NN (l_prep) of/IN (l_pobj) status/NN (l_conj) confusion/NN
C041359_D012804 NONE terbinafine/NN (r_compound) interaction/NN (r_conj) metoprolol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_advcl) report/VB (l_dobj) bradycardia/NN -PUNC- terbinafine/NN (r_conj) metoprolol/NN (r_pobj) between/IN (r_prep) interaction/NN (r_conj) bradycardia/NNP -PUNC- terbinafine/NN (r_nsubj) decreased/VBN (l_advcl) leading/VBG (l_prep) in/IN (l_pobj) accumulation/NN (l_relcl) resulted/VBN (l_prep) in/IN (l_pobj) bradycardia/NN
D008790_D001919 CID metoprolol/NN (r_compound) terbinafine/NN (r_compound) combination/NN (r_nsubj) induced/VBN (l_dobj) bradycardia/NN
D008790_D014009 NONE metoprolol/NN (r_nsubjpass) prescribed/VBN (l_npadvmod) day/NN (l_prep) for/IN (l_pobj) onychomycosis/NN
C041359_D014009 NONE terbinafine/NN (r_pobj) of/IN (r_prep) course/NN (r_dobj) prescribed/VBN (l_npadvmod) day/NN (l_prep) for/IN (l_pobj) onychomycosis/NN
C041359_D001919 CID terbinafine/NN (r_compound) combination/NN (r_nsubj) induced/VBN (l_dobj) bradycardia/NN
C041359_D003324 NONE terbinafine/NN (r_pobj) of/IN (r_prep) course/NN (r_dobj) prescribed/VBN (l_nsubjpass) metoprolol/NN (l_prep) for/IN (l_pobj) disease/NN
C041359_D064420 NONE terbinafine/NN (r_conj) metoprolol/NN (r_pobj) between/IN (r_prep) interaction/NN (r_conj) bradycardia/NNP (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) indicates/VBZ (l_nsubj) score/NN (l_prep) on/IN (l_pobj) scale/NN (l_compound) probability/NN (l_compound) reaction/NN
D008790_D064420 NONE metoprolol/NN (r_pobj) between/IN (r_prep) interaction/NN (r_conj) bradycardia/NNP (r_pobj) between/IN (r_prep) relationship/NN (r_dobj) indicates/VBZ (l_nsubj) score/NN (l_prep) on/IN (l_pobj) scale/NN (l_compound) probability/NN (l_compound) reaction/NN
7173007
D007485_D064420 NONE Hexabrix/NNP (r_nmod) polyvidone/NN (r_nsubjpass) considered/VBN (l_conj) preferred/VBN (l_prep) because/IN (l_pobj) toxicity/NN -PUNC- Hexabrix/NNP (r_nsubjpass) preferred/VBN (l_prep) because/IN (l_pobj) toxicity/NN
D003287_D064420 NONE media/NNS (r_oprd) considered/VBN (l_conj) preferred/VBN (l_prep) because/IN (l_pobj) toxicity/NN
C025504_D004244 CID X/NNP (r_compound) group/NN (r_nsubj) had/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN (l_conj) dizziness/NN
D000100_D064420 NONE polyvidone/NN (r_nsubjpass) considered/VBN (l_conj) preferred/VBN (l_prep) because/IN (l_pobj) toxicity/NN
C025504_D009325 CID X/NNP (r_compound) group/NN (r_nsubj) had/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) nausea/NN
C006753_D015746 CID Endografine/NNP (r_compound) group/NN (r_nsubj) had/VBD (l_dobj) incidence/NN (l_prep) of/IN (l_pobj) pain/NN
15953230
C012052_D008133 CID amisulpride/JJ (r_amod) overdose/NN (r_pobj) of/IN (r_prep) cases/NNS (l_appos) cause/NN (l_prep) for/IN (l_pobj) syndrome/NN
D002125_D008133 NONE gluconate/VBN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) respond/VB (r_xcomp) appeared/VBD (l_nsubj) prolongation/NN
C012052_D062787 NONE amisulpride/JJ (r_amod) overdose/NN
C012052_D011041 NONE amisulpride/NN (r_pobj) of/IN (r_prep) g/NN (r_conj) poisoning/NN
7248895
D003520_D014571 NONE cyclophosphamide/NN (r_pobj) of/IN (r_prep) ability/NN (r_nsubj) is/VBZ (r_advcl) is/VBZ (r_auxpass) appreciated/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) tract/NN -PUNC- cyclophosphamide/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) reported/VBN (r_acl) cancer/NN
D003520_D002277 CID cyclophosphamide/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) cause/VB (l_conj) urine/NN (l_dobj) abnormalities/NNS (l_amod) indistinguishable/JJ (l_prep) from/IN (l_pobj) carcinoma/NN
D003520_D006417 CID cyclophosphamide/NN (r_pobj) wtih/IN (r_prep) treated/VBN (r_pcomp) after/IN (r_prep) had/VBD (l_dobj) hematuria/NN
D003520_D003556 NONE cyclophosphamide/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) cause/VB (l_dobj) cystitis/NN
D003520_-1 NONE cyclophosphamide/NN (r_compound) treatment/NN (r_pobj) for/IN (r_prep) candidates/NNS (r_attr) are/VBP (r_relcl) Patients/NNS (r_nsubjpass) evaluated/VBN (l_prep) for/IN (l_pobj) uropathy/NN
D003520_D009369 NONE cyclophosphamide/NN (r_pobj) to/IN (r_prep) epithelium/NN (r_pobj) of/IN (r_prep) exposure/NN (r_dobj) intensified/VBN (r_conj) prolonged/VBN (r_ccomp) suggests/VBZ (l_nsubj) association/NN (l_prep) of/IN (l_pobj) tumor/NN
D003520_D006470 NONE cyclophosphamide/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) cause/VB (l_dobj) cystitis/NN
D003520_D006869 NONE cyclophosphamide/NN (r_pobj) wtih/IN (r_prep) treated/VBN (r_pcomp) after/IN (r_prep) had/VBD (l_nsubj) woman/NN (l_prep) with/IN (l_pobj) hydroureteronephrosis/NN -PUNC- cyclophosphamide/NN (r_pobj) to/IN (r_prep) epithelium/NN (r_pobj) of/IN (r_prep) exposure/NN (r_dobj) intensified/VBN (r_conj) prolonged/VBN (r_ccomp) suggests/VBZ (l_nsubj) association/NN (l_prep) with/IN (l_pobj) hydroureteronephrosis/NN
D003520_D010386 NONE cyclophosphamide/NN (r_compound) therapy/NN (r_dobj) following/VBG (r_prep) pelvis/NN -PUNC- cyclophosphamide/NN (r_compound) treatment/NN (r_pobj) with/IN (r_prep) association/NN (r_pobj) in/IN (r_prep) reported/VBD (r_acl) pelvis/NN
D003520_D020293 NONE cyclophosphamide/NN (r_pobj) wtih/IN (r_prep) treated/VBN (l_prep) for/IN (l_pobj) vasculitis/NN
24659727
D003520_D064420 NONE cyclophosphamide/NN (r_conj) lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN -PUNC- CTX/NNP (r_appos) cyclophosphamide/NN (r_conj) lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN
D008130_D064420 NONE lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN -PUNC- CCNU/NNP (r_appos) lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN
D008130_D008223 NONE lomustine/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) lymphoma/NN -PUNC- lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) lymphoma/NN -PUNC- CCNU/NNP (r_appos) lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) lymphoma/NN
D003520_D008223 NONE cyclophosphamide/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) lomustine/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) lymphoma/NN -PUNC- cyclophosphamide/NN (r_conj) lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) lymphoma/NN -PUNC- CTX/NNP (r_appos) cyclophosphamide/NN (r_conj) lomustine/NN (r_pobj) of/IN (r_prep) protocol/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) lymphoma/NN
D003520_D009503 CID CTX/NNP (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) neutropenia/NN (r_conj) was/VBD (l_nsubj) Neutropenia/NNP -PUNC- CTX/NNP (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) neutropenia/NN
D008130_D009503 CID CCNU/NNP (r_nmod) CTX/NNP (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) neutropenia/NN (r_conj) was/VBD (l_nsubj) Neutropenia/NNP -PUNC- CCNU/NNP (r_nmod) CTX/NNP (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) neutropenia/NN
12051122
D014750_D007177 CID Vincristine/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) reported/VBN (r_acl) hormone/NN -PUNC- vincristine/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) among/IN (r_prep) SIADH/NNP (r_appos) hormone/NN -PUNC- vincristine/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) among/IN (r_prep) SIADH/NNP -PUNC- vincristine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) during/IN (r_prep) reported/VBN (r_relcl) Lilly/NNP (l_conj) database/NN (l_prep) for/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hyponatremia/NN (l_conj) SIADH/NNP -PUNC- vincristine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) total/NN (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hyponatremia/NN (l_conj) SIADH/NNP -PUNC- vincristine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) risk/NN (l_prep) of/IN (l_pobj) hyponatremia/NN (l_conj) SIADH/NNP -PUNC- vincristine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) rate/NN (l_prep) of/IN (l_pobj) SIADH/NNP
D014750_D007010 CID Vincristine/NNP (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) reported/VBN (r_acl) hormone/NN (r_pobj) of/IN (r_prep) syndrome/NN (r_conj) Hyponatremia/NNP -PUNC- vincristine/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) among/IN (r_prep) SIADH/NNP (r_appos) hormone/NN (r_pobj) of/IN (r_prep) secretion/NN (r_pobj) of/IN (r_prep) syndrome/NN (r_conj) hyponatremia/NN -PUNC- vincristine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) during/IN (r_prep) reported/VBN (r_relcl) Lilly/NNP (l_conj) database/NN (l_prep) for/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hyponatremia/NN -PUNC- vincristine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) total/NN (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) hyponatremia/NN -PUNC- vincristine/NN (r_compound) use/NN (r_pobj) with/IN (r_prep) associated/VBD (r_acl) risk/NN (l_prep) of/IN (l_pobj) hyponatremia/NN
2650911
D012834_D009369 NONE silver/NN (r_compound) grains/NNS (r_pobj) of/IN (r_prep) concentration/NN (r_dobj) revealed/VBD (l_ccomp) increased/VBN (l_prep) over/IN (l_pobj) nuclei/NNS (l_prep) of/IN (l_pobj) cells/NNS (l_compound) tumor/NN
D004054_D002292 CID diethylstilbesterol/NN (r_pobj) of/IN (r_prep) nuclei/NNS (r_pobj) in/IN (r_prep) sites/NNS (r_pobj) of/IN (r_prep) evidence/NN (r_nsubj) induced/VBN (l_dobj) carcinomas/NNS -PUNC- diethylstilbesterol/NN (r_pobj) in/IN (r_prep) autoradiography/NN (r_pobj) by/IN (r_agent) demonstrated/VBN (l_conj) induced/VBD (l_dobj) carcinomas/NNS
D004958_D009369 NONE estradiol/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) increased/VBN (l_prep) over/IN (l_pobj) nuclei/NNS (l_prep) of/IN (l_pobj) cells/NNS (l_compound) tumor/NN
D004967_D002292 NONE estrogen/NN (r_nmod) sites/NNS (r_pobj) of/IN (r_prep) evidence/NN (r_nsubj) induced/VBN (l_dobj) carcinomas/NNS -PUNC- Estrogen/NN (r_nmod) sites/NNS (r_nsubjpass) demonstrated/VBN (l_conj) induced/VBD (l_dobj) carcinomas/NNS -PUNC- estrogen/NN (r_pobj) of/IN (r_prep) binding/NN (r_pobj) in/IN (r_prep) preferential/NN (r_dobj) documenting/VBG (r_acl) report/NN (l_acl) induced/VBD (l_dobj) carcinomas/NNS -PUNC- estrogen/NN (r_pobj) in/IN (r_prep) cells/NNS (r_pobj) of/IN (r_prep) nuclei/NNS (r_pobj) to/IN (r_prep) documenting/VBG (r_acl) report/NN (l_acl) induced/VBD (l_dobj) carcinomas/NNS
17255138
D000082_D009203 NONE acetaminophen/RB (r_conj) NSAIDs/NNPS (r_conj) inhibitors/NNS (r_dobj) using/VBG (r_acl) patients/NNS (r_pobj) among/IN (r_prep) bleeding/VBG (r_acl) risks/NNS (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) AMI/NNP -PUNC- acetaminophen/NN (r_pobj) vs/IN (r_prep) GI/NNP (l_nmod) AMI/NNP -PUNC- acetaminophen/RB (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) toxicity/NN (l_compound) GI/NNP (l_nmod) AMI/NNP
D000082_D006471 NONE acetaminophen/RB (r_conj) NSAIDs/NNPS (r_conj) inhibitors/NNS (r_dobj) using/VBG (r_acl) patients/NNS (r_pobj) among/IN (r_prep) bleeding/VBG
D007052_D009203 NONE ibuprofen/NNP (r_conj) diclofenac/NN (r_conj) naproxen/NN (r_appos) rofecoxib/XX (r_nsubj) were/VBD (l_nsubj) group/NN (l_nmod) ratios/NNS (l_appos) interval/NN (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) GI/NNP (l_nmod) AMI/NNP
D000894_D009203 CID drugs/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) offset/VB (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- drugs/NNS (r_pobj) with/IN (r_prep) compared/VBN (r_prep) offset/VB (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) infarction/NN (l_appos) AMI/NNP
C116926_D009203 CID rofecoxib/XX (r_nsubj) were/VBD (l_nsubj) group/NN (l_nmod) ratios/NNS (l_appos) interval/NN (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) GI/NNP (l_nmod) AMI/NNP -PUNC- rofecoxib/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) better/JJR (r_acomp) be/VB (r_xcomp) seemed/VBD (r_conj) was/VBD (l_nsubj) toxicity/NN (l_compound) GI/NNP (l_nmod) AMI/NNP
C105934_D064420 NONE celecoxib/NN (r_pobj) of/IN (r_prep) toxicity/NN
D000082_D064420 NONE acetaminophen/RB (r_pobj) of/IN (r_prep) that/DT (r_pobj) to/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) toxicity/NN
C116926_D064420 NONE rofecoxib/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) better/JJR (r_acomp) be/VB (r_xcomp) seemed/VBD (r_conj) was/VBD (l_nsubj) toxicity/NN
D052246_D006471 NONE inhibitors/NNS (r_dobj) using/VBG (r_acl) patients/NNS (r_pobj) among/IN (r_prep) bleeding/VBG
D001241_D006471 NONE aspirin/NN (r_pobj) of/IN (r_prep) users/NNS (r_punct) ,/, (r_punct) seemed/VBD (l_xcomp) carry/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) bleeding/NN
D009288_D006471 CID naproxen/NN (r_nsubj) seemed/VBD (l_xcomp) carry/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) bleeding/NN
D052246_D009203 CID inhibitors/NNS (r_pobj) with/IN (r_prep) infarction/NN -PUNC- inhibitors/NNS (r_pobj) with/IN (r_prep) infarction/NN (l_appos) AMI/NNP -PUNC- inhibitors/NNS (r_dobj) using/VBG (r_acl) patients/NNS (r_pobj) among/IN (r_prep) bleeding/VBG (r_acl) risks/NNS (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) AMI/NNP
D001241_D009203 NONE aspirin/NN (r_pobj) of/IN (r_prep) users/NNS (r_punct) ,/, (r_punct) were/VBD (l_nsubj) group/NN (l_nmod) ratios/NNS (l_appos) interval/NN (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) GI/NNP (l_nmod) AMI/NNP -PUNC- aspirin/NN (r_pobj) with/IN (r_parataxis) GI/NNP (l_nmod) AMI/NNP -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) users/NNS (r_punct) ,/, (r_punct) seemed/VBD (l_xcomp) carry/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) bleeding/NN (l_compound) GI/NNP (l_nmod) AMI/NNP
C105934_D009203 NONE celecoxib/NN (r_conj) rofecoxib/XX (r_nsubj) were/VBD (l_nsubj) group/NN (l_nmod) ratios/NNS (l_appos) interval/NN (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) GI/NNP (l_nmod) AMI/NNP -PUNC- celecoxib/NN (r_pobj) of/IN (r_prep) toxicity/NN (l_compound) GI/NNP (l_nmod) AMI/NNP
D004008_D009203 NONE diclofenac/NN (r_conj) naproxen/NN (r_appos) rofecoxib/XX (r_nsubj) were/VBD (l_nsubj) group/NN (l_nmod) ratios/NNS (l_appos) interval/NN (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) GI/NNP (l_nmod) AMI/NNP
D009288_D009203 CID naproxen/NN (r_appos) rofecoxib/XX (r_nsubj) were/VBD (l_nsubj) group/NN (l_nmod) ratios/NNS (l_appos) interval/NN (l_prep) of/IN (l_pobj) hospitalization/NN (l_prep) for/IN (l_pobj) GI/NNP (l_nmod) AMI/NNP -PUNC- naproxen/NN (r_nsubj) seemed/VBD (l_xcomp) carry/VB (l_dobj) risk/NN (l_prep) for/IN (l_pobj) bleeding/NN (l_compound) GI/NNP (l_nmod) AMI/NNP
3297909
D013827_D001649 NONE thiabendazole/NN (r_compound) administration/NN (r_pobj) after/IN (r_prep) injury/NN
D013827_D007565 NONE thiabendazole/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) jaundice/NN
17496739
C085143_D007676 NONE tazobactam/NN (r_conj) confusion/NN (r_conj) behavior/NN (r_conj) tremor/NN (r_conj) speech/NN (r_dobj) developed/VBD (r_relcl) dialysis/NN (r_dobj) receiving/VBG (r_acl) disease/NN
C085143_D004830 CID tazobactam/NN (r_conj) confusion/NN (l_conj) episodes/NNS (l_prep) of/IN (l_pobj) seizure/NN -PUNC- tazobactam/NN (r_conj) confusion/NN (l_conj) episodes/NNS (l_parataxis) GTCS/NNP -PUNC- tazobactam/NN (r_pobj) after/IN (r_prep) recurred/VBD (l_nsubj) episode/NN (l_amod) GTCS/NNP
C085143_D003221 CID tazobactam/NN (r_conj) confusion/NN
D000641_D007964 NONE ammonia/NN (r_compound) levels/NNS (l_conj) leukocytosis/NN
C085143_D012640 NONE tazobactam/NN (r_advmod) induced/VBN (r_amod) seizure/NN
D010878_D020258 NONE piperacillin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) Despite/IN (r_prep) goes/VBZ (l_nsubj) neurotoxicity/NN -PUNC- piperacillin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) neurotoxicity/NN
C085143_D060085 NONE tazobactam/NN (r_conj) confusion/NN (r_conj) behavior/NN (r_conj) tremor/NN (r_conj) speech/NN (r_dobj) developed/VBD (r_relcl) dialysis/NN (r_dobj) receiving/VBG (r_acl) disease/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubjpass) given/VBN (l_prep) for/IN (l_pobj) bronchiectasis/NN (l_prep) with/IN (l_pobj) infection/NN
C085143_D014202 CID tazobactam/NN (r_conj) confusion/NN (r_conj) behavior/NN (r_conj) tremor/NN
D010878_D001927 NONE Piperacillin/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- piperacillin/NN (r_dobj) removing/VBG (r_pcomp) in/IN (r_prep) inefficient/JJ (r_acomp) is/VBZ (l_advcl) terminate/VB (l_dobj) encephalopathy/NN -PUNC- piperacillin/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN
C085143_D001987 NONE tazobactam/NN (r_conj) confusion/NN (r_conj) behavior/NN (r_conj) tremor/NN (r_conj) speech/NN (r_dobj) developed/VBD (r_relcl) dialysis/NN (r_dobj) receiving/VBG (r_acl) disease/NN (r_pobj) with/IN (r_prep) woman/NN (r_nsubjpass) given/VBN (l_prep) for/IN (l_pobj) bronchiectasis/NN
D010878_D006463 NONE Piperacillin/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN (r_nsubjpass) considered/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) uremic/JJ
23666265
D003520_D010146 CID CYP/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) behaviors/NNS (l_compound) pain/NN -PUNC- Cyclophosphamide/NNP (r_compound) treatment/NN (r_nsubj) increased/VBD (l_dobj) scores/NNS (l_compound) behaviors/NNS (l_compound) pain/NN
D003520_D003556 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN -PUNC- cyclophosphamide/NN (r_pobj) on/IN (r_prep) antagonists/NNS (l_appos) cystitis/NN -PUNC- CYP)-induced/VBN (r_amod) cystitis/NN -PUNC- CYP/NNP (r_npadvmod) induced/VBN (r_amod) cystitis/NN
16880771
D007980_D020521 NONE levodopa/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) enhances/VBZ (l_dobj) learning/VBG (l_prep) in/IN (l_pobj) subjects/NNS (l_conj) patients/NNS (l_compound) stroke/NN
D004298_D020521 NONE dopamine/NN (r_compound) precursor/NN (r_compound) levodopa/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) enhances/VBZ (l_dobj) learning/VBG (l_prep) in/IN (l_pobj) subjects/NNS (l_conj) patients/NNS (l_compound) stroke/NN -PUNC- dopamine/NN (r_nsubj) enhances/VBZ (l_dobj) learning/NN (l_prep) in/IN (l_pobj) subjects/NNS (l_conj) patients/NNS (l_compound) stroke/NN
D004298_D007859 NONE dopamine/NN (r_compound) agonist/NN (r_nsubj) impaired/JJ (r_amod) learning/NN
11745287
D016190_D002583 NONE carboplatin/NN (r_pobj) of/IN (r_prep) study/NN (l_conj) liposomal/JJ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cervix/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) study/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- carboplatin/NN (r_nmod) area/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) liposomal/JJ (r_ccomp) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- carboplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) has/VBZ (l_dobj) activity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D016190_D002294 NONE carboplatin/NN (r_pobj) of/IN (r_prep) study/NN (l_conj) liposomal/JJ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cervix/NN -PUNC- carboplatin/NN (r_nmod) area/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) liposomal/JJ (r_ccomp) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D004317_D064420 NONE doxorubicin/NN (r_dobj) liposomal/JJ (r_ccomp) administered/VBN (l_advcl) determine/VB (l_dobj) activity/NN (l_conj) profile/NN (l_compound) toxicity/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) liposomal/JJ (r_ccomp) administered/VBN (l_advcl) determine/VB (l_dobj) activity/NN (l_conj) profile/NN (l_compound) toxicity/NN
D004317_D002583 NONE doxorubicin/NN (r_dobj) liposomal/JJ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cervix/NN -PUNC- doxorubicin/NN (r_conj) carboplatin/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) of/IN (r_prep) activity/NN (r_nsubjpass) tested/VBN (l_prep) in/IN (l_pobj) study/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- doxorubicin/NN (r_dobj) liposomal/JJ (r_ccomp) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) liposomal/JJ (r_ccomp) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) has/VBZ (l_dobj) activity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
D016190_D064420 NONE carboplatin/NN (r_nmod) area/NN (r_pobj) of/IN (r_prep) combination/NN (r_nsubj) liposomal/JJ (r_ccomp) administered/VBN (l_advcl) determine/VB (l_dobj) activity/NN (l_conj) profile/NN (l_compound) toxicity/NN
D004317_D002294 NONE doxorubicin/NN (r_dobj) liposomal/JJ (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN (l_prep) of/IN (l_pobj) cervix/NN -PUNC- doxorubicin/NN (r_dobj) liposomal/JJ (r_ccomp) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- Doxil/NNS (r_appos) doxorubicin/NN (r_dobj) liposomal/JJ (r_ccomp) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) carcinoma/NN
17356399
C042705_D020803 NONE asparaginase/NN (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_dobj) multiagent/JJ (l_nsubj) encephalopathy/JJ
D003561_D006212 CID cytarabine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) vasospasm/NN (r_pobj) with/IN (r_prep) weakness/NN (r_conj) hallucinations/NNS
D003561_D020301 CID cytarabine/NN (r_conj) asparaginase/NN (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_dobj) multiagent/JJ (l_nsubj) encephalopathy/JJ (l_conj) vasospasm/NN -PUNC- cytarabine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) vasospasm/NN
D003561_D020803 NONE cytarabine/NN (r_conj) asparaginase/NN (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_dobj) multiagent/JJ (l_nsubj) encephalopathy/JJ -PUNC- cytarabine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) vasospasm/NN (r_pobj) with/IN (r_prep) weakness/NN (r_conj) hallucinations/NNS (r_conj) incontinence/NN (r_conj) aphasia/NN (r_conj) changes/NNS (r_pobj) by/IN (r_agent) evidenced/VBN (r_acl) encephalopathy/NN
D003561_D018908 CID cytarabine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) vasospasm/NN (r_pobj) with/IN (r_prep) weakness/NN
D003561_D001037 CID cytarabine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) vasospasm/NN (r_pobj) with/IN (r_prep) weakness/NN (r_conj) hallucinations/NNS (r_conj) incontinence/NN (r_conj) aphasia/NN
D003561_D014549 CID cytarabine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) vasospasm/NN (r_pobj) with/IN (r_prep) weakness/NN (r_conj) hallucinations/NNS (r_conj) incontinence/NN
C042705_D054198 NONE asparaginase/NN (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_dobj) multiagent/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) leukemia/NN
C042705_D020301 CID asparaginase/NN (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_dobj) multiagent/JJ (l_nsubj) encephalopathy/JJ (l_conj) vasospasm/NN
D003561_D054198 NONE cytarabine/NN (r_conj) asparaginase/NN (r_pobj) including/VBG (r_prep) chemotherapy/NN (r_dobj) multiagent/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) leukemia/NN
7315949
D009638_D013035 CID norepinephrine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) changes/NNS (l_prep) in/IN (l_pobj) spasm/NN
D009638_D006547 NONE norepinephrine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) vasoconstriction/NN (r_nsubj) produced/VBD (l_dobj) hernias/NNS
6687006
D009638_D006948 NONE noradrenaline/NN (r_amod) uptake/NN (r_compound) agent/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) reduction/NN (l_prep) of/IN (l_pobj) hyperactivity/NN
D000661_D019956 NONE amphetamine/NN (r_npadvmod) induced/VBN (r_amod) stereotypies/NNS
C012102_D006948 NONE DSP4/NNP (r_compound) pretreatment/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_nsubjpass) hyperactivity/NN -PUNC- DSP4/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) reduction/NN (l_prep) of/IN (l_pobj) hyperactivity/NN -PUNC- DSP4/NNP (r_pobj) of/IN (r_prep) action/NN (r_dobj) prevents/VBZ (r_relcl) agent/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) reduction/NN (l_prep) of/IN (l_pobj) hyperactivity/NN
D000661_D006948 NONE amphetamine/NN (r_compound) hyperactivity/NN
D000661_D020258 NONE amphetamine/NN (r_compound) hyperactivity/NN (r_pobj) of/IN (r_prep) reduction/NN (r_nsubjpass) blocked/VBN (l_agent) by/IN (l_pobj) pretreatment/NN (l_prep) with/IN (l_pobj) agent/NN (l_relcl) prevents/VBZ (l_dobj) action/NN (l_amod) neurotoxic/JJ
D003891_D006948 NONE desipramine/NN (r_appos) agent/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) reduction/NN (l_prep) of/IN (l_pobj) hyperactivity/NN
C012102_D020258 NONE DSP4/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) reduction/NN (r_nsubjpass) blocked/VBN (l_agent) by/IN (l_pobj) pretreatment/NN (l_prep) with/IN (l_pobj) agent/NN (l_relcl) prevents/VBZ (l_dobj) action/NN (l_amod) neurotoxic/JJ -PUNC- DSP4/NNP (r_pobj) of/IN (r_prep) action/NN (l_amod) neurotoxic/JJ
D003891_D020258 NONE desipramine/NN (r_appos) agent/NN (l_relcl) prevents/VBZ (l_dobj) action/NN (l_amod) neurotoxic/JJ
D009638_D020258 NONE noradrenaline/NN (r_amod) uptake/NN (r_compound) agent/NN (l_relcl) prevents/VBZ (l_dobj) action/NN (l_amod) neurotoxic/JJ
C012102_D019956 NONE DSP4/NNP (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) by/IN (r_agent) blocked/VBN (l_nsubjpass) rearings/NNS (l_conj) stereotypies/NNS
D003913_D006948 CID amphetamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) hyperactivity/NN
24816962
D008795_D064420 NONE metronidazole/JJ (r_amod) toxicity/NN
D008795_D001927 CID Metronidazole/NNP (r_npadvmod) induced/VBN (r_amod) encephalopathy/NN -PUNC- metronidazole/NN (r_compound) intake/NN (r_pobj) following/VBG (r_prep) features/NNS (l_prep) of/IN (l_pobj) encephalopathy/JJ
7121659
D012293_D051437 NONE rifampicin/NN (r_npadvmod) associated/VBN (r_amod) failure/NN
D012293_D006461 CID rifampicin/NNS (r_pobj) of/IN (r_prep) reintroduction/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patients/NNS (l_appos) 3/CD (l_prep) with/IN (l_pobj) thrombopenia/NN (l_conj) hemolysis/NN
D012293_D013921 CID rifampicin/NNS (r_pobj) of/IN (r_prep) reintroduction/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patients/NNS (l_appos) 3/CD (l_prep) with/IN (l_pobj) thrombopenia/NN
D012293_D058186 NONE rifampicin/NNS (r_pobj) of/IN (r_prep) reintroduction/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
24114426
D018817_D010554 CID 3,4-methylenedioxymethamphetamine/NNP (r_pobj) of/IN (r_prep) users/NNS (r_conj) Depression/NN (l_conj) impulsiveness/NN -PUNC- MDMA/NNP (r_nmod) ecstasy/NN (r_pobj) of/IN (r_prep) users/NNS (r_conj) Depression/NN (l_conj) impulsiveness/NN -PUNC- ecstasy/NN (r_pobj) of/IN (r_prep) users/NNS (r_conj) Depression/NN (l_conj) impulsiveness/NN -PUNC- ecstasy/NN (r_compound) users/NNS (r_pobj) of/IN (r_prep) generation/NN (r_pobj) for/IN (r_prep) prognosis/NN (r_nsubj) is/VBZ (l_prep) Given/VBN (l_pobj) record/NN (l_prep) of/IN (l_pobj) memory/NN (l_conj) levels/NNS (l_prep) of/IN (l_pobj) depression/NN (l_conj) impulsiveness/NN
D018817_D020920 CID ecstasy/NN (r_compound) users/NNS (r_pobj) of/IN (r_prep) generation/NN (r_pobj) for/IN (r_prep) prognosis/NN (r_nsubj) is/VBZ (l_prep) Given/VBN (l_pobj) record/NN (l_prep) of/IN (l_pobj) memory/NN (l_conj) levels/NNS (l_prep) of/IN (l_pobj) depression/NN (l_conj) impulsiveness/NN (l_conj) disturbance/NN
D018817_D003866 CID 3,4-methylenedioxymethamphetamine/NNP (r_pobj) of/IN (r_prep) users/NNS (r_conj) Depression/NN -PUNC- MDMA/NNP (r_nmod) ecstasy/NN (r_pobj) of/IN (r_prep) users/NNS (r_conj) Depression/NN -PUNC- ecstasy/NN (r_pobj) of/IN (r_prep) users/NNS (r_conj) Depression/NN -PUNC- ecstasy/NN (r_compound) users/NNS (r_pobj) of/IN (r_prep) generation/NN (r_pobj) for/IN (r_prep) prognosis/NN (r_nsubj) is/VBZ (l_prep) Given/VBN (l_pobj) record/NN (l_prep) of/IN (l_pobj) memory/NN (l_conj) levels/NNS (l_prep) of/IN (l_pobj) depression/NN
D018817_D008569 NONE ecstasy/NN (r_compound) users/NNS (r_pobj) of/IN (r_prep) generation/NN (r_pobj) for/IN (r_prep) prognosis/NN (r_nsubj) is/VBZ (l_prep) Given/VBN (l_pobj) record/NN (l_prep) of/IN (l_pobj) memory/NN
9128918
D006220_D006966 CID haloperidol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) Hyperprolactinemia/NNP -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN
D004298_D006966 NONE dopamine/NN (r_compound) neurons/NNS (r_pobj) in/IN (r_prep) changes/NNS (r_conj) hyperprolactinemia/NN -PUNC- dopamine/NN (r_compound) antagonist/NN (r_appos) haloperidol/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) Hyperprolactinemia/NNP -PUNC- dopamine/NN (r_nmod) concentrations/NNS (r_nsubj) increased/VBN (l_prep) After/IN (l_pobj) months/NNS (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- DA/NNP (r_nmod) concentrations/NNS (r_nsubj) increased/VBN (l_prep) After/IN (l_pobj) months/NNS (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- DA/NNP (r_compound) concentrations/NNS (r_pobj) in/IN (r_prep) increase/NN (r_dobj) produced/VBD (l_nsubj) months/NNS (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- DA/NNP (r_compound) response/NN (r_nsubjpass) lost/VBN (l_advcl) followed/VBN (l_nsubjpass) hyperprolactinemia/NN -PUNC- DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- DA/NNP (r_compound) concentrations/NNS (r_pobj) in/IN (r_prep) increase/NN (r_conj) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- DA/NNP (r_compound) concentrations/NNS (r_pobj) in/IN (r_prep) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
D006897_D006966 NONE acid/NN (r_pobj) in/IN (r_prep) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- acid/NN (r_pobj) in/IN (r_prep) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- 5-HIAA/CD (r_appos) acid/NN (r_pobj) in/IN (r_prep) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- 5-HIAA/CD (r_appos) acid/NN (r_pobj) in/IN (r_prep) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
D012701_D006966 NONE serotonin/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- serotonin/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- 5-HT/CD (r_appos) serotonin/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- 5-HT/CD (r_appos) serotonin/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
D009638_D006966 NONE norepinephrine/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- norepinephrine/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- NE/NNP (r_appos) norepinephrine/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_prep) after/IN (l_pobj) 6-months/IN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- NE/NNP (r_appos) norepinephrine/NN (r_appos) DA/NNP (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) in/IN (r_prep) change/NN (r_attr) was/VBD (l_attr) putamen/NNS (l_prep) except/IN (l_prep) for/IN (l_pobj) decrease/NN (l_conj) increase/NN (l_prep) after/IN (l_pobj) 9-months/JJ (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
10975596
C118667_D001145 NONE dronedarone/NN (r_nsubj) be/VB (l_acomp) suitable/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) arrhythmias/NNS
C118667_D009203 NONE dronedarone/NN (l_conj) amiodarone/NN (l_prep) with/IN (l_pobj) infarction/NN -PUNC- dronedarone/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) compared/VBN (l_prep) with/IN (l_pobj) those/DT (l_prep) at/IN (l_conj) during/IN (l_pobj) stimulation/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) infarction/NN
D007545_D013610 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN (r_dobj) decreased/VBD (r_conj) reduced/VBD (l_dobj) tachycardia/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN
D000638_D009203 NONE amiodarone/NN (l_prep) with/IN (l_pobj) infarction/NN -PUNC- amiodarone/NN (r_pobj) to/IN (r_prep) related/VBN (r_amod) effects/NNS (r_nsubjpass) compared/VBN (l_prep) with/IN (l_pobj) those/DT (l_prep) at/IN (l_conj) during/IN (l_pobj) stimulation/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) infarction/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) those/DT (l_prep) at/IN (l_conj) during/IN (l_pobj) stimulation/NN (l_prep) in/IN (l_pobj) dogs/NNS (l_prep) with/IN (l_pobj) infarction/NN
D000638_D013610 NONE amiodarone/NN (r_conj) dronedarone/NN (r_nsubj) reduced/VBD (l_dobj) tachycardia/NN -PUNC- amiodarone/NN (r_conj) dronedarone/NN (r_nsubj) reduced/VBD (l_conj) decreased/VBD (l_dobj) tachycardia/NN
C118667_D013610 NONE dronedarone/NN (r_nsubj) reduced/VBD (l_dobj) tachycardia/NN -PUNC- dronedarone/NN (r_nsubj) reduced/VBD (l_conj) decreased/VBD (l_dobj) tachycardia/NN
1395192
D001971_D009203 CID bromocriptine/NN (r_dobj) receiving/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) infarction/NN -PUNC- Bromocriptine/NNP (r_nsubjpass) implicated/VBN (l_prep) in/IN (l_pobj) reports/NNS (l_prep) of/IN (l_pobj) infarction/NN
23952588
D007980_D004409 CID levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- levodopa/NN (r_compound) therapy/NN (r_nsubj) leads/VBZ (l_prep) to/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) fluctuations/NNS (l_conj) dyskinesia/NN -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) present/JJ (r_acomp) was/VBD (l_nsubj) Dyskinesia/NNP -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_dobj) had/VBD (l_nsubj) Patients/NNS (l_prep) with/IN (l_pobj) dyskinesia/JJ -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (l_appos) dose/NN (l_conj) scores/NNS (l_appos) p/NN (l_prep) than/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) dyskinesia/JJ -PUNC- levodopa/NN (r_compound) dose/NN (r_appos) duration/NN (r_dobj) had/VBD (l_nsubj) Patients/NNS (l_prep) with/IN (l_pobj) dyskinesia/JJ -PUNC- levodopa/NN (r_compound) dose/NN (l_conj) scores/NNS (l_appos) p/NN (l_prep) than/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) dyskinesia/JJ -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_attr) were/VBD (l_nsubj) predictors/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ -PUNC- levodopa/NN (r_compound) dose/NN (r_conj) age/NN (r_conj) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_attr) were/VBD (l_nsubj) predictors/NNS (l_prep) of/IN (l_pobj) dyskinesia/JJ -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN
D007980_D010300 NONE levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_prep) with/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) disease/NN -PUNC- levodopa/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) disease/NN (l_appos) PD/NNP -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) dyskinesia/NN (l_prep) among/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) PD/NNP -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) patients/NNS (l_prep) with/IN (l_pobj) PD/NNP
16876986
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_amod) injections/NNS (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) seizures/NNS
3409843
D002220_D001855 NONE carbamazepine/NN (r_pobj) to/IN (r_pcomp) due/IN (r_prep) concerns/NNS (l_prep) of/IN (l_pobj) toxicity/NN
D002220_D004827 NONE carbamazepine/NN (r_compound) treatment/NN (l_prep) in/IN (l_pobj) woman/NN (l_amod) epileptic/JJ
D002220_D000741 CID carbamazepine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patient/NN (r_pobj) in/IN (r_prep) anemia/NN -PUNC- carbamazepine/NN (r_compound) treatment/NN (r_pobj) due/IN (r_amod) case/NN (l_prep) of/IN (l_pobj) anemia/NN
19728177
D000082_D007035 NONE acetaminophen/NN (r_compound) overdose/NN (r_pobj) from/IN (r_prep) edema/NN (r_conj) FHF/NNP (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) In/IN (r_prep) used/VBN (l_nsubjpass) hypothermia/NN
D000082_D064420 NONE acetaminophen/NN (r_pobj) from/IN (r_prep) toxicity/NN
D000082_D017114 CID acetaminophen/NN (r_pobj) from/IN (r_prep) facility/NN (l_prep) in/IN (l_pobj) female/NN (l_prep) with/IN (l_pobj) FHF/NNP -PUNC- acetaminophen/NN (r_pobj) from/IN (r_prep) confirmed/VBN (l_dobj) FHF/NNP -PUNC- acetaminophen/NN (r_compound) overdose/NN (r_pobj) from/IN (r_prep) edema/NN (r_conj) FHF/NNP
D000082_D062787 NONE acetaminophen/NN (r_compound) overdose/NN
D000082_D001929 CID acetaminophen/NN (r_pobj) from/IN (r_prep) facility/NN (r_pobj) in/IN (r_prep) observations/NNS (l_conj) edema/NN -PUNC- acetaminophen/NN (l_conj) edema/NN -PUNC- acetaminophen/NN (r_compound) overdose/NN (r_pobj) from/IN (r_prep) edema/NN
7018927
D006220_D006966 CID haloperidol/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN -PUNC- haloperidol/NN (r_amod) infusions/NNS (r_pobj) of/IN (r_prep) course/NN (r_pobj) During/IN (r_prep) found/VBN (l_nsubjpass) hyperprolactinemia/NN
16323982
D004967_D003324 NONE estrogen/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) effect/NN (r_pobj) than/IN (r_prep) other/JJ (r_conj) mediated/VBN (l_nsubjpass) arteriosclerosis/NN
D004967_D050171 NONE estrogen/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) effect/NN
D002784_D050171 NONE cholesterol/NN (r_pobj) in/IN (r_prep) changes/NNS (r_pobj) through/IN (r_prep) mediated/VBN (l_conj) other/JJ (l_prep) than/IN (l_pobj) effect/NN
D017373_D003324 CID CPA/NN (r_compound) therapy/NN (r_pobj) by/IN (r_agent) caused/VBN (r_advcl) arteriosclerosis/NN
D002784_D003324 NONE cholesterol/NN (r_pobj) in/IN (r_prep) changes/NNS (r_pobj) through/IN (r_prep) mediated/VBN (l_nsubjpass) arteriosclerosis/NN
D017373_D050171 CID CPA/NN (r_compound) therapy/NN (r_pobj) by/IN (r_agent) caused/VBN (r_advcl) arteriosclerosis/NN (r_nsubjpass) mediated/VBN (l_conj) other/JJ (l_prep) than/IN (l_pobj) effect/NN
D017373_D003327 NONE CPA/NN (r_compound) treatment/NN (r_pobj) on/IN (r_prep) years/NNS (r_pobj) of/IN (r_prep) period/NN (r_pobj) After/IN (r_prep) found/VBN (l_xcomp) affected/VBN (l_agent) by/IN (l_pobj) disease/NN
9782254
D007980_D009127 NONE DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) rigidity/NN
D007980_D010300 NONE DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) rigidity/NN (r_conj) bradykinesia/NN (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) for/IN (r_prep) underwent/VBD (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D007980_D018476 NONE DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS (r_conj) rigidity/NN (r_conj) bradykinesia/NN
D007980_D004409 CID DOPA/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS
10933650
D000666_D064420 NONE B/NN (r_dobj) incorporating/VBG (r_acl) lipid/NN (r_nsubj) is/VBZ (l_conj) has/VBZ (l_dobj) toxicity/NN -PUNC- Fungizone/NNP (r_nmod) deoxycholate/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) with/IN (r_punct) ;/: (r_punct) using/VBG (r_advcl) compared/VBD (l_dobj) toxicity/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) study/NN (r_conj) kidney/NN (r_pobj) of/IN (r_prep) study/NN (r_appos) analysis/NN (r_pobj) by/IN (r_prep) using/VBG (r_advcl) compared/VBD (l_dobj) toxicity/NN
C059765_D064420 NONE deoxycholate/NN (r_pobj) of/IN (r_prep) that/DT (r_pobj) with/IN (r_punct) ;/: (r_punct) using/VBG (r_advcl) compared/VBD (l_dobj) toxicity/NN -PUNC- AmB/NNP (r_nsubj) using/VBG (r_advcl) compared/VBD (l_dobj) toxicity/NN
C059765_D007683 CID AmB/VBN (r_dep) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) necrosis/NN
D000666_D007674 NONE B./NNP (r_appos) Attenuation/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN -PUNC- B/NNP (r_pobj) of/IN (r_prep) incorporation/NN (r_nsubj) attenuates/VBZ (l_dobj) nephrotoxicity/NN -PUNC- B./NNP (r_pobj) of/IN (r_prep) nephrotoxicity/NN
1424076
D003907_D009101 NONE dexamethasone/NN (r_pobj) of/IN (r_prep) days/NNS (r_conj) doxorubicin/NN (r_conj) infusion/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) myeloma/NN
D004317_D009101 NONE doxorubicin/NN (r_conj) infusion/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) myeloma/NN
D014750_D007177 CID vincristine/NN (r_pobj) after/IN (r_prep) Syndrome/NN (l_prep) of/IN (l_pobj) secretion/NN (l_prep) of/IN (l_pobj) hormone/NN -PUNC- vincristine/NN (r_compound) infusion/NN (r_pobj) to/IN (r_prep) attributed/VBN (r_relcl) hormone/NN
D014750_D009101 NONE vincristine/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) myeloma/NN
1289188
D003676_D013789 NONE desferrioxamine/NN (r_dobj) undergoing/VBG (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) thalassemia/NN -PUNC- DFX/NNP (r_nmod) treatment/NN (r_appos) desferrioxamine/NN (r_dobj) undergoing/VBG (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) thalassemia/NN
D003676_D058186 NONE desferrioxamine/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) occurring/VBG (r_acl) failure/NN -PUNC- desferrioxamine/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) failure/NN
6985297
D015764_D013610 NONE Bepridil/NN (r_advmod) induced/VBD (l_dobj) bradycardia/NNS (l_conj) effect/NN (l_amod) tachycardial/JJ
D015764_D000787 NONE Bepridil/NN (r_advmod) induced/VBD (l_nsubj) compound/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) attacks/NNS
D015764_D001919 CID bepridil/NN (r_pcomp) by/IN (r_prep) induced/VBN (l_nsubj) Studies/NNS (l_prep) on/IN (l_pobj) bradycardia/NN -PUNC- Bepridil/NN (r_advmod) induced/VBD (l_dobj) bradycardia/NNS
3155884
D007545_D005355 CID isoproterenol/NN (r_pobj) of/IN (r_prep) study/NN (r_nsubj) induced/VBN (l_dobj) fibrosis/NN -PUNC- ISO/NN (r_nsubjpass) given/VBN (l_conj) induced/VBD (l_dobj) fibrosis/NN -PUNC- ISO/NN (r_nsubj) induced/VBD (l_dobj) fibrosis/NN
D005947_D005355 NONE glucose/NN (r_pobj) in/IN (r_prep) fall/NN (r_pobj) of/IN (r_prep) slope/NN (r_pobj) to/IN (r_prep) correlation/NN (r_conj) analyzed/VBN (r_conj) given/VBN (l_conj) induced/VBD (l_dobj) fibrosis/NN
D007545_D066126 NONE isoproterenol/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) cardiotoxic/JJ -PUNC- isoproterenol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) cardiotoxic/JJ -PUNC- ISO/NN (r_appos) doses/NNS (r_pobj) of/IN (r_prep) effect/NN (l_amod) cardiotoxic/JJ
D013311_D066126 NONE streptozotocin/JJ (r_nmod) rats/NNS (r_pobj) in/IN (r_prep) effect/NN (l_amod) cardiotoxic/JJ -PUNC- streptozotocin/JJ (r_compound) diabetes/NNS (l_prep) against/IN (l_pobj) effect/NN (l_amod) cardiotoxic/JJ
D007545_D003920 NONE isoproterenol/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ -PUNC- isoproterenol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effect/NN (r_pobj) against/IN (r_prep) diabetes/NNS -PUNC- ISO/NN (r_appos) doses/NNS (r_pobj) of/IN (r_prep) effect/NN (r_pobj) against/IN (r_prep) diabetes/NNS -PUNC- ISO/NN (r_compound) resistance/NN (l_conj) points/NNS (l_prep) towards/IN (l_pobj) effect/NN (l_prep) on/IN (l_pobj) sensitivity/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
D002395_D003920 NONE catecholamines/NNS (r_pobj) of/IN (r_prep) content/NN (r_nsubjpass) estimated/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ -PUNC- catecholamine/NN (r_compound) sensitivity/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
D013311_D003920 CID streptozotocin/JJ (r_nmod) rats/NNS (l_amod) diabetic/JJ -PUNC- streptozotocin/JJ (r_compound) diabetes/NNS -PUNC- streptozotocin/JJ (r_nsubj) causes/VBZ (l_dobj) resistance/NN (l_conj) points/NNS (l_prep) towards/IN (l_pobj) effect/NN (l_prep) on/IN (l_pobj) sensitivity/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) diabetic/JJ
17484470
D011433_D008944 NONE propranolol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_ccomp) confirmed/VBN (l_nsubjpass) absence/NN (l_prep) of/IN (l_pobj) MR/NNP
D011433_D006333 CID propranolol/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) failure/NN
9132810
D008727_D054198 NONE methotrexate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN
D008727_D056784 CID methotrexate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) leukemia/NN (r_pobj) from/IN (r_prep) developed/VBD (r_relcl) leukoencephalopathy/JJ
17572393
D008550_D054220 NONE melatonin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) upon/IN (l_pobj) cortex/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) dysplasia/NN -PUNC- melatonin/NN (l_prep) upon/IN (l_pobj) dysplasia/NN
D002330_D054220 CID BCNU/NNP (r_npadvmod) induced/VBN (r_amod) dysplasia/NN -PUNC- BCNU/NNP (l_conj) investigate/VB (l_dobj) effects/NNS (l_prep) of/IN (l_pobj) melatonin/NN (l_prep) upon/IN (l_pobj) dysplasia/NN -PUNC- BCNU/NNP (r_npadvmod) induced/VBN (r_amod) dysplasia/NN -PUNC- BCNU/NNP (r_npadvmod) exposed/VBN (r_amod) group/NN (l_compound) dysplasia/NN
25084821
C069541_D006402 NONE Quetiapine/NNP (r_nsubj) is/VBZ (l_advcl) has/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) causing/VBG (l_dobj) dyscrasias/NNS
C069541_D006528 NONE Quetiapine/NNP (r_npadvmod) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN -PUNC- quetiapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) patient/NN (l_prep) with/IN (l_pobj) carcinoma/NN
D003024_D006402 NONE clozapine/NN (r_pobj) to/IN (r_prep) similar/JJ (r_amod) derivative/JJ (r_attr) is/VBZ (l_advcl) has/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) causing/VBG (l_dobj) dyscrasias/NNS
C069541_D008107 NONE quetiapine/NN (r_pobj) to/IN (r_prep) reaction/NN (r_pobj) for/IN (r_prep) marker/NN (r_attr) be/VB (r_conj) be/VB (l_nsubj) dysfunction/NN
C069541_D009503 CID Quetiapine/NNP (r_npadvmod) induced/VBN (l_dobj) neutropenia/NN -PUNC- Quetiapine/NNP (r_nsubj) is/VBZ (l_advcl) has/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) causing/VBG (l_dobj) dyscrasias/NNS (l_appos) neutropenia/NN -PUNC- quetiapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) neutropenia/NN -PUNC- quetiapine/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) neutropenia/NN
C069541_D005334 CID quetiapine/NN (r_pobj) to/IN (r_prep) reaction/NN (r_pobj) for/IN (r_prep) marker/NN (r_attr) be/VB (l_nsubj) fever/NN
D003024_D009503 NONE clozapine/NN (r_pobj) to/IN (r_prep) similar/JJ (r_amod) derivative/JJ (r_attr) is/VBZ (l_advcl) has/VBZ (l_dobj) risk/NN (l_prep) of/IN (l_pcomp) causing/VBG (l_dobj) dyscrasias/NNS (l_appos) neutropenia/NN
C069541_D001714 NONE Quetiapine/NNP (r_npadvmod) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_amod) bipolar/JJ
C069541_D007970 CID quetiapine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_pcomp) after/IN (r_prep) developed/VBD (l_dobj) leucopenia/JJ
20859899
D000809_D006947 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitor/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) during/IN (r_prep) caused/VBD (l_agent) by/IN (l_pobj) hyperkalemia/NN
D013148_D013575 NONE spironolactone/NN (r_conj) inhibitor/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) during/IN (r_prep) caused/VBD (r_acl) Syncope/NNP
D013148_D006947 CID spironolactone/NN (r_conj) inhibitor/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) during/IN (r_prep) caused/VBD (l_agent) by/IN (l_pobj) hyperkalemia/NN -PUNC- spiranolactone/NN (r_pobj) of/IN (r_prep) doses/NNS (r_attr) be/VB (r_xcomp) considered/VBN (l_nsubjpass) cause/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN
D011188_D006947 NONE potassium/NN (r_compound) agents/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) using/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) be/VB (l_acomp) alert/JJ (l_prep) to/IN (l_pobj) possibility/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN
D000450_D006947 NONE aldosterone/NN (r_compound) antagonist/NN (r_appos) spiranolactone/NN (r_pobj) of/IN (r_prep) doses/NNS (r_attr) be/VB (r_xcomp) considered/VBN (l_nsubjpass) cause/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN
D011188_D007674 NONE potassium/NN (r_compound) agents/NNS (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) using/VBG (r_acl) patients/NNS (r_pobj) in/IN (l_conj) have/VBP (l_dobj) disturbance/NN
D000809_D013575 NONE angiotensin/NN (r_npadvmod) converting/VBG (r_amod) inhibitor/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) during/IN (r_prep) caused/VBD (r_acl) Syncope/NNP
D017257_D006947 CID ramipril/NN (r_pobj) of/IN (r_prep) intake/NN (r_pobj) to/IN (r_prep) addition/NN (r_pobj) in/IN (r_prep) be/VB (r_xcomp) considered/VBN (l_nsubjpass) cause/NN (l_prep) of/IN (l_pobj) hyperkalemia/NN
11299446
C027429_D010302 CID veralipride/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) after/IN (r_prep) Worsening/VBG (l_prep) of/IN (l_pobj) Parkinsonism/NN -PUNC- veralipride/NN (r_pobj) with/IN (r_prep) symptoms/NNS (r_appos) therapy/NN (r_pobj) following/VBG (r_prep) shown/VBN (r_relcl) disease/NN
6806735
D002945_D010051 NONE platinum/NN (r_nmod) adriamycin/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cisplatinum/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D004317_D010051 NONE adriamycin/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- adriamycin/NNS (r_amod) m2/NN (r_npadvmod) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D006585_D010051 NONE hexamethylmelamine/NN (r_conj) cyclophosphamide/NN (r_conj) adriamycin/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- hexamethylmelamine/NN (r_conj) m2/NN (r_npadvmod) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN -PUNC- HMM/NNP (r_appos) hexamethylmelamine/NN (r_conj) m2/NN (r_npadvmod) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D003520_D010051 NONE cyclophosphamide/NN (r_conj) adriamycin/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) Treatment/NN (l_prep) of/IN (l_pobj) cancer/NN -PUNC- cyclophosphamide/NN (r_conj) m2/NN (r_conj) adriamycin/NNS (r_amod) m2/NN (r_npadvmod) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
D006585_D005767 NONE HMM/UH (r_compound) toxicity/NN
C034868_D010051 NONE CPDD/NNP (r_appos) cisplatinum/NN (r_pobj) of/IN (r_prep) combination/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) cancer/NN
6529939
D011433_D001146 CID propranolol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) Alternating/VBG (l_dobj) rhythm/NN -PUNC- propranolol/NN (r_pobj) with/IN (r_prep) angina/NN (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) observed/VBN (l_advcl) Alternating/VBG (l_dobj) rhythm/NN
D011433_D000787 NONE propranolol/NN (r_pobj) with/IN (r_prep) angina/NN
D011433_D019955 NONE propranolol/NN (r_pcomp) for/IN (l_pcomp) being/VBG (l_attr) cause/NN (l_prep) of/IN (l_pobj) disorder/NN
D011433_D012848 CID propranolol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_xcomp) Alternating/VBG (l_dobj) rhythm/NN (l_conj) block/NN -PUNC- propranolol/NN (r_pobj) with/IN (r_prep) angina/NN (r_pobj) for/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) observed/VBN (l_nsubjpass) block/NN -PUNC- propranolol/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) with/IN (r_prep) disappeared/VBD (r_ccomp) seen/VBN (l_nsubjpass) block/NN
24345882
D008727_D054198 NONE methotrexate/JJ (r_compound) consequence/NN (r_appos) risk/NN (l_appos) protocols/NNS (l_compound) leukemia/NN -PUNC- methotrexate/NN (r_nmod) neurotoxicity/NN (r_pobj) about/IN (r_prep) Concerns/NNS (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) modifications/NNS (l_prep) in/IN (l_pobj) therapy/NN (l_conj) rescue/NN (l_conj) frequency/NN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- MTX/NNP (r_nmod) neurotoxicity/NN (r_pobj) about/IN (r_prep) Concerns/NNS (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) modifications/NNS (l_prep) in/IN (l_pobj) therapy/NN (l_conj) rescue/NN (l_conj) frequency/NN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN -PUNC- MTX/NNP (r_compound) administration/NN (r_pobj) of/IN (r_prep) frequency/NN (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) leukemia/NN
D008727_D020258 NONE methotrexate/NN (r_nmod) neurotoxicity/NN -PUNC- MTX/NNP (r_nmod) neurotoxicity/NN -PUNC- MTX/NNP (r_compound) administration/NN (r_pobj) of/IN (r_prep) frequency/NN (r_conj) rescue/NN (r_conj) therapy/NN (r_pobj) in/IN (r_prep) modifications/NNS (r_pobj) to/IN (r_prep) led/VBD (l_nsubj) Concerns/NNS (l_prep) about/IN (l_pobj) neurotoxicity/NN
24729111
D000638_D003128 CID Amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN
D000638_D012131 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) have/VB (l_dobj) bradycardia/VBN (l_conj) hypothermia/NN (l_conj) failure/NN
D000638_D001919 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) have/VB (l_dobj) bradycardia/VBN
D000638_D007035 CID amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) have/VB (l_dobj) bradycardia/VBN (l_conj) hypothermia/NN
D000638_D013959 NONE amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN (l_prep) with/IN (l_pobj) history/NN (l_amod) significant/JJ (l_prep) for/IN (l_pobj) disease/NN
D000638_D007037 CID Amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) myxoedema/NN (r_compound) coma/NN
D000638_D001281 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) initiation/NN (l_prep) for/IN (l_pobj) fibrillation/NN
17379047
C081489_D007008 NONE VAL/NNP (r_nmod) HCTZ/NNP (r_compound) combinations/NNS (r_pobj) with/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) hypokalemia/NN -PUNC- VAL/NNP (r_nmod) HCTZ/NNP (r_pobj) with/IN (r_prep) therapies/NNS (r_nsubjpass) associated/VBN (l_conj) tolerated/VBN (l_conj) associated/VBN (l_prep) with/IN (l_pobj) hypokalemia/NN
D006852_C562386 NONE hydrochlorothiazide/NN (r_conj) VAL/NNP (r_appos) valsartan/JJ (l_appos) HCTZ)-monotherapy/NN (l_conj) combinations/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- HCTZ)-monotherapy/NN (l_conj) combinations/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- HCTZ/NNP (r_appos) VAL/NNP (r_appos) groups/NNS (r_pobj) to/IN (r_prep) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- HCTZ/NNP (r_appos) VAL/NNP (r_appos) groups/NNS (r_pobj) to/IN (r_prep) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D006852_D007008 CID HCTZ/NNP (r_compound) combinations/NNS (r_pobj) with/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) hypokalemia/NN -PUNC- HCTZ/NNP (r_compound) monotherapies/NNS (r_pobj) with/IN (r_prep) than/IN (r_prep) lower/JJR (r_acomp) was/VBD (l_nsubj) incidence/NN (l_prep) of/IN (l_pobj) hypokalemia/NN -PUNC- HCTZ/NNP (r_pobj) with/IN (r_prep) therapies/NNS (r_nsubjpass) associated/VBN (l_conj) tolerated/VBN (l_conj) associated/VBN (l_prep) with/IN (l_pobj) hypokalemia/NN -PUNC- HCTZ/NNP (r_pobj) than/IN (r_prep) hypokalemia/NN
C081489_D006973 NONE valsartan/JJ (r_nmod) therapy/NN (r_pobj) of/IN (r_prep) Comparison/NN (l_appos) study/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) therapy/NN (l_prep) in/IN (l_pobj) adults/NNS (l_amod) hypertensive/JJ
D006852_D006973 NONE hydrochlorothiazide/JJ (r_compound) therapy/NN (r_pobj) of/IN (r_prep) Comparison/NN (l_appos) study/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) therapy/NN (l_prep) in/IN (l_pobj) adults/NNS (l_amod) hypertensive/JJ
C081489_C562386 NONE valsartan/JJ (l_appos) HCTZ)-monotherapy/NN (l_conj) combinations/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- VAL/NNP (r_appos) valsartan/JJ (l_appos) HCTZ)-monotherapy/NN (l_conj) combinations/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- VAL/NNP (r_appos) groups/NNS (r_pobj) to/IN (r_prep) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- VAL/NNP (r_nmod) HCTZ/NNP (r_appos) VAL/NNP (r_appos) groups/NNS (r_pobj) to/IN (r_prep) randomized/VBN (l_nsubjpass) Patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
16112787
D014640_-1 NONE VCM/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) vacuolization/NN (l_conj) atrophy/NN (l_conj) desquamation/NN
C048498_-1 NONE erdosteine/NN (r_amod) groups/NNS (r_conj) control/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) more/JJR (r_amod) dilatation/NN (l_conj) vacuolization/NN (l_conj) atrophy/NN (l_conj) desquamation/NN
C048498_D001284 NONE erdosteine/NN (r_amod) groups/NNS (r_conj) control/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) more/JJR (r_amod) dilatation/NN (l_conj) vacuolization/NN (l_conj) atrophy/NN
C048498_D009336 NONE erdosteine/NN (r_amod) groups/NNS (r_conj) control/NN (r_pobj) of/IN (r_prep) those/DT (r_pobj) than/IN (r_prep) more/JJR (r_amod) dilatation/NN (l_conj) vacuolization/NN (l_conj) atrophy/NN (l_conj) desquamation/NN (l_conj) necrosis/NN
D014640_D007674 CID vancomycin/NNP (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- vancomycin/NNP (r_det) stress/NN (r_dobj) examine/VB (l_advcl) investigate/VB (l_dobj) role/NN (l_appos) agent/NN (l_prep) on/IN (l_pobj) tissue/NN (l_prep) against/IN (l_pobj) impairment/NN -PUNC- VCM)-induced/VBN (r_amod) stress/NN (r_dobj) examine/VB (l_advcl) investigate/VB (l_dobj) role/NN (l_appos) agent/NN (l_prep) on/IN (l_pobj) tissue/NN (l_prep) against/IN (l_pobj) impairment/NN -PUNC- VCM/NN (r_npadvmod) induced/VBN (r_amod) impairment/NN -PUNC- VCM/NN (r_compound) administration/NN (r_nsubj) control/VB (l_dobj) malondialdehyde/NN (l_appos) excretion/NN (l_nmod) glucosaminidase/NN (l_appos) NAG/NN (l_appos) marker/NN (l_prep) of/IN (l_pobj) injury/NN -PUNC- VCM/NNP (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- VCM/NNP (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- VCM/NNP (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN (r_pobj) in/IN (r_prep) role/NN (r_dobj) plays/VBZ (r_ccomp) concluded/VBN (l_conj) reduces/VBZ (l_dobj) damage/NN -PUNC- VCM/NNP (r_npadvmod) induced/VBN (r_amod) damage/NN (r_dobj) reduces/VBZ (r_conj) concluded/VBN (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- VCM/NNP (r_npadvmod) induced/VBN (r_amod) damage/NN
D010100_D007674 NONE oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) production/NN (r_dobj) promotes/VBZ (r_relcl) stress/NN (r_dobj) examine/VB (l_advcl) investigate/VB (l_dobj) role/NN (l_appos) agent/NN (l_prep) on/IN (l_pobj) tissue/NN (l_prep) against/IN (l_pobj) impairment/NN
C048498_D007674 NONE erdosteine/NN (r_pobj) by/IN (r_prep) protection/NN (r_appos) nephrotoxicity/NN -PUNC- erdosteine/NN (r_pobj) of/IN (r_prep) role/NN (l_appos) agent/NN (l_prep) on/IN (l_pobj) tissue/NN (l_prep) against/IN (l_pobj) impairment/NN -PUNC- Erdosteine/NNP (r_nsubj) showed/VBD (l_dobj) protection/NN (l_prep) against/IN (l_pobj) nephrotoxicity/NN -PUNC- erdosteine/NN (r_pobj) with/IN (r_prep) modulation/NN (r_conj) role/NN (l_prep) in/IN (l_pobj) nephrotoxicity/NN -PUNC- erdosteine/NN (r_pobj) with/IN (r_prep) modulation/NN (r_conj) role/NN (r_dobj) plays/VBZ (r_ccomp) concluded/VBN (l_conj) reduces/VBZ (l_dobj) damage/NN
D008315_D007674 NONE malondialdehyde/NN (l_appos) excretion/NN (l_nmod) glucosaminidase/NN (l_appos) NAG/NN (l_appos) marker/NN (l_prep) of/IN (l_pobj) injury/NN -PUNC- MDA/NNP (r_appos) malondialdehyde/NN (l_appos) excretion/NN (l_nmod) glucosaminidase/NN (l_appos) NAG/NN (l_appos) marker/NN (l_prep) of/IN (l_pobj) injury/NN
D014640_D009336 NONE VCM/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) vacuolization/NN (l_conj) atrophy/NN (l_conj) desquamation/NN (l_conj) necrosis/NN
D014640_D001284 NONE VCM/NNP (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) vacuolization/NN (l_conj) atrophy/NN
D013481_D007674 NONE superoxide/NN (r_amod) dismutase/NN (r_dobj) decreased/VBD (r_conj) control/VB (l_dobj) malondialdehyde/NN (l_appos) excretion/NN (l_nmod) glucosaminidase/NN (l_appos) NAG/NN (l_appos) marker/NN (l_prep) of/IN (l_pobj) injury/NN
17346443
D019345_D006527 NONE acetate/NN (r_pobj) of/IN (r_prep) utility/NN (r_conj) dermatitis/NN (l_prep) in/IN (l_pobj) patient/JJ (l_compound) disease/NN -PUNC- acetate/NN (r_pobj) with/IN (r_prep) therapy/NN (r_nsubj) represented/VBD (l_dobj) treatment/NN (l_prep) for/IN (l_pobj) patient/NN (l_compound) disease/NN -PUNC- acetate/NN (r_pobj) of/IN (r_prep) safety/NN (r_nsubj) allowed/VBD (r_ccomp) is/VBZ (l_prep) in/IN (l_pobj) line/NN (l_prep) with/IN (l_pobj) evidence/NN (l_prep) on/IN (l_pobj) efficacy/NN (l_prep) of/IN (l_pobj) drug/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) disease/NN
D010396_D001008 NONE Penicillamine/NN (r_npadvmod) related/VBN (r_amod) dermatitis/NN (l_prep) in/IN (l_pobj) patient/JJ (l_prep) with/IN (l_pobj) presentation/NN (l_conj) anxiety/NN
D010396_D017512 CID Penicillamine/NN (r_npadvmod) related/VBN (r_amod) dermatitis/NN -PUNC- penicillamine/NN (r_nsubjpass) interrupted/VBN (l_prep) after/IN (l_pobj) appearance/NN (l_prep) of/IN (l_pobj) dermatitis/NN
D010396_D012871 NONE penicillamine/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) of/IN (r_prep) most/JJS (r_nsubj) seem/VB (l_xcomp) develop/VB (l_dobj) lesion/NN
D019345_D017512 NONE acetate/NN (r_pobj) of/IN (r_prep) utility/NN (r_conj) dermatitis/NN -PUNC- acetate/NN (r_nsubj) permitted/VBD (r_conj) interrupted/VBN (l_prep) after/IN (l_pobj) appearance/NN (l_prep) of/IN (l_pobj) dermatitis/NN
D003300_D009422 NONE copper/NN (r_compound) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (l_prep) with/IN (l_pobj) accumulation/NN (l_prep) in/IN (l_pobj) tissues/NNS (l_conj) disorders/NNS -PUNC- copper/NN (r_compound) accumulation/NN (l_prep) in/IN (l_pobj) tissues/NNS (l_conj) disorders/NNS
D019345_D001008 NONE acetate/NN (r_pobj) of/IN (r_prep) utility/NN (r_conj) dermatitis/NN (l_prep) in/IN (l_pobj) patient/JJ (l_prep) with/IN (l_pobj) presentation/NN (l_conj) anxiety/NN
D003300_D001523 NONE copper/NN (r_compound) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (l_prep) with/IN (l_pobj) accumulation/NN (l_prep) in/IN (l_pobj) tissues/NNS (l_conj) disorders/NNS -PUNC- copper/NN (r_compound) accumulation/NN (l_prep) in/IN (l_pobj) tissues/NNS (l_conj) disorders/NNS
D003300_D006527 NONE copper/NN (r_compound) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (r_attr) is/VBZ (l_nsubj) disease/NN -PUNC- copper/NN (r_compound) accumulation/NN (r_pobj) with/IN (r_prep) disorder/NN (r_attr) is/VBZ (l_nsubj) disease/NN
D010396_D006527 NONE Penicillamine/NN (r_npadvmod) related/VBN (r_amod) dermatitis/NN (l_prep) in/IN (l_pobj) patient/JJ (l_compound) disease/NN -PUNC- penicillamine/NN (r_npadvmod) related/VBN (r_amod) effects/NNS (r_nsubj) appeared/VBD (r_relcl) treatment/NN (l_prep) for/IN (l_pobj) patient/NN (l_compound) disease/NN -PUNC- penicillamine/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_nmod) disease/NN
D003300_D056486 NONE copper/NN (r_compound) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (l_prep) with/IN (l_pobj) accumulation/NN (l_prep) in/IN (l_pobj) tissues/NNS (l_conj) disorders/NNS -PUNC- copper/NN (r_compound) accumulation/NN (l_prep) in/IN (l_pobj) tissues/NNS (l_conj) disorders/NNS
D003300_D064420 NONE copper/NN (r_compound) metabolism/NN (r_pobj) of/IN (r_prep) disorder/NN (l_prep) with/IN (l_pobj) accumulation/NN (l_conj) toxicity/NN -PUNC- copper/NN (r_compound) accumulation/NN (l_conj) toxicity/NN
23872883
D007545_D066126 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
24582773
D003006_D011618 NONE zuclopenthixol/NN (r_appos) antipsychotics/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) by/IN (r_agent) treated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) suffering/NN (l_prep) from/IN (l_pobj) disorder/NN
C069541_D011618 NONE quetiapine/NN (r_amod) doses/NNS (l_prep) in/IN (l_pobj) disorder/NN
D008094_D011618 NONE lithium/NN (r_conj) zuclopenthixol/NN (r_appos) antipsychotics/NNS (r_pobj) of/IN (r_prep) combination/NN (r_pobj) by/IN (r_agent) treated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) suffering/NN (l_prep) from/IN (l_pobj) disorder/NN -PUNC- lithium=0.85/NN (r_punct) serum/NN (r_parataxis) treated/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) suffering/NN (l_prep) from/IN (l_pobj) disorder/NN
C069541_D011595 CID quetiapine/NN (r_amod) doses/NNS (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) agitation/NN -PUNC- quetiapine/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) following/VBG (r_prep) h/NN (r_pobj) Within/IN (r_prep) presented/VBD (l_dobj) agitation/NN -PUNC- quetiapine/NN (r_pobj) of/IN (r_prep) reintroduction/NN (l_relcl) led/VBD (l_prep) to/IN (l_pobj) agitation/NN -PUNC- quetiapine/NN (r_pobj) of/IN (r_prep) reintroduction/NN (r_conj) withdrawal/NN (r_nsubj) enabled/VBD (l_xcomp) attribute/VB (l_dobj) agitation/NN -PUNC- quetiapine/NN (r_pobj) to/IN (r_prep) attribute/VB (r_xcomp) enabled/VBD (l_nsubj) withdrawal/NN (l_conj) reintroduction/NN (l_relcl) led/VBD (l_prep) to/IN (l_pobj) agitation/NN -PUNC- quetiapine/NN (r_pobj) to/IN (r_prep) attribute/VB (l_dobj) agitation/NN
C069541_D010554 NONE quetiapine/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) following/VBG (r_prep) h/NN (r_pobj) Within/IN (r_prep) presented/VBD (l_advcl) contrasting/VBG (l_prep) with/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) aggressiveness/NN -PUNC- quetiapine/NN (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) following/VBG (r_prep) h/NN (r_pobj) Within/IN (r_prep) presented/VBD (l_advcl) contrasting/VBG (l_prep) with/IN (l_pobj) absence/NN (l_prep) of/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) aggressiveness/NN (l_conj) disorder/NN
11380496
D011441_D019226 CID PTU/NNP (r_compound) therapy/NN (r_dobj) stopping/VBG (r_pcomp) after/IN (r_prep) resolved/VBD (r_conj) developed/VBD (l_dobj) fever/NN (l_conj) ulcers/NNS -PUNC- PTU/NNP (r_dobj) discontinuing/VBG (r_pcomp) after/IN (r_prep) decreased/VBD (r_conj) resolved/VBD (r_conj) developed/VBD (l_dobj) fever/NN (l_conj) ulcers/NNS
D011441_D006980 NONE PTU/NNP (r_compound) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) vasculitis/NN (r_pobj) for/IN (r_conj) investigated/VBD (l_dobj) patients/NNS (l_prep) with/IN (l_pobj) hyperthyroidism/NN
D011441_D018771 CID PTU/NNP (r_compound) therapy/NN (r_dobj) stopping/VBG (r_pcomp) after/IN (r_prep) resolved/VBD (r_conj) developed/VBD (l_dobj) fever/NN (l_conj) ulcers/NNS (l_conj) polyarthralgia/NN -PUNC- PTU/NNP (r_dobj) discontinuing/VBG (r_pcomp) after/IN (r_prep) decreased/VBD (r_conj) resolved/VBD (r_conj) developed/VBD (l_dobj) fever/NN (l_conj) ulcers/NNS (l_conj) polyarthralgia/NN
D011441_D006111 NONE propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) patients/NNS (l_compound) disease/NN -PUNC- propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) disease/NN -PUNC- PTU/NNP (r_appos) propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) disease/NN -PUNC- PTU/NNP (r_compound) therapy/NN (r_pobj) during/IN (r_prep) appearance/NN (r_pobj) between/IN (r_prep) relationship/NN (r_pobj) on/IN (r_prep) studies/NNS (r_attr) been/VBN (l_conj) on/IN (l_pobj) ANCA/NNP (l_prep) in/IN (l_pobj) patients/NNS (l_compound) disease/NN -PUNC- PTU/NNP (r_compound) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) vasculitis/NN (r_pobj) for/IN (r_conj) investigated/VBD (l_prep) due/IN (l_pobj) disease/NN
D011441_D005334 CID PTU/NNP (r_compound) therapy/NN (r_dobj) stopping/VBG (r_pcomp) after/IN (r_prep) resolved/VBD (r_conj) developed/VBD (l_dobj) fever/NN -PUNC- PTU/NNP (r_dobj) discontinuing/VBG (r_pcomp) after/IN (r_prep) decreased/VBD (r_conj) resolved/VBD (r_conj) developed/VBD (l_dobj) fever/NN
D011441_D014657 NONE propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) disease/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) vasculitis/NN -PUNC- PTU/NNP (r_appos) propylthiouracil/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) disease/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) vasculitis/NN -PUNC- PTU/NNP (r_compound) therapy/NN (r_pobj) during/IN (r_prep) appearance/NN (l_prep) of/IN (l_pobj) MPO/NNP (l_appos) ANCA/NNP (l_conj) vasculitis/NN -PUNC- PTU/NNP (r_compound) therapy/NN (r_dobj) starting/VBG (r_pcomp) after/IN (r_prep) vasculitis/NN
D011441_D014652 NONE PTU/NNP (r_compound) therapy/NN (r_pobj) despite/IN (r_prep) increased/VBD (l_conj) developed/VBD (l_nsubj) disorders/NNS
19815465
D020888_D012164 CID VGB/NNP (r_pobj) with/IN (r_prep) associated/VBN (r_acl) toxicity/NN
D020888_D004827 NONE VGB/NNP (r_pobj) to/IN (r_prep) exposure/NN (r_appos) therapy/NN (r_pobj) of/IN (r_prep) basis/NN (r_pobj) on/IN (r_prep) grouped/VBN (l_nsubjpass) people/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
D020888_D014786 CID vigabatrin/NN (r_pobj) to/TO (r_prep) specific/JJ (r_acomp) are/VBP (l_nsubj) defects/NNS -PUNC- vigabatrin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) defects/NNS -PUNC- VGB/NNP (r_appos) vigabatrin/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) defects/NNS
19154241
D008094_D049950 NONE lithium/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) effect/NN (r_attr) is/VBZ (l_nsubj) hyperparathyroidism/NN
D008094_D006961 CID lithium/NN (r_compound) therapy/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) hyperparathyroidism/NN
D008094_D006934 CID lithium/NN (r_npadvmod) treated/VBN (r_amod) patient/NN (l_relcl) had/VBD (l_dobj) hypercalcemia/NN -PUNC- lithium/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_nsubj) become/VBP (l_acomp) hypercalcemic/JJ
25071004
C039726_D000740 NONE artesunate/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) Delayed/JJ (l_dobj) anemia/NN
C039726_D008288 NONE artesunate/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) described/VBN (l_appos) Organization/NNP (l_parataxis) WHO)-recommended/VBN (l_dobj) drug/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) malaria/NN -PUNC- artesunate/NN (l_prep) for/IN (l_pobj) malaria/NN
C039726_D000743 CID artesunate/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) described/VBN (l_nsubjpass) Cases/NNS (l_prep) of/IN (l_pobj) anemia/NN
19020118
689020
D012312_D014202 CID HCl/NN (r_compound) infusion/NN (r_pobj) following/VBG (r_acl) those/DT (r_pobj) than/IN (r_prep) faster/RBR (r_advmod) decreased/VBD (l_nsubj) amplitudes/NNS (l_compound) tremor/NN
D005280_D014202 CID hydrobromide/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) end/NN (r_pobj) After/IN (r_prep) decreased/VBD (l_nsubj) amplitudes/NNS (l_compound) tremor/NN
3685052
D012970_D012640 NONE glutamate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) treated/VBD (l_nsubj) thresholds/NNS (l_compound) seizure/NN -PUNC- glutamate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) treated/VBD (l_dobj) evaluation/NN (l_prep) of/IN (l_pobj) parameters/NNS (l_prep) in/IN (l_pobj) testing/NN (l_compound) seizure/NN -PUNC- MSG/NNP (r_appos) glutamate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) treated/VBD (l_nsubj) thresholds/NNS (l_compound) seizure/NN -PUNC- MSG/NNP (r_appos) glutamate/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) with/IN (r_prep) treated/VBD (l_dobj) evaluation/NN (l_prep) of/IN (l_pobj) parameters/NNS (l_prep) in/IN (l_pobj) testing/NN (l_compound) seizure/NN -PUNC- glutamate/NN (r_nmod) administration/NN (r_nsubj) produces/VBZ (l_dobj) convulsions/NNS -PUNC- MSG/NNP (r_nmod) administration/NN (r_nsubj) produces/VBZ (l_dobj) convulsions/NNS -PUNC- MSG/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) produced/VBD (l_dobj) alterations/NNS (l_prep) in/IN (l_pobj) susceptibility/NN (l_compound) seizure/NN -PUNC- MSG/NNP (r_pobj) of/IN (r_prep) injections/NNS (r_dobj) received/VBD (r_relcl) susceptibility/NN (r_dobj) evaluate/VB (r_xcomp) used/VBN (l_nsubjpass) technique/NN (l_compound) screening/NN (l_compound) seizure/NN -PUNC- MSG/NNP (r_pobj) of/IN (r_prep) injections/NNS (r_dobj) received/VBD (r_relcl) susceptibility/NN (l_compound) seizure/NN -PUNC- MSG/NNP (r_compound) treatment/NN (r_nsubj) resulted/VBD (l_conj) alter/VB (l_dobj) threshold/NN (l_compound) seizure/NN -PUNC- MSG/NNP (r_npadvmod) treated/VBN (r_amod) mice/NNS (r_pobj) of/IN (r_prep) control/NN (r_pobj) of/IN (r_prep) thresholds/NNS (l_compound) seizure/NN
D005481_D007035 CID Flurothyl/NNP (r_compound) ether/NN (r_nsubj) produced/VBD (l_dobj) hypothermia/NN -PUNC- Flurothyl/NNP (r_compound) ether/NN (r_nsubj) produced/VBD (r_ccomp) was/VBD (l_nsubj) relationship/NN (l_prep) of/IN (l_pobj) hypothermia/NN -PUNC- flurothyl/JJ (r_compound) exposure/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_relcl) hypothermia/NN -PUNC- flurothyl/JJ (r_compound) exposure/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_relcl) hypothermia/NN (r_dobj) produced/VBD (r_ccomp) was/VBD (l_nsubj) relationship/NN (l_prep) of/IN (l_pobj) hypothermia/NN
D009270_D012640 NONE naloxone/NN (r_nmod) challenge/NN (r_nsubj) was/VBD (l_prep) in/IN (l_pcomp) altering/VBG (l_dobj) thresholds/NNS (l_compound) seizure/NN
D004986_D012640 NONE ether/NN (r_compound) technique/NN (l_compound) screening/NN (l_compound) seizure/NN -PUNC- ether/NN (r_compound) technique/NN (r_nsubjpass) used/VBN (l_xcomp) evaluate/VB (l_dobj) susceptibility/NN (l_compound) seizure/NN -PUNC- ether/NN (r_nsubj) produced/VBD (r_ccomp) was/VBD (l_nsubj) relationship/NN (l_prep) to/IN (l_pobj) induction/NN (l_compound) seizure/NN
D005481_D012640 NONE Flurothyl/JJ (r_compound) thresholds/NNS (l_compound) seizure/NN -PUNC- Flurothyl/JJ (r_compound) thresholds/NNS (r_nsubj) treated/VBD (l_dobj) evaluation/NN (l_prep) of/IN (l_pobj) parameters/NNS (l_prep) in/IN (l_pobj) testing/NN (l_compound) seizure/NN -PUNC- flurothyl/JJ (r_compound) testing/NN (r_pobj) in/IN (r_prep) parameters/NNS (r_pobj) of/IN (r_prep) evaluation/NN (r_dobj) treated/VBD (l_nsubj) thresholds/NNS (l_compound) seizure/NN -PUNC- flurothyl/JJ (r_compound) testing/NN (l_compound) seizure/NN -PUNC- flurothyl/JJ (r_nmod) technique/NN (l_compound) screening/NN (l_compound) seizure/NN -PUNC- flurothyl/JJ (r_nmod) technique/NN (r_nsubjpass) used/VBN (l_xcomp) evaluate/VB (l_dobj) susceptibility/NN (l_compound) seizure/NN -PUNC- Flurothyl/NNP (r_compound) ether/NN (r_nsubj) produced/VBD (r_ccomp) was/VBD (l_nsubj) relationship/NN (l_prep) to/IN (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- flurothyl/JJ (r_compound) exposure/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_relcl) hypothermia/NN (r_dobj) produced/VBD (r_ccomp) was/VBD (l_nsubj) relationship/NN (l_prep) to/IN (l_pobj) induction/NN (l_compound) seizure/NN -PUNC- Flurothyl/JJ (r_compound) testing/NN (l_compound) seizure/NN -PUNC- Flurothyl/JJ (r_compound) testing/NN (r_nsubj) proved/VBD (l_xcomp) be/VB (l_attr) technique/NN (l_relcl) evaluate/VB (l_dobj) susceptibility/NN (l_compound) seizure/NN
D004986_D007035 NONE ether/NN (r_nsubj) produced/VBD (l_dobj) hypothermia/NN -PUNC- ether/NN (r_nsubj) produced/VBD (r_ccomp) was/VBD (l_nsubj) relationship/NN (l_prep) of/IN (l_pobj) hypothermia/NN
1420650
D008094_D020258 NONE lithium/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_nsubjpass) used/VBN (r_advcl) consider/VBP (l_ccomp) be/VB (l_attr) sign/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D003024_D020258 NONE clozapine/NN (r_conj) lithium/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_nsubjpass) used/VBN (r_advcl) consider/VBP (l_ccomp) be/VB (l_attr) sign/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D003024_D020820 CID clozapine/NN (r_conj) lithium/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_nsubjpass) used/VBN (r_advcl) consider/VBP (l_ccomp) be/VB (l_nsubj) asterixis/NNS
D008094_D020820 CID lithium/NN (r_pobj) as/IN (r_prep) drugs/NNS (r_nsubjpass) used/VBN (r_advcl) consider/VBP (l_ccomp) be/VB (l_nsubj) asterixis/NNS
D002220_D020820 NONE carbamazepine/NN (r_compound) therapy/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Asterixis/NNS -PUNC- carbamazepine/NN (r_dobj) adding/VBG (r_pcomp) by/IN (r_prep) triggered/VBN (l_nsubjpass) asterixis/NNS -PUNC- CBZ/NNP (r_appos) carbamazepine/NN (r_dobj) adding/VBG (r_pcomp) by/IN (r_prep) triggered/VBN (l_nsubjpass) asterixis/NNS -PUNC- CBZ/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) used/VBN (r_advcl) consider/VBP (l_ccomp) be/VB (l_nsubj) asterixis/NNS
D002220_D020258 NONE CBZ/NN (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) used/VBN (r_advcl) consider/VBP (l_ccomp) be/VB (l_attr) sign/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
24158386
C056507_D064420 NONE Gemcitabine/NNP (r_nsubj) have/VBP (l_dobj) activity/NN (l_prep) in/IN (l_pobj) toxicity/NN
D008775_D006689 NONE methylprednisolone/NN (r_advcl) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) HL/NN
C056507_D006689 NONE GEM/NN (r_compound) P/NN (r_compound) chemotherapy/NN (r_nsubj) is/VBZ (l_acomp) active/JJ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) lymphoma/NN -PUNC- Gemcitabine/NNP (r_nsubj) have/VBP (l_dobj) activity/NN (l_prep) in/IN (l_pobj) toxicity/NN (l_amod) overlapping/VBG (l_npadvmod) HL/NNP -PUNC- gemcitabine/NN (r_amod) day/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) HL/NN -PUNC- GEM/NNP (r_compound) P/NNP (r_appos) days/NNS (r_appos) D15/NNP (r_dobj) cisplatin/NN (r_nsubjpass) included/VBN (r_conj) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) HL/NN -PUNC- GEM/NN (r_compound) P/NNP (r_nsubj) is/VBZ (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) HL/NN
D002945_D064420 NONE cisplatin/NN (r_conj) Gemcitabine/NNP (r_nsubj) have/VBP (l_dobj) activity/NN (l_prep) in/IN (l_pobj) toxicity/NN
D002945_D006689 NONE cisplatin/NN (r_conj) Gemcitabine/NNP (r_nsubj) have/VBP (l_dobj) activity/NN (l_prep) in/IN (l_pobj) toxicity/NN (l_amod) overlapping/VBG (l_npadvmod) HL/NNP -PUNC- cisplatin/NN (r_nsubjpass) included/VBN (r_conj) treated/VBN (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) HL/NN
9272404
D007052_D010146 CID ibuprofen/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) followed/VBN (l_agent) by/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) pain/NN -PUNC- ibuprofen/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) followed/VBN (l_agent) by/IN (l_pobj) decrease/NN (l_appos) increase/NN (l_prep) in/IN (l_pobj) correlates/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- ibuprofen/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubjpass) followed/VBN (l_advcl) indicating/VBG (l_dobj) effect/NN (l_prep) on/IN (l_pobj) interaction/NN (l_prep) between/IN (l_pobj) stimuli/NNS (l_compound) pain/NN -PUNC- ibuprofen/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) indicating/VBG (r_advcl) followed/VBN (l_agent) by/IN (l_pobj) decrease/NN (l_prep) in/IN (l_pobj) pain/NN -PUNC- ibuprofen/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) indicating/VBG (r_advcl) followed/VBN (l_agent) by/IN (l_pobj) decrease/NN (l_appos) increase/NN (l_prep) in/IN (l_pobj) correlates/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- ibuprofen/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) interaction/NN (l_prep) between/IN (l_pobj) stimuli/NNS (l_compound) pain/NN
D002245_D010146 NONE CO2/NN (r_pobj) of/IN (r_prep) pulses/NNS (r_pobj) of/IN (r_prep) means/NNS (r_pobj) by/IN (r_agent) applied/VBN (l_nsubjpass) pain/NN -PUNC- CO2/NN (r_pobj) of/IN (r_prep) pulses/NNS (r_pobj) of/IN (r_prep) means/NNS (r_pobj) by/IN (r_agent) applied/VBN (l_parataxis) duration/NN (l_conj) induced/VBN (l_nsubjpass) pain/NN -PUNC- CO2/NN (r_compound) stimuli/NNS (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) obtained/VBN (l_nsubjpass) CSSEPs/NNS (l_prep) as/IN (l_pobj) correlates/NNS (l_prep) of/IN (l_pobj) pain/NN
24739405
D000661_D002375 NONE Amphetamine/NN (r_nsubj) induced/VBD (l_conj) induced/VBN (l_conj) induced/VBD (l_ccomp) used/VBN (l_nsubjpass) tests/NNS (l_compound) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_nsubj) induced/VBD (l_ccomp) used/VBN (l_nsubjpass) tests/NNS (l_compound) catalepsy/NN -PUNC- haloperidol/NN (r_npadvmod) induced/VBN (r_amod) test/NN (l_compound) catalepsy/NN
D006220_D006948 NONE haloperidol/NN (r_nsubj) induced/VBD (r_conj) induced/VBN (r_conj) induced/VBD (l_dobj) locomotion/NN (l_amod) hyper/JJ
D003687_D012559 NONE dehydroepiandrosterone/NN (l_prep) in/IN (l_pobj) models/NNS (l_compound) schizophrenia/NN -PUNC- dehydroepiandrosterone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- DHEA/NNP (r_appos) dehydroepiandrosterone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- DHEA/NNP (r_nsubj) displays/VBZ (l_conj) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) schizophrenia/NN
D001058_D006948 NONE apomorphine/NN (r_conj) locomotion/NN (l_amod) hyper/JJ
D001058_D012559 CID apomorphine/NN (r_conj) locomotion/NN (r_dobj) induced/VBD (l_conj) induced/VBN (l_conj) induced/VBD (l_ccomp) used/VBN (l_prep) as/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) schizophrenia/NN
D001058_D002375 NONE apomorphine/NN (r_conj) locomotion/NN (r_dobj) induced/VBD (l_conj) induced/VBN (l_conj) induced/VBD (l_ccomp) used/VBN (l_nsubjpass) tests/NNS (l_compound) catalepsy/NN
D000661_D012559 CID amphetamine/NN (r_npadvmod) induced/VBN (r_amod) models/NNS (l_compound) schizophrenia/NN -PUNC- Amphetamine/NN (r_nsubj) induced/VBD (l_conj) induced/VBN (l_conj) induced/VBD (l_ccomp) used/VBN (l_prep) as/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) schizophrenia/NN
D006220_D012559 CID haloperidol/NN (r_nsubj) induced/VBD (l_ccomp) used/VBN (l_prep) as/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) schizophrenia/NN
D003687_D002375 NONE DHEA/NNP (r_nsubj) activity/NN (l_conj) catalepsy/NN
D000661_D006948 NONE Amphetamine/NN (r_nsubj) induced/VBD (l_dobj) locomotion/NN (l_amod) hyper/JJ
26033014
C051786_D009369 NONE metolachlor/JJ (r_amod) use/NN (r_conj) incidence/NN (l_compound) Cancer/NN -PUNC- metolachlor/NN (r_dobj) using/VBG (r_xcomp) reported/VBD (r_advcl) evaluated/VBD (l_dobj) incidence/NN (l_compound) cancer/NN -PUNC- metolachlor/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) metrics/NNS (l_conj) incidence/NN (l_compound) cancer/NN -PUNC- metolachlor/JJ (r_amod) use/NN (l_conj) incidence/NN (l_prep) of/IN (l_pobj) cancers/NNS -PUNC- metolachlor/JJ (r_amod) use/NN (r_pobj) between/IN (r_prep) association/NN (l_prep) with/IN (l_pobj) lag/NN (l_conj) cancers/NNS
C051786_D008113 CID Metolachlor/NNP (r_nsubjpass) classified/VBN (l_prep) based/VBN (l_prep) on/IN (l_pobj) neoplasms/NNS -PUNC- metolachlor/NN (r_nmod) cancer/NN -PUNC- metolachlor/NN (r_nmod) cancer/NN (r_pobj) between/IN (r_prep) association/NN (r_pobj) of/IN (r_prep) suggestion/NN (r_nsubj) is/VBZ (l_attr) finding/NN (l_conj) echoes/VBZ (l_dobj) observation/NN (l_prep) of/IN (l_pobj) neoplasms/NNS -PUNC- metolachlor/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/TO (r_prep) up/NN (r_conj) cancer/NN
C051786_D008223 NONE metolachlor/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) to/TO (r_prep) up/NN (l_compound) warrant/NN (l_compound) lymphoma/NN
C051786_D008175 NONE metolachlor/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) at/IN (r_prep) risk/NN (l_compound) cancer/NN
17543491
3711722
D003035_D009202 CID cobalt/NN (r_compound) cardiomyopathy/NN
D004317_D006333 CID doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) failure/NN
3975902
D010424_D009202 NONE pentobarbital/NN (r_appos) contractility/NN (r_nsubj) suggest/VBP (l_dobj) existence/NN (l_prep) of/IN (l_pobj) disorder/NN
D010424_D008659 NONE pentobarbital/NN (r_appos) contractility/NN (l_conj) disturbances/NNS
D001464_D006973 NONE Barium/NN (r_npadvmod) supplemented/VBN (r_amod) rats/NNS (r_nsubjpass) characterized/VBN (l_agent) by/IN (l_pobj) hypertension/NN -PUNC- barium/NN (r_pobj) of/IN (r_prep) month/NN (r_pobj) after/IN (r_prep) was/VBD (r_relcl) hypertension/NN
D001464_D002318 NONE barium/NN (r_npadvmod) induced/VBN (r_amod) disturbances/NNS (l_prep) within/IN (l_pobj) system/NN
D001464_D008659 NONE barium/NN (r_compound) exposure/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) disorder/NN (r_pobj) of/IN (r_prep) existence/NN (r_dobj) suggest/VBP (l_nsubj) contractility/NN (l_conj) disturbances/NNS
D001464_D004342 NONE barium/NN (r_compound) effect/NN (r_pobj) of/IN (r_prep) aspect/NN (r_nsubj) was/VBD (l_attr) hypersensitivity/NN -PUNC- barium/NN (r_compound) exposure/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) disorder/NN (r_pobj) of/IN (r_prep) existence/NN (r_dobj) suggest/VBP (l_nsubj) contractility/NN (l_conj) disturbances/NNS (l_conj) hypersensitivity/NN
C024986_D004342 NONE chloride/NN (r_compound) ingestion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) dysfunction/NN (l_conj) hypersensitivity/NN
D010424_D002318 NONE pentobarbital/NN (r_amod) dysfunction/NN
C024986_D002318 NONE chloride/NN (r_compound) ingestion/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) dysfunction/NN
D010424_D004342 NONE pentobarbital/NN (r_amod) dysfunction/NN (l_conj) hypersensitivity/NN -PUNC- pentobarbital/NN (r_amod) hypersensitivity/NN -PUNC- pentobarbital/NN (r_appos) contractility/NN (l_conj) disturbances/NNS (l_conj) hypersensitivity/NN
D001464_D009202 NONE barium/NN (r_compound) exposure/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) disorder/NN
11026989
D014331_D015878 CID tropicamide/NN (r_pobj) with/IN (r_prep) dilation/NN -PUNC- tropicamide/NN (r_advmod) using/VBG (r_acl) dilation/NN
10939760
D013411_D014123 NONE Sulfadiazine/NN (r_nmod) nephrotoxicity/NN (r_nsubj) reviving/VBG (l_prep) because/IN (l_pobj) use/NN (l_prep) in/IN (l_pobj) toxoplasmosis/NN
D013411_D058186 CID sulfadiazine/NN (r_nmod) nephrotoxicity/NN -PUNC- Sulfadiazine/NN (r_nmod) nephrotoxicity/NN
20495512
D006493_D013921 CID Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- Heparin/NNP (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_appos) HIT/NN -PUNC- heparin/JJ (r_compound) exposure/NN (r_pobj) after/IN (r_prep) occurs/VBZ (r_ccomp) suspected/VBN (r_conj) acknowledged/VBN (l_nsubjpass) HIT/NNP -PUNC- heparin/JJ (r_compound) exposure/NN (r_pobj) of/IN (r_prep) cessation/NN (r_dobj) mandates/NNS (l_nsubj) treatment/NN (l_prep) of/IN (l_pobj) HIT/NNP -PUNC- heparin/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) HIT/NN -PUNC- heparin/NN (r_nsubj) remains/VBZ (l_prep) with/IN (l_pobj) potential/NN (l_prep) for/IN (l_pobj) HIT/NN -PUNC- heparin/JJ (r_compound) exposure/NN (r_pobj) with/IN (r_prep) potential/NN (l_prep) for/IN (l_pobj) HIT/NN -PUNC- heparin/JJ (r_nsubjpass) initiated/VBN (r_advcl) practiced/VBN (l_advcl) remains/VBZ (l_prep) with/IN (l_pobj) potential/NN (l_prep) for/IN (l_pobj) HIT/NN
D006493_D013927 CID heparin/JJ (r_compound) exposure/NN (r_pobj) after/IN (r_prep) occurs/VBZ (r_ccomp) suspected/VBN (r_conj) acknowledged/VBN (l_prep) for/IN (l_pobj) predilection/NN (l_prep) for/IN (l_pobj) thrombosis/NN -PUNC- heparin/JJ (r_compound) exposure/NN (r_pobj) after/IN (r_prep) occurs/VBZ (l_nsubj) thrombosis/NN
D000991_D013921 NONE inhibitor/NN (r_dobj) using/VBG (r_advcl) mandates/NNS (l_nsubj) treatment/NN (l_prep) of/IN (l_pobj) HIT/NNP -PUNC- inhibitors/NNS (r_nsubj) are/VBP (l_attr) alternatives/NNS (l_prep) to/IN (l_pobj) heparin/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) HIT/NN
25986755
D002110_D005921 NONE caffeine/NN (r_compound) exposure/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) offspring/NN (r_pobj) in/IN (r_prep) mediates/VBZ (l_dobj) origin/NN (l_prep) of/IN (l_pobj) glomerulosclerosis/NN
D003404_D005355 NONE creatinine/NN (r_nmod) protein/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) by/IN (r_agent) accompanied/VBN (r_advcl) exhibited/VBD (l_dobj) glomerulosclerosis/NN (l_conj) fibrosis/NN
D003404_D005921 NONE creatinine/NN (r_nmod) protein/NN (r_pobj) of/IN (r_prep) levels/NNS (r_pobj) by/IN (r_agent) accompanied/VBN (r_advcl) exhibited/VBD (l_dobj) glomerulosclerosis/NN
D002110_D005317 CID caffeine/NN (r_compound) exposure/NN (r_nsubj) induce/VB (l_dobj) retardation/NN -PUNC- caffeine/NN (r_compound) exposure/NN (r_nsubj) induce/VB (l_dobj) retardation/NN (l_appos) IUGR/NNP
891494
D010672_D005076 NONE DPH/NNP (r_pobj) of/IN (r_prep) concentration/NN (r_nsubj) was/VBD (r_ccomp) presented/VBD (l_dobj) rash/JJ -PUNC- DPH/NNP (r_compound) treatment/NN (r_pobj) during/IN (r_prep) presented/VBD (l_dobj) rash/JJ -PUNC- DPH/NNP (r_compound) injection/NN (r_nsubj) had/VBD (r_conj) was/VBD (l_ccomp) presented/VBD (l_dobj) rash/JJ
D010672_D001927 CID Phenytoin/NNP (r_compound) encephalopathy/NNP -PUNC- phenytoin/NNP (r_nmod) encephalopathy/JJ -PUNC- DPH/NNP (r_nmod) encephalopathy/JJ
D010672_D012640 NONE phenytoin/NNP (r_nmod) encephalopathy/JJ (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- DPH/NNP (r_nmod) encephalopathy/JJ (l_prep) with/IN (l_pobj) seizures/NNS -PUNC- DPH/NNP (r_compound) treatment/NN (r_dobj) starting/VBG (r_acl) patient/NN (r_pobj) in/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- DPH/NNP (r_dobj) eliminating/VBG (r_pcomp) for/IN (r_prep) need/NN (r_pobj) to/IN (r_prep) alert/VB (l_prep) in/IN (l_pobj) increase/NN (l_prep) in/IN (l_pobj) seizures/NNS
24091473
D004837_D066126 NONE epinephrine/NN (l_conj) both/DT (l_prep) in/IN (l_pobj) toxicity/NN
C476513_D002318 CID levobupivacaine/PRP (r_dobj) received/VBD (l_advcl) occurred/VBD (l_nsubj) collapse/NN
D004837_D064420 NONE epinephrine/NN (r_conj) emulsion/NN (r_pobj) of/IN (r_prep) regimens/NNS (r_nsubjpass) determined/VBN (l_prep) in/IN (l_pobj) neonates/NNS (l_prep) in/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) toxicity/NN
C476513_D066126 NONE levobupivacaine/NN (r_npadvmod) induced/VBN (r_amod) toxicity/NN
15096374
D016559_D012393 CID Tacrolimus/NNP (r_compound) ointment/NN (r_nsubjpass) used/VBN (l_conj) indicate/VBP (l_ccomp) is/VBZ (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) rosacea/NN
D016559_D019557 NONE Tacrolimus/NNP (r_compound) ointment/NN (r_nsubjpass) used/VBN (l_conj) indicate/VBP (l_ccomp) is/VBZ (l_acomp) effective/JJ (l_prep) in/IN (l_pobj) rosacea/NN (l_conj) dermatitis/NN
D013256_D019557 NONE steroid/NN (r_npadvmod) aggravated/VBN (r_amod) rosacea/NN (l_conj) dermatitis/NN
D016559_D003872 NONE tacrolimus/NN (r_compound) ointment/NN (r_pobj) with/IN (r_prep) dermatoses/NNS (r_pobj) of/IN (r_prep) treatment/NN (r_pobj) during/IN (r_prep) Induction/NN (l_prep) of/IN (l_pobj) dermatitis/NN -PUNC- tacrolimus/NN (r_compound) ointment/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) report/VBP (l_prep) on/IN (l_pobj) dermatitis/NN -PUNC- tacrolimus/NN (r_compound) ointment/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) spectrum/NN (l_prep) of/IN (l_pobj) dermatitis/NN
D016559_D005148 NONE tacrolimus/NN (r_compound) ointment/NN (r_pobj) with/IN (r_prep) dermatoses/NNS -PUNC- tacrolimus/NN (r_compound) ointment/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) dermatoses/NNS
D013256_D012393 NONE steroid/NN (r_npadvmod) aggravated/VBN (r_amod) rosacea/NN
26115410
D001152_D009369 CID iAs/NNP (r_compound) exposure/NN (l_prep) in/IN (l_pobj) relationship/NN (l_prep) to/IN (l_pobj) cancer/NN -PUNC- iAs/NNP (r_compound) exposure/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) risk/NN (l_prep) of/IN (l_pobj) development/NN (l_compound) cancer/NN -PUNC- iAs/NNP (r_compound) exposure/NN (r_nsubj) elicits/VBZ (r_relcl) mechanisms/NNS (r_attr) are/VBP (l_nsubj) development/NN (l_prep) of/IN (l_pobj) cells/NNS (l_compound) cancer/NN -PUNC- iAs/NNP (r_compound) exposure/NN (l_conj) development/NN (l_compound) cancer/NN
9759693
D018170_D009203 NONE sumatriptan/JJ (r_compound) use/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_acl) infarction/NN
D018170_D017091 CID sumatriptan/JJ (r_amod) use/NN (r_conj) colitis/NN -PUNC- sumatriptan/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) migraine/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) cases/NNS (l_prep) of/IN (l_pobj) colitis/NN
D018170_D003329 NONE sumatriptan/JJ (r_compound) use/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_acl) infarction/NN (r_conj) ischemia/NN (r_conj) vasospasm/NN
D018170_D017202 NONE sumatriptan/JJ (r_compound) use/NN (r_pobj) after/IN (r_prep) occurring/VBG (r_acl) infarction/NN (r_conj) ischemia/NN
D018170_D008881 NONE sumatriptan/NNP (r_pobj) with/IN (r_prep) treated/VBN (r_acl) migraine/NN
2320485
D008750_D014947 NONE methyldopa/NN (r_pobj) with/IN (r_prep) treated/VBN (l_prep) during/IN (l_pobj) admission/NN (l_compound) trauma/NN
D008750_D013575 NONE Methyldopa/NNP (r_nsubj) induced/VBN (l_advcl) presenting/VBG (l_prep) as/IN (l_pobj) syncope/NN -PUNC- methyldopa/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN (l_prep) in/IN (l_pobj) boy/NN (l_relcl) presented/VBD (l_prep) with/IN (l_pobj) syncope/NN
D008750_D000743 CID Methyldopa/NNP (r_nsubj) induced/VBN (l_dobj) anemia/NN -PUNC- methyldopa/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN
D008750_D004630 NONE methyldopa/NN (r_npadvmod) induced/VBN (r_amod) anemia/NN (l_prep) in/IN (l_pobj) boy/NN (l_relcl) presented/VBD (l_prep) to/IN (l_pobj) department/NN
D008750_D000744 NONE Methyldopa/NNP (r_nsubj) causes/VBZ (l_dobj) anemia/NN
20595935
D014700_-1 NONE verapamil/NN (r_pobj) to/IN (r_prep) unresponsiveness/NN (r_nsubj) defined/VBN (r_ccomp) revealed/VBD (l_conj) discriminated/VBD (l_npadvmod) sensitivity/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) pseudoprolactinoma/NN
D018967_D006966 CID risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN -PUNC- risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN
D014700_D015175 NONE verapamil/NN (r_pobj) of/IN (r_prep) value/NN (l_prep) in/IN (l_pobj) population/NN (l_relcl) screened/VBN (l_prep) for/IN (l_pobj) macroprolactinemia/NN -PUNC- Verapamil/NNP (r_nsubj) increased/VBD (l_advcl) macroprolactinoma/NN -PUNC- Verapamil/NNP (r_nsubj) increased/VBD (l_advcl) macroprolactinoma/NN (l_appos) PRL/NN (l_conj) microprolactinoma/NN -PUNC- Verapamil/NNP (r_nsubj) increased/VBD (l_advcl) macroprolactinoma/NN (l_appos) PRL/NN (l_appos) macroprolactinemia/JJ
D018967_-1 NONE risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN (r_conj) PRL/NN (l_conj) in/IN (l_pobj) pseudoprolactinoma/NN -PUNC- risperidone/NN (r_npadvmod) induced/VBN (r_amod) hyperprolactinemia/NN (r_conj) pseudoprolactinoma/NN
D014700_D006966 NONE Verapamil/NNP (r_compound) test/NN (l_prep) in/IN (l_pobj) hyperprolactinemia/NN -PUNC- Verapamil/NNP (r_compound) test/NN (r_nsubjpass) investigated/VBN (l_prep) as/IN (l_pobj) tool/NN (l_prep) for/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- verapamil/NN (r_pobj) to/IN (r_prep) responses/NNS (l_prep) with/IN (l_pobj) hyperprolactinemia/NN -PUNC- verapamil/NN (r_pobj) to/IN (r_prep) unresponsiveness/NN (r_nsubj) defined/VBN (r_ccomp) revealed/VBD (l_conj) discriminated/VBD (l_npadvmod) sensitivity/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) pseudoprolactinoma/NN (l_conj) hyperprolactinemia/NN -PUNC- Verapamil/NNP (r_compound) responsiveness/NN (r_nsubj) is/VBZ (l_attr) finding/NN (l_prep) for/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) hyperprolactinemia/NN -PUNC- verapamil/NN (r_compound) unresponsiveness/NN (r_nsubj) discriminates/VBZ (l_dobj) effect/NN (l_parataxis) inhibited/JJ (l_prep) from/IN (l_pobj) causes/NNS (l_prep) of/IN (l_pobj) hyperprolactinemia/NN
24275640
D004317_D066126 CID doxorubicin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_pobj) of/IN (r_prep) mechanism/NN (r_nsubj) remains/VBZ (l_nsubj) cardiotoxicity/NN -PUNC- DOX)-induced/JJ (r_amod) cardiotoxicity/NN -PUNC- DOX/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) cardiotoxicity/NN
D004317_D009336 CID DOX/NNP (r_pobj) of/IN (r_prep) dose/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) disarrangement/NN (l_conj) necrosis/NN
D004317_D006331 NONE DOX/NNP (r_pobj) of/IN (r_prep) dose/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) disarrangement/NN
1280054
D014750_D007049 CID Vincristine/NNP (r_nsubjpass) given/VBN (l_advcl) producing/VBG (l_dobj) dysfunction/NN
D014750_D001927 CID vincristine/NN (r_compound) administration/NN (r_pobj) due/IN (r_prep) myeloencephalopathy/NN -PUNC- Vincristine/NNP (r_nsubjpass) given/VBN (l_advcl) producing/VBG (l_dobj) dysfunction/NN (l_acl) followed/VBN (l_agent) by/IN (l_pobj) encephalopathy/JJ
D014750_D007938 NONE Vincristine/NNP (r_nsubjpass) given/VBN (l_dative) to/IN (l_pobj) child/NN (l_prep) with/IN (l_pobj) leukaemia/NN
16723784
D015764_D001282 NONE bepridil/NN (r_amod) administration/NN (r_pobj) during/IN (r_prep) effects/NNS (l_prep) for/IN (l_pobj) fibrillation/NN (l_conj) flutter/JJ -PUNC- hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN (l_conj) flutter/NN -PUNC- hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN (l_conj) flutter/NN (l_appos) AFL/NNP -PUNC- Bpd/NNP (r_appos) hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN (l_conj) flutter/NN -PUNC- Bpd/NNP (r_appos) hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN (l_conj) flutter/NN (l_appos) AFL/NNP -PUNC- Bpd/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) comprising/VBG (l_dobj) cases/NNS (l_compound) AFL/NNP
D015764_D001281 NONE bepridil/NN (r_amod) administration/NN (r_pobj) during/IN (r_prep) effects/NNS (l_prep) for/IN (l_pobj) fibrillation/NN (l_conj) flutter/JJ -PUNC- hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN -PUNC- hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN (l_appos) AF/NNP -PUNC- Bpd/NNP (r_appos) hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN -PUNC- Bpd/NNP (r_appos) hydrochloride/NN (r_nsubj) attracted/VBN (l_prep) as/IN (l_pobj) drug/NN (l_prep) for/IN (l_pobj) fibrillation/NN (l_appos) AF/NNP -PUNC- Bpd/NNP (r_nsubjpass) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_acl) comprising/VBG (l_dobj) cases/NNS (l_nmod) AF/NNP
16920333
C416835_D012640 NONE acetate/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- 093/CD (r_appos) acetate/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- acetate/NN (l_prep) on/IN (l_pobj) model/NN (l_relcl) elicited/VBN (l_nsubjpass) seizures/NNS -PUNC- acetate/NN (l_prep) on/IN (l_pobj) model/NN (l_relcl) elicited/VBN (l_prep) without/IN (l_pobj) changes/NNS (l_prep) in/IN (l_pobj) threshold/NN (l_conj) patterns/NNS (l_compound) seizure/NN
D010852_D012640 CID picrotoxin/NN (r_pobj) of/IN (r_prep) microperfusion/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) seizures/NNS -PUNC- picrotoxin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) was/VBD (l_nsubj) number/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- picrotoxin/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_acl) animals/NNS (r_pobj) In/IN (r_prep) was/VBD (l_conj) was/VBD (l_nsubj) duration/NN (l_compound) seizure/NN -PUNC- picrotoxin/NN (r_compound) microperfusion/NN (r_nsubj) prevented/VBD (l_dobj) seizures/NNS
11229942
C066444_D066126 NONE cocaethylene/NN (l_dobj) cardiotoxity/NN -PUNC- cocaethylene/NN (r_pobj) due/JJ (r_acomp) be/VB (l_ccomp) be/VB (l_nsubj) toxicity/NN -PUNC- CE/NNP (r_appos) cocaethylene/NN (r_pobj) due/JJ (r_acomp) be/VB (l_ccomp) be/VB (l_nsubj) toxicity/NN -PUNC- CE/NNP (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) cardiotoxicity/NN
C066444_D000437 NONE cocaethylene/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
C066444_D009202 NONE cocaethylene/NN (r_compound) concentrations/NNS (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) depression/NN
D000431_D000437 NONE ethanol/NN (l_conj) cocaethylene/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
D003042_D019970 NONE Cocaine/NN (l_appos) ethanol/NN (l_conj) cocaethylene/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
D003042_D000437 NONE Cocaine/NN (l_appos) ethanol/NN (l_conj) cocaethylene/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
C066444_D019970 NONE cocaethylene/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
C066444_D002303 CID CE/NNP (r_compound) levels/NNS (r_nsubjpass) associated/VBN (l_conj) decrease/NN (l_prep) in/IN (l_pobj) output/NN
D003042_D066126 NONE Cocaine/NN (l_appos) ethanol/NN (l_conj) cocaethylene/NN (l_dobj) cardiotoxity/NN -PUNC- cocaine/NN (r_compound) metabolite/NN (r_appos) cocaethylene/NN (r_pobj) due/JJ (r_acomp) be/VB (l_ccomp) be/VB (l_nsubj) toxicity/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN
D000431_D019970 NONE ethanol/NN (l_conj) cocaethylene/NN (l_prep) in/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) cocaine/NN (l_conj) abuse/NN
D000431_D066126 NONE ethanol/NN (l_conj) cocaethylene/NN (l_dobj) cardiotoxity/NN -PUNC- ethanol/NN (r_pobj) of/IN (r_prep) presence/NN (r_pobj) in/IN (r_prep) formed/VBN (r_acl) metabolite/NN (r_appos) cocaethylene/NN (r_pobj) due/JJ (r_acomp) be/VB (l_ccomp) be/VB (l_nsubj) toxicity/NN -PUNC- ethanol/NN (r_conj) cocaine/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN
24717468
D015742_D001919 CID propofol/NN (r_conj) receive/VBP (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) prevalence/NN (r_pobj) at/IN (r_prep) occur/VBP (l_nsubj) hypotension/NN (l_conj) bradycardia/NN
D020927_D007022 CID dexmedetomidine/NN (r_dobj) receive/VBP (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) prevalence/NN (r_pobj) at/IN (r_prep) occur/VBP (l_nsubj) hypotension/NN
D020927_D001919 CID dexmedetomidine/NN (r_dobj) receive/VBP (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) prevalence/NN (r_pobj) at/IN (r_prep) occur/VBP (l_nsubj) hypotension/NN (l_conj) bradycardia/NN
D015742_D007022 CID propofol/NN (r_conj) receive/VBP (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) prevalence/NN (r_pobj) at/IN (r_prep) occur/VBP (l_nsubj) hypotension/NN
16911931
D019259_D006509 NONE lamivudine/NN (r_pobj) with/IN (r_prep) combined/VBN (r_acl) globulin/NN (l_compound) B/NNP -PUNC- lamivudine/NN (l_prep) in/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) recurrence/NN (l_compound) B/NNP -PUNC- lamivudine/NN (r_conj) HBIg/NNP (r_appos) globulin/NN (l_compound) B/NNP -PUNC- lamivudine/NN (l_prep) in/IN (l_pobj) prophylaxis/NN (l_prep) of/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) B/NNP
D006514_D006509 NONE HBsAg/JJ (r_nmod) patients/NNS (r_pobj) of/IN (r_prep) survival/NN (r_dobj) improved/VBN (l_nsubj) globulin/NN (l_compound) B/NNP -PUNC- HBsAg/JJ (r_nmod) patients/NNS (r_pobj) of/IN (r_prep) survival/NN (r_dobj) improved/VBN (l_nsubj) globulin/NN (l_appos) HBIg/NNP (l_conj) lamivudine/NN (l_prep) in/IN (l_pobj) prophylaxis/NN (l_prep) of/IN (l_pobj) recurrence/NN (l_prep) of/IN (l_pobj) B/NNP
24434397
D014148_D004830 CID TNA/NNP (r_pobj) of/IN (r_prep) dose/NN (r_pobj) after/IN (r_prep) had/VBD (l_dobj) episode/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D014148_D012640 NONE acid/NN (r_compound) seizure/NN -PUNC- TNA/NNP (r_pobj) of/IN (r_prep) overdose/NN (r_attr) be/VB (r_xcomp) believed/VBN (l_nsubjpass) cause/NN (l_prep) of/IN (l_pobj) convulsions/NNS
D014148_D006470 NONE acid/NN (r_nsubjpass) administered/VBN (l_advcl) control/VB (l_xcomp) bleeding/NN -PUNC- TNA/NNP (r_appos) acid/NN (r_nsubjpass) administered/VBN (l_advcl) control/VB (l_xcomp) bleeding/NN
D014148_D051437 NONE acid/NN (r_compound) seizure/NN (l_prep) in/IN (l_pobj) failure/NN
D014148_D062787 NONE TNA/NNP (r_pobj) of/IN (r_prep) overdose/NN
19419794
D007980_D004409 CID DOPA/NNP (r_compound) induced/VBN (r_amod) dyskinesias/NNS -PUNC- DOPA/NNP (r_compound) induced/VBN (r_amod) dyskinesias/NNS
C005177_D004409 NONE DOPA+benserazide/NNP (r_pobj) with/IN (r_prep) Treatment/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) dyskinesias/NNS
D016627_D004409 NONE 6-hydroxydopamine/CD (r_compound) lesion/NN (l_conj) development/NN (l_prep) of/IN (l_pobj) dyskinesias/NNS
D004298_D004409 NONE DA/NNP (r_compound) lesion/NN (r_conj) impairment/NN (r_pobj) of/IN (r_prep) severity/NN (r_dobj) increased/VBD (l_conj) reduced/VBN (l_dobj) dyskinesias/NNS
8829135
D001058_D000647 CID apomorphine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- apomorphine/NN (r_pobj) Given/VBN (r_prep) inhibits/VBZ (r_ccomp) evaluated/VBD (l_dobj) ability/NN (l_acl) attenuate/VB (l_dobj) amnesia/NN -PUNC- apomorphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D012601_D007859 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) learning/NN (l_conj) deficits/NNS
D011760_D007859 NONE pyrrolidone/NN (r_compound) derivative/NN (l_relcl) attenuates/VBZ (l_dobj) learning/NN (l_conj) deficits/NNS
C058876_D000647 NONE Nefiracetam/NNP (r_nsubj) reverses/VBZ (l_dobj) amnesia/NN -PUNC- DM-9384/NNP (r_appos) Nefiracetam/NNP (r_nsubj) reverses/VBZ (l_dobj) amnesia/NN -PUNC- nefiracetam/NN (r_pobj) of/IN (r_prep) ability/NN (l_acl) attenuate/VB (l_dobj) amnesia/NN -PUNC- nefiracetam/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reversed/VBD (l_dobj) amnesia/NN
C058876_D007859 NONE Nefiracetam/NNP (r_nsubj) is/VBZ (l_attr) derivative/NN (l_relcl) attenuates/VBZ (l_dobj) learning/NN (l_conj) deficits/NNS
6305660
18165598
D002045_D010146 NONE bupivacaine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) lidocaine/NN (l_prep) on/IN (l_pobj) release/NN (l_conj) expression/NN (l_conj) pain/NN -PUNC- bupivacaine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_conj) lidocaine/NN (l_prep) on/IN (l_pobj) release/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN -PUNC- bupivacaine/NN (r_nmod) rofecoxib/NN (r_compound) group/NN (r_nsubj) reported/VBD (l_dobj) pain/NN -PUNC- bupivacaine/NN (r_nmod) placebo/NN (r_compound) group/NN (r_nsubj) reported/VBD (l_dobj) pain/NN -PUNC- bupivacaine/NN (r_nsubj) stimulates/VBZ (l_prep) after/IN (l_pobj) injury/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) production/NN (l_conj) pain/NN
D015232_D010149 NONE E2/NNP (r_nmod) production/NN (r_nmod) expression/NN (l_relcl) increases/VBZ (l_dobj) pain/NN -PUNC- PGE2/NNP (r_appos) E2/NNP (r_nmod) production/NN (r_nmod) expression/NN (l_relcl) increases/VBZ (l_dobj) pain/NN
D002045_D010149 CID bupivacaine/NN (l_prep) on/IN (l_pobj) expression/NN (l_relcl) increases/VBZ (l_dobj) pain/NN
D008012_D010146 NONE lidocaine/NN (l_prep) on/IN (l_pobj) release/NN (l_conj) expression/NN (l_conj) pain/NN -PUNC- lidocaine/NN (l_prep) on/IN (l_pobj) release/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN
D002045_D017695 NONE bupivacaine/NN (r_nsubj) stimulates/VBZ (l_prep) after/IN (l_pobj) injury/NN
D015232_D010146 NONE E2/NNP (r_compound) release/NN (l_conj) expression/NN (l_conj) pain/NN -PUNC- E2/NNP (r_compound) release/NN (l_prep) in/IN (l_pobj) model/NN (l_compound) pain/NN -PUNC- PGE2/NNP (r_conj) h/NN (r_nmod) levels/NNS (r_pobj) at/IN (r_prep) reported/VBD (l_dobj) pain/NN -PUNC- PGE2/NNP (r_compound) production/NN (l_conj) pain/NN
C116926_D010146 NONE rofecoxib/NN (r_compound) group/NN (r_nsubj) reported/VBD (l_dobj) pain/NN
D015232_D017695 NONE PGE2/NNP (r_compound) production/NN (r_pobj) with/IN (r_prep) associated/VBN (r_relcl) injury/NN
12498738
C043211_D064420 NONE carvedilol/NN (r_nsubj) protects/VBZ (l_prep) against/IN (l_pobj) dysfunction/NN (l_acl) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
C043211_D009202 NONE Carvedilol/NNP (r_nsubj) protects/VBZ (l_prep) against/IN (l_pobj) cardiomyopathy/NN -PUNC- carvedilol/NN (r_pobj) by/IN (r_prep) protection/NN (r_nsubj) afford/VB (l_prep) in/IN (l_pcomp) minimizing/VBG (l_dobj) dysfunction/NN (l_conj) cardiomyopathy/NN
D004317_D028361 NONE doxorubicin/NN (r_compound) therapy/NN (r_dobj) accompanies/VBZ (r_relcl) dysfunction/NN
D004317_D064420 NONE doxorubicin/JJ (r_compound) toxicity/NN
C043211_D028361 NONE carvedilol/NN (r_pobj) by/IN (r_prep) protection/NN (r_nsubj) afford/VB (l_prep) in/IN (l_pcomp) minimizing/VBG (l_dobj) dysfunction/NN
D004317_D009369 NONE doxorubicin/NN (r_compound) therapy/NN (r_dobj) accompanies/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
C043211_D009369 NONE carvedilol/NN (r_pobj) by/IN (r_prep) protection/NN (r_nsubj) afford/VB (l_prep) in/IN (l_pcomp) minimizing/VBG (l_dobj) dysfunction/NN (l_relcl) accompanies/VBZ (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN
D004317_D009202 CID doxorubicin/RB (r_npadvmod) induced/VBN (r_amod) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_acl) cardiomyopathy/NN -PUNC- doxorubicin/NN (r_compound) therapy/NN (r_dobj) accompanies/VBZ (r_relcl) dysfunction/NN (l_conj) cardiomyopathy/NN
17028363
D000880_D058186 NONE anthraquinones/NNS (r_dobj) containing/VBG (r_acl) pills/NNS (r_pobj) of/IN (r_prep) intake/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) failure/NN -PUNC- anthraquinone/NN (r_compound) derivatives/NNS (r_dobj) contained/VBD (r_relcl) pill/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) failure/NN -PUNC- anthraquinone/NN (r_npadvmod) containing/VBG (r_amod) agent/NN (l_conj) injury/NN
D000880_D007674 NONE anthraquinone/NN (r_npadvmod) containing/VBG (r_amod) agent/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) between/IN (r_prep) relationship/NN (r_nsubj) remains/VBZ (r_advcl) considered/VBN (l_nsubjpass) nephropathy/NN
D000880_D051437 NONE anthraquinone/NN (r_npadvmod) containing/VBG (r_amod) agent/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) between/IN (r_prep) relationship/NN (r_nsubj) remains/VBZ (r_advcl) considered/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) present/VBP (l_prep) with/IN (l_pobj) failure/NN
D004008_D058186 CID diclofenac/NN (r_appos) drug/NN (r_pobj) of/IN (r_prep) intake/NN (r_pobj) by/IN (r_agent) aggravated/VBN (l_nsubjpass) injury/NN
D034341_D007674 NONE acids/NNS (r_pobj) of/IN (r_prep) use/NN (r_dobj) involving/VBG (r_advcl) reported/VBN (l_nsubjpass) Nephropathy/NNP
D004365_D058186 CID herbal/JJ (r_amod) pill/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) failure/NN
D004365_D007674 NONE herbs/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) Nephropathy/NNP
15614572
D012701_D002375 NONE 5-HT/CD (r_compound) 2C/NNP (r_compound) receptors/NNS (r_dobj) blocking/VBG (r_pcomp) by/IN (r_prep) trazodone/NNP (r_nsubj) releases/VBZ (l_conj) potentiates/VBZ (l_conj) antagonizes/VBZ (l_dobj) catalepsy/NN -PUNC- 5-HT/CD (r_pobj) by/IN (r_agent) caused/VBN (r_acl) inhibition/NN (r_pobj) from/IN (r_prep) neurons/NNS (r_dobj) releases/VBZ (l_conj) potentiates/VBZ (l_conj) antagonizes/VBZ (l_dobj) catalepsy/NN
D006220_D002375 CID haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- haloperidol/NN (r_det) catalepsy/NN -PUNC- haloperidol/NN (r_det) catalepsy/NN
D014196_D009062 NONE trazodone/NN (r_pobj) with/IN (r_prep) pretreatment/NN (l_prep) on/IN (l_pobj) stereotypies/NNS
D005473_D009062 NONE fluoxetine/NN (r_advmod) induced/VBN (r_amod) erections/NNS (r_conj) behavior/NN (r_pobj) on/IN (r_prep) studied/VBN (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) pretreatment/NN (l_prep) on/IN (l_pobj) stereotypies/NNS
D001058_D002375 CID apomorphine/NN (r_conj) dexamphetamine-/FW (r_npadvmod) induced/VBN (r_amod) stereotypies/NNS (r_pobj) on/IN (r_prep) pretreatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- apomorphine/NN (r_conj) haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN -PUNC- apomorphine/NN (r_dobj) antagonize/VB (r_conj) induce/VB (l_dobj) catalepsy/NN -PUNC- apomorphine/NN (r_dobj) antagonize/VB (l_dobj) catalepsy/NN -PUNC- apomorphine/NN (r_conj) stereotypy/NN (r_nmod) catalepsy/NN (r_dobj) antagonize/VB (r_conj) induce/VB (l_dobj) catalepsy/NN -PUNC- apomorphine/NN (r_conj) stereotypy/NN (r_nmod) catalepsy/NN -PUNC- apomorphine/NN (r_dobj) antagonized/VBN (r_conj) induced/VBN (l_dobj) catalepsy/NN
D003913_D002375 NONE dexamphetamine-/FW (r_npadvmod) induced/VBN (r_amod) stereotypies/NNS (r_pobj) on/IN (r_prep) pretreatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- dexamphetamine/NN (r_compound) stereotypy/NN (r_pobj) with/IN (r_prep) pretreatment/NN (l_conj) antagonized/VBD (l_dobj) catalepsy/NN -PUNC- dexamphetamine/NN (r_compound) stereotypies/NNS (r_conj) apomorphine/NN (r_dobj) antagonized/VBN (r_conj) induced/VBN (l_dobj) catalepsy/NN -PUNC- dexamphetamine/NN (r_compound) stereotypy/NN (r_dobj) potentiates/VBZ (l_conj) antagonizes/VBZ (l_dobj) catalepsy/NN
D004874_D009062 NONE ergometrine/NN (r_advmod) induced/VBN (r_amod) behavior/NN (r_pobj) on/IN (r_prep) studied/VBN (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) pretreatment/NN (l_prep) on/IN (l_pobj) stereotypies/NNS
D005473_D002375 NONE fluoxetine/NN (r_advmod) induced/VBN (r_amod) erections/NNS (r_conj) behavior/NN (r_pobj) on/IN (r_prep) studied/VBN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- fluoxetine/NN (r_advmod) induced/VBN (r_amod) erections/NNS (r_conj) behavior/NN (r_conj) catalepsy/NN
D004874_D002375 NONE ergometrine/NN (r_advmod) induced/VBN (r_amod) behavior/NN (r_pobj) on/IN (r_prep) studied/VBN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- ergometrine/NN (r_advmod) induced/VBN (r_amod) behavior/NN (r_conj) catalepsy/NN
D003913_D009062 NONE dexamphetamine-/FW (r_npadvmod) induced/VBN (r_amod) stereotypies/NNS
D014196_D002375 NONE trazodone/NN (r_pobj) with/IN (r_prep) pretreatment/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubjpass) studied/VBN (l_prep) on/IN (l_pobj) catalepsy/NN -PUNC- trazodone/NN (r_nsubj) induces/VBZ (l_dobj) catalepsy/NN -PUNC- Trazodone/NNP (r_nsubj) induce/VB (l_dobj) catalepsy/NN -PUNC- Trazodone/NNP (r_nsubj) induce/VB (l_conj) antagonize/VB (l_dobj) catalepsy/NN -PUNC- trazodone/NNP (r_nmod) stereotypy/NN (r_pobj) with/IN (r_prep) pretreatment/NN (l_conj) antagonized/VBD (l_dobj) catalepsy/NN -PUNC- Trazodone/NNP (r_nsubj) induced/VBN (l_dobj) catalepsy/NN -PUNC- trazodone/NNP (r_nsubj) releases/VBZ (l_conj) potentiates/VBZ (l_conj) antagonizes/VBZ (l_dobj) catalepsy/NN
D001058_D009062 NONE apomorphine/NN (r_conj) dexamphetamine-/FW (r_npadvmod) induced/VBN (r_amod) stereotypies/NNS -PUNC- apomorphine/NN (r_conj) haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN (r_pobj) on/IN (r_prep) studied/VBN (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) pretreatment/NN (l_prep) on/IN (l_pobj) stereotypies/NNS
D006220_D009062 NONE haloperidol/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN (r_pobj) on/IN (r_prep) studied/VBN (l_nsubjpass) effect/NN (l_prep) of/IN (l_pobj) pretreatment/NN (l_prep) on/IN (l_pobj) stereotypies/NNS
8184922
D007545_D006332 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) hypertrophy/NN
19531695
D017374_D003693 CID paroxetine/NN (r_pobj) with/IN (r_prep) interaction/NN (r_pobj) of/IN (r_prep) role/NN (r_appos) Delirium/NN -PUNC- paroxetine/NN (r_pobj) with/IN (r_prep) interaction/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) delirium/NN -PUNC- paroxetine/NN (l_appos) inhibitor/NN (l_conj) reports/NNS (l_prep) of/IN (l_pobj) delirium/NN -PUNC- paroxetine/NN (r_conj) flecainide/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) indicates/VBZ (l_ccomp) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) delirium/NN
D005424_D001281 NONE Flecainide/NNP (r_nsubjpass) started/VBN (l_advmod) prior/RB (l_prep) for/IN (l_pobj) fibrillation/NN
D012964_D003693 NONE sodium/NN (r_compound) channels/NNS (r_pobj) with/IN (r_prep) interact/VBP (r_relcl) agents/NNS (r_nsubj) cause/VB (l_dobj) delirium/NN
D005424_D003693 CID flecainide/JJ (r_amod) concentrations/NNS (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) Delirium/NN -PUNC- flecainide/RB (r_advmod) induced/VBN (r_amod) delirium/NN -PUNC- Flecainide/NNP (r_amod) agents/NNS (r_nsubj) cause/VB (l_dobj) delirium/NN -PUNC- flecainide/NN (r_pobj) between/IN (r_prep) interaction/NN (r_pobj) on/IN (r_prep) study/NN (l_conj) substrate/NN (l_conj) paroxetine/NN (l_appos) inhibitor/NN (l_conj) reports/NNS (l_prep) of/IN (l_pobj) delirium/NN -PUNC- flecainide/RB (r_advmod) induced/VBN (r_amod) delirium/NN -PUNC- flecainide/NN (r_advmod) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) delirium/NN -PUNC- flecainide/NN (r_pobj) between/IN (r_prep) interaction/NN (r_dobj) indicates/VBZ (l_ccomp) was/VBD (l_attr) cause/NN (l_prep) of/IN (l_pobj) delirium/NN -PUNC- flecainide/JJ (r_amod) concentrations/NNS (r_nsubj) cause/VB (l_dobj) delirium/NN
D005424_D064420 NONE flecainide/JJ (r_nsubjpass) prescribed/VBN (r_advcl) occur/VB (l_nsubj) toxicity/NN -PUNC- flecainide/JJ (r_amod) concentrations/NNS (r_conj) paroxetine/NN (r_pobj) with/IN (r_prep) prescribed/VBN (r_advcl) occur/VB (l_nsubj) toxicity/NN
D017374_D064420 NONE paroxetine/NN (r_pobj) with/IN (r_prep) prescribed/VBN (r_advcl) occur/VB (l_nsubj) toxicity/NN
6453500
D004221_D056486 CID disulfiram/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) hepatitis/NN -PUNC- disulfiram/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) woman/NN (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) damage/NN
15987266
D003513_D004827 NONE cycloheximide/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubj) expression/NN (l_prep) in/IN (l_pobj) layer/NN (l_prep) of/IN (l_pobj) rats/NNS (l_amod) epileptic/JJ
D010862_D013226 CID pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_amod) epilepticus/NN -PUNC- Pilo/NNP (r_appos) pilocarpine/NN (r_pobj) by/IN (r_agent) induced/VBN (l_amod) epilepticus/NN
D003513_D013226 NONE cycloheximide/NN (r_pobj) with/IN (r_conj) injected/VBN (r_conj) assessed/VBD (l_dobj) intensity/NN (l_acl) induced/VBN (l_amod) epilepticus/NN -PUNC- CHX/NNP (r_appos) injected/VBN (r_conj) assessed/VBD (l_dobj) intensity/NN (l_acl) induced/VBN (l_amod) epilepticus/NN
24284476
D012601_D000647 CID scopolamine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) amnesia/NN
D047310_D000647 NONE apigenin/NN (r_nsubj) prevent/VB (l_dobj) amnesia/NN
7949506
D014700_D054537 CID verapamil/NN (r_conj) clonidine/NN (r_pobj) between/IN (r_prep) interaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) block/NN
D003000_D054537 CID clonidine/NN (r_pobj) between/IN (r_prep) interaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) block/NN -PUNC- clonidine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) After/IN (r_prep) developed/VBD (l_dobj) block/NN -PUNC- clonidine/JJ (r_pobj) of/IN (r_prep) addition/NN (r_pobj) After/IN (r_prep) developed/VBD (l_dobj) block/NN
D014700_D007022 CID verapamil/NN (r_conj) clonidine/NN (r_pobj) between/IN (r_prep) interaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) block/NN (l_prep) in/IN (l_pobj) patients/NNS (l_conj) hypotension/NN
D014700_D006929 NONE verapamil/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) hyperaldosteronism/NN
D013148_D006929 NONE spironolactone/CD (r_conj) treated/VBN (l_nsubjpass) woman/NN (l_prep) with/IN (l_pobj) hyperaldosteronism/NN
D003000_D007022 CID clonidine/NN (r_pobj) between/IN (r_prep) interaction/NN (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) block/NN (l_prep) in/IN (l_pobj) patients/NNS (l_conj) hypotension/NN -PUNC- clonidine/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) After/IN (r_prep) developed/VBD (l_dobj) block/NN (l_conj) hypotension/NN
1451544
D017275_D006973 NONE Isradipine/NNP (r_compound) treatment/NN (l_prep) for/IN (l_pobj) hypertension/NN
D017275_D004244 CID isradipine/NN (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_advcl) frequent/JJ (r_acomp) were/VBD (l_nsubj) headache/NN (l_conj) dizziness/NN
D017275_D005483 CID isradipine/NN (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_advcl) frequent/JJ (r_acomp) were/VBD (l_nsubj) headache/NN (l_conj) dizziness/NN (l_conj) palpitation/NN (l_conj) flushing/NN
D017275_D006261 CID isradipine/NN (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_advcl) frequent/JJ (r_acomp) were/VBD (l_nsubj) headache/NN
D017275_-1 NONE isradipine/NN (r_pobj) with/IN (r_prep) studies/NNS (r_pobj) in/IN (r_prep) reported/VBN (r_advcl) frequent/JJ (r_acomp) were/VBD (l_nsubj) headache/NN (l_conj) dizziness/NN (l_conj) palpitation/NN
14748761
C030852_D009369 NONE VNR/VBN (r_dobj) comparing/VBG (l_prep) with/IN (l_pobj) agents/NNS (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) malignancies/NNS -PUNC- VNR/VBN (r_dobj) comparing/VBG (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) cancer/NN
C030852_D066126 CID VNR/VBN (r_nmod) events/NNS (r_pobj) of/IN (r_prep) risk/NN (r_nsubj) was/VBD (l_conj) drugs/NNS (l_amod) cardiotoxic/JJ
D018943_D066126 NONE anthracyclines/NNS (r_appos) drugs/NNS (l_amod) cardiotoxic/JJ
D014751_D066126 NONE vindesine/NN (r_xcomp) similar/JJ (r_acomp) was/VBD (l_conj) drugs/NNS (l_amod) cardiotoxic/JJ -PUNC- VDS/NNP (r_appos) vindesine/NN (r_xcomp) similar/JJ (r_acomp) was/VBD (l_conj) drugs/NNS (l_amod) cardiotoxic/JJ
D005472_D066126 NONE fluorouracil/NN (r_nmod) anthracyclines/NNS (r_appos) drugs/NNS (l_amod) cardiotoxic/JJ
C056507_D066126 NONE gemcitabine/NN (r_appos) drugs/NNS (l_amod) cardiotoxic/JJ -PUNC- GEM/NNP (r_appos) gemcitabine/NN (r_appos) drugs/NNS (l_amod) cardiotoxic/JJ
11395263
D000431_D009203 NONE ethanol/NN (r_compound) extract/NN (r_pobj) of/IN (r_prep) effect/NN (l_prep) on/IN (l_pobj) infarction/NN
D007545_D009203 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) infarction/NN
19715529
8748050
D000639_D009459 NONE amitriptyline/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) Encephalopathy/VBG (r_nsubj) are/VBP (l_attr) syndrome/NN
D000639_D003866 NONE amitriptyline/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) encephalopathy/NN (r_pobj) of/IN (r_prep) case/NN (r_dobj) describes/VBZ (l_prep) during/IN (l_pobj) remission/NN (l_prep) of/IN (l_pobj) depression/NN
D000639_D001927 CID amitriptyline/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) Encephalopathy/VBG -PUNC- amitriptyline/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) in/IN (r_prep) developed/VBN (r_acl) encephalopathy/NN
D000639_D020230 NONE amitriptyline/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) Encephalopathy/VBG (r_nsubj) are/VBP (l_attr) syndrome/NN (l_conj) disorders/NNS (l_compound) syndrome/NN
18801087
D000638_D008175 NONE amiodarone/NN (r_npadvmod) related/VBN (r_amod) lesion/NN (r_attr) was/VBD (r_ccomp) indicating/VBG (r_advcl) composed/VBN (r_conj) suspected/VBN (l_xcomp) be/VB (l_attr) cancer/NN
D000638_D011507 NONE amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) mass/NN (l_appos) cm/NNS (l_conj) proteinuria/NN
D000638_D001145 NONE Amiodarone/NN (r_nsubj) is/VBZ (l_attr) drug/NN (l_amod) arrhythmic/JJ
D000638_D009369 NONE amiodarone/NN (r_npadvmod) related/VBN (r_amod) lesion/NN (l_conj) neoplasm/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) be/VB (r_ccomp) suggests/VBZ (r_conj) highlights/VBZ (l_dobj) possibility/NN (l_acl) be/VB (l_nsubj) diagnosis/NN (l_prep) between/IN (l_pobj) lesion/NN (l_conj) neoplasm/NN
D000638_D006349 NONE Amiodarone/NN (r_npadvmod) related/VBN (r_amod) mass/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) disease/NN -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (r_relcl) patient/NN (r_pobj) in/IN (r_prep) Reported/VBN (l_auxpass) is/VBZ (l_attr) case/NN (l_prep) of/IN (l_pobj) disease/NN
D000638_D055370 CID Amiodarone/NN (r_npadvmod) related/VBN (r_amod) mass/NN -PUNC- amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) mass/NN -PUNC- amiodarone/NN (r_npadvmod) related/VBN (r_amod) lesion/NN (r_attr) was/VBD (r_ccomp) indicating/VBG (r_advcl) composed/VBN (r_conj) suspected/VBN (l_nsubjpass) mass/NN -PUNC- amiodarone/NN (r_npadvmod) related/VBN (r_amod) lesion/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) be/VB (r_ccomp) suggests/VBZ (r_conj) highlights/VBZ (l_dobj) possibility/NN (l_acl) be/VB (l_nsubj) diagnosis/NN (l_prep) between/IN (l_pobj) lesion/NN
D000638_D013610 NONE Amiodarone/NN (r_nsubj) is/VBZ (l_attr) drug/NN (l_prep) for/IN (l_pobj) tachycardia/NN
D000638_D015433 CID Amiodarone/NN (r_npadvmod) related/VBN (r_amod) mass/NN (l_conj) glomerulonephritis/NN -PUNC- amiodarone/NN (r_npadvmod) related/VBN (r_amod) lesion/NN (r_pobj) between/IN (r_prep) diagnosis/NN (r_nsubj) be/VB (r_acl) possibility/NN (r_dobj) highlights/VBZ (l_conj) suggests/VBZ (l_ccomp) be/VB (l_nsubj) glomerulonephritis/NN -PUNC- amiodarone/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) be/VB (l_nsubj) glomerulonephritis/NN
24778426
D002945_D009369 NONE cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) cancer/NN -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (l_compound) cancer/NN -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (l_compound) cancer/NN -PUNC- cisplatin/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_dobj) evaluated/VBD (r_ccomp) had/VBD (l_prep) as/IN (l_pobj) malignancy/NN
D008353_D009369 NONE mannitol/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (l_compound) cancer/NN
D008353_D007674 NONE mannitol/NN (r_pobj) without/IN (r_conj) with/IN (r_prep) cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) nephrotoxicity/NN -PUNC- mannitol/NN (r_dobj) receive/VB (r_relcl) Patients/NNS (r_nsubj) were/VBD (l_acomp) likely/JJ (l_xcomp) develop/VB (l_dobj) nephrotoxicity/NN -PUNC- mannitol/NNS (r_pobj) of/IN (r_prep) quantities/NNS (r_nsubj) are/VBP (r_advcl) given/VBN (l_dative) to/IN (l_pobj) patients/NNS (l_prep) at/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN -PUNC- mannitol/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) from/IN (r_prep) benefit/VB (r_conj) are/VBP (l_prep) at/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D008353_D006973 NONE mannitol/NN (r_pobj) of/IN (r_prep) addition/NN (r_pobj) from/IN (r_prep) benefit/VB (r_conj) are/VBP (l_nsubj) weeks/NNS (l_conj) those/DT (l_prep) with/IN (l_pobj) hypertension/NN
D002945_D006258 NONE cisplatin/NN (r_dobj) received/VBD (r_relcl) patients/NNS (r_dobj) evaluated/VBD (r_ccomp) had/VBD (l_dobj) cancer/NN
D002945_D006973 NONE cisplatin/NN (l_advcl) are/VBP (l_nsubj) weeks/NNS (l_conj) those/DT (l_prep) with/IN (l_pobj) hypertension/NN
D002945_D007674 NONE cisplatin/JJ (r_amod) use/NN (r_pobj) of/IN (r_prep) complications/NNS (r_pobj) of/IN (r_prep) One/CD (r_nsubj) is/VBZ (l_attr) nephrotoxicity/NN -PUNC- cisplatin/NN (r_advmod) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- cisplatin/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) nephrotoxicity/NN -PUNC- cisplatin/NN (l_advcl) are/VBP (l_prep) at/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) nephrotoxicity/NN
D008353_D064420 NONE mannitol/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) including/VBG (r_prep) prevent/VB (l_dobj) toxicity/NN
12828076
D000082_D017114 CID paracetamol/JJ (r_compound) overdose/NN (r_pobj) due/IN (r_prep) serum/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) failure/NN -PUNC- paracetamol/JJ (r_compound) overdose/NN (r_pobj) due/IN (r_prep) patients/NNS (l_prep) with/IN (l_pobj) failure/NN
D000082_D062787 NONE paracetamol/JJ (r_compound) overdose/NN -PUNC- paracetamol/JJ (r_compound) overdose/NN
D000082_D056486 NONE paracetamol/JJ (r_compound) overdose/NN (r_pobj) due/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) greater/JJR (r_acomp) were/VBD (l_npadvmod) mL/NN (l_punct) ,/, (l_punct) to/IN (l_pobj) hepatitis/NN
851038
D000450_D007008 NONE aldosterone/NN (r_conj) sodium/NN (r_conj) potassium/NN (r_pobj) of/IN (r_prep) excretion/NN (r_conj) potassium/NN (r_pobj) of/IN (r_prep) concentration/NN (r_conj) rate/NN (r_conj) flow/NN (r_pobj) of/IN (r_prep) determination/NN (r_pobj) by/IN (r_prep) patients/NNS (r_pobj) in/IN (r_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN
D007980_D007008 CID dopa/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_nsubjpass) Hypokalemia/NNP -PUNC- dopa/NN (r_pobj) of/IN (r_prep) influence/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN
D012964_D007008 NONE sodium/NN (r_conj) potassium/NN (r_pobj) of/IN (r_prep) concentration/NN (r_conj) rate/NN (r_conj) flow/NN (r_pobj) of/IN (r_prep) determination/NN (r_pobj) by/IN (r_prep) patients/NNS (r_pobj) in/IN (r_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN -PUNC- sodium/NN (r_conj) potassium/NN (r_pobj) of/IN (r_prep) excretion/NN (r_conj) potassium/NN (r_pobj) of/IN (r_prep) concentration/NN (r_conj) rate/NN (r_conj) flow/NN (r_pobj) of/IN (r_prep) determination/NN (r_pobj) by/IN (r_prep) patients/NNS (r_pobj) in/IN (r_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN
D007980_D010300 NONE dopa/NN (r_compound) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) parkinsonian/JJ -PUNC- dopa/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (l_amod) parkinsonian/JJ
D011188_D007008 NONE potassium/NN (r_pobj) of/IN (r_prep) excretion/NN (r_pobj) on/IN (r_prep) dopa/NN (r_pobj) of/IN (r_prep) influence/NN (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN -PUNC- potassium/NN (r_pobj) of/IN (r_prep) concentration/NN (r_conj) rate/NN (r_conj) flow/NN (r_pobj) of/IN (r_prep) determination/NN (r_pobj) by/IN (r_prep) patients/NNS (r_pobj) in/IN (r_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN -PUNC- potassium/NN (r_pobj) of/IN (r_prep) excretion/NN (r_conj) potassium/NN (r_pobj) of/IN (r_prep) concentration/NN (r_conj) rate/NN (r_conj) flow/NN (r_pobj) of/IN (r_prep) determination/NN (r_pobj) by/IN (r_prep) patients/NNS (r_pobj) in/IN (r_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) hypokalemia/NN
1837756
D012701_D011605 NONE serotonin/NN (r_compound) inhibitors/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) exacerbations/NNS (r_pobj) to/IN (r_prep) present/VB (l_nsubj) disorders/NNS (l_prep) including/VBG (l_pobj) atypicality/NN (l_conj) chronicity/NN (l_conj) psychosis/NN -PUNC- serotonin/NN (r_compound) inhibitors/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) exacerbations/NNS (r_pobj) to/IN (r_prep) present/VB (l_nsubj) disorders/NNS (l_prep) including/VBG (l_prep) in/IN (l_pobj) course/NN (l_prep) of/IN (l_pobj) psychosis/NN
D004298_D010259 NONE dopamine/NN (r_compound) release/NN (r_pobj) including/VBG (r_prep) mechanisms/NNS (r_attr) remain/VBP (l_nsubj) pharmacology/NN (l_prep) of/IN (l_pobj) paranoia/NN
D012701_D003866 NONE serotonin/NN (r_compound) inhibitors/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) exacerbations/NNS (r_pobj) to/IN (r_prep) present/VB (l_nsubj) disorders/NNS
D012701_D010259 NONE Serotonin/NNP (r_compound) inhibitors/NNS (l_appos) paranoia/NN -PUNC- serotonin/NN (r_compound) inhibitors/NNS (r_pobj) with/IN (r_prep) exacerbation/NN (l_amod) paranoid/JJ -PUNC- serotonin/NN (r_compound) inhibitors/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) exacerbations/NNS (l_amod) paranoid/JJ -PUNC- serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) exacerbations/NNS (l_amod) paranoid/JJ -PUNC- serotonin/NN (r_compound) blockers/NNS (r_pobj) with/IN (r_prep) exacerbations/NNS (r_pobj) to/IN (r_prep) call/VBP (l_conj) raise/VB (l_dobj) considerations/NNS (l_acl) regarding/VBG (l_pobj) paranoia/NN
D005473_D010259 CID fluoxetine/NN (r_advmod) cases/NNS (l_prep) of/IN (l_pobj) exacerbation/NN (l_amod) paranoid/JJ
D000639_D010259 CID amitriptyline/NN (r_conj) fluoxetine/NN (r_advmod) cases/NNS (l_prep) of/IN (l_pobj) exacerbation/NN (l_amod) paranoid/JJ
15859361
C105934_D003875 NONE celecoxib/NN (r_pobj) of/IN (r_prep) Safety/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) reactions/NNS -PUNC- CE/NNP (r_pobj) of/IN (r_prep) tolerability/NN (r_dobj) evaluated/VBD (l_prep) in/IN (l_pobj) group/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) history/NN (l_prep) of/IN (l_pobj) reactions/NNS
D000082_D004342 NONE P/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN -PUNC- P/NN (r_nmod) patients/NNS (r_pobj) among/IN (r_prep) documented/VBN (l_nsubjpass) reaction/NN (l_compound) hypersensitivity/NN
C012655_D004342 NONE N/NN (r_conj) P/NN (r_pobj) to/IN (r_prep) hypersensitivity/NN -PUNC- N/NN (r_conj) P/NN (r_nmod) patients/NNS (r_pobj) among/IN (r_prep) documented/VBN (l_nsubjpass) reaction/NN (l_compound) hypersensitivity/NN
C012655_D003875 CID nimesulide/NN (r_conj) paracetamol/NNP (r_appos) reactions/NNS -PUNC- N/NNP (r_conj) P/NN (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- N/NN (r_npadvmod) induced/VBN (r_conj) P/NN (r_nmod) reactions/NNS
C105934_D004342 NONE CE/NNP (r_pobj) to/IN (r_prep) reaction/NN (l_compound) hypersensitivity/NN
D000082_D003875 CID acetaminophen/RB (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- paracetamol/NNP (r_appos) reactions/NNS -PUNC- P/NN (r_pobj) to/IN (r_prep) reactions/NNS -PUNC- P/NN (r_nmod) reactions/NNS
20129423
D002220_D004802 CID carbamazepine/NN (r_nsubj) induced/VBD (l_dobj) hypersensitivity/NN (l_amod) eosinophilic/JJ
D002220_D009205 CID carbamazepine/NN (r_nsubj) induced/VBD (l_dobj) hypersensitivity/NN (l_amod) myocarditis/NN -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) necrotizing/VBG (l_oprd) myocarditis/NN -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) secondary/JJ (l_advmod) myocarditis/NN -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) case/NN (l_acl) induced/VBN (l_dobj) myocarditis/NN
D002220_D004342 CID carbamazepine/NN (r_nsubj) induced/VBD (l_dobj) hypersensitivity/NN -PUNC- carbamazepine/NN (r_nsubj) induced/VBD (l_dobj) hypersensitivity/NN (l_appos) emphasis/NN (l_prep) on/IN (l_pobj) characteristics/NNS (l_prep) of/IN (l_pobj) hypersensitivity/NN -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) necrotizing/VBG (l_oprd) myocarditis/NN (l_nmod) hypersensitivity/NN -PUNC- carbamazepine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) hypersensitivity/NN
6310832
D001379_D007239 CID Aza/NNP (r_compound) patients/NNS (r_nsubj) had/VBD (l_dobj) infections/NNS -PUNC- Aza/NNP (r_compound) patients/NNS (r_nsubj) had/VBD (l_dobj) infections/NNS (l_appos) P/NN (l_conj) infections/NNS -PUNC- Aza/NNP (r_nmod) patients/NNS (r_pobj) than/IN (r_prep) infections/NNS (r_conj) infections/NNS -PUNC- Aza/NNP (r_nmod) patients/NNS (r_pobj) than/IN (r_prep) infections/NNS -PUNC- Aza/NNP (r_conj) cyclosporine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) deaths/NNS (r_attr) were/VBD (l_conj) played/VBD (l_nsubj) infection/NN -PUNC- Aza/NNP (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) than/IN (r_prep) were/VBD (l_nsubj) infections/NNS
D016572_D016470 NONE cyclosporine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_nsubj) had/VBD (l_dobj) bacteremias/NNS
D016572_D007239 CID cyclosporine/NN (r_pobj) on/IN (r_prep) recipients/NNS (r_conj) heart/NN (r_conj) kidney/NN (r_pobj) in/IN (r_prep) infections/NNS -PUNC- cyclosporine/NN (r_compound) patients/NNS (r_pobj) than/IN (r_prep) had/VBD (l_dobj) infections/NNS -PUNC- cyclosporine/NN (r_compound) patients/NNS (r_pobj) than/IN (r_prep) had/VBD (l_dobj) infections/NNS (l_appos) P/NN (l_conj) infections/NNS -PUNC- cyclosporine/JJ (r_nmod) patients/NNS (r_pobj) than/IN (r_prep) infections/NNS -PUNC- cyclosporine/JJ (r_nmod) patients/NNS (r_pobj) than/IN (r_prep) infections/NNS (l_conj) infections/NNS -PUNC- cyclosporine/NN (r_pobj) on/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) deaths/NNS (r_attr) were/VBD (l_conj) played/VBD (l_nsubj) infection/NN -PUNC- cyclosporine/NN (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) were/VBD (l_nsubj) infections/NNS
D016572_D003586 NONE cyclosporine/JJ (r_compound) patients/NNS (r_pobj) Of/IN (r_prep) %/NN (r_nsubj) had/VBD (l_dobj) symptoms/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) infection/NN
D001379_D009181 NONE Aza/NNP (r_compound) patients/NNS (r_nsubj) had/VBD (l_conj) occurred/VBD (l_nsubj) infections/NNS
D001379_D013203 NONE Aza/NNP (r_compound) patients/NNS (r_nsubj) had/VBD (l_dobj) infections/NNS
D016572_D020031 NONE cyclosporine/NN (r_compound) patients/NNS (r_pobj) of/IN (r_prep) %/NN (r_pobj) in/IN (r_prep) found/VBN (l_nsubjpass) evidence/NN (l_prep) for/IN (l_pobj) infection/NN
1563460
D014859_D020758 CID coumadin/NN (r_amod) therapy/NN (r_pobj) to/IN (r_prep) hematomyelia/NNS
439781
D007213_D007022 CID Indomethacin/NNP (r_nsubj) induced/VBD (l_dobj) hypotension/NN
D012964_D007022 NONE sodium/NN (r_npadvmod) depleted/VBN (r_amod) rats/NNS (r_dobj) induced/VBD (l_dobj) hypotension/NN
15321332
D004329_D001008 CID droperidol/NN (r_pobj) due/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) anxiety/NN -PUNC- droperidol/NN (r_npadvmod) induced/VBN (r_amod) disturbance/NN
23949582
D015080_D030342 NONE Mesna/NNP (r_nsubj) reduces/VBZ (l_dobj) genotoxicity/NN
D007069_D030342 NONE IFO/NNP (r_poss) genotoxicity/NN
24684312
D002211_D006930 CID capsaicin/NN (r_compound) injections/NNS (r_conj) glutamate/NN (l_appos) variability/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- capsaicin/NN (r_compound) injections/NNS (r_conj) glutamate/NN (l_appos) variability/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- capsaicin/NN (r_conj) glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_advcl) mimic/VBP (l_nsubj) hyperalgesia/NN -PUNC- capsaicin/NN (r_conj) glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_advcl) mimic/VBP (l_nsubj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- capsaicin/NN (r_pobj) For/IN (r_prep) detected/VBN (l_nsubjpass) hyperalgesia/NN -PUNC- Capsaicin/NN (r_compound) injection/NN (r_nsubj) was/VBD (l_acomp) reproducible/JJ (l_prep) for/IN (l_pobj) hyperalgesia/NN -PUNC- Capsaicin/NN (r_compound) injection/NN (r_nsubj) was/VBD (l_attr) allodynia/NN -PUNC- capsaicin/NN (r_conj) glutamate/NN (r_nmod) yield/NN (r_nmod) responses/NNS (l_amod) hyperalgesic/JJ -PUNC- capsaicin/NN (r_conj) glutamate/NN (r_nmod) yield/NN (r_nmod) responses/NNS (l_amod) hyperalgesic/JJ (l_conj) allodynic/JJ
D002211_D013001 NONE capsaicin/NN (r_conj) glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_advcl) mimic/VBP (l_dobj) aspects/NNS (l_prep) of/IN (l_pobj) disorders/NNS
D018698_D006930 NONE glutamate/NN (l_appos) variability/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- glutamate/NN (l_appos) variability/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_advcl) mimic/VBP (l_nsubj) hyperalgesia/NN -PUNC- glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_advcl) mimic/VBP (l_nsubj) hyperalgesia/NN (l_conj) allodynia/NN -PUNC- glutamate/NN (r_compound) injection/NN (r_pobj) after/IN (r_prep) gauges/VBZ (r_pobj) to/IN (r_prep) response/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) as/IN (r_prep) observed/VBN (l_nsubjpass) hyperalgesia/NN -PUNC- glutamate/NN (r_nmod) yield/NN (r_nmod) responses/NNS (l_amod) hyperalgesic/JJ -PUNC- glutamate/NN (r_nmod) yield/NN (r_nmod) responses/NNS (l_amod) hyperalgesic/JJ (l_conj) allodynic/JJ
D002211_D010146 NONE capsaicin/NN (r_conj) glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_acomp) attractive/JJ (l_xcomp) use/VB (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D018698_D010146 NONE glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_acomp) attractive/JJ (l_xcomp) use/VB (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D018698_D013001 NONE glutamate/NN (r_pobj) of/IN (r_prep) injections/NNS (r_nsubj) are/VBP (l_advcl) mimic/VBP (l_dobj) aspects/NNS (l_prep) of/IN (l_pobj) disorders/NNS
44072
C024986_D001145 CID BaCl2/NN (r_pobj) with/IN (r_prep) used/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN -PUNC- BaCl2/NN (r_pobj) with/IN (r_conj) in/IN (r_prep) causing/VBG (r_advcl) manifests/VBZ (l_dobj) activity/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN -PUNC- BaCl2/NN (r_pobj) with/IN (r_conj) in/IN (r_prep) causing/VBG (l_dobj) inhibition/NN (l_prep) on/IN (l_pobj) arrhythmia/NN
D004837_D001145 CID adrenaline/NN (r_pobj) with/IN (r_conj) with/IN (r_prep) used/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN -PUNC- adrenaline/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) arrhythmia/NN (r_pobj) on/IN (r_prep) inhibition/NN (r_dobj) causing/VBG (r_advcl) manifests/VBZ (l_dobj) activity/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN -PUNC- adrenaline/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) arrhythmia/NN
D010042_D001145 CID G/NN (r_pobj) with/IN (r_prep) used/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN
D002725_D001145 CID chloroform/NN (r_compound) adrenaline/NN (r_pobj) with/IN (r_conj) with/IN (r_prep) used/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN -PUNC- chloroform/NN (r_compound) adrenaline/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) arrhythmia/NN (r_pobj) on/IN (r_prep) inhibition/NN (r_dobj) causing/VBG (r_advcl) manifests/VBZ (l_dobj) activity/NN (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN -PUNC- chloroform/NN (r_compound) adrenaline/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) arrhythmia/NN
D000157_D001145 CID aconitine/NN (r_pobj) with/IN (r_conj) with/IN (r_prep) used/VBN (l_nsubjpass) types/NNS (l_prep) of/IN (l_pobj) arrhythmia/NN
10986547
C076029_D001714 NONE olanzapine/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) mania/NN -PUNC- olanzapine/NN (r_pobj) of/IN (r_prep) efficacy/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) mania/NN -PUNC- olanzapine/NN (r_xcomp) randomized/VBN (l_nsubjpass) total/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) disorder/NN -PUNC- olanzapine/NN (r_xcomp) randomized/VBN (l_nsubjpass) total/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) disorder/NN (l_amod) manic/JJ -PUNC- Olanzapine/NNP (r_nsubj) demonstrated/VBD (l_dobj) efficacy/NN (l_prep) than/IN (l_pobj) placebo/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) mania/NN
C076029_D006970 CID olanzapine/RB (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_nsubj) had/VBD (l_dobj) mean/JJ (l_appos) gain/NN (l_conj) experienced/VBD (l_dobj) somnolence/NN
C076029_D015430 CID olanzapine/RB (r_npadvmod) treated/VBN (r_amod) patients/NNS (r_nsubj) had/VBD (l_dobj) mean/JJ (l_appos) gain/NN
12699527
D013390_D013035 CID suxamethonium/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) spasm/NN
D002712_D009224 NONE chloride/NN (r_compound) channel/NN (r_compound) function/NN (r_pobj) in/IN (r_prep) defect/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) congenita/NN -PUNC- chloride/NN (r_compound) channel/NN (r_compound) function/NN (r_pobj) in/IN (r_prep) defect/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) congenita/NN (l_appos) MC/NNP
D002712_-1 NONE chloride/NN (r_compound) channel/NN (r_compound) function/NN (r_pobj) in/IN (r_prep) defect/NN (l_relcl) cause/VB (l_dobj) depolarisation/NN
18422462
D000409_D000740 NONE alanine/NN (r_compound) aminotransferase/FW (r_pobj) with/IN (r_prep) jaundice/NN (r_appos) hepatitis/NN (r_nsubj) limits/NNS (r_conj) observed/VBN (l_nsubjpass) anemia/NN
D019829_D010523 NONE NVP/NNP (r_compound) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pcomp) developing/VBG (l_prep) with/IN (l_pcomp) developing/VBG (l_dobj) neuropathy/NN
D018119_D010523 CID T/NN (r_compound) therapy/NN (r_conj) developing/VBG (l_prep) with/IN (l_pcomp) developing/VBG (l_dobj) neuropathy/NN
D000409_D056486 NONE alanine/NN (r_compound) aminotransferase/FW (r_pobj) with/IN (r_prep) jaundice/NN (r_appos) hepatitis/NN
D000409_D007565 NONE alanine/NN (r_compound) aminotransferase/FW (r_pobj) with/IN (r_prep) jaundice/NN
D019829_D005076 CID NVP/NNP (r_compound) therapy/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pcomp) developing/VBG (l_dobj) rash/NN
D018119_D005076 NONE T/NN (r_compound) therapy/NN (r_conj) developing/VBG (l_dobj) rash/NN
24190587
D018817_D001008 NONE ecstasy/NN (r_npadvmod) polydrug/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) observations/NNS (r_pobj) with/IN (r_prep) line/NN (r_pobj) in/IN (r_prep) are/VBP (l_nsubj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN
D018817_D003866 CID ecstasy/NN (r_npadvmod) polydrug/NN (r_compound) users/NNS (r_pobj) in/IN (r_prep) observations/NNS (r_pobj) with/IN (r_prep) line/NN (r_pobj) in/IN (r_prep) are/VBP (l_nsubj) increases/NNS (l_prep) in/IN (l_pobj) anxiety/NN (l_conj) depression/NN
D018817_D008107 NONE Ecstasy/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) dysfunction/NN -PUNC- MDMA/NNP (r_appos) Ecstasy/NNP (r_nsubj) is/VBZ (l_attr) drug/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) dysfunction/NN
17828434
C002647_D012640 NONE MIP/NNP (r_compound) inhibition/NN (r_nsubj) replicate/VB (l_conj) augment/VB (l_dobj) effects/NNS (l_prep) in/IN (l_pobj) model/NN (l_compound) seizures/NNS
D008094_D012640 NONE lithium/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) model/NN (l_compound) seizures/NNS
D007294_D012640 NONE inositol/JJ (r_npadvmod) sensitive/JJ (r_amod) model/NN (l_compound) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS
19293073
D001241_D006470 NONE aspirin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) for/IN (l_pobj) events/NNS (l_compound) bleeding/NN -PUNC- Aspirin/NNP (r_compound) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) for/IN (l_pobj) events/NNS (l_compound) bleeding/NN
D001241_D020521 CID aspirin/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) infarctions/NNS (l_conj) strokes/NNS -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) reviews/NNS (r_conj) analyses/NNS (r_conj) studies/NNS (r_conj) trials/NNS (r_nsubjpass) selected/VBN (r_ccomp) decrease/NN (l_dobj) events/NNS (l_conj) strokes/NNS -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) reviews/NNS (r_conj) analyses/NNS (r_conj) studies/NNS (r_conj) trials/NNS (r_nsubjpass) selected/VBN (r_ccomp) decrease/NN (l_dobj) events/NNS (l_conj) strokes/NNS (l_conj) death/NN (l_prep) from/IN (l_pobj) events/NNS (l_conj) stroke/NN -PUNC- aspirin/NN (r_nsubj) decrease/NN (l_dobj) events/NNS (l_conj) strokes/NNS -PUNC- aspirin/NN (r_nsubj) decrease/NN (l_dobj) events/NNS (l_conj) strokes/NNS (l_conj) death/NN (l_prep) from/IN (l_pobj) events/NNS (l_conj) stroke/NN -PUNC- aspirin/NN (r_nsubj) increase/VB (l_dobj) strokes/NNS -PUNC- aspirin/JJ (r_compound) use/NN (r_pobj) with/IN (r_prep) strokes/NNS -PUNC- Aspirin/NNP (r_nsubj) reduces/VBZ (l_dobj) risk/NN (l_prep) for/IN (l_pobj) infarction/NN (l_prep) in/IN (l_pobj) men/NNS (l_conj) strokes/NNS
D001241_D006471 CID aspirin/NN (r_nsubj) increase/VB (l_dobj) strokes/NNS (l_nmod) bleeding/NN -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubj) increases/VBZ (l_dobj) risk/NN (l_prep) for/IN (l_pobj) events/NNS (l_appos) events/NNS (l_compound) bleeding/NN
D001241_D003327 NONE aspirin/NN (r_dobj) discuss/VB (l_prep) with/IN (l_pobj) adults/NNS (l_relcl) are/VBP (l_prep) at/IN (l_pobj) risk/NN (l_prep) for/IN (l_pobj) disease/NN
D001241_D009203 NONE aspirin/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) infarctions/NNS -PUNC- Aspirin/NNP (r_nsubj) reduces/VBZ (l_dobj) risk/NN (l_prep) for/IN (l_pobj) infarction/NN
D001241_D002318 NONE aspirin/NN (r_pobj) of/IN (r_prep) reviews/NNS (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) reviews/NNS (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) CVD/NN -PUNC- aspirin/NN (r_pobj) of/IN (r_prep) reviews/NNS (r_conj) analyses/NNS (r_conj) studies/NNS (r_conj) trials/NNS (r_nsubjpass) selected/VBN (r_ccomp) decrease/NN (l_dobj) events/NNS (l_conj) strokes/NNS (l_conj) death/NN (l_conj) mortality/NN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) without/IN (l_pobj) CVD/NN -PUNC- aspirin/NN (r_nsubj) decrease/NN (l_ccomp) selected/VBN (l_nsubjpass) trials/NNS (l_conj) studies/NNS (l_conj) analyses/NNS (l_conj) reviews/NNS (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- aspirin/NN (r_nsubj) decrease/NN (l_ccomp) selected/VBN (l_nsubjpass) trials/NNS (l_conj) studies/NNS (l_conj) analyses/NNS (l_conj) reviews/NNS (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) disease/NN (l_appos) CVD/NN -PUNC- aspirin/NN (r_nsubj) decrease/NN (l_dobj) events/NNS (l_conj) strokes/NNS (l_conj) death/NN (l_conj) mortality/NN (l_prep) in/IN (l_pobj) adults/NNS (l_prep) without/IN (l_pobj) CVD/NN -PUNC- aspirin/JJ (r_compound) use/NN (r_nsubj) reduces/VBZ (l_dobj) number/NN (l_prep) of/IN (l_pobj) events/NNS (l_compound) CVD/NN -PUNC- aspirin/JJ (r_compound) use/NN (r_nsubj) reduces/VBZ (l_dobj) number/NN (l_prep) of/IN (l_pobj) events/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) without/IN (l_pobj) CVD/NNP -PUNC- Aspirin/NNP (r_nsubj) seem/VB (l_xcomp) affect/VB (l_dobj) mortality/NN (l_compound) CVD/NN -PUNC- aspirin/NN (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) CVD/NNP
D001241_D020300 CID aspirin/NN (r_nsubj) increase/VB (l_dobj) strokes/NNS -PUNC- aspirin/JJ (r_compound) use/NN (r_pobj) with/IN (r_prep) strokes/NNS
19841052
D016578_D006679 CID cocaine/NN (r_pobj) of/IN (r_prep) smokers/NNS (r_pobj) among/IN (r_prep) seroconversion/NN -PUNC- cocaine/NN (r_dobj) crack/VB (r_pcomp) of/IN (r_prep) smokers/NNS (r_attr) were/VBD (r_relcl) participants/NNS (r_pobj) among/IN (r_prep) seroconversion/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) Smoking/NN (r_nsubjpass) found/VBN (l_xcomp) be/VB (l_attr) factor/NN (l_prep) for/IN (l_pobj) seroconversion/NN
D016578_D015658 NONE cocaine/NN (r_dobj) crack/VB (l_prep) as/IN (l_pobj) factor/NN (l_prep) for/IN (l_pobj) infection/NN -PUNC- cocaine/NN (r_dobj) crack/VBP (r_relcl) role/NN (l_acl) has/VBZ (l_prep) on/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) infection/NN -PUNC- cocaine/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) Given/VBN (r_prep) sought/VBD (l_xcomp) examine/VB (l_ccomp) become/VBN (l_attr) factor/NN (l_prep) for/IN (l_pobj) infection/NN
19139825
D019772_D005910 NONE Topotecan/NNP (r_nsubj) is/VBZ (l_advcl) exhibits/VBZ (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) glioma/NN
D019772_D005909 NONE Topotecan/JJ (l_prep) in/IN (l_pobj) combination/NN (l_prep) with/IN (l_pobj) radiotherapy/NN (l_prep) in/IN (l_pobj) glioblastoma/NN -PUNC- topotecan/JJ (l_prep) in/IN (l_pobj) adults/NNS (l_prep) with/IN (l_pobj) GBM/NNP
16906379
D008911_D005334 NONE minocycline/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) fever/NN
D008911_D013733 NONE minocycline/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) fever/NN (l_conj) myalgias/NNS (l_conj) polyneuropathy/VBP (l_conj) pain/NN
D008911_D011565 NONE minocycline/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) fever/NN (l_nmod) pustulosis/NN
D008911_D063806 NONE minocycline/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) fever/NN (l_conj) myalgias/NNS
D008911_D010488 CID Minocycline/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN (l_acl) fulfilling/VBG (l_dobj) criteria/NNS (l_prep) of/IN (l_pobj) nodosa/NN
D008911_D014657 NONE Minocycline/NNP (r_npadvmod) induced/VBN (r_amod) vasculitis/NN -PUNC- minocycline/NN (r_npadvmod) induced/VBN (r_amod) vasculitis/NN
D008911_D011115 NONE minocycline/NN (r_dobj) taking/VBG (l_prep) for/IN (l_pobj) fever/NN (l_conj) myalgias/NNS (l_conj) polyneuropathy/VBP
17879100
D007052_D005334 NONE ibuprofen/NN (r_dobj) took/VBD (l_prep) for/IN (l_pobj) fever/NN
D001241_D005334 NONE aspirin/JJ (r_pobj) on/IN (r_prep) put/VBN (l_conj) took/VBD (l_prep) for/IN (l_pobj) fever/NN
1423336
D007980_D007022 CID levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) hypotensive/JJ -PUNC- levodopa/NN (r_pobj) with/IN (r_prep) competing/VBG (r_advcl) reduced/VBD (l_dobj) effects/NNS (l_amod) hypotensive/JJ -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hypotensive/JJ -PUNC- levodopa/NN (r_nsubj) has/VBZ (l_dobj) action/NN (l_amod) hypotensive/JJ
D007980_D010300 NONE levodopa/NN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) parkinsonian/JJ -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) parkinsonian/JJ -PUNC- levodopa/VB (r_advcl) examined/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_amod) parkinsonian/JJ
D010649_D007022 NONE Phenylalanine/NNP (r_nsubj) competing/VBG (r_advcl) reduced/VBD (l_dobj) effects/NNS (l_amod) hypotensive/JJ
D000596_D007022 NONE acid/NN (r_appos) Phenylalanine/NNP (r_nsubj) competing/VBG (r_advcl) reduced/VBD (l_dobj) effects/NNS (l_amod) hypotensive/JJ
3109094
D003520_D004487 NONE cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN (r_nsubjpass) characterized/VBN (l_dobj) edema/NN
D003520_D009336 NONE cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN (r_nsubjpass) characterized/VBN (l_dobj) edema/NN (l_acl) owing/VBG (l_prep) to/IN (l_pobj) damage/NN (l_prep) to/IN (l_pobj) bed/NN (l_conj) necroses/NNS
D003520_D001745 CID cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) lesions/NNS (l_prep) of/IN (l_pobj) bladder/NN
D015080_D001745 NONE mesna/NN (r_pobj) by/IN (r_prep) prevention/NN (r_conj) lesions/NNS (l_prep) of/IN (l_pobj) bladder/NN
D003520_D003556 NONE cyclophosphamide/NN (r_npadvmod) induced/VBN (r_amod) cystitis/NN
10764869
D016559_D009901 CID tacrolimus/NN (r_pobj) on/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) neuropathy/NN -PUNC- FK506/NNP (r_appos) tacrolimus/NN (r_pobj) on/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) neuropathy/NN -PUNC- tacrolimus/NN (r_dobj) receiving/NN (r_acl) patient/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) neuropathy/NN -PUNC- 506/CD (r_nummod) FK/NNP (r_appos) tacrolimus/NN (r_dobj) receiving/NN (r_acl) patient/NN (r_pobj) in/IN (r_prep) case/NN (l_prep) of/IN (l_pobj) neuropathy/NN -PUNC- Tacrolimus/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) toxicity/NN
D016559_D015354 NONE tacrolimus/NN (r_pobj) of/IN (r_prep) discontinuation/NN (r_pobj) despite/IN (r_prep) occurred/VBD (l_nsubj) Deterioration/NN (l_prep) of/IN (l_pobj) vision/NN
9725303
D019469_D052878 NONE indinavir/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) describe/VBP (l_dobj) inhibitor/NN (l_relcl) associated/VBN (l_prep) with/IN (l_pobj) incidence/NN (l_prep) of/IN (l_pobj) urolithiasis/NN
D019469_D015658 NONE indinavir/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (l_amod) infected/VBN -PUNC- indinavir/NNS (r_compound) therapy/NN (r_dobj) receive/VBP (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) infection/NN
D019469_D014514 CID indinavir/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) describe/VBP (l_dobj) features/NNS (l_prep) of/IN (l_pobj) calculi/NNS -PUNC- indinavir/NNS (r_compound) therapy/NN (r_dobj) receive/VBP (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) stones/NNS (l_conj) obstruction/NN
D019469_D014517 NONE indinavir/NNS (r_compound) therapy/NN (r_dobj) undergoing/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) causing/VBG (l_dobj) obstruction/NN -PUNC- indinavir/JJ (r_compound) crystals/NNS (r_pobj) by/IN (r_agent) caused/VBN (r_acl) obstruction/NN -PUNC- indinavir/NNS (r_compound) therapy/NN (r_dobj) receive/VBP (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) stones/NNS (l_conj) obstruction/NN
1280707
D002045_D001145 CID bupivacaine/NN (r_dobj) determining/VBG (r_pcomp) After/IN (r_prep) determined/VBD (l_punct) (/-LRB- (l_preconj) concentration/NN (l_relcl) caused/VBD (l_dobj) %/NN (l_prep) of/IN (l_pcomp) beating/VBG (l_advcl) become/VB (l_acomp) arrhythmic/JJ -PUNC- bupivacaine/NN (r_pobj) of/IN (r_prep) concentration/NN (l_relcl) caused/VBD (l_dobj) %/NN (l_prep) of/IN (l_pcomp) beating/VBG (l_advcl) become/VB (l_acomp) arrhythmic/JJ -PUNC- bupivacaine/NN (r_compound) arrhythmia/NN
D006851_D001145 NONE HCl/NN (r_compound) exposure/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) determined/VBD (l_punct) (/-LRB- (l_preconj) concentration/NN (l_relcl) caused/VBD (l_dobj) %/NN (l_prep) of/IN (l_pcomp) beating/VBG (l_advcl) become/VB (l_acomp) arrhythmic/JJ
D011374_D001145 CID progesterone/NN (r_compound) HCl/NN (r_compound) exposure/NN (r_pobj) of/IN (r_prep) effect/NN (r_dobj) determined/VBD (l_punct) (/-LRB- (l_preconj) concentration/NN (l_relcl) caused/VBD (l_dobj) %/NN (l_prep) of/IN (l_pcomp) beating/VBG (l_advcl) become/VB (l_acomp) arrhythmic/JJ
24742750
D015283_D016171 CID Citalopram/NNP (r_conj) Terfenadine/NNP (r_appos) blockers/NNS (l_relcl) reported/VBN (l_xcomp) cause/VB (l_ccomp) produced/VBD (l_nsubj) Pointes/NNP -PUNC- Citalopram/NNP (r_conj) Terfenadine/NNP (r_appos) blockers/NNS (l_relcl) reported/VBN (l_xcomp) cause/VB (l_ccomp) produced/VBD (l_nsubj) Pointes/NNP (l_appos) TdP/NNP
D016593_D016171 CID Terfenadine/NNP (r_appos) blockers/NNS (l_relcl) reported/VBN (l_xcomp) cause/VB (l_ccomp) produced/VBD (l_nsubj) Pointes/NNP -PUNC- Terfenadine/NNP (r_appos) blockers/NNS (l_relcl) reported/VBN (l_xcomp) cause/VB (l_ccomp) produced/VBD (l_nsubj) Pointes/NNP (l_appos) TdP/NNP
24641119
D007654_D003875 CID ketoconazole/RB (r_dobj) using/VBG (r_pcomp) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) eruption/NN
D007654_-1 NONE ketoconazole/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) syndrome/NN -PUNC- ketoconazole/NN (r_pobj) to/IN (r_prep) sensitivity/NN (r_dobj) included/VBD (r_relcl) history/NN (r_pobj) on/IN (r_prep) based/VBN (r_acl) syndrome/NN -PUNC- ketoconazole/RB (r_npadvmod) induced/VBN (r_amod) syndrome/NN
16731636
D007545_D006332 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) hypertrophy/NN -PUNC- Iso/NNP (r_compound) treatment/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) hypertrophy/NN
17954033
D019259_D019694 NONE lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (l_prep) with/IN (l_pobj) infection/NN -PUNC- Lamivudine/NNP (r_nsubjpass) used/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (l_prep) with/IN (l_pobj) B/NNP -PUNC- lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) mutants/NNS (r_pobj) of/IN (r_prep) occurrence/NN (r_nsubjpass) reported/VBN (r_advcl) detected/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_compound) B/NNP -PUNC- lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) detected/VBN (l_advcl) reported/VBN (l_nsubjpass) occurrence/NN (l_prep) of/IN (l_pobj) mutants/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) B/NNP -PUNC- lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (l_compound) B/NNP
D019259_D006509 NONE lamivudine/NN (r_npadvmod) untreated/VBN (r_amod) patients/NNS (r_pobj) in/IN (r_prep) variability/NN (r_pobj) as/IN (r_prep) occur/VBP (l_nsubj) mutants/NNS (l_appos) virus/NN (l_compound) B/NNP
24088636
C098010_D014786 NONE linezolid/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) vision/NN -PUNC- linezolid/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_prep) was/VBD (r_relcl) patient/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) loss/NN (l_prep) of/IN (l_pobj) vision/NN
D004977_D014786 NONE ethambutol/NN (r_conj) linezolid/NN (r_pobj) including/VBG (r_prep) drugs/NNS (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) on/IN (r_prep) was/VBD (r_relcl) patient/NN (r_nsubj) presented/VBN (l_prep) with/IN (l_pobj) loss/NN (l_prep) of/IN (l_pobj) vision/NN
D004977_D015354 NONE ethambutol/NN (r_pobj) of/IN (r_prep) withdrawal/NN (r_pobj) despite/IN (r_prep) occurred/VBD (l_nsubj) Deterioration/NN (l_prep) of/IN (l_pobj) vision/NN
C098010_D054908 NONE linezolid/NN (l_conj) ethambutol/NN (l_prep) for/IN (l_pobj) tuberculosis/NN -PUNC- linezolid/NN (l_conj) ethambutol/NN (l_prep) for/IN (l_pobj) tuberculosis/NN (l_appos) TB/NNP
C098010_D009901 CID Linezolid/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN
D004977_D054908 NONE ethambutol/NN (l_prep) for/IN (l_pobj) tuberculosis/NN -PUNC- ethambutol/NN (l_prep) for/IN (l_pobj) tuberculosis/NN (l_appos) TB/NNP
D004977_D009901 NONE Ethambutol/NNP (r_npadvmod) induced/VBN (r_amod) neuropathy/NN -PUNC- ethambutol/NN (r_nsubjpass) withdrawn/VBN (r_conj) suspected/VBN (l_nsubjpass) neuropathy/NN
20927253
D004164_D010024 NONE bisphosphonates/NNS (r_nsubjpass) used/VBN (r_conj) caused/VBN (l_nsubjpass) Osteoporosis/NN -PUNC- bisphosphonate/NN (r_npadvmod) related/VBN (r_amod) pain/NN (r_nsubjpass) considered/VBN (r_conj) report/VB (l_nsubj) patients/NNS (l_prep) with/IN (l_pobj) osteoporosis/NN -PUNC- bisphosphonate/NN (r_npadvmod) related/VBN (r_amod) pain/NN (r_nsubjpass) considered/VBN (l_prep) before/IN (l_pcomp) ascribing/VBG (l_prep) to/IN (l_pobj) osteoporosis/NN
-1_D010024 NONE biphosphonate/NN (r_appos) Alendronate/NNP (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) osteoporosis/NN
D019386_D010146 CID alendronate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) pain/NN -PUNC- alendronate/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) admitted/VBN (l_prep) with/IN (l_pobj) pain/NN
D019386_D010024 NONE Alendronate/NNP (r_nsubj) is/VBZ (l_acomp) effective/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) osteoporosis/NN
D004164_D010146 NONE bisphosphonate/NN (r_npadvmod) related/VBN (r_amod) pain/NN (r_nsubjpass) considered/VBN (r_conj) report/VB (l_dobj) pain/NN -PUNC- bisphosphonate/NN (r_npadvmod) related/VBN (r_amod) pain/NN
20192893
D003287_D007674 CID medium/NN (r_amod) nephrotoxicity/NN -PUNC- medium/NN (r_amod) CM/NNP (r_nmod) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) dysfunction/NN -PUNC- CM/NNP (r_nmod) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) dysfunction/NN -PUNC- CM/NNP (r_pobj) of/IN (r_prep) effect/NN (l_amod) nephrotoxic/JJ -PUNC- CM/NNP (r_compound) administration/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) damage/NN
D003287_D064420 NONE CM/NNP (r_compound) toxicity/NN
17069550
D005702_D019958 NONE galantamine/NN (r_nsubj) was/VBD (l_conj) appeared/VBD (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pcomp) interfering/VBG (l_dobj) behaviors/NNS (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) autism/NN (l_appos) aggression/NN (l_conj) dyscontrol/NN (l_conj) inattention/NN
D005702_D001523 NONE galantamine/NN (r_nsubj) was/VBD (l_conj) appeared/VBD (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pcomp) interfering/VBG (l_dobj) behaviors/NNS (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) autism/NN (l_appos) aggression/NN
D005702_D001321 NONE galantamine/NN (r_pobj) of/IN (r_prep) trial/NN (l_prep) in/IN (l_pobj) disorder/NN -PUNC- galantamine/NN (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pcomp) interfering/VBG (l_dobj) behaviors/NNS (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) autism/NN -PUNC- galantamine/NN (r_pobj) of/IN (r_prep) trial/NN (r_pobj) in/IN (r_prep) participated/VBD (l_nsubj) children/NNS (l_prep) with/IN (l_pobj) autism/NN -PUNC- galantamine/NN (r_nsubj) was/VBD (l_conj) appeared/VBD (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pcomp) interfering/VBG (l_dobj) behaviors/NNS (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) autism/NN
D005702_D002653 NONE galantamine/NN (r_nsubj) was/VBD (l_conj) appeared/VBD (l_xcomp) be/VB (l_acomp) beneficial/JJ (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pcomp) interfering/VBG (l_dobj) behaviors/NNS (l_prep) in/IN (l_pobj) children/NNS (l_prep) with/IN (l_pobj) autism/NN (l_appos) aggression/NN (l_conj) dyscontrol/NN
D005702_D006261 CID galantamine/NN (r_nsubj) was/VBD (l_prep) with/IN (l_pobj) effects/NNS (l_advmod) apart/RB (l_prep) from/IN (l_pobj) headaches/NNS
1359137
D001971_D005687 NONE bromocriptine/NN (r_nsubjpass) evaluated/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN (l_conj) galactorrhea/NN
D014150_D006966 CID Neuroleptic/RB (r_npadvmod) associated/VBN (r_amod) hyperprolactinemia/NN -PUNC- neuroleptic/NN (r_npadvmod) associated/VBN (r_amod) hyperprolactinemia/NN
D014150_D000568 CID neuroleptic/NN (r_npadvmod) associated/VBN (r_amod) hyperprolactinemia/NN (l_conj) galactorrhea/NN (l_nmod) amenorrhea/NN
D001971_D011618 CID bromocriptine/NN (r_dobj) taking/VBG (r_advcl) developed/VBN (l_dobj) symptoms/NNS
D001971_D000568 NONE bromocriptine/NN (r_nsubjpass) evaluated/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN (l_conj) galactorrhea/NN (l_nmod) amenorrhea/NN
D001971_D009839 NONE bromocriptine/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) associated/VBN (l_nsubj) oligomenorrhea/NN
D014150_D009839 CID medications/NNS (r_pobj) with/IN (r_prep) associated/VBN (l_nsubj) oligomenorrhea/NN
D001971_D006966 NONE bromocriptine/NN (r_nsubjpass) evaluated/VBN (l_prep) as/IN (l_pobj) therapy/NN (l_prep) for/IN (l_pobj) hyperprolactinemia/NN
D014150_D005687 NONE neuroleptic/NN (r_npadvmod) associated/VBN (r_amod) hyperprolactinemia/NN (l_conj) galactorrhea/NN
35781
D010423_D002375 NONE pentazocine/NN (r_conj) fentanyl/NN (r_conj) codeine/NN (r_conj) morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) analgesia/NN (r_pobj) on/IN (r_prep) xylometazoline/NN (r_conj) naphazoline/NN (r_conj) clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ
C009695_D002375 CID xylometazoline/NN (r_conj) naphazoline/NN (r_conj) clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ -PUNC- xylometazoline/NN (r_conj) naphazoline/NN (r_pobj) by/IN (r_prep) decreased/VBD (r_conj) increased/VBN (l_nsubjpass) catalepsy/NN
D009020_D002375 CID morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) analgesia/NN (r_pobj) on/IN (r_prep) xylometazoline/NN (r_conj) naphazoline/NN (r_conj) clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ -PUNC- morphine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) cataleptic/JJ -PUNC- morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D005283_D002375 CID fentanyl/NN (r_conj) codeine/NN (r_conj) morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) analgesia/NN (r_pobj) on/IN (r_prep) xylometazoline/NN (r_conj) naphazoline/NN (r_conj) clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ -PUNC- fentanyl/NN (r_conj) codine/NN (r_conj) morphine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) cataleptic/JJ -PUNC- fentanyl/NN (r_conj) morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) catalepsy/NN
D009638_D002375 NONE NA/NNP (r_compound) receptors/NNS (r_dobj) stimulating/VBG (r_acl) drugs/NNS (r_nsubj) failed/VBD (l_conj) enhanced/VBD (l_dobj) catalepsy/NN
D009278_D002375 CID naphazoline/NN (r_conj) clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ -PUNC- naphazoline/NN (r_pobj) by/IN (r_prep) decreased/VBD (r_conj) increased/VBN (l_nsubjpass) catalepsy/NN
D003000_D002375 CID clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ -PUNC- clonidine/NN (r_pobj) by/IN (r_agent) increased/VBN (l_nsubjpass) catalepsy/NN
D003061_D002375 CID codeine/NN (r_conj) morphine/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) analgesia/NN (r_pobj) on/IN (r_prep) xylometazoline/NN (r_conj) naphazoline/NN (r_conj) clonidine/NN (r_pobj) of/IN (l_conj) on/IN (l_pobj) effect/NN (l_amod) cataleptic/JJ -PUNC- codine/NN (r_conj) morphine/NN (r_pobj) of/IN (r_prep) effect/NN (l_amod) cataleptic/JJ -PUNC- Codeine/NNP (r_compound) catalepsy/NN
2710809
C036432_D001919 NONE lactate/NN (r_pobj) of/IN (r_prep) application/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) reaction/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) bradycardia/NN
D009116_D001919 NONE muscarine/NN (r_compound) receptors/NNS (r_pobj) on/IN (r_prep) effect/NN (r_pobj) to/IN (r_conj) to/IN (r_prep) attributed/VBN (l_nsubjpass) Bradycardia/NNS
D001285_D001919 NONE atropine/NN (r_npadvmod) like/JJ (r_amod) drugs/NNS (r_pobj) of/IN (r_prep) effect/NN (r_pobj) to/IN (r_conj) to/IN (r_prep) attributed/VBN (l_nsubjpass) Bradycardia/NNS
C036432_D003680 NONE lactate/NN (r_pobj) of/IN (r_prep) application/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) reaction/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) bradycardia/NN (l_conj) dysarthria/NN (l_conj) dysphagia/NN
C036432_D014277 NONE lactate/NN (r_pobj) of/IN (r_prep) application/NN (r_nsubj) led/VBD (l_prep) In/IN (l_pobj) patient/NN (l_acl) suffering/NN (l_prep) from/IN (l_pobj) neuralgia/NN
C036432_D006562 NONE lactate/NN (r_pobj) of/IN (r_prep) application/NN (r_nsubj) led/VBD (l_prep) In/IN (l_pobj) patient/NN (l_acl) suffering/NN (l_prep) from/IN (l_pobj) neuralgia/NN (l_nmod) postzosteric/JJ
C036432_D004401 NONE lactate/NN (r_pobj) of/IN (r_prep) application/NN (r_nsubj) led/VBD (l_prep) to/IN (l_pobj) reaction/NN (l_acl) characterized/VBN (l_agent) by/IN (l_pobj) bradycardia/NN (l_conj) dysarthria/NN
D001712_D001919 CID biperiden/VBN (l_nsubj) Bradycardia/NNS -PUNC- biperiden/VBN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) Bradycardia/NNS
4082466
D009020_D012640 CID Morphine/NNP (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- sulfate/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) during/IN (r_prep) suffered/VBD (l_prep) from/IN (l_pobj) seizures/NNS -PUNC- morphine/NN (r_pobj) of/IN (r_prep) cessation/NN (r_pobj) after/IN (r_prep) stopped/VBD (r_conj) ruled/VBN (l_nsubjpass) reasons/NNS (l_prep) for/IN (l_pobj) seizures/NNS -PUNC- morphine/NN (r_pobj) of/IN (r_prep) cessation/NN (r_pobj) after/IN (r_prep) stopped/VBD (l_nsubj) convulsions/NNS
11474137
D007501_D006311 NONE iron/NN (r_compound) complexes/NNS (r_nsubj) catalyze/VBP (r_acl) observations/NNS (r_pobj) from/IN (r_prep) deduced/VBN (l_nsubjpass) participation/NN (l_prep) of/IN (l_pobj) species/NNS (l_prep) in/IN (l_pobj) ototoxicity/NN -PUNC- iron/NN (r_compound) complexes/NNS (r_nsubj) catalyze/VBP (l_conj) attenuate/VBP (l_dobj) ototoxicity/NN
D013481_D006311 NONE superoxide/JJ (r_amod) radicals/NNS (r_pobj) of/IN (r_prep) formation/NN (r_dobj) catalyze/VBP (r_acl) observations/NNS (r_pobj) from/IN (r_prep) deduced/VBN (l_nsubjpass) participation/NN (l_prep) of/IN (l_pobj) species/NNS (l_prep) in/IN (l_pobj) ototoxicity/NN -PUNC- superoxide/JJ (r_amod) radicals/NNS (r_pobj) of/IN (r_prep) formation/NN (r_dobj) catalyze/VBP (l_conj) attenuate/VBP (l_dobj) ototoxicity/NN -PUNC- superoxide/NN (r_amod) dismutase/NN (r_pobj) of/IN (r_prep) overexpression/NN (r_nsubj) protect/VB (l_prep) from/IN (l_pobj) ototoxicity/NN -PUNC- superoxide/NN (r_amod) dismutase/NN (r_pobj) of/IN (r_prep) overexpression/NN (r_pobj) by/IN (r_prep) protection/NN (r_nsubj) supports/VBZ (l_dobj) hypothesis/NN (l_acl) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) ototoxicity/NN
D015032_D006311 NONE Zn/NNP (r_compound) superoxide/NN (r_amod) dismutase/NN (r_pobj) of/IN (r_prep) overexpression/NN (r_nsubj) protect/VB (l_prep) from/IN (l_pobj) ototoxicity/NN
D003300_D006311 NONE Cu/NNP (r_nmod) dismutase/NN (r_pobj) of/IN (r_prep) overexpression/NN (r_nsubj) protect/VB (l_prep) from/IN (l_pobj) ototoxicity/NN
D015032_D034381 NONE zinc/NN (r_npadvmod) superoxide/NN (r_amod) dismutase/NN (r_pobj) of/IN (r_prep) Overexpression/NN (r_nsubj) protects/VBZ (l_prep) from/IN (l_pobj) loss/NN
D003300_D034381 NONE copper/NN (r_npadvmod) superoxide/NN (r_amod) dismutase/NN (r_pobj) of/IN (r_prep) Overexpression/NN (r_nsubj) protects/VBZ (l_prep) from/IN (l_pobj) loss/NN
D010100_D006311 NONE oxygen/NN (r_compound) species/NNS (l_prep) in/IN (l_pobj) ototoxicity/NN -PUNC- oxygen/NN (r_compound) species/NNS (r_pobj) of/IN (r_prep) participation/NN (r_nsubjpass) deduced/VBN (l_prep) from/IN (l_pobj) observations/NNS (l_acl) catalyze/VBP (l_conj) attenuate/VBP (l_dobj) ototoxicity/NN
D000617_D006311 NONE aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) ototoxicity/NN -PUNC- aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) ototoxicity/NN (r_pobj) in/IN (r_prep) species/NNS (r_pobj) of/IN (r_prep) participation/NN (r_nsubjpass) deduced/VBN (l_prep) from/IN (l_pobj) observations/NNS (l_acl) catalyze/VBP (l_conj) attenuate/VBP (l_dobj) ototoxicity/NN -PUNC- aminoglycoside/NN (r_compound) iron/NN (r_compound) complexes/NNS (r_nsubj) catalyze/VBP (r_acl) observations/NNS (r_pobj) from/IN (r_prep) deduced/VBN (l_nsubjpass) participation/NN (l_prep) of/IN (l_pobj) species/NNS (l_prep) in/IN (l_pobj) ototoxicity/NN -PUNC- aminoglycoside/NN (r_compound) iron/NN (r_compound) complexes/NNS (r_nsubj) catalyze/VBP (l_conj) attenuate/VBP (l_dobj) ototoxicity/NN -PUNC- aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) ototoxicity/NN
D007612_D034381 CID kanamycin/NN (r_npadvmod) induced/VBN (r_amod) loss/NN
D013481_D034381 NONE superoxide/NN (r_amod) dismutase/NN (r_pobj) of/IN (r_prep) Overexpression/NN (r_nsubj) protects/VBZ (l_prep) from/IN (l_pobj) loss/NN
3798047
D008775_D006331 NONE MP/NNP (r_nsubjpass) contraindicated/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN
D008775_D001919 CID methylprednisolone/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) Bradycardia/NNS
D008775_D001172 NONE methylprednisolone/NN (r_dobj) received/VBD (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN -PUNC- MP/NNP (r_nmod) therapy/NN (r_appos) methylprednisolone/NN (r_dobj) received/VBD (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) arthritis/NN
8701013
D015738_D003693 CID Famotidine/NN (r_npadvmod) associated/VBN (r_amod) delirium/NN -PUNC- famotidine/NN (r_pobj) with/IN (r_prep) associated/VBN (l_advcl) shown/VBN (l_dobj) propensity/NN (l_acl) cause/VB (l_dobj) delirium/NN -PUNC- famotidine/NN (r_npadvmod) associated/VBN (r_amod) delirium/NN -PUNC- famotidine/NN (r_pobj) of/IN (r_prep) removal/NN (r_pobj) upon/IN (r_prep) cleared/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) delirium/NN
D015738_D014456 NONE Famotidine/NNP (r_nsubj) is/VBZ (l_attr) antagonist/NN (l_acl) used/VBD (l_prep) in/IN (l_pobj) settings/NNS (l_prep) for/IN (l_pobj) prevention/NN (l_prep) of/IN (l_pobj) ulcers/NNS
3375885
D008528_D007674 CID acid/NN (r_compound) nephropathy/NN
D009288_D006994 CID naproxen/NN (r_conj) indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) hyperkalemia/NN (l_conj) hypoaldosteronism/NN
D009288_D007674 NONE naproxen/NN (r_conj) indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_relcl) nephropathy/NN
D008528_D001172 NONE acid/NN (r_compound) nephropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_conj) arthritis/NN
D007213_D001172 NONE indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_relcl) nephropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_conj) arthritis/NN
D005438_D006947 NONE fludrocortisone/NN (r_pobj) by/IN (r_agent) reversed/VBN (r_conj) induced/VBN (l_nsubj) Hyperkalemia/NNP -PUNC- fludrocortisone/NN (r_nsubjpass) added/VBN (l_advcl) correcting/VBG (l_dobj) hyperkalemia/NN
D007213_D006947 CID indomethacin/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Hyperkalemia/NNP -PUNC- indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) hyperkalemia/NN -PUNC- indomethacin/NN (r_compound) therapy/NN (r_nsubjpass) continued/VBN (r_ccomp) allowing/VBG (r_conj) correcting/VBG (l_dobj) hyperkalemia/NN
D011453_D007674 NONE prostaglandin/JJ (r_amod) inhibitors/NNS (r_pobj) with/IN (r_prep) type/VB (r_advcl) predisposed/VBD (l_nsubj) disease/NN
D009288_D001172 NONE naproxen/NN (r_conj) indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_relcl) nephropathy/NN (r_pobj) of/IN (r_prep) history/NN (r_conj) arthritis/NN
D007213_D007674 NONE indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (r_relcl) nephropathy/NN
D009288_D006947 CID naproxen/NN (r_conj) indomethacin/NN (r_pobj) by/IN (r_prep) induced/VBN (l_nsubj) Hyperkalemia/NNP -PUNC- naproxen/NN (r_conj) indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) hyperkalemia/NN
D011453_D006994 NONE prostaglandin/JJ (r_amod) inhibitors/NNS (r_pobj) with/IN (r_prep) type/VB (l_dobj) acidosis/NN
D008528_D006947 NONE acid/NN (r_compound) nephropathy/NN (l_relcl) caused/VBN (l_nsubjpass) hyperkalemia/NN
D007213_D006994 CID indomethacin/NN (r_pobj) by/IN (r_agent) caused/VBN (l_nsubjpass) hyperkalemia/NN (l_conj) hypoaldosteronism/NN
D008528_D006994 NONE acid/NN (r_compound) nephropathy/NN (l_relcl) caused/VBN (l_nsubjpass) hyperkalemia/NN (l_conj) hypoaldosteronism/NN
15018178
D015662_D000743 CID sulfomethoxazole/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) crisis/NN (l_compound) anemia/NN
D015662_D002534 NONE sulfomethoxazole/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) crisis/NN (r_dobj) had/VBD (r_relcl) girl/NN (r_pobj) of/IN (r_prep) findings/NNS (r_dobj) present/VBP (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) anoxia/NN
6695685
D014700_D002637 NONE verapamil/NN (r_nsubj) increased/VBD (l_prep) In/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) syndromes/NNS (l_compound) pain/NN
D014700_D001145 CID verapamil/NN (r_compound) therapy/NN (r_pobj) during/IN (r_prep) rhythms/NNS -PUNC- verapamil/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) accelerated/VBD (l_dobj) rhythms/NNS
18340638
D001379_D000740 CID azathioprine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) include/VBP (l_dobj) anemia/NN -PUNC- Azathioprine/NN (r_nsubj) triggers/VBZ (l_npadvmod) effect/NN (l_acl) contributing/VBG (l_prep) to/IN (l_pobj) anemia/NN -PUNC- azathioprine/RB (r_advmod) induced/VBN (r_amod) anemia/NN
D010718_D000740 NONE phosphatidylserine/NN (r_pobj) of/IN (r_prep) exposure/NN (r_pobj) by/IN (r_agent) characterized/VBN (r_relcl) death/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) anemia/NN -PUNC- PS/NNP (r_appos) phosphatidylserine/NN (r_pobj) of/IN (r_prep) exposure/NN (r_pobj) by/IN (r_agent) characterized/VBN (r_relcl) death/NN (r_pobj) from/IN (r_prep) result/VB (l_nsubj) anemia/NN
24881749
D013747_D001943 NONE tetrabenazine/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) disease/NN (l_prep) at/IN (l_pobj) stage/NN (l_prep) of/IN (l_pobj) cancer/NN
D063325_D001943 NONE tiapride/NN (r_conj) tetrabenazine/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) disease/NN (l_prep) at/IN (l_pobj) stage/NN (l_prep) of/IN (l_pobj) cancer/NN
D063325_D006816 NONE tiapride/NN (r_conj) tetrabenazine/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) disease/NN -PUNC- tiapride/NN (r_pobj) with/IN (r_prep) initiation/NN (l_prep) for/IN (l_pobj) disease/NN
D063325_D009459 CID tiapride/NN (r_conj) tetrabenazine/NN (r_pobj) with/IN (r_prep) induced/VBN (l_nsubj) syndrome/NN -PUNC- tiapride/NN (r_pobj) with/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) occurred/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- tiapride/NN (r_conj) tetrabenazine/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) due/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) syndrome/NN
D013747_D009459 CID tetrabenazine/NN (r_pobj) with/IN (r_prep) induced/VBN (l_nsubj) syndrome/NN -PUNC- tetrabenazine/NN (r_conj) initiation/NN (r_pobj) after/IN (r_prep) occurred/VBD (r_relcl) woman/NN (l_prep) with/IN (l_pobj) syndrome/NN -PUNC- tetrabenazine/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) due/IN (r_prep) occurrence/NN (l_prep) of/IN (l_pobj) syndrome/NN
D013747_D006816 NONE tetrabenazine/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) disease/NN -PUNC- tetrabenazine/NN (r_conj) initiation/NN (l_prep) for/IN (l_pobj) disease/NN
1905439
D016595_D006261 NONE Misoprostol/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) reactions/NNS (l_prep) including/VBG (l_pobj) symptoms/NNS (l_conj) problems/NNS (l_conj) headache/NN
D016595_D003693 CID misoprostol/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) woman/NN (r_pobj) in/IN (r_prep) Delirium/NN -PUNC- misoprostol/NNP (r_nsubjpass) discontinued/VBN (r_advcl) improved/VBD (l_nsubj) delirium/NN -PUNC- misoprostol/NNP (r_compound) therapy/NN (r_pobj) from/IN (r_prep) resulted/VBD (l_nsubj) delirium/NN
920167
D014859_D005315 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) embryopathy/JJ
D014859_D002806 CID warfarin/RB (r_npadvmod) induced/VBN (r_amod) embryopathy/JJ (l_prep) with/IN (l_pobj) hypoplasia/NN (l_conj) epiphyses/NNS -PUNC- warfarin/RB (r_npadvmod) induced/VBN (r_amod) embryopathy/JJ (l_prep) with/IN (l_pobj) hypoplasia/NN (l_conj) epiphyses/NNS (l_appos) punctata/NN -PUNC- warfarin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_acl) infants/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) hypoplasia/NN (l_prep) with/IN (l_conj) without/IN (l_pobj) epiphyses/NNS
D014859_-1 NONE warfarin/RB (r_npadvmod) induced/VBN (r_amod) embryopathy/JJ (l_prep) with/IN (l_pobj) hypoplasia/NN -PUNC- warfarin/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) mothers/NNS (r_pobj) to/IN (r_prep) born/VBN (r_acl) infants/NNS (r_pobj) in/IN (r_prep) reported/VBN (l_nsubjpass) hypoplasia/NN
2907577
D005839_D058186 CID gentamicin/NN (r_npadvmod) induced/VBN (r_amod) failure/NN -PUNC- gentamicin/NN (r_pobj) of/IN (r_prep) injections/NNS (r_pobj) after/IN (r_prep) developing/VBG (l_dobj) failure/NN -PUNC- gentamicin/NN (r_npadvmod) induced/VBN (r_amod) ARF/NN
D003404_D009336 NONE creatinine/NN (r_conj) urea/NN (l_conj) analysis/NN (l_conj) degree/NN (l_prep) of/IN (l_pobj) necrosis/NN
C028322_D058186 NONE 8-phenyltheophylline/NN (r_punct) ,/, (r_punct) antagonists/NNS (r_pobj) as/IN (r_prep) potencies/NNS (r_pobj) with/IN (r_prep) alkylxanthines/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) developing/VBG (l_dobj) failure/NN
-1_D058186 NONE alkylxanthines/NNS (l_prep) on/IN (l_pobj) failure/NN -PUNC- alkylxanthines/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) developing/VBG (l_dobj) failure/NN -PUNC- alkylxanthines/NNS (r_pobj) with/IN (r_prep) noted/VBN (l_ccomp) indicates/VBZ (l_ccomp) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) ARF/NN
D000241_D007511 NONE Adenosine/NNP (r_amod) antagonists/NNS (r_nsubjpass) shown/VBN (l_xcomp) be/VB (l_prep) in/IN (l_pobj) models/NNS (l_amod) ischaemic/JJ
D013806_D058186 NONE theophylline/NN (r_amod) antagonists/NNS (r_pobj) as/IN (r_prep) potencies/NNS (r_pobj) with/IN (r_prep) alkylxanthines/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) developing/VBG (l_dobj) failure/NN
D000241_D007674 NONE Adenosine/NNP (r_amod) antagonists/NNS (r_nsubjpass) shown/VBN (l_xcomp) be/VB (l_prep) in/IN (l_pobj) models/NNS (l_amod) ischaemic/JJ (l_conj) nephrotoxic/JJ
D010130_D009336 NONE acid/NN (r_compound) clearances/NNS (r_conj) analysis/NN (l_conj) degree/NN (l_prep) of/IN (l_pobj) necrosis/NN
D000241_D058186 NONE Adenosine/NNP (r_amod) antagonists/NNS (r_nsubjpass) shown/VBN (l_xcomp) be/VB (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) failure/NN -PUNC- Adenosine/NNP (r_amod) antagonists/NNS (r_nsubjpass) shown/VBN (l_xcomp) be/VB (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) failure/NN (l_appos) ARF/NNP -PUNC- adenosine/NN (r_amod) antagonists/NNS (r_pobj) as/IN (r_prep) potencies/NNS (r_pobj) with/IN (r_prep) alkylxanthines/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) developing/VBG (l_dobj) failure/NN -PUNC- adenosine/NN (r_nsubj) plays/VBZ (l_dobj) role/NN (l_prep) in/IN (l_pobj) ARF/NN
D014508_D009336 NONE urea/NN (l_conj) analysis/NN (l_conj) degree/NN (l_prep) of/IN (l_pobj) necrosis/NN
C034347_D058186 NONE enprofylline/NN (r_conj) theophylline/NN (r_amod) antagonists/NNS (r_pobj) as/IN (r_prep) potencies/NNS (r_pobj) with/IN (r_prep) alkylxanthines/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) examined/VBN (l_prep) in/IN (l_pobj) rats/NNS (l_acl) developing/VBG (l_dobj) failure/NN
6728873
-1_D064420 NONE alkylxanthines/NNS (r_pobj) of/IN (r_prep) testing/NN (l_compound) toxicity/NN
D002110_D012640 CID caffeine/NN (r_compound) doses/NNS (r_pobj) at/IN (r_prep) scored/VBN (l_nsubjpass) characteristics/NNS (l_acl) righting/VBG (l_dobj) ability/NN (l_conj) induction/NN (l_compound) seizure/NN
2400986
D002998_D020258 NONE clonazepam/NN (r_pobj) by/IN (r_agent) prevented/VBN (r_conj) is/VBZ (l_nsubj) neurotoxicity/NN
D002066_D012640 CID busulfan/NNS (r_amod) course/NN (r_pobj) of/IN (r_prep) days/NNS (r_pobj) during/IN (r_prep) developed/VBN (l_dobj) seizures/NNS
D002066_D009369 NONE busulfan/NNS (r_dobj) receiving/VBG (l_prep) before/IN (l_pobj) transplantation/NN (l_prep) for/IN (l_pobj) tumors/NNS
D002066_D020258 NONE busulfan/NNS (r_pobj) of/IN (r_prep) neurotoxicity/NN -PUNC- Busulfan/NNPS (r_nsubjpass) known/VBN (l_xcomp) be/VB (l_acomp) neurotoxic/JJ -PUNC- Busulfan/NNPS (r_nsubjpass) known/VBN (l_conj) remains/VBZ (l_nsubj) neurotoxicity/NN -PUNC- busulfan/NNS (r_compound) dose/NN (r_nsubjpass) taken/VBN (r_advcl) was/VBD (l_attr) difference/NN (l_prep) in/IN (l_pobj) terms/NNS (l_prep) of/IN (l_pobj) incidence/JJ (l_compound) neurotoxicity/NN -PUNC- busulfan/NNS (r_amod) neurotoxicity/NN -PUNC- busulfan/NNS (r_compound) dose/NN (r_nsubjpass) followed/VBN (l_agent) by/IN (l_pobj) neurotoxicity/NN -PUNC- busulfan/NNS (r_compound) dose/NN (r_nsubjpass) followed/VBN (l_advmod) close/JJ (l_prep) to/IN (l_pobj) incidence/NN (l_compound) neurotoxicity/NN
D002066_D009461 NONE busulfan/NNS (r_nmod) dose/NN (r_dobj) given/VBN (r_ccomp) had/VBD (l_dobj) symptoms/NNS
D002998_D002493 NONE clonazepam/NN (r_pobj) with/IN (r_prep) busulfan/NNS (r_pobj) under/IN (r_prep) assay/NN (l_prep) without/IN (l_pobj) disease/NN
D002998_D009461 NONE clonazepam/NN (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) with/IN (r_prep) dose/NN (r_dobj) given/VBN (r_ccomp) had/VBD (l_dobj) symptoms/NNS
D002066_D002493 NONE Busulfan/NNS (r_compound) levels/NNS (r_nsubjpass) measured/VBN (l_agent) by/IN (l_pobj) assay/NN (l_prep) without/IN (l_pobj) disease/NN -PUNC- busulfan/NNS (r_pobj) under/IN (r_prep) assay/NN (l_prep) without/IN (l_pobj) disease/NN -PUNC- busulfan/NNS (r_amod) ratio/NN (r_nsubj) was/VBD (r_conj) measured/VBN (l_agent) by/IN (l_pobj) assay/NN (l_prep) without/IN (l_pobj) disease/NN
D002066_D001932 NONE busulfan/NNS (r_dobj) receiving/VBG (r_acl) study/NN (r_dobj) report/VBP (l_conj) excluded/VBD (l_nsubj) tumors/NNS
14616590
D015742_D013924 CID Disoprivan/NNP (r_pobj) with/IN (r_prep) than/IN (r_prep) with/IN (r_prep) occurred/VBD (l_nsubj) Pain/NN (l_conj) thrombophlebitis/NN
D015742_D010146 CID Disoprivan/NNP (r_pobj) with/IN (r_prep) than/IN (r_prep) with/IN (r_prep) occurred/VBD (l_nsubj) Pain/NN
24709919
C035054_D006930 NONE ginsenosides/NNS (l_prep) on/IN (l_pobj) OIH/NNP -PUNC- ginsenosides/NNS (r_nsubj) failed/VBD (l_xcomp) prevent/VB (l_dobj) OIH/NNP -PUNC- Rg1/NNP (r_nsubj) showed/VBD (l_dobj) tendency/NN (l_acl) aggravate/VB (l_dobj) OIH/NNP -PUNC- Rg1/NN (r_conj) ginsenoside/NN (r_nsubj) contribute/VB (l_prep) toward/IN (l_pobj) reversal/NN (l_prep) of/IN (l_pobj) OIH/NNP
D036145_D006930 NONE ginsenosides/NNS (l_prep) on/IN (l_pobj) hyperalgesia/NN
C049864_D006930 NONE ginsenosides/NNS (l_prep) on/IN (l_pobj) OIH/NNP -PUNC- Re/IN (l_appos) mg/kg/NNS (l_dobj) OIH/NNP -PUNC- Re/IN (r_prep) ginsenoside/NN (r_nsubj) contribute/VB (l_prep) toward/IN (l_pobj) reversal/NN (l_prep) of/IN (l_pobj) OIH/NNP
D019342_D006930 NONE acid/NN (r_npadvmod) induced/VBN (r_advcl) acetic/JJ (r_conj) test/NN (r_pobj) in/IN (r_prep) mg/kg/NNS (l_dobj) OIH/NNP -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) writhing/VBG (r_compound) test/NN (r_pobj) in/IN (r_prep) aggravate/VB (l_dobj) OIH/NNP
C442759_D006930 NONE ginsenosides/NNS (l_prep) on/IN (l_pobj) OIH/NNP -PUNC- ginsenosides/NNS (r_nsubj) failed/VBD (l_xcomp) prevent/VB (l_dobj) OIH/NNP -PUNC- Rb1/NN (r_conj) Rg1/NN (r_conj) ginsenoside/NN (r_nsubj) contribute/VB (l_prep) toward/IN (l_pobj) reversal/NN (l_prep) of/IN (l_pobj) OIH/NNP
D009020_D006930 CID morphine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) achieved/VBN (l_nsubjpass) OIH/NNP
8312983
C036139_D006948 NONE desmethylfluoxetine/NN (r_conj) fluoxetine/NN (r_nmod) concentration/NN (r_pobj) with/IN (r_prep) connected/VBN (r_acl) delirium/NN (l_amod) hyperkinetic/JJ
D015283_D006970 NONE citalopram/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) somnolence/NN
D015283_D020820 NONE citalopram/NN (r_pobj) of/IN (r_prep) concentration/NN (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) somnolence/NN (l_conj) difficulties/NNS
D005473_D006948 CID fluoxetine/NN (r_nmod) concentration/NN (r_pobj) with/IN (r_prep) connected/VBN (r_acl) delirium/NN (l_amod) hyperkinetic/JJ -PUNC- fluoxetine/NN (r_nmod) concentration/NN (r_pobj) with/IN (r_prep) connected/VBN (r_acl) delirium/NN (l_amod) hyperkinetic/JJ
D005473_D003693 CID fluoxetine/NN (r_amod) treatment/NN (r_pobj) during/IN (r_prep) Delirium/NN -PUNC- fluoxetine/NN (r_nmod) concentration/NN (r_pobj) with/IN (r_prep) connected/VBN (r_acl) delirium/NN -PUNC- fluoxetine/NN (r_nmod) concentration/NN (r_pobj) with/IN (r_prep) connected/VBN (r_acl) delirium/NN
C036139_D003693 NONE desmethylfluoxetine/NN (r_conj) fluoxetine/NN (r_nmod) concentration/NN (r_pobj) with/IN (r_prep) connected/VBN (r_acl) delirium/NN
19178808
D015742_D007022 CID propofol/NN (r_compound) remifentanil/NN (r_compound) total/JJ (r_amod) anesthesia/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anesthesia/NN (l_compound) hypotension/NN -PUNC- propofol/JJ (r_compound) TIVA/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) anesthesia/NN (l_compound) hypotension/NN
D015742_D006470 NONE propofol/NN (r_compound) remifentanil/NN (r_compound) total/JJ (r_amod) anesthesia/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anesthesia/NN (r_dobj) maintaining/VBG (r_pcomp) in/IN (r_prep) using/VBG (r_advcl) compare/VB (l_dobj) conditions/NNS (l_prep) including/VBG (l_pobj) amount/NN (l_prep) of/IN (l_pobj) bleeding/NN
C071741_D007022 CID remifentanil/NN (r_compound) total/JJ (r_amod) anesthesia/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anesthesia/NN (l_compound) hypotension/NN -PUNC- remifentanil/NN (r_compound) TIVA/NNP (r_pobj) by/IN (r_agent) caused/VBN (r_acl) anesthesia/NN (l_compound) hypotension/NN -PUNC- remifentanil/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) rates/NNS (r_dobj) using/VBG (r_xcomp) using/VBG (r_acl) period/NN (r_pobj) within/IN (r_prep) achieved/VBN (l_nsubjpass) hypotension/NN -PUNC- remifentanil/NN (r_pobj) of/IN (r_prep) dose/NN (r_dobj) achieved/VBN (l_nsubjpass) hypotension/NN -PUNC- remifentanil/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) hypotension/NN (r_pobj) for/IN (r_prep) allowed/VBN (r_conj) using/VBG (l_prep) during/IN (l_pobj) anesthesia/NN (l_compound) hypotension/NN -PUNC- remifentanil/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) with/IN (r_prep) hypotension/NN
C071741_D006470 NONE remifentanil/NN (r_compound) total/JJ (r_amod) anesthesia/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) anesthesia/NN (r_dobj) maintaining/VBG (r_pcomp) in/IN (r_prep) using/VBG (r_advcl) compare/VB (l_dobj) conditions/NNS (l_prep) including/VBG (l_pobj) amount/NN (l_prep) of/IN (l_pobj) bleeding/NN
3812624
D002220_D009759 NONE carbamazepine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) cases/NNS (l_prep) of/IN (l_pobj) nystagmus/NN -PUNC- carbamazepine/NN (r_compound) therapy/NN (r_pobj) to/IN (r_prep) related/VBN (r_amod) nystagmus/NN -PUNC- carbamazepine/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) reduction/NN (r_pobj) after/IN (r_prep) resolved/VBN (l_nsubj) nystagmus/NN
D002220_D015835 CID carbamazepine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) cases/NNS (l_prep) of/IN (l_pobj) nystagmus/NN (l_conj) oscillopsia/NN
8188982
D001127_D006973 CID AVP/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- vasopressin/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) compare/VB (l_conj) rats/NNS (l_amod) hypertensive/JJ -PUNC- AVP/NNP (r_appos) vasopressin/NN (r_pobj) of/IN (r_prep) influence/NN (r_dobj) compare/VB (l_conj) rats/NNS (l_amod) hypertensive/JJ
D010656_D007022 NONE phenylephrine/NN (r_nmod) hypotension/NN -PUNC- Phe)-induced/VBN (r_amod) hypertension/NN (r_nmod) hypotension/NN
D010656_D006973 CID phenylephrine/NN (r_nmod) hypotension/NN (l_nmod) hypertension/NN -PUNC- Phe)-induced/VBN (r_amod) hypertension/NN
D009599_D007022 CID nitroprusside/NN (r_amod) hypotension/NN -PUNC- SN)-induced/JJ (r_amod) hypotension/NN -PUNC- SN/NNP (r_npadvmod) induced/VBN (r_amod) hypotension/NN
D009599_D006973 NONE nitroprusside/NN (r_amod) hypotension/NN (l_nmod) hypertension/NN -PUNC- SN)-induced/JJ (r_amod) hypotension/NN (l_nmod) hypertension/NN
D001127_D007022 NONE AVP/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) reduced/VBN (l_prep) during/IN (l_pobj) hypotension/NN
12359538
D003042_D009202 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) difficult/JJ (r_ccomp) make/VBP (l_nsubj) abnormalities/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) necrosis/NN
D003042_D002637 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN -PUNC- cocaine/NN (r_compound) chest/NN (r_compound) pain/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN
D003042_D009336 NONE cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) necrosis/NN
D003042_D009203 CID cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) difficult/JJ (r_ccomp) make/VBP (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) infarction/NN -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) difficult/JJ (r_ccomp) make/VBP (l_dobj) diagnosis/NN (l_prep) of/IN (l_pobj) infarction/NN (l_appos) MI/NNP -PUNC- cocaine/NN (r_compound) chest/NN (r_compound) pain/NN (r_pobj) with/IN (r_prep) patients/NNS (r_pobj) in/IN (r_prep) positivity/NN (l_acl) admitted/VBD (l_prep) for/IN (l_pobj) exclusion/NN (l_prep) of/IN (l_pobj) MI/NNP -PUNC- cocaine/NN (r_compound) use/NN (r_pobj) after/IN (r_prep) admitted/VBN (l_prep) for/IN (l_pobj) MI/NNP -PUNC- cocaine/NN (r_npadvmod) associated/VBN (r_amod) pain/NN (l_conj) MI/NNP
25951420
D010126_D010300 CID Ozone/NN (r_pobj) of/IN (r_prep) Associations/NNS (l_prep) With/IN (l_pobj) Disease/NNP -PUNC- ozone/NN (r_pobj) of/IN (r_prep) associations/NNS (r_dobj) describes/VBZ (l_prep) with/IN (l_pobj) disease/NN -PUNC- ozone/NN (r_pobj) with/IN (r_prep) disease/NN
D052638_D010300 CID matter/NN (r_conj) ozone/NN (r_pobj) of/IN (r_prep) associations/NNS (r_dobj) describes/VBZ (l_prep) with/IN (l_pobj) disease/NN -PUNC- matter/NN (r_conj) 0.98/CD (r_appos) ratio/NN (r_appos) associations/NNS (l_prep) of/IN (l_pobj) disease/NN
24802403
D008687_D012640 NONE Metformin/NNP (r_nsubj) protects/VBZ (l_prep) against/IN (l_pobj) seizures/NNS -PUNC- metformin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS -PUNC- metformin/NN (r_nsubj) be/VB (l_attr) agent/NN (l_prep) for/IN (l_pobj) treatment/NN (l_conj) medicine/NN (l_acl) induced/VBN (l_agent) by/IN (l_pobj) seizures/NNS
D010433_D012640 CID pentylenetetrazole/NN (r_npadvmod) induced/VBN (r_amod) kindling/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairments/NNS (r_conj) seizures/NNS -PUNC- pentylenetetrazole/NN (r_npadvmod) induced/VBN (r_amod) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (r_acl) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS
D008687_D003072 NONE metformin/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS (l_conj) impairment/NN -PUNC- metformin/NN (r_nsubj) suppressed/VBD (l_conj) ameliorated/VBD (l_dobj) impairment/NN -PUNC- metformin/NN (r_nsubj) be/VB (l_attr) agent/NN (l_prep) for/IN (l_pobj) treatment/NN (l_conj) medicine/NN (l_prep) against/IN (l_pobj) impairment/NN
D008687_D004827 NONE metformin/NN (r_nsubj) be/VB (l_attr) agent/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) epilepsy/NN
D008687_D008569 NONE Metformin/NNP (r_nsubj) protects/VBZ (l_prep) against/IN (l_pobj) seizures/NNS (l_conj) impairments/NNS
D010433_D003072 CID pentylenetetrazole/NN (r_npadvmod) induced/VBN (r_amod) animals/NNS (r_pobj) in/IN (r_prep) observed/VBN (r_acl) effects/NNS (l_prep) on/IN (l_pobj) seizures/NNS (l_conj) impairment/NN
D010433_D007859 CID pentylenetetrazole/NN (r_npadvmod) induced/VBN (r_amod) kindling/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairments/NNS
D008687_D007859 NONE Metformin/NNP (r_nsubj) protects/VBZ (l_prep) against/IN (l_pobj) seizures/NNS (l_conj) impairments/NNS
D010433_D008569 CID pentylenetetrazole/NN (r_npadvmod) induced/VBN (r_amod) kindling/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) impairments/NNS
15817013
D014859_D006470 CID warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN (r_pobj) in/IN (r_prep) 75/CD (r_dobj) aged/VBN (r_acl) People/NNS (l_appos) rate/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN (r_pobj) with/IN (r_prep) aged/VBN (r_acl) people/NNS (r_pobj) in/IN (r_prep) stroke/NN (r_conj) hemorrhage/NN -PUNC- warfarin/JJ (r_compound) use/NN (r_conj) strokes/NNS (r_conj) episodes/NNS (l_compound) bleeding/VBG -PUNC- warfarin/NN (r_pobj) on/IN (r_prep) rate/NN (r_nsubj) was/VBD (r_ccomp) resulted/VBD (r_conj) was/VBD (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) hemorrhage/NN -PUNC- warfarin/JJ (r_compound) treatment/NN (r_nsubj) is/VBZ (r_ccomp) demonstrating/VBG (r_advcl) resulted/VBD (r_conj) was/VBD (l_nsubj) rate/NN (l_prep) of/IN (l_pobj) hemorrhage/NN
D014859_D001281 NONE warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN -PUNC- warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN -PUNC- warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN
D014859_D020521 NONE warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN (r_pobj) in/IN (r_prep) 75/CD (r_dobj) aged/VBN (r_acl) People/NNS (l_appos) rate/NN (l_prep) of/IN (l_pobj) hemorrhage/NN (l_conj) stroke/NN -PUNC- warfarin/NN (r_pobj) on/IN (r_prep) fibrillation/NN (r_pobj) with/IN (r_prep) aged/VBN (r_acl) people/NNS (r_pobj) in/IN (r_prep) stroke/NN -PUNC- warfarin/JJ (r_compound) use/NN (r_conj) strokes/NNS -PUNC- warfarin/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) rate/NN (l_compound) stroke/NN -PUNC- warfarin/NN (r_pobj) on/IN (r_prep) rate/NN (l_compound) stroke/NN -PUNC- warfarin/JJ (r_compound) treatment/NN (r_nsubj) is/VBZ (r_ccomp) demonstrating/VBG (r_advcl) resulted/VBD (l_ccomp) was/VBD (l_nsubj) rate/NN (l_compound) stroke/NN
3833372
D013999_D006973 NONE maleate/NN (r_pobj) of/IN (r_prep) mg/NN (r_dobj) containing/VBG (r_acl) combination/NN (l_acl) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_amod) hypertensive/JJ
D006852_D006973 NONE hydrochlorothiazide/NN (r_pobj) of/IN (r_prep) mg/NN (r_conj) mg/NN (r_dobj) containing/VBG (r_acl) combination/NN (l_acl) administered/VBN (l_prep) to/IN (l_pobj) patients/NNS (l_amod) hypertensive/JJ
11799346
D004917_D001714 CID erythromycin/NN (r_conj) metronidazole/NNP (r_conj) Cotrimoxazole/NNP (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) episodes/NNS (l_amod) manic/JJ
D015662_D001714 CID Cotrimoxazole/NNP (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) episodes/NNS (l_amod) manic/JJ
D017291_D001714 CID clarithromycin/NN (r_dobj) showed/VBD (l_xcomp) be/VB (l_attr) the/DT (l_acl) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) mania/NN
D002939_D001714 CID ciprofloxacin/NNS (r_conj) clarithromycin/NN (r_dobj) showed/VBD (l_xcomp) be/VB (l_attr) the/DT (l_acl) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) mania/NN
D008795_D001714 CID metronidazole/NNP (r_conj) Cotrimoxazole/NNP (r_nsubjpass) involved/VBN (l_prep) in/IN (l_pobj) episodes/NNS (l_amod) manic/JJ
978847
D003891_D006973 CID desmethylimipramine/NN (r_pobj) by/IN (r_agent) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_prep) of/IN (l_pobj) pressure/NN
D010646_D013610 NONE phentolamine/NN (r_conj) hexamethonium/NN (r_conj) injection/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_conj) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_conj) tachycardia/NNS
D011433_D006973 NONE propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_prep) of/IN (l_pobj) pressure/NN
D003891_D013610 NONE desmethylimipramine/NN (r_pobj) by/IN (r_agent) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_conj) tachycardia/NNS
D018738_D006973 NONE hexamethonium/NN (r_conj) injection/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_conj) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_prep) of/IN (l_pobj) pressure/NN
D006145_D013610 NONE guanethidine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_conj) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_conj) tachycardia/NNS
D010646_D006973 NONE phentolamine/NN (r_conj) hexamethonium/NN (r_conj) injection/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_conj) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_prep) of/IN (l_pobj) pressure/NN
D011433_D013610 NONE propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_conj) tachycardia/NNS
D002217_D006973 CID carbachol/NN (r_dobj) following/VBG (r_acl) tachycardia/NNS (r_conj) enlargement/NN (l_prep) of/IN (l_pobj) pressure/NN
D018738_D013610 NONE hexamethonium/NN (r_conj) injection/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_conj) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_conj) tachycardia/NNS
D006145_D006973 NONE guanethidine/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) reduced/VBN (l_conj) potentiated/VBN (l_advcl) propranolol/NN (l_conj) inhibited/VBD (l_dobj) enlargement/NN (l_prep) of/IN (l_pobj) pressure/NN
D002217_D013610 CID carbachol/NN (r_dobj) following/VBG (r_acl) tachycardia/NNS
12678199
D000638_-1 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) context/NN (r_pobj) in/IN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) proarrhythmia/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) proarrhythmia/NN
D004077_D016171 NONE digoxin/JJ (r_compound) excess/NN (r_conj) hypokalemia/NN (r_pobj) including/VBG (r_prep) factors/NNS (r_pobj) of/IN (r_prep) context/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) case/NN (l_prep) of/IN (l_pobj) TdP/NNP
D000638_D007008 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) In/IN (r_prep) induce/VB (l_prep) despite/IN (l_pobj) hypokalemia/NN
D000638_D016171 CID Amiodarone/NN (r_npadvmod) induced/VBN (r_amod) torsade/NN (r_nmod) pointes/FW -PUNC- amiodarone/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pointes/FW -PUNC- amiodarone/NN (r_compound) therapy/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) pointes/FW (l_appos) TdP/NN -PUNC- amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) In/IN (r_prep) induce/VB (l_dobj) TdP/NN
D000638_C537153 NONE amiodarone/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) In/IN (r_prep) induce/VB (l_prep) despite/IN (l_pobj) hypokalemia/NN (l_conj) hypomagnesemia/NN
D004077_D007008 NONE digoxin/JJ (r_compound) excess/NN (r_conj) hypokalemia/NN
16565833
C522803_D066126 NONE monoHER/NN (r_pobj) between/IN (r_prep) interval/NN (r_pobj) of/IN (r_prep) influence/NN (l_conj) administration/NN (l_prep) on/IN (l_pobj) protection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN -PUNC- monohydroxyethylrutoside/NN (r_nsubj) showed/VBD (l_dobj) cardioprotection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN -PUNC- monoHER/NN (r_appos) monohydroxyethylrutoside/NN (r_nsubj) showed/VBD (l_dobj) cardioprotection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN
D004317_D066126 NONE doxorubicin/NN (r_compound) administration/NN (l_prep) on/IN (l_pobj) protection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN -PUNC- doxorubicin/NN (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN -PUNC- doxorubicin/NN (l_prep) Despite/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_appos) doxorubicin/NN (l_prep) Despite/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_npadvmod) induced/VBN (r_amod) cardiotoxicity/NN
D005419_D066126 NONE flavonoid/NN (r_compound) monohydroxyethylrutoside/NN (r_nsubj) showed/VBD (l_dobj) cardioprotection/NN (l_prep) against/IN (l_pobj) cardiotoxicity/NN
D007501_D066126 NONE iron/NN (r_compound) chelating/VBG (r_compound) properties/NNS (r_pobj) through/IN (r_prep) cardiotoxicity/NN
D004317_D006331 NONE DOX/NNP (r_npadvmod) induced/VBN (r_amod) damage/NN -PUNC- DOX/NNP (r_pobj) by/IN (r_prep) radicals/NNS (r_pobj) of/IN (r_prep) formation/NN (r_pobj) from/IN (r_prep) results/VBZ (l_nsubj) damage/NN -PUNC- DOX/NNP (r_pobj) with/IN (r_prep) treatment/NN (r_nsubj) induced/VBD (l_dobj) damage/NN
11835460
D007980_D015835 CID Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesias/NNS -PUNC- Levodopa/NNP (r_npadvmod) induced/VBN (r_amod) dyskinesias/NNS -PUNC- levodopa/NN (r_pobj) of/IN (r_prep) effect/NN (r_pobj) during/IN (r_prep) report/VBP (l_conj) hypothesize/VB (l_ccomp) needed/VBN (l_prep) for/IN (l_pobj) appearance/NN (l_prep) of/IN (l_pobj) dyskinesias/NNS -PUNC- levodopa/NN (r_npadvmod) induce/VB (r_amod) dyskinesias/NNS
D007980_D010300 NONE Levodopa/NNP (r_npadvmod) induced/VBN (l_dobj) dyskinesias/NNS (l_prep) in/IN (l_pobj) disease/NN
9428298
D000420_D001249 NONE albuterol/NN (l_prep) in/IN (l_pobj) exacerbations/NNS (l_prep) of/IN (l_pobj) asthma/NN -PUNC- albuterol/NN (r_nmod) CNA/NNP (r_dobj) received/VBD (r_relcl) exacerbations/NNS (l_prep) of/IN (l_pobj) asthma/NN -PUNC- albuterol/NN (r_nmod) treatments/NNS (r_pobj) versus/IN (r_prep) received/VBD (r_relcl) exacerbations/NNS (l_prep) of/IN (l_pobj) asthma/NN
146391
D010672_D003875 CID diphenylhydantoin/NN (r_dobj) taking/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) lymphadenopathy/NN (r_conj) dermatitis/NN
D010672_D012010 CID diphenylhydantoin/NN (r_dobj) taking/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) lymphadenopathy/NN (r_conj) dermatitis/NN (r_conj) aplasia/NN -PUNC- diphenylhydantoin/NN (r_dobj) taking/VBG (r_acl) patient/NN (r_nsubj) developed/VBD (l_dobj) rash/NN (l_appos) aplasia/NN -PUNC- diphenylhydantoin/NN (r_compound) medication/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) aplasia/NN -PUNC- diphenylhydantoin/NN (r_pobj) of/IN (r_prep) ingestion/NN (l_conj) occurrence/NN (l_prep) of/IN (l_pobj) rash/NN (l_conj) lymphadenopathy/JJ (l_conj) aplasia/NN
D010672_D008206 CID diphenylhydantoin/NN (r_dobj) taking/VBG (r_acl) patient/NN (r_pobj) in/IN (r_prep) lymphadenopathy/NN -PUNC- diphenylhydantoin/NN (r_dobj) taking/VBG (r_acl) patient/NN (r_nsubj) developed/VBD (l_dobj) rash/NN (l_appos) aplasia/NN (l_amod) lymphadenopathy/JJ -PUNC- diphenylhydantoin/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_advcl) is/VBZ (l_acomp) lymphadenopathy/NN -PUNC- diphenylhydantoin/NN (r_pobj) of/IN (r_prep) ingestion/NN (l_conj) occurrence/NN (l_prep) of/IN (l_pobj) rash/NN (l_conj) lymphadenopathy/JJ
D010672_D005076 NONE diphenylhydantoin/NN (r_dobj) taking/VBG (r_acl) patient/NN (r_nsubj) developed/VBD (l_dobj) rash/NN -PUNC- diphenylhydantoin/NN (r_compound) treatment/NN (r_pobj) of/IN (r_prep) complication/NN (r_attr) is/VBZ (l_nsubj) rash/NN -PUNC- diphenylhydantoin/NN (r_pobj) of/IN (r_prep) ingestion/NN (l_conj) occurrence/NN (l_prep) of/IN (l_pobj) rash/NN
24812279
D004317_D066126 NONE Doxorubicin/NNP (r_nsubj) is/VBZ (l_conj) associated/VBN (l_prep) with/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_appos) Doxorubicin/NNP (r_nsubj) is/VBZ (l_conj) associated/VBN (l_prep) with/IN (l_pobj) cardiotoxicity/NN -PUNC- DOX/NNP (r_compound) cardiotoxicity/NN
D004317_D009369 NONE Doxorubicin/NNP (r_nsubj) is/VBZ (l_attr) therapeutic/NN (l_compound) cancer/NN -PUNC- DOX/NNP (r_appos) Doxorubicin/NNP (r_nsubj) is/VBZ (l_attr) therapeutic/NN (l_compound) cancer/NN
D004317_D006333 CID DOX/NNP (r_npadvmod) induced/VBN (r_amod) failure/NN
D018943_D066126 NONE anthracycline/NN (r_amod) cardiotoxicity/NN
15276093
C451780_D006937 NONE lovastatin/NN (r_appos) Niacin/NNP (r_nsubj) is/VBZ (l_attr) product/NN (l_acl) approved/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypercholesterolemia/NN
D003401_D009135 NONE creatine/NN (r_compound) phosphokinase/NN (r_pobj) of/IN (r_prep) increase/NN (r_nsubj) occurred/VBD (l_conj) observed/VBN (l_nsubjpass) cases/NNS (l_prep) of/IN (l_pobj) myopathy/NNS
C451780_D050171 NONE lovastatin/NN (r_appos) Niacin/NNP (r_nsubj) is/VBZ (l_attr) product/NN (l_acl) approved/VBN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) hypercholesterolemia/NN (l_conj) dyslipidemia/NN -PUNC- lovastatin/NN (r_conj) dyslipidemia/NN
6615679
D013999_D001919 CID timolol/NN (r_nmod) drops/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hypotension/NN (r_conj) bradycardia/NNP -PUNC- maleate/NN (r_amod) drops/NNS (r_dobj) timolol/NN (r_conj) nitrate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) bradycardia/NN
D010862_D001919 CID pilocarpine/VB (r_conj) timolol/NN (r_nmod) drops/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hypotension/NN (r_conj) bradycardia/NNP -PUNC- nitrate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_dobj) bradycardia/NN
D013999_D007022 CID timolol/NN (r_nmod) drops/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hypotension/NN -PUNC- maleate/NN (r_amod) drops/NNS (r_dobj) timolol/NN (r_conj) nitrate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_conj) became/VBD (l_acomp) hypotensive/JJ
D006221_D001919 NONE halothane/NN (r_compound) anaesthesia/NN (r_pobj) during/IN (r_prep) became/VBD (r_conj) developed/VBD (l_dobj) bradycardia/NN -PUNC- halothane/NN (r_compound) anaesthesia/NN (l_prep) with/IN (l_pobj) bradycardia/NN
D010862_D007022 CID pilocarpine/VB (r_conj) timolol/NN (r_nmod) drops/NNS (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hypotension/NN -PUNC- nitrate/NN (r_pobj) with/IN (r_prep) treated/VBN (r_relcl) man/NN (r_nsubj) developed/VBD (l_conj) became/VBD (l_acomp) hypotensive/JJ
D006221_D007022 NONE halothane/NN (r_compound) anaesthesia/NN (r_pobj) during/IN (r_prep) became/VBD (l_acomp) hypotensive/JJ -PUNC- halothane/NN (r_compound) anaesthesia/NN (l_prep) with/IN (l_pobj) bradycardia/NN (l_conj) hypotension/NN
15605432
C027576_D028361 NONE 4HNE/CD (r_compound) protein/NN (r_compound) adducts/NNS (r_dobj) induced/VBD (l_prep) at/IN (l_pobj) point/NN (l_prep) as/IN (l_pcomp) appeared/VBD (l_nsubj) injury/NN
D010100_D066126 NONE oxygen/NN (r_nsubj) reported/VBD (r_ccomp) determine/VB (r_xcomp) was/VBD (l_conj) resulted/VBD (l_nsubj) cardiotoxicity/NN
D009584_D066126 NONE ROS)/nitrogen/NN (r_compound) species/NNS (r_appos) oxygen/NN (r_nsubj) reported/VBD (r_ccomp) determine/VB (r_xcomp) was/VBD (l_conj) resulted/VBD (l_nsubj) cardiotoxicity/NN
D004317_D028361 CID adriamycin/NNS (r_npadvmod) induced/VBN (r_amod) injury/NN -PUNC- ADR/NNP (r_nsubj) induced/VBD (l_prep) at/IN (l_pobj) point/NN (l_prep) as/IN (l_pcomp) appeared/VBD (l_nsubj) injury/NN
D004317_D066126 NONE adriamycin/NNS (r_acomp) was/VBD (l_conj) resulted/VBD (l_nsubj) cardiotoxicity/NN -PUNC- ADR)-induced/JJ (r_compound) cardiotoxicity/NN
20024739
D000431_D015658 NONE alcohol/NN (r_compound) use/NN (l_prep) with/IN (l_pobj) progression/NN (l_compound) disease/NN -PUNC- alcohol/NN (r_compound) consumption/NN (r_pobj) of/IN (r_prep) association/NN (r_dobj) evaluated/VBD (l_conj) effects/NNS (l_prep) on/IN (l_pobj) progression/NN (l_compound) disease/NN
D000431_D003866 CID alcohol/NN (r_compound) consumption/NN (l_conj) depression/NN -PUNC- alcohol/NN (r_compound) use/NN (r_compound) assessment/NN (r_conj) had/VBD (l_dobj) examination/NN (l_appos) measurement/NN (l_prep) of/IN (l_pobj) symptoms/NNS (l_compound) depression/NN -PUNC- alcohol/NN (r_compound) use/NN (r_compound) assessment/NN (r_conj) had/VBD (l_advcl) using/VBG (l_dobj) Center/NNP (l_prep) for/IN (l_pobj) Scale/NNP (l_compound) Depression/NNP -PUNC- alcohol/NN (r_compound) consumption/NN (l_conj) depression/NN -PUNC- alcohol/NN (r_compound) consumption/NN (r_nsubj) has/VBZ (l_dobj) association/NN (l_prep) with/IN (l_pobj) depression/NN
3538855
D000617_D008107 NONE aminoglycoside/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) duration/NN (l_appos) disease/NN
D003404_D008107 NONE creatinine/NN (r_compound) clearance/NN (r_conj) age/NN (r_conj) disease/NN
D000617_D058186 NONE aminoglycosides/NNS (r_pobj) of/IN (r_prep) trials/NNS (r_nsubj) indicate/VBP (l_ccomp) ranges/VBZ (l_nsubj) risk/NN (l_prep) for/IN (l_pcomp) developing/VBG (l_dobj) failure/NN
D000617_D007674 CID aminoglycoside/NN (r_compound) nephrotoxicity/NN -PUNC- aminoglycoside/NN (r_pobj) of/IN (r_prep) epidemiology/NN (r_nsubj) induced/VBN (r_amod) nephrotoxicity/NN -PUNC- aminoglycosides/NNS (r_dobj) indicate/VBP (l_conj) cause/VBP (l_conj) cause/VB (l_dobj) dysfunction/NN -PUNC- aminoglycoside/NN (r_compound) levels/NNS (r_pobj) of/IN (r_prep) duration/NN (r_nsubj) increase/VBP (l_dobj) risk/NN (l_prep) for/IN (l_pobj) nephrotoxicity/NN -PUNC- aminoglycoside/NN (r_npadvmod) induced/VBN (r_amod) nephrotoxicity/NN
D003404_D007674 NONE creatinine/NN (r_compound) clearance/NN (r_conj) age/NN (r_conj) disease/NN (r_appos) duration/NN (r_nsubj) increase/VBP (l_dobj) risk/NN (l_prep) for/IN (l_pobj) nephrotoxicity/NN
19553912
D020123_D000740 CID sirolimus/NN (r_pobj) of/IN (r_prep) role/NN (r_appos) anemia/NN -PUNC- Sirolimus/NNP (r_nsubjpass) implicated/VBN (l_prep) as/IN (l_pcomp) playing/VBG (l_dobj) role/NN (l_prep) in/IN (l_pobj) anemia/NN -PUNC- rapamycin/NNS (r_compound) inhibitor/NN (r_pobj) of/IN (r_prep) target/NN (r_appos) Sirolimus/NNP (r_nsubjpass) implicated/VBN (l_prep) as/IN (l_pcomp) playing/VBG (l_dobj) role/NN (l_prep) in/IN (l_pobj) anemia/NN -PUNC- sirolimus/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) anemia/NN
48835
D011433_D007003 NONE propranolol/NN (l_prep) of/IN (l_pobj) effects/NNS (l_prep) of/IN (l_pobj) hypoglycaemia/NN
17297207
D011803_D016778 NONE Quinine/NN (r_npadvmod) induced/VBN (r_amod) arrhythmia/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) malaria/NN -PUNC- quinine/NN (r_compound) infusion/NN (r_nsubjpass) reported/VBN (r_ccomp) getting/VBG (r_advcl) was/VBD (l_attr) case/NN (l_prep) of/IN (l_pobj) patient/NN (l_compound) malaria/NN -PUNC- quinine/NN (r_compound) infusion/NN (r_dobj) got/VBD (r_conj) diagnosed/VBN (l_prep) as/IN (l_pobj) malaria/NN
D011803_D012848 NONE quinine/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) hours/NNS (r_pobj) After/IN (r_prep) felt/VBD (l_parataxis) showed/VBD (l_ccomp) wave/VBP (l_nmod) block/NN
D011802_D018879 NONE quinidine/NN (r_pobj) like/IN (r_prep) is/VBZ (l_advcl) arrhythmic/JJ (l_ccomp) cause/VB (l_dobj) arrhythmias/NNS (l_prep) including/VBG (l_pobj) arrhythmia/NN (l_prep) as/IN (l_pobj) PVC/NN
D011803_-1 NONE quinine/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) hours/NNS (r_pobj) After/IN (r_prep) felt/VBD (l_dobj) palpitation/NN
D011803_D014839 NONE quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) have/VBP (l_dobj) diseases/NNS (l_conj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_relcl) occurs/VBZ (l_advcl) vomiting/NN
D011803_D007565 NONE quinine/NN (r_compound) infusion/NN (r_nsubjpass) reported/VBN (r_ccomp) getting/VBG (r_advcl) was/VBD (l_attr) case/NN (l_prep) of/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) jaundice/NN -PUNC- quinine/NN (r_compound) infusion/NN (r_dobj) got/VBD (r_conj) diagnosed/VBN (l_prep) as/IN (l_pobj) malaria/NN (l_prep) with/IN (l_pobj) jaundice/NN
D011803_D001145 NONE Quinine/NN (r_npadvmod) induced/VBN (r_amod) arrhythmia/NN -PUNC- quinine/NN (r_compound) infusion/NN (r_nsubjpass) reported/VBN (r_ccomp) getting/VBG (r_advcl) was/VBD (l_attr) case/NN (l_prep) of/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) jaundice/NN (l_relcl) presented/VBD (l_prep) with/IN (l_pobj) arrhythmia/NN -PUNC- Quinine/NN (r_nsubj) is/VBZ (l_attr) alkaloid/NN (l_relcl) has/VBZ (l_dobj) property/NN (l_amod) arrhythmic/JJ -PUNC- Quinine/NN (r_nsubj) is/VBZ (l_advcl) arrhythmic/JJ -PUNC- Quinine/NN (r_nsubj) is/VBZ (l_advcl) arrhythmic/JJ (l_ccomp) cause/VB (l_dobj) arrhythmias/NNS -PUNC- Quinine/NN (r_nsubj) is/VBZ (l_advcl) arrhythmic/JJ (l_ccomp) cause/VB (l_dobj) arrhythmias/NNS (l_prep) including/VBG (l_pobj) arrhythmia/NN -PUNC- quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_amod) arrhythmic/JJ
D011188_D018879 NONE potassium/NN (r_compound) level/NN (r_nsubj) was/VBD (l_ccomp) reduced/VBN (l_nsubj) frequency/NN (l_prep) of/IN (l_pobj) PVC/NNP
D011802_D001145 NONE quinidine/NN (r_pobj) like/IN (r_prep) is/VBZ (l_attr) alkaloid/NN (l_relcl) has/VBZ (l_dobj) property/NN (l_amod) arrhythmic/JJ -PUNC- quinidine/NN (r_pobj) like/IN (r_prep) is/VBZ (l_advcl) arrhythmic/JJ -PUNC- quinidine/NN (r_pobj) like/IN (r_prep) is/VBZ (l_advcl) arrhythmic/JJ (l_ccomp) cause/VB (l_dobj) arrhythmias/NNS -PUNC- quinidine/NN (r_pobj) like/IN (r_prep) is/VBZ (l_advcl) arrhythmic/JJ (l_ccomp) cause/VB (l_dobj) arrhythmias/NNS (l_prep) including/VBG (l_pobj) arrhythmia/NN
D011803_D014883 NONE quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) have/VBP (l_dobj) diseases/NNS (l_conj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN
D005947_D016778 NONE dextrose/NN (r_pobj) in/IN (r_prep) infusion/NN (r_dobj) got/VBD (r_conj) diagnosed/VBN (l_prep) as/IN (l_pobj) malaria/NN
D011803_D018879 CID quinine/NN (r_compound) infusion/NN (r_nsubjpass) reported/VBN (r_ccomp) getting/VBG (r_advcl) was/VBD (l_attr) case/NN (l_appos) contraction/NN -PUNC- quinine/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) hours/NNS (r_pobj) After/IN (r_prep) felt/VBD (l_parataxis) showed/VBD (l_dobj) contraction/NN -PUNC- quinine/NN (r_compound) infusion/NN (r_pobj) of/IN (r_prep) hours/NNS (r_pobj) After/IN (r_prep) felt/VBD (l_parataxis) showed/VBD (l_dobj) contraction/NN (l_appos) PVC/NN -PUNC- Quinine/NN (r_nsubj) is/VBZ (l_advcl) arrhythmic/JJ (l_ccomp) cause/VB (l_dobj) arrhythmias/NNS (l_prep) including/VBG (l_pobj) arrhythmia/NN (l_prep) as/IN (l_pobj) PVC/NN
D011803_D007008 NONE quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) have/VBP (l_dobj) diseases/NNS (l_conj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_appos) hypokalemia/NN
D011803_D008288 NONE quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) have/VBP (l_dobj) diseases/NNS (l_conj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_relcl) occurs/VBZ (l_advcl) vomiting/NN (l_conj) diarrhea/NN (l_prep) in/IN (l_pobj) cases/NNS (l_compound) malaria/NN
D005947_D007565 NONE dextrose/NN (r_pobj) in/IN (r_prep) infusion/NN (r_dobj) got/VBD (r_conj) diagnosed/VBN (l_prep) as/IN (l_pobj) malaria/NN (l_prep) with/IN (l_pobj) jaundice/NN
D011803_D006331 NONE quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) have/VBP (l_dobj) diseases/NNS
D011803_D003967 NONE quinine/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubjpass) done/VBN (l_prep) because/IN (l_pobj) effect/NN (l_prep) in/IN (l_pobj) patients/NNS (l_relcl) have/VBP (l_dobj) diseases/NNS (l_conj) patients/NNS (l_prep) with/IN (l_pobj) disorder/NN (l_relcl) occurs/VBZ (l_advcl) vomiting/NN (l_conj) diarrhea/NN
1943082
D005978_D015427 NONE glutathione/NN (r_pobj) in/IN (r_prep) change/NN (l_prep) following/VBG (l_pobj) injury/NN
D005978_D007511 NONE glutathione/NN (r_pobj) in/IN (r_prep) change/NN (l_prep) following/VBG (l_pobj) injury/NN (l_compound) reperfusion/NN (l_compound) ischemia/NN
24911645
D001224_D012640 NONE aspartate/NN (r_conj) glutamine/NN (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- aspartate/NN (r_conj) glutamine/NN (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS
C573355_D013226 NONE GFC/NNP (r_nsubj) exert/VB (l_conj) reduce/VB (l_advmod) epilepticus/NN
D005978_D012640 NONE glutathione/NN (r_conj) aspartate/NN (r_conj) glutamine/NN (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- glutathione/NN (r_conj) aspartate/NN (r_conj) glutamine/NN (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS
C573355_D012640 NONE FC/NNP (r_pobj) with/IN (r_prep) pretreated/VBN (l_prep) in/IN (l_pobj) seizures/NNS -PUNC- GFC/NNP (r_compound) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- GFC/NNP (r_compound) effects/NNS (r_dobj) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS -PUNC- GFC/NNP (r_nsubj) produced/VBD (l_dobj) latency/NN (l_prep) to/IN (l_pobj) seizure/NN -PUNC- GFC/NNP (r_nsubj) exert/VB (l_conj) reduce/VB (l_advcl) demonstrated/VBN (l_agent) by/IN (l_pobj) increase/NN (l_prep) to/IN (l_pobj) seizure/NN
D010862_D013226 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) of/IN (r_prep) installation/NN (r_pobj) of/IN (r_prep) frequency/NN (r_dobj) reduce/VB (l_advmod) epilepticus/NN
D000596_D012640 NONE acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS
D005680_D012640 NONE acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS -PUNC- GABA/NNP (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- GABA/NNP (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS
D018698_D012640 NONE glutamine/NN (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (l_dobj) effects/NNS (l_prep) at/IN (l_pobj) doses/NNS (l_prep) on/IN (l_pobj) parameters/NNS (l_compound) seizure/NN -PUNC- glutamine/NN (r_appos) acid/NN (r_appos) acid/NN (r_pobj) on/IN (r_prep) effects/NNS (r_conj) activity/NN (r_dobj) determine/VB (r_advcl) evaluate/VB (r_xcomp) aimed/VBN (r_acl) study/NN (r_nsubj) levels/NNS (l_prep) on/IN (l_pobj) acetylcholinesterase/NN (l_appos) activity/NN (l_prep) in/IN (l_pobj) hippocampus/NN (l_prep) after/IN (l_pobj) seizures/NNS
D010862_D012640 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) seizures/NNS -PUNC- pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) status/NN (r_pobj) of/IN (r_prep) installation/NN (r_pobj) of/IN (r_prep) frequency/NN (r_dobj) reduce/VB (l_advcl) demonstrated/VBN (l_agent) by/IN (l_pobj) increase/NN (l_prep) to/IN (l_pobj) seizure/NN
18341442
C026098_D012640 NONE levetiracetam/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) initiation/NN (r_nsubjpass) compared/VBN (l_nsubjpass) frequencies/NNS (l_compound) Seizure/NN -PUNC- levetiracetam/NN (r_pcomp) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) was/VBD (l_nsubj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/NN (l_appos) seizures/NNS -PUNC- levetiracetam/NN (r_pcomp) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) was/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/NN (r_pcomp) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) was/VBD (l_prep) after/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) treatment/NN (l_appos) seizures/NNS -PUNC- levetiracetam/NN (r_pcomp) with/IN (r_prep) treatment/NN (r_pobj) to/IN (r_prep) prior/RB (r_advmod) was/VBD (l_conj) classified/VBN (l_prep) as/IN (l_pcomp) responded/VBN (l_attr) reduction/NN (l_prep) in/IN (l_pobj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) was/VBD (l_nsubj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) was/VBD (l_advmod) prior/RB (l_prep) to/IN (l_pobj) treatment/NN (l_prep) with/IN (l_pcomp) levetiracetam/NN (l_appos) seizures/NNS -PUNC- levetiracetam/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) was/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/NN (r_amod) treatment/NN (l_appos) seizures/NNS -PUNC- levetiracetam/NN (r_amod) treatment/NN (r_pobj) of/IN (r_prep) initiation/NN (r_pobj) after/IN (r_prep) was/VBD (l_conj) classified/VBN (l_prep) as/IN (l_pcomp) responded/VBN (l_attr) reduction/NN (l_prep) in/IN (l_pobj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/VB (r_xcomp) responded/VBN (r_pcomp) as/IN (r_prep) classified/VBN (r_conj) was/VBD (l_nsubj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/VB (r_xcomp) responded/VBN (r_pcomp) as/IN (r_prep) classified/VBN (r_conj) was/VBD (l_advmod) prior/RB (l_prep) to/IN (l_pobj) treatment/NN (l_prep) with/IN (l_pcomp) levetiracetam/NN (l_appos) seizures/NNS -PUNC- levetiracetam/VB (r_xcomp) responded/VBN (r_pcomp) as/IN (r_prep) classified/VBN (r_conj) was/VBD (l_acomp) higher/JJR (l_prep) than/IN (l_pobj) frequency/NN (l_compound) seizure/NN -PUNC- levetiracetam/VB (r_xcomp) responded/VBN (r_pcomp) as/IN (r_prep) classified/VBN (r_conj) was/VBD (l_prep) after/IN (l_pobj) initiation/NN (l_prep) of/IN (l_pobj) treatment/NN (l_appos) seizures/NNS -PUNC- levetiracetam/VB (r_xcomp) responded/VBN (l_attr) reduction/NN (l_prep) in/IN (l_pobj) frequency/NN (l_compound) seizure/NN
C026098_C562694 NONE Levetiracetam/NNP (l_advcl) phenobarbital/JJ (l_dobj) treatment/NN (l_prep) in/IN (l_pobj) cats/NNS (l_prep) with/IN (l_pobj) epilepsy/NN -PUNC- levetiracetam/NN (l_advcl) phenobarbital/JJ (l_dobj) treatment/NN (l_prep) in/IN (l_pobj) cats/NNS (l_prep) with/IN (l_pobj) epilepsy/NN -PUNC- levetiracetam/NN (r_nsubjpass) tolerated/VBN (l_conj) be/VB (l_acomp) useful/JJ (l_prep) as/IN (l_pobj) adjunct/NN (l_relcl) phenobarbital/JJ (l_dobj) treatment/NN (l_prep) in/IN (l_pobj) cats/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
D010634_C562694 NONE phenobarbital/JJ (l_dobj) treatment/NN (l_prep) in/IN (l_pobj) cats/NNS (l_prep) with/IN (l_pobj) epilepsy/NN -PUNC- phenobarbital/JJ (l_dobj) treatment/NN (l_prep) in/IN (l_pobj) cats/NNS (l_prep) with/IN (l_pobj) epilepsy/NN -PUNC- phenobarbital/JJ (r_pobj) with/IN (r_prep) controlled/VBN (r_relcl) epilepsy/NN -PUNC- phenobarbital/NN (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) had/VBD (r_conj) controlled/VBN (r_relcl) epilepsy/NN -PUNC- phenobarbital/JJ (l_dobj) treatment/NN (l_prep) in/IN (l_pobj) cats/NNS (l_prep) with/IN (l_pobj) epilepsy/NN
816141
D002512_D007674 NONE cephalothin/JJ (r_compound) therapy/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_nsubj) patient/NN (l_prep) with/IN (l_pobj) disease/NN
D002512_D000743 CID Cephalothin/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN -PUNC- cephalothin/JJ (r_compound) therapy/NN (r_dobj) receiving/VBG (r_advcl) developed/VBD (l_dobj) anemia/NN
573555
D011433_D006932 NONE propranolol/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_conj) are/VBP (l_nsubj) hypoglycemia/NN (l_conj) hyperbilirubinemia/NN
D011433_D007003 NONE propranolol/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_conj) are/VBP (l_nsubj) hypoglycemia/NN
D011433_D001049 NONE propranolol/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_conj) are/VBP (l_nsubj) hypoglycemia/NN (l_conj) hyperbilirubinemia/NN (l_conj) polycythemia/NN (l_conj) apnea/NN
D011433_D011086 NONE propranolol/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_conj) are/VBP (l_nsubj) hypoglycemia/NN (l_conj) hyperbilirubinemia/NN (l_conj) polycythemia/NN
D011433_D001919 NONE propranolol/NN (r_amod) therapy/NN (r_pobj) with/IN (r_prep) correlated/VBN (r_conj) are/VBP (l_nsubj) hypoglycemia/NN (l_conj) hyperbilirubinemia/NN (l_conj) polycythemia/NN (l_conj) apnea/NN (l_conj) bradycardia/NN
931801
D009005_D007674 NONE monosaccharides/NNS (r_pobj) by/IN (r_agent) spared/VBN (l_prep) from/IN (l_pobj) lesions/NNS
C038936_D051437 NONE 6,3-dilactone/CD (r_appos) D/NNP (r_nmod) rats/NNS (l_prep) against/IN (l_pobj) failure/NN
D000617_D058186 CID aminoglycoside/NN (r_compound) antibiotics/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_acl) failure/NN
D000617_D007674 NONE aminoglycoside/NN (r_conj) antibiotics/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) damage/NN
D000617_D003681 NONE aminoglycoside/NN (r_compound) antibiotics/NNS (r_pobj) of/IN (r_prep) injection/NN (r_pobj) following/VBG (r_acl) failure/NN (r_dobj) develop/VBP (l_nsubj) rats/NNS (l_amod) Dehydrated/JJ
D005937_D007674 NONE Glucarates/NNP (r_pobj) of/IN (r_prep) Effect/NN (l_prep) on/IN (l_pobj) damage/NN -PUNC- Glucarates/NNP (r_nsubj) were/VBD (l_acomp) effective/JJ (l_prep) against/IN (l_pobj) damage/NN -PUNC- glucarate/NN (r_pobj) With/IN (r_prep) obtained/VBN (l_prep) against/IN (l_pobj) damages/NNS -PUNC- Glucarates/NNP (r_nsubj) had/VBD (l_dobj) ability/NN (l_acl) prevent/VB (l_dobj) damage/NN -PUNC- glucarates/NNS (l_prep) against/IN (l_pobj) nephrotoxicity/NN
D007612_D051437 NONE kanamycin/NN (r_compound) dextran/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) failure/NN
24588023
D014148_D007035 NONE acid/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) arrest/NN (l_amod) hypothermic/JJ
D014148_D006333 NONE acid/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) arrest/NN (r_conj) failure/NN
D014148_D012640 CID acid/NN (l_conj) seizures/NNS (l_amod) convulsive/JJ -PUNC- acid/NN (l_conj) seizures/NNS -PUNC- acid/NN (r_pobj) of/IN (r_prep) duration/NN (r_conj) arrest/NN (r_conj) failure/NN (r_conj) calcification/NN (r_conj) surgery/NN (r_dobj) redo/VB (r_conj) included/VBD (l_nsubj) predictors/NNS (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acid/NN (r_nsubj) was/VBD (l_attr) predictor/NN (l_prep) of/IN (l_pobj) seizures/NNS -PUNC- acid/NN (r_nsubj) is/VBZ (r_advcl) weighed/VBN (l_prep) against/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) seizures/NNS
22836123
D016559_D012595 CID tacrolimus/NN (r_compound) use/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) SSc/NNS
D016572_D057049 CID cyclosporine/NN (r_pobj) by/IN (r_agent) precipitated/VBN (r_acl) microangiopathy/NN
D011239_D007674 NONE prednisolone/NN (r_conj) tacrolimus/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) crisis/NN
D000305_D007674 NONE corticosteroid/NN (r_compound) use/NN (r_pobj) to/IN (r_prep) Moderate/JJ (r_nsubjpass) recognized/VBN (l_prep) as/IN (l_pobj) factor/NN (l_prep) for/IN (l_pobj) SRC/NNP -PUNC- corticosteroids/NNS (r_conj) tacrolimus/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patient/NN (l_prep) with/IN (l_pobj) SRC/NNP
D016559_D007674 NONE tacrolimus/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) crisis/NN -PUNC- tacrolimus/NNS (r_pobj) by/IN (r_agent) induced/VBN (r_acl) patient/NN (l_prep) with/IN (l_pobj) SRC/NNP
D016572_D012595 NONE cyclosporine/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) SSc/NNS
20589632
D014295_D000743 CID Trimethoprim/NNP (r_npadvmod) induced/VBN (r_amod) anemia/NN
3323599
D011479_D007676 NONE PS/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) enhances/VBZ (l_conj) produces/VBZ (l_dobj) FSGS/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) disease/NN
D011692_D007676 CID AMNS/NNP (r_pobj) of/IN (r_prep) toxicity/NN (r_dobj) enhances/VBZ (l_conj) produces/VBZ (l_dobj) FSGS/NNS (l_prep) in/IN (l_pobj) rats/NNS (l_acl) resulting/VBG (l_prep) in/IN (l_pobj) disease/NN
D011692_D064420 NONE AMNS/NNP (r_pobj) of/IN (r_prep) toxicity/NN
D011479_D064420 NONE PS/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) enhances/VBZ (l_dobj) toxicity/NN
D011692_D009401 NONE aminonucleoside/JJ (r_amod) nephrosis/NN
D011479_D005923 NONE sulfate/NN (r_dobj) protamine/NN (r_conj) AMNS/NNP (r_appos) aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_prep) of/IN (l_pobj) sclerosis/NN -PUNC- sulfate/NN (r_dobj) protamine/NN (r_conj) AMNS/NNP (r_appos) aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_appos) FSGS/NNP -PUNC- PS/NNP (r_appos) sulfate/NN (r_dobj) protamine/NN (r_conj) AMNS/NNP (r_appos) aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_prep) of/IN (l_pobj) sclerosis/NN -PUNC- PS/NNP (r_appos) sulfate/NN (r_dobj) protamine/NN (r_conj) AMNS/NNP (r_appos) aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_appos) FSGS/NNP -PUNC- PS/NNP (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) enhances/VBZ (l_conj) produces/VBZ (l_dobj) FSGS/NNS
D011692_D005923 CID aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_prep) of/IN (l_pobj) sclerosis/NN -PUNC- aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_appos) FSGS/NNP -PUNC- AMNS/NNP (r_appos) aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_prep) of/IN (l_pobj) sclerosis/NN -PUNC- AMNS/NNP (r_appos) aminonucleoside/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) by/IN (r_agent) developed/VBN (l_nsubjpass) model/NN (l_appos) FSGS/NNP -PUNC- AMNS/NNP (r_pobj) of/IN (r_prep) toxicity/NN (r_dobj) enhances/VBZ (l_conj) produces/VBZ (l_dobj) FSGS/NNS
23864035
D003907_D009101 NONE dexamethasone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- bort)-dexamethasone/NNP (r_nmod) dex/NN (r_appos) Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN -PUNC- bort)-dexamethasone/NNP (r_nmod) dex/NN (r_appos) Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN (l_appos) MM/NNP -PUNC- dex/NN (r_appos) Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN -PUNC- dex/NN (r_appos) Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN (l_appos) MM/NNP -PUNC- dex/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP -PUNC- dex/NN (r_nsubj) was/VBD (l_attr) treatment/NN (l_prep) for/IN (l_pobj) patients/NNS (l_compound) MM/NNP
C400082_D009101 NONE Bortezomib/NNP (l_conj) dexamethasone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) myeloma/NN -PUNC- Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN -PUNC- Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN (l_appos) MM/NNP -PUNC- bort)-dexamethasone/NNP (r_nmod) dex/NN (r_appos) Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN -PUNC- bort)-dexamethasone/NNP (r_nmod) dex/NN (r_appos) Bortezomib/NNP (r_nsubj) is/VBZ (l_attr) therapy/NN (l_prep) for/IN (l_pobj) R/NNP (l_appos) myeloma/NN (l_appos) MM/NNP -PUNC- bort/NN (r_pobj) of/IN (r_prep) combination/NN (r_dobj) investigated/VBD (l_conj) dex/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP -PUNC- bort/NN (r_pobj) after/IN (r_prep) day/NN (r_conj) dex/NN (l_prep) as/IN (l_pobj) treatment/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) MM/NNP -PUNC- Bort/NNP (r_compound) dex/NN (r_nsubj) was/VBD (l_attr) treatment/NN (l_prep) for/IN (l_pobj) patients/NNS (l_compound) MM/NNP
6299641
D007545_D013610 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) tachycardia/NN -PUNC- isoproterenol/NN (r_compound) tachycardia/NNS -PUNC- isoproterenol/NN (r_nsubj) activates/VBZ (r_advcl) are/VBP (l_acomp) consistent/JJ (l_prep) with/IN (l_pobj) hypothesis/NN (l_relcl) results/NNS (l_nsubj) tachycardia/NN
D001285_D013610 NONE atropine/NN (r_pobj) after/IN (r_prep) IV/NNP (r_conj) before/RB (r_prep) determined/VBN (l_nsubjpass) effects/NNS (l_prep) on/IN (l_pobj) tachycardia/NNS
D011433_D013610 NONE propranolol/NN (l_conj) placebo/NN (l_prep) on/IN (l_pobj) exercise-/JJ (l_conj) tachycardia/NN
D001262_D013610 NONE atenolol/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) compared/VBD (r_ccomp) propranolol/NN (l_conj) placebo/NN (l_prep) on/IN (l_pobj) exercise-/JJ (l_conj) tachycardia/NN
20682692
D000804_D003928 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubj) retard/VB (l_advcl) suggesting/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) nephropathy/NN -PUNC- angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubj) retard/VB (l_advcl) suggesting/VBG (l_ccomp) involved/VBN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) nephropathy/NN (l_appos) nephropathy/NN
D000804_D007674 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) blockade/NN (r_nsubj) retard/VB (l_dobj) progression/NN (l_prep) of/IN (l_pobj) nephropathy/NN
D000804_D003922 NONE angiotensin/NN (r_compound) system/NN (r_pobj) of/IN (r_prep) blockade/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS
D013311_D003920 NONE streptozotocin/JJ (r_nmod) diabetes/NNS -PUNC- STZ)-induced/VBN (r_amod) diabetes/NNS
D013311_D005355 NONE streptozotocin/JJ (r_nmod) diabetes/NNS (r_pobj) with/IN (r_prep) mice/NNS (r_pobj) in/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) fibrosis/NN -PUNC- STZ)-induced/VBN (r_amod) diabetes/NNS (r_pobj) with/IN (r_prep) mice/NNS (r_pobj) in/IN (r_prep) development/NN (l_prep) of/IN (l_pobj) fibrosis/NN
D013311_D003928 CID streptozotocin/NNS (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- STZ/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN -PUNC- STZ/NNP (r_npadvmod) induced/VBN (r_amod) nephropathy/NN
3864191
-1_D006932 NONE glucuronyl/NN (r_compound) transferase/NN (r_pobj) of/IN (r_prep) absence/NN (r_pobj) due/IN (r_amod) hyperbilirubinemia/NN
D011453_D006417 NONE prostaglandin/NN (r_amod) synthesis/NN (r_pobj) in/IN (r_prep) changes/NNS (r_nsubjpass) accompanied/VBN (l_agent) by/IN (l_pobj) evidence/NN (l_conj) rats/NNS (l_conj) incidence/NN (l_prep) of/IN (l_pobj) hematuria/NN
D011453_D058186 NONE prostaglandin/NN (r_amod) synthesis/NN (r_nsubj) contributes/VBZ (l_conj) lead/VB (l_prep) to/IN (l_pobj) lesions/NNS -PUNC- prostaglandin/JJ (r_amod) synthesis/NN (r_pobj) of/IN (r_prep) inhibition/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) lesions/NNS
D001241_D006417 NONE aspirin/NN (r_npadvmod) treated/VBN (r_amod) jj/UH (r_pobj) in/IN (r_prep) damage/NN (r_pobj) of/IN (r_prep) evidence/NN (l_conj) rats/NNS (l_conj) incidence/NN (l_prep) of/IN (l_pobj) hematuria/NN -PUNC- aspirin/NN (r_npadvmod) treated/VBN (r_amod) jJ/NNP (r_conj) jj/NNS (r_pobj) to/IN (r_prep) compared/VBN (r_prep) p/XX (r_appos) increase/VB (r_conj) creatinine/NN (r_conj) rats/NNS (l_conj) incidence/NN (l_prep) of/IN (l_pobj) hematuria/NN
D001663_D006932 NONE bilirubin/NN (r_amod) deposition/NN (r_pobj) to/IN (r_prep) leading/VBG (r_advcl) have/VBP (l_dobj) hyperbilirubinemia/NN
D012459_D007674 NONE Salicylate/NNP (r_compound) nephropathy/NN
D001241_D007674 CID aspirin/NN (r_npadvmod) treated/VBN (r_amod) jj/UH (r_pobj) in/IN (r_prep) damage/NN -PUNC- aspirin/NN (r_npadvmod) treated/VBN (r_amod) jJ/NNP (r_conj) jj/NNS (r_pobj) to/IN (r_prep) compared/VBN (r_prep) p/XX (r_appos) increase/VB (r_conj) creatinine/NN (r_conj) rats/NNS (r_conj) evidence/NN (l_prep) of/IN (l_pobj) damage/NN
D003404_D006417 NONE creatinine/NN (r_conj) rats/NNS (l_conj) incidence/NN (l_prep) of/IN (l_pobj) hematuria/NN
D003404_D007674 NONE creatinine/NN (r_conj) rats/NNS (r_conj) evidence/NN (l_prep) of/IN (l_pobj) damage/NN
D011453_D007674 NONE prostaglandins/NNS (r_pobj) of/IN (r_prep) role/NN (r_appos) nephropathy/NN -PUNC- prostaglandins/NNS (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) nephropathy/NN -PUNC- prostaglandin/NN (r_amod) synthesis/NN (r_pobj) in/IN (r_prep) changes/NNS (r_nsubjpass) accompanied/VBN (l_agent) by/IN (l_pobj) evidence/NN (l_prep) of/IN (l_pobj) damage/NN -PUNC- prostaglandin/NN (r_amod) synthesis/NN (r_nsubj) contributes/VBZ (l_conj) lead/VB (l_prep) to/IN (l_pobj) lesions/NNS (l_conj) deterioration/NN (l_prep) of/IN (l_pobj) function/NN -PUNC- prostaglandin/JJ (r_amod) synthesis/NN (r_pobj) of/IN (r_prep) inhibition/NN (r_nsubj) lead/VB (l_prep) to/IN (l_pobj) lesions/NNS (l_conj) deterioration/NN (l_prep) of/IN (l_pobj) function/NN
20447294
C401121_D007249 NONE CNSB002/NNP (r_conj) morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) for/IN (r_prep) curves/VBZ (r_nsubjpass) constructed/VBN (r_ccomp) inflammation/NN
D009020_D009422 NONE morphine/NN (r_conj) CNSB002/NNP (r_pobj) for/IN (r_prep) model/NN (l_compound) neuropathy/NN -PUNC- morphine/NN (r_pobj) for/IN (r_prep) values/NNS (r_nsubj) were/VBD (l_acomp) less/JJR (l_conj) 1.37/CD (l_prep) in/IN (l_pobj) model/NN (l_compound) neuropathy/NN -PUNC- morphine/NN (r_pobj) after/IN (r_prep) antinociception/NN (r_nsubjpass) increased/VBN (l_prep) from/IN (l_conj) reversal/NN (l_prep) in/IN (l_pobj) models/NNS (l_amod) inflammatory/JJ (l_conj) neuropathic/JJ
D002351_D007249 CID carrageenan/NN (r_npadvmod) induced/VBN (r_amod) inflammation/NN
C401121_D010146 NONE CNSB002/NNP (r_conj) morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) for/IN (r_prep) curves/VBZ (r_nsubjpass) constructed/VBN (l_prep) for/IN (l_pobj) effect/NN (l_acl) using/VBG (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
C401121_D009437 NONE CNSB002/NNP (r_appos) blocker/NN (r_conj) morphine/NN (r_pobj) between/IN (r_prep) synergy/NN (r_pobj) of/IN (r_prep) Studies/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- CNSB002/NNP (l_appos) blocker/NN (l_prep) with/IN (l_conj) in/IN (l_pobj) combinations/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D009020_D003929 NONE morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) for/IN (r_prep) curves/VBZ (r_nsubjpass) constructed/VBN (r_ccomp) inflammation/NN (l_appos) neuropathy/NN
D013311_D007249 NONE streptozotocin/JJ (r_conj) inflammation/NN -PUNC- STZ)-induced/VBN (r_amod) neuropathy/NN (r_appos) inflammation/NN
C401121_D006930 NONE CNSB002/NNP (r_pobj) for/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) 7.54/CD (r_attr) were/VBD (l_nsubj) doses/NNS (l_acl) calculated/VBN (l_advcl) cause/VB (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- CNSB002/NNP (r_pobj) with/IN (r_punct) from/IN (l_conj) reversal/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN
D013311_D003929 CID streptozotocin/JJ (r_conj) inflammation/NN (l_appos) neuropathy/NN -PUNC- STZ)-induced/VBN (r_amod) neuropathy/NN
D009020_D010146 NONE morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) for/IN (r_prep) curves/VBZ (r_nsubjpass) constructed/VBN (l_prep) for/IN (l_pobj) effect/NN (l_acl) using/VBG (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D002351_D010146 NONE carrageenan/NN (r_npadvmod) induced/VBN (r_amod) inflammation/NN (l_ccomp) constructed/VBN (l_prep) for/IN (l_pobj) effect/NN (l_acl) using/VBG (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
C401121_D009422 NONE CNSB002/NNP (r_pobj) for/IN (r_prep) model/NN (l_compound) neuropathy/NN -PUNC- CNSB002/NNP (r_pobj) with/IN (r_prep) combination/NN (r_pobj) in/IN (r_prep) given/VBN (r_advcl) values/NNS (r_nsubj) were/VBD (l_acomp) less/JJR (l_conj) 1.37/CD (l_prep) in/IN (l_pobj) model/NN (l_compound) neuropathy/NN -PUNC- CNSB002/NNP (r_pobj) with/IN (r_punct) from/IN (l_conj) reversal/NN (l_prep) in/IN (l_pobj) models/NNS (l_amod) inflammatory/JJ (l_conj) neuropathic/JJ
D012964_D009437 NONE sodium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_conj) morphine/NN (r_pobj) between/IN (r_prep) synergy/NN (r_pobj) of/IN (r_prep) Studies/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- sodium/NN (r_compound) channel/NN (r_compound) blocker/NN (l_prep) with/IN (l_conj) in/IN (l_pobj) combinations/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN
C401121_D003929 NONE CNSB002/NNP (r_conj) morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) for/IN (r_prep) curves/VBZ (r_nsubjpass) constructed/VBN (r_ccomp) inflammation/NN (l_appos) neuropathy/NN
D009020_D007249 NONE morphine/NN (r_pobj) of/IN (r_prep) doses/NNS (r_pobj) for/IN (r_prep) curves/VBZ (r_nsubjpass) constructed/VBN (r_ccomp) inflammation/NN
D013311_D009422 NONE STZ/NNP (r_npadvmod) induced/VBN (r_amod) model/NN (l_compound) neuropathy/NN
D002351_D003929 NONE carrageenan/NN (r_npadvmod) induced/VBN (r_amod) inflammation/NN (l_appos) neuropathy/NN
D013311_D006930 CID STZ/NNP (r_npadvmod) induced/VBN (r_amod) model/NN (r_pobj) in/IN (r_prep) 7.54/CD (r_attr) were/VBD (l_nsubj) doses/NNS (l_acl) calculated/VBN (l_advcl) cause/VB (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN
D013311_D010146 NONE streptozotocin/JJ (r_conj) inflammation/NN (l_ccomp) constructed/VBN (l_prep) for/IN (l_pobj) effect/NN (l_acl) using/VBG (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN -PUNC- STZ)-induced/VBN (r_amod) neuropathy/NN (r_appos) inflammation/NN (l_ccomp) constructed/VBN (l_prep) for/IN (l_pobj) effect/NN (l_acl) using/VBG (l_prep) in/IN (l_pobj) models/NNS (l_compound) pain/NN
D009020_D009437 NONE morphine/NN (r_pobj) between/IN (r_prep) synergy/NN (r_pobj) of/IN (r_prep) Studies/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN -PUNC- morphine/NN (r_pobj) with/IN (r_prep) combinations/NNS (l_prep) in/IN (l_pobj) models/NNS (l_prep) of/IN (l_pobj) pain/NN
D002351_D006930 CID carrageenan/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) 4.83/CD (r_conj) 7.54/CD (r_attr) were/VBD (l_nsubj) doses/NNS (l_acl) calculated/VBN (l_advcl) cause/VB (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN
D002351_D009422 NONE carrageenan/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) 4.83/CD (r_conj) 7.54/CD (l_prep) in/IN (l_pobj) model/NN (l_compound) neuropathy/NN -PUNC- carrageenan/NN (r_compound) model/NN (r_pobj) in/IN (r_prep) dose/NN (r_pobj) than/IN (r_prep) less/JJR (l_conj) 1.37/CD (l_prep) in/IN (l_pobj) model/NN (l_compound) neuropathy/NN
D009020_D006930 NONE morphine/NN (r_conj) CNSB002/NNP (r_pobj) for/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) 7.54/CD (r_attr) were/VBD (l_nsubj) doses/NNS (l_acl) calculated/VBN (l_advcl) cause/VB (l_dobj) reversal/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN -PUNC- morphine/NN (r_pobj) after/IN (r_prep) antinociception/NN (r_nsubjpass) increased/VBN (l_prep) from/IN (l_conj) reversal/NN (l_prep) of/IN (l_pobj) hyperalgesia/NN
11988250
D007052_D006976 CID ibuprofen/NNP (r_compound) prophylaxis/NN (r_pobj) after/IN (r_prep) hypertension/NN
D007052_D000860 CID ibuprofen/NNP (r_compound) administration/NN (r_pobj) after/IN (r_prep) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) hypoxaemia/JJ -PUNC- ibuprofen/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) of/IN (r_prep) trial/NN (r_pobj) during/IN (r_prep) report/VBP (l_dobj) cases/NNS (l_prep) of/IN (l_pobj) hypoxaemia/JJ -PUNC- ibuprofen/NNP (r_pobj) of/IN (r_prep) administration/NN (r_pobj) after/IN (r_prep) occurs/VBZ (l_nsubj) hypoxaemia/JJ
D009569_D000860 NONE oxide/NN (r_compound) therapy/NN (r_pobj) on/IN (r_prep) resolved/VBD (l_nsubj) Hypoxaemia/NNP
D007052_D004374 NONE ibuprofen/NNP (r_compound) administration/NN (r_pobj) after/IN (r_prep) report/VBP (l_prep) during/IN (l_pobj) trial/NN (l_prep) of/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) arteriosus/NN -PUNC- ibuprofen/NN (r_pobj) with/IN (r_prep) treatment/NN (l_prep) of/IN (l_pobj) arteriosus/NN
18945509
D005905_D003324 CID glibenclamide/NN (r_pobj) with/IN (r_prep) increased/VBN (r_acl) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) hazard/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) CAD/NNP -PUNC- glibenclamide/NN (r_pobj) with/IN (r_prep) diabetes/NNS (r_dobj) Initiating/VBG (r_csubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) CAD/NNP
C057619_D003324 NONE glimepiride/NN (r_conj) gliclazide/VB (r_pobj) to/TO (r_prep) comparison/NN (r_pobj) in/IN (r_prep) risk/NN (l_prep) of/IN (l_pobj) CAD/NNP
D005907_D003324 NONE gliclazide/VB (r_pobj) to/TO (r_prep) comparison/NN (r_pobj) in/IN (r_prep) risk/NN (l_prep) of/IN (l_pobj) CAD/NNP
-1_D003324 NONE sulphonylurea/JJ (r_compound) treatment/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) disease/NN -PUNC- sulphonylureas/NNS (r_pobj) with/IN (r_prep) diabetes/NNS (r_dobj) developing/VBG (l_dobj) disease/NN -PUNC- sulphonylureas/NNS (r_pobj) with/IN (r_prep) diabetes/NNS (r_dobj) developing/VBG (l_dobj) disease/NN (l_appos) CAD/NNP
D005913_D003924 NONE glipizide/NN (r_conj) glibenclamide/NN (r_pobj) with/IN (r_prep) diabetes/NNS
C057619_D003924 NONE glimepiride/NN (r_conj) gliclazide/VB (r_pobj) to/TO (r_prep) comparison/NN (r_pobj) in/IN (r_prep) risk/NN (r_pobj) with/IN (r_prep) associated/VBN (l_csubjpass) Initiating/VBG (l_dobj) diabetes/NNS
D005913_D003324 NONE glipizide/NN (r_pobj) with/IN (r_prep) 2-fold/JJ (r_appos) hazard/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) CAD/NNP -PUNC- glipizide/NN (r_conj) glibenclamide/NN (r_pobj) with/IN (r_prep) diabetes/NNS (r_dobj) Initiating/VBG (r_csubjpass) associated/VBN (l_prep) with/IN (l_pobj) risk/NN (l_prep) of/IN (l_pobj) CAD/NNP
D008687_D003324 NONE metformin/NN (r_pobj) with/IN (r_prep) unchanged/JJ (r_acomp) was/VBD (r_conj) 2-fold/JJ (r_appos) hazard/NN (l_prep) of/IN (l_pcomp) developing/VBG (l_dobj) CAD/NNP
D005905_D003924 NONE glibenclamide/NN (r_pobj) with/IN (r_prep) diabetes/NNS
D005907_D003924 NONE gliclazide/VB (r_pobj) to/TO (r_prep) comparison/NN (r_pobj) in/IN (r_prep) risk/NN (r_pobj) with/IN (r_prep) associated/VBN (l_csubjpass) Initiating/VBG (l_dobj) diabetes/NNS
-1_D003924 NONE sulphonylurea/JJ (r_compound) treatment/NN (l_prep) of/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) diabetes/NNS -PUNC- sulphonylureas/NNS (r_pobj) with/IN (r_prep) diabetes/NNS
17151160
C076029_D010302 NONE olanzapine/NN (r_pobj) with/IN (r_prep) risperidone/NN (r_pobj) with/IN (r_prep) were/VBD (l_ccomp) differ/VB (l_nsubj) outcomes/NNS (l_conj) measures/NNS (l_prep) of/IN (l_pobj) parkinsonism/NN
C076029_D011618 NONE olanzapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_xcomp) assigned/VBN (l_nsubjpass) disorder/NN -PUNC- olanzapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_xcomp) assigned/VBN (l_nsubjpass) disorder/NN (l_conj) disorder/NN
D018967_D015430 CID risperidone/NN (r_pobj) with/IN (r_prep) than/IN (r_prep) occurred/VBD (l_nsubj) gain/NN -PUNC- risperidone/NN (r_pobj) with/IN (r_prep) %/NN (r_conj) olanzapine/NN (r_pobj) with/IN (r_prep) %/NN (r_attr) was/VBD (r_conj) occurred/VBD (l_nsubj) gain/NN
D018967_D017109 NONE risperidone/NN (r_pobj) with/IN (r_prep) were/VBD (l_ccomp) differ/VB (l_nsubj) outcomes/NNS (l_conj) akathisia/NN
C076029_D001480 CID olanzapine/NN (r_pobj) with/IN (r_prep) risperidone/NN (r_pobj) with/IN (r_prep) were/VBD (l_ccomp) differ/VB (l_prep) between/IN (l_pobj) scores/NNS (l_compound) symptom/NN
C076029_D015430 CID olanzapine/NN (r_pobj) with/IN (r_prep) occurred/VBD (l_nsubj) gain/NN -PUNC- olanzapine/NN (r_pobj) with/IN (r_prep) %/NN (r_attr) was/VBD (r_conj) occurred/VBD (l_nsubj) gain/NN -PUNC- olanzapine/NN (r_pobj) with/IN (r_prep) greater/JJR (r_acomp) was/VBD (r_conj) caused/VBD (l_dobj) gain/NN -PUNC- olanzapine/NN (r_pobj) with/IN (r_prep) greater/JJR (r_acomp) was/VBD (l_nsubj) gain/NN
D018967_D001480 CID risperidone/NN (r_pobj) with/IN (r_prep) were/VBD (l_ccomp) differ/VB (l_prep) between/IN (l_pobj) scores/NNS (l_compound) symptom/NN
D018967_D011618 NONE risperidone/NN (r_conj) treatment/NN (r_xcomp) assigned/VBN (l_nsubjpass) disorder/NN -PUNC- risperidone/NN (r_conj) treatment/NN (r_xcomp) assigned/VBN (l_nsubjpass) disorder/NN (l_conj) disorder/NN
D018967_D012559 NONE risperidone/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- risperidone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS (l_compound) schizophrenia/NN -PUNC- risperidone/NN (r_conj) treatment/NN (r_xcomp) assigned/VBN (r_conj) mean/JJ (l_prep) with/IN (l_pobj) schizophrenia/NN
C076029_D012559 NONE olanzapine/NN (l_prep) versus/IN (l_pobj) risperidone/NN (l_prep) for/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) schizophrenia/NN -PUNC- olanzapine/NN (l_prep) versus/IN (l_pobj) risperidone/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disorders/NNS (l_compound) schizophrenia/NN -PUNC- olanzapine/NN (r_pobj) with/IN (r_prep) treatment/NN (r_xcomp) assigned/VBN (r_conj) mean/JJ (l_prep) with/IN (l_pobj) schizophrenia/NN
D018967_D010302 NONE risperidone/NN (r_pobj) with/IN (r_prep) were/VBD (l_ccomp) differ/VB (l_nsubj) outcomes/NNS (l_conj) measures/NNS (l_prep) of/IN (l_pobj) parkinsonism/NN
C076029_D017109 NONE olanzapine/NN (r_pobj) with/IN (r_prep) risperidone/NN (r_pobj) with/IN (r_prep) were/VBD (l_ccomp) differ/VB (l_nsubj) outcomes/NNS (l_conj) akathisia/NN
24897009
D004977_D010523 NONE ethambutol/NN (r_amod) overtreatment/NN (r_pobj) due/IN (r_prep) Optochiasmatic/JJ (l_conj) neuropathy/NN
D004977_D014786 CID ethambutol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) loss/NN
D004977_D064420 NONE ethambutol/VB (l_dobj) toxicity/NN
D004977_D010292 CID ethambutol/NN (r_pobj) of/IN (r_prep) dose/NN (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) of/IN (r_prep) weeks/NNS (r_pobj) after/IN (r_prep) developed/VBD (l_dobj) loss/NN (l_conj) paresthesias/NNS
D004977_D011115 CID Ethambutol/NNP (r_nsubjpass) known/VBN (l_conj) polyneuropathy/NN
D004977_D009901 CID Ethambutol/NNP (r_nsubjpass) known/VBN (l_xcomp) cause/VB (l_dobj) neuropathy/NN
19392810
D008691_D002544 NONE methadone/NN (r_compound) therapy/NN (r_pobj) under/IN (r_prep) stroke/NN -PUNC- methadone/NN (r_dobj) using/VBG (r_acl) Those/DT (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) rhabdomyolysis/NN (l_conj) stroke/NN
D003932_D012206 CID heroin/NN (r_npadvmod) dependent/JJ (r_amod) male/NN (r_pobj) in/IN (r_prep) stroke/NN (l_nmod) Rhabdomyolysis/NNP -PUNC- heroin/NN (r_pobj) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) rhabdomyolysis/NN -PUNC- heroin/NN (r_conj) methadone/NN (r_dobj) using/VBG (r_acl) Those/DT (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) rhabdomyolysis/NN -PUNC- heroin/NN (r_npadvmod) related/VBN (r_amod) rhabdomyolysis/NN -PUNC- heroin/NN (r_compound) abusers/NNS (r_pobj) in/IN (r_prep) stroke/NN (r_conj) rhabdomyolysis/NN
D008691_D012206 CID methadone/NN (r_compound) therapy/NN (r_pobj) under/IN (r_prep) stroke/NN (l_nmod) Rhabdomyolysis/NNP -PUNC- methadone/NN (r_dobj) using/VBG (r_acl) Those/DT (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) rhabdomyolysis/NN
D003932_D002544 NONE heroin/NN (r_npadvmod) dependent/JJ (r_amod) male/NN (r_pobj) in/IN (r_prep) stroke/NN -PUNC- heroin/NN (r_pobj) after/IN (r_prep) presented/VBN (l_prep) with/IN (l_pobj) rhabdomyolysis/NN (l_conj) stroke/NN -PUNC- heroin/NN (r_conj) methadone/NN (r_dobj) using/VBG (r_acl) Those/DT (r_nsubj) increase/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) rhabdomyolysis/NN (l_conj) stroke/NN
D003932_D020521 CID heroin/NN (r_npadvmod) related/VBN (r_amod) rhabdomyolysis/NN (l_conj) stroke/NN -PUNC- heroin/NN (r_compound) abusers/NNS (r_pobj) in/IN (r_prep) stroke/NN
2217015
D008528_D009503 CID acid/NN (r_npadvmod) induced/VBN (l_dobj) neutropenia/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) failure/NN (l_conj) occurring/VBG (l_compound) neutropenia/NN
D008528_D051437 CID acid/NN (r_npadvmod) induced/VBN (l_dobj) neutropenia/NN (l_conj) failure/NN -PUNC- acid/NN (r_npadvmod) induced/VBN (r_amod) failure/NN
D008528_D007037 NONE acid/NN (r_npadvmod) induced/VBN (l_dobj) neutropenia/NN (l_prep) with/IN (l_pobj) hypothyroidism/NN -PUNC- acid/NN (r_dobj) use/VB (l_prep) in/IN (l_pobj) patients/NNS (l_amod) hypothyroid/JJ -PUNC- acid/NN (r_dobj) use/VB (l_advcl) corrected/VBN (l_nsubjpass) hypothyroidism/NN
9538487
D005947_D018500 NONE glucose/NN (r_compound) concentrations/NNS (r_pobj) despite/IN (r_prep) remained/VBD (r_ccomp) indicated/VBD (l_dobj) insipidus/NN
D008094_D011141 CID lithium/NN (r_npadvmod) induced/VBN (r_acomp) be/VB (r_xcomp) likely/JJ (r_amod) indicated/VBD (l_ccomp) remained/VBD (l_acomp) polyuric/JJ
D005947_D059606 NONE glucose/NN (r_pobj) for/IN (r_prep) negative/JJ (r_acomp) been/VBN (r_relcl) history/NN (l_prep) of/IN (l_pobj) polyuria/NN (l_conj) polydipsia/NN
D008094_D018500 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN -PUNC- lithium/NN (r_npadvmod) induced/VBN (r_acomp) be/VB (r_xcomp) likely/JJ (r_amod) indicated/VBD (l_dobj) insipidus/NN
D008094_-1 NONE lithium/NN (r_npadvmod) induced/VBN (r_acomp) be/VB (r_xcomp) likely/JJ (r_amod) indicated/VBD (l_ccomp) remained/VBD (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hyperglycaemia/NN
D005947_-1 NONE glucose/NN (r_compound) concentrations/NNS (r_pobj) despite/IN (r_prep) remained/VBD (l_prep) After/IN (l_pobj) recovery/NN (l_prep) from/IN (l_pobj) hyperglycaemia/NN
D008094_D001714 NONE lithium/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) depression/NN
D008094_D006944 CID lithium/NN (r_npadvmod) induced/VBN (r_amod) insipidus/NN (r_pobj) by/IN (r_agent) precipitated/VBD (l_nsubj) coma/NN -PUNC- lithium/NN (r_pobj) with/IN (r_prep) treated/VBN (r_acl) depression/NN (r_pobj) of/IN (r_prep) history/NN (r_pobj) with/IN (r_prep) admitted/VBN (l_npadvmod) coma/NN
D005947_D011141 NONE glucose/NN (r_pobj) for/IN (r_prep) negative/JJ (r_acomp) been/VBN (r_relcl) history/NN (l_prep) of/IN (l_pobj) polyuria/NN -PUNC- glucose/NN (r_compound) concentrations/NNS (r_pobj) despite/IN (r_prep) remained/VBD (l_acomp) polyuric/JJ
24733133
D006493_D055499 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) with/IN (r_prep) patient/NN (r_pobj) in/IN (r_prep) thrombolysis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_dobj) developed/VBD (l_conj) treated/VBN (l_prep) with/IN (l_pobj) thrombolysis/NN
C031942_D055499 NONE argatroban/NN (r_amod) thrombolysis/NN -PUNC- argatroban/NN (r_amod) thrombolysis/NN
C031942_D013479 NONE argatroban/NN (r_amod) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_prep) with/IN (l_pobj) amyloidosis/NN (l_conj) syndrome/NN
D006493_D011655 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) embolism/NN
C031942_D013921 NONE argatroban/NN (r_amod) thrombolysis/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) thrombocytopenia/NN -PUNC- argatroban/NN (r_amod) thrombolysis/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) developed/VBD (l_dobj) thrombocytopenia/NN -PUNC- argatroban/NN (r_amod) thrombolysis/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) developed/VBD (l_dobj) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP -PUNC- argatroban/NN (r_amod) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_prep) to/IN (l_pobj) HITT/NNP
D006493_D020246 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) embolism/NN (r_conj) thrombosis/NN (l_appos) DVT/NNP
D006493_D013927 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP
C031942_D000686 NONE argatroban/NN (r_amod) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_prep) with/IN (l_pobj) amyloidosis/NN
D006493_D056824 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) embolism/NN (r_conj) thrombosis/NN
C031942_D004844 NONE argatroban/NN (r_amod) on/IN (r_prep) restarted/VBN (r_conj) resolved/VBD (l_nsubj) epistaxis/NN
D006493_D013921 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN
C031942_D013927 NONE argatroban/NN (r_amod) thrombolysis/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- argatroban/NN (r_amod) thrombolysis/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) developed/VBD (l_dobj) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN -PUNC- argatroban/NN (r_amod) thrombolysis/NN (r_pobj) with/IN (r_prep) treated/VBN (r_conj) developed/VBD (l_dobj) thrombocytopenia/NN (l_prep) with/IN (l_pobj) thrombosis/NN (l_appos) HITT/NNP -PUNC- argatroban/NN (r_amod) with/IN (r_prep) treated/VBN (l_nsubjpass) man/NN (l_prep) to/IN (l_pobj) HITT/NNP
D006493_D000686 NONE heparin/NN (r_npadvmod) induced/VBN (r_amod) thrombocytopenia/NN (r_pobj) to/IN (r_prep) secondary/JJ (r_amod) embolism/NN (r_conj) thrombosis/NN (r_dobj) developed/VBD (l_nsubj) man/NN (l_prep) with/IN (l_pobj) amyloidosis/NN
24100055
D006493_D013921 CID heparin/NN (r_npadvmod) induced/VBN (r_amod) II/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) II/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) II/NNP (l_appos) II/NNP -PUNC- heparin/NN (r_npadvmod) induced/VBN (r_amod) II/NNP (r_pobj) of/IN (r_prep) impact/NN (l_prep) as/IN (l_pobj) cause/NN (l_prep) of/IN (l_pobj) thrombocytopenia/NN -PUNC- heparin/NN (r_pobj) of/IN (r_prep) use/NN (r_nsubjpass) avoided/VBN (l_prep) For/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) II/NNP -PUNC- heparin/NN (r_pobj) with/IN (r_prep) performed/VBN (r_conj) avoided/VBN (l_prep) For/IN (l_pobj) reduction/NN (l_prep) of/IN (l_pobj) II/NNP
16810074
D019335_D006973 NONE arginine/NN (r_nmod) hypertension/NN -PUNC- LNNA/NNP (r_nmod) hypertension/NN -PUNC- LNNA/NNP (r_compound) hypertension/NN -PUNC- LNNA/NNP (r_pobj) after/IN (r_prep) elevated/VBN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- LNNA/NNS (r_nmod) rats/NNS (l_amod) hypertensive/JJ
D018738_D006973 NONE hexamethonium/NN (r_pobj) with/IN (r_prep) blockade/NN (r_nsubj) caused/VBD (l_dobj) fall/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ
D009569_D006973 CID oxide/NN (r_nmod) deficiency/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Mechanisms/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- NO/NNP (r_intj) deficiency/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubj) Mechanisms/NNS (l_prep) of/IN (l_pobj) hypertension/NN -PUNC- oxide/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- NO/NNP (r_appos) oxide/NN (l_prep) in/IN (l_pobj) hypertension/NN -PUNC- NO/UH (r_pobj) of/IN (r_prep) removal/NN (r_pobj) by/IN (r_agent) created/VBN (r_acl) hypertension/NN -PUNC- NO/DT (r_det) deficiency/NN (r_nsubj) increases/VBZ (r_advcl) make/VB (l_dobj) contribution/NN (l_prep) to/IN (l_pobj) form/NN (l_prep) of/IN (l_pobj) hypertension/NN
D009569_D018754 NONE oxide/NN (r_pobj) of/IN (r_prep) Loss/NN (r_nsubj) is/VBZ (l_attr) hallmark/NN (l_prep) of/IN (l_pobj) dysfunction/NN -PUNC- NO/NNP (r_appos) oxide/NN (r_pobj) of/IN (r_prep) Loss/NN (r_nsubj) is/VBZ (l_attr) hallmark/NN (l_prep) of/IN (l_pobj) dysfunction/NN
9889429
D001806_D005885 NONE nitrogen/NN (r_compound) levels/NNS (r_pobj) in/IN (r_prep) increase/NN (l_prep) in/IN (l_pobj) 9/CD (l_prep) of/IN (l_pobj) patients/NNS (l_prep) of/IN (l_pobj) hyperplasia/NN
D009543_D005885 CID nifedipine/NN (r_conj) A/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) events/NNS (r_nsubj) included/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) 9/CD (l_prep) of/IN (l_pobj) patients/NNS (l_prep) of/IN (l_pobj) hyperplasia/NN -PUNC- nifedipine/NN (r_nsubj) is/VBZ (l_conj) monitored/VBN (l_prep) for/IN (l_pobj) hyperplasia/NN
D009543_D006973 NONE nifedipine/JJ (r_amod) tablets/NNS (l_prep) for/IN (l_pobj) cyclosporin/NN (l_dobj) hypertension/NN -PUNC- nifedipine/NN (r_dobj) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- nifedipine/NN (r_nsubj) is/VBZ (l_prep) for/IN (l_pobj) patients/NNS (l_amod) hypertensive/JJ
D002118_D006973 NONE calcium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN
D009543_D011565 NONE nifedipine/JJ (r_amod) tablets/NNS (l_prep) for/IN (l_pobj) cyclosporin/NN (l_dobj) hypertension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psoriasis/NN -PUNC- nifedipine/NN (r_dobj) treated/VBN (l_nsubjpass) patients/NNS (l_amod) psoriatic/JJ -PUNC- nifedipine/NN (r_nsubj) is/VBZ (l_prep) for/IN (l_pobj) patients/NNS (l_amod) psoriatic/JJ
D002118_D011565 NONE calcium/NN (r_compound) channel/NN (r_compound) blocker/NN (r_pobj) with/IN (r_prep) treated/VBN (l_nsubjpass) patients/NNS (l_amod) psoriatic/JJ
D016572_D005885 CID A/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) during/IN (r_prep) events/NNS (r_nsubj) included/VBD (l_dobj) increase/NN (l_prep) in/IN (l_pobj) 9/CD (l_prep) of/IN (l_pobj) patients/NNS (l_prep) of/IN (l_pobj) hyperplasia/NN -PUNC- A/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) patients/NNS (r_pobj) for/IN (r_prep) is/VBZ (l_conj) monitored/VBN (l_prep) for/IN (l_pobj) hyperplasia/NN
D016572_D006973 CID A/NNP (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- A/NNP (r_det) therapy/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) during/IN (r_prep) patients/NNS (l_prep) with/IN (l_pobj) hypertension/NN -PUNC- A/NNP (r_det) therapy/NN (r_dobj) cyclosporin/NN (r_pcomp) before/IN (r_prep) exhibited/VBN (l_dobj) state/NN (l_amod) hypertensive/JJ -PUNC- A/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) patients/NNS (l_amod) hypertensive/JJ
D016572_D011565 NONE A/NNP (r_npadvmod) induced/VBN (r_amod) hypertension/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) psoriasis/NN -PUNC- A/NNP (r_det) therapy/NN (r_pobj) of/IN (r_prep) course/NN (r_pobj) during/IN (r_prep) patients/NNS (l_amod) psoriatic/JJ -PUNC- A/NN (r_pobj) with/IN (r_prep) treatment/NN (r_pobj) under/IN (r_prep) patients/NNS (l_amod) psoriatic/JJ
24840785
D000157_D064420 NONE aconitine/NN (r_pobj) of/IN (r_prep) effects/NNS (r_dobj) investigate/VB (r_advcl) performed/VBD (l_dobj) assay/NN (l_compound) cytotoxicity/NN
D012964_D066126 NONE Na(+/NN (r_cc) dependent/JJ (r_nmod) channels/NNS (r_nsubj) have/VBP (l_prep) in/IN (l_pobj) cardiotoxicity/NN
D000157_D009202 NONE aconitine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) injury/NN -PUNC- aconitine/NN (r_nsubj) resulted/VBD (l_prep) in/IN (l_pobj) injury/NN
D019344_D009202 NONE lactate/NN (r_compound) dehydrogenase/NN (r_compound) level/NN (r_conj) assay/NN (r_dobj) performed/VBD (l_advcl) investigate/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) injury/NN
D019344_D064420 NONE lactate/NN (r_compound) dehydrogenase/NN (r_compound) level/NN (r_conj) assay/NN (l_compound) cytotoxicity/NN
D002118_D011041 NONE Ca(2/NNP (r_pobj) of/IN (r_prep) role/NN (r_pobj) on/IN (r_prep) available/JJ (r_acomp) are/VBP (l_prep) in/IN (l_pobj) poisoning/NN -PUNC- Ca(2/NNP (r_pobj) of/IN (r_prep) importance/NN (r_dobj) explored/VBD (l_advcl) signaling/NN (l_prep) in/IN (l_pobj) poisoning/NN
D000157_D066126 CID aconitine/NN (r_pobj) of/IN (r_prep) cardiotoxicity/NN
D000157_D001145 CID Aconitine/NNP (r_npadvmod) induced/VBN (r_amod) Ca2/NN (r_nsubj) causes/NNS (l_dobj) arrhythmia/NN -PUNC- aconitine/NN (r_nsubj) aggravates/VBZ (l_dobj) overload/NN (l_conj) causes/VBZ (l_dobj) arrhythmia/NN
D000157_D011041 CID aconitine/NN (r_compound) poisoning/NN -PUNC- aconitine/NN (r_compound) poisoning/NN
D002118_D001145 NONE Ca2/NN (r_nsubj) causes/NNS (l_dobj) arrhythmia/NN -PUNC- Ca(2/NNP (r_nsubj) lead/NN (l_conj) caused/VBD (l_dobj) arrhythmia/NN -PUNC- Ca(2/NNP (r_nmod) overload/NN (l_conj) causes/VBZ (l_dobj) arrhythmia/NN
3746148
D004176_D007511 NONE dipyridamole/NN (r_pobj) After/IN (r_prep) observed/VBN (l_nsubjpass) depression/NN (l_amod) ischemic/JJ
D004176_D003866 NONE dipyridamole/NN (r_pobj) After/IN (r_prep) observed/VBN (l_nsubjpass) depression/NN
D004176_D056988 NONE dipyridamole/NN (r_pobj) After/IN (r_prep) observed/VBN (l_prep) in/IN (l_pobj) %/NN (l_appos) %/NN (l_prep) of/IN (l_pobj) group/NN (l_compound) MI/NNP
D004176_D003324 NONE dipyridamole/NN (r_compound) infusion/NN (r_pobj) after/IN (r_prep) detection/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- dipyridamole/NN (r_compound) infusion/NN (r_pobj) after/IN (r_prep) changes/NNS (r_nsubjpass) studied/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) disease/NN -PUNC- dipyridamole/NN (r_compound) test/NN (r_nsubj) is/VBZ (l_acomp) useful/JJ (l_prep) as/IN (l_pobj) test/NN (l_prep) for/IN (l_pobj) assessment/NN (l_prep) of/IN (l_pobj) disease/NN
D004176_D056989 NONE dipyridamole/NN (r_pobj) After/IN (r_prep) observed/VBN (l_prep) in/IN (l_pobj) %/NN (l_appos) %/NN (l_appos) %/NN (l_prep) of/IN (l_pobj) group/NN (l_compound) MI/NNP
D004176_D017202 CID dipyridamole/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN
D004176_D009203 NONE dipyridamole/NN (r_pobj) After/IN (r_prep) observed/VBN (l_prep) in/IN (l_pobj) %/NN (l_prep) of/IN (l_pobj) group/NN (l_compound) MI/NNP
8135424
D005442_D012640 CID Flumazenil/NNP (r_nsubj) induces/VBZ (l_dobj) seizures/NNS -PUNC- flumazenil/JJ (r_appos) Administration/NN (r_nsubj) unmask/VB (l_dobj) seizures/NNS -PUNC- Flumazenil/NNP (r_nsubj) unmask/VB (l_dobj) seizures/NNS
D001569_D012640 NONE benzodiazepine/JJ (r_amod) antagonist/NN (r_pobj) of/IN (r_prep) Administration/NN (r_nsubj) unmask/VB (l_dobj) seizures/NNS -PUNC- benzodiazepine/NN (r_amod) intoxication/NN (r_pobj) in/IN (r_prep) seizures/NNS
D003975_D012640 CID diazepam/NN (r_compound) intoxications/NNS (r_pobj) in/IN (r_prep) seizures/NNS -PUNC- diazepam/NN (r_compound) intoxications/NNS (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) increase/VB (r_conj) unmask/VB (l_dobj) seizures/NNS
D003042_D012640 CID cocaine/NN (r_compound) diazepam/NN (r_compound) intoxications/NNS (r_pobj) in/IN (r_prep) seizures/NNS -PUNC- cocaine/NN (r_compound) benzodiazepine/NN (r_amod) intoxication/NN (r_pobj) in/IN (r_prep) seizures/NNS -PUNC- cocaine/NN (r_compound) diazepam/NN (r_compound) intoxications/NNS (r_pobj) of/IN (r_prep) model/NN (r_pobj) in/IN (r_prep) increase/VB (r_conj) unmask/VB (l_dobj) seizures/NNS
3088653
D012601_D000647 CID scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN -PUNC- Scopolamine/NNP (r_nsubj) induced/VBD (l_dobj) amnesia/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) amnesia/NN
D009270_D000647 NONE naloxone/NN (r_pobj) by/IN (r_prep) avoidance/NN (r_pobj) of/IN (r_prep) amnesia/NN -PUNC- naloxone/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) attenuated/VBD (l_dobj) amnesia/NN
D012601_D010146 NONE scopolamine/NN (r_npadvmod) induced/VBN (r_amod) deficit/NN (r_pobj) on/IN (r_prep) naloxone/NN (r_pobj) of/IN (r_prep) influence/NN (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) appear/VBP (l_nsubj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_compound) pain/NN
D009270_D008569 NONE naloxone/NN (l_prep) on/IN (l_pobj) deficit/NN -PUNC- Naloxone/NN (r_nsubj) injected/VBD (l_advcl) attenuated/VBD (l_dobj) deficit/NN -PUNC- naloxone/NN (r_appos) sensitivity/NN (r_pobj) in/IN (r_prep) increase/NN (r_nsubj) appear/VBP (l_xcomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) influence/NN (l_prep) of/IN (l_pobj) naloxone/NN (l_prep) on/IN (l_pobj) deficit/NN -PUNC- naloxone/NN (r_appos) state/NN (r_conj) increase/NN (r_nsubj) appear/VBP (l_xcomp) be/VB (l_acomp) responsible/JJ (l_prep) for/IN (l_pobj) influence/NN (l_prep) of/IN (l_pobj) naloxone/NN (l_prep) on/IN (l_pobj) deficit/NN -PUNC- naloxone/NN (l_prep) on/IN (l_pobj) deficit/NN
D009270_D010146 NONE naloxone/NN (r_appos) sensitivity/NN (l_compound) pain/NN -PUNC- naloxone/NN (r_appos) state/NN (r_conj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_compound) pain/NN -PUNC- naloxone/NN (r_pobj) of/IN (r_prep) influence/NN (r_pobj) for/IN (r_prep) responsible/JJ (r_acomp) be/VB (r_xcomp) appear/VBP (l_nsubj) increase/NN (l_prep) in/IN (l_pobj) sensitivity/NN (l_compound) pain/NN
D019832_D000647 NONE scopolamine/NN (r_conj) Scopolamine/NNP (r_nsubj) induced/VBD (l_dobj) amnesia/NN
D012601_D008569 NONE scopolamine/NN (r_npadvmod) induced/VBN (r_amod) deficit/NN -PUNC- scopolamine/NN (r_npadvmod) induced/VBN (r_amod) deficit/NN
946593
D008727_C536409 NONE methotrexate/NNP (r_compound) contaminants/NNS (l_conj) deficiency/NN -PUNC- methotrexate/NNP (r_compound) toxicity/NN (r_pobj) of/IN (r_prep) pathogenesis/NN (r_pobj) in/IN (r_prep) role/NN (l_prep) of/IN (l_pobj) contaminants/NNS (l_conj) deficiency/NN
D008727_D020258 NONE methothexate/NN (r_compound) concentration/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) preservatives/NNS (l_amod) neurotoxic/JJ -PUNC- methotrexate/NN (r_compound) doses/NNS (r_pobj) to/TO (r_conj) related/VBN (r_acl) concentration/NN (l_conj) presence/NN (l_prep) of/IN (l_pobj) preservatives/NNS (l_amod) neurotoxic/JJ -PUNC- methotrexate/NN (r_compound) preparations/NNS (r_pobj) in/IN (r_prep) presence/NN (l_prep) of/IN (l_pobj) preservatives/NNS (l_amod) neurotoxic/JJ -PUNC- methotrexate/NN (r_compound) diluents/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) presence/NN (l_prep) of/IN (l_pobj) preservatives/NNS (l_amod) neurotoxic/JJ -PUNC- methotrexate/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) employing/VBG (r_pcomp) by/IN (r_prep) reduced/VBN (l_nsubjpass) incidence/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN -PUNC- methotrexate/NNP (r_compound) levels/NNS (r_pobj) of/IN (r_prep) monitoring/NN (r_nsubj) be/VB (l_acomp) predictive/JJ (l_prep) of/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) neurotoxicity/NN
D008727_D002493 NONE methothexate/NN (r_compound) concentration/NN (r_appos) dynamics/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NN (r_compound) doses/NNS (r_pobj) to/TO (r_conj) related/VBN (r_acl) concentration/NN (r_appos) dynamics/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NN (r_compound) preparations/NNS (r_pobj) in/IN (r_prep) presence/NN (r_conj) concentration/NN (r_appos) dynamics/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NN (r_compound) diluents/NNS (r_pobj) of/IN (r_prep) use/NN (r_conj) presence/NN (r_conj) concentration/NN (r_appos) dynamics/NNS (l_acl) related/VBN (l_prep) to/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) leukemia/NN -PUNC- methotrexate/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) employing/VBG (l_prep) in/IN (l_pobj) presence/NN (l_prep) of/IN (l_pobj) leukemia/NN
D008727_D064420 NONE methotrexate/NNP (r_compound) contaminants/NNS (r_pobj) of/IN (r_prep) role/NN (l_prep) in/IN (l_pobj) pathogenesis/NN (l_prep) of/IN (l_pobj) toxicity/NN -PUNC- methotrexate/NNP (r_compound) toxicity/NN
D008727_D010264 CID methotrexate/NN (r_dobj) following/VBG (r_prep) Paraplegia/NNP -PUNC- methotrexate/NNP (r_pobj) of/IN (r_prep) instillation/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) paraplegia/NNS
2974281
D009952_D006332 NONE ornithine/NN (r_compound) decarboxylase/NN (r_compound) activity/NN (l_prep) with/IN (l_pobj) blockers/NNS (l_prep) in/IN (l_pobj) hearts/NNS
D011433_D006332 NONE propranolol/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) hypertrophy/NN -PUNC- propranolol/NN (l_conj) have/VBP (l_advcl) prevent/VB (l_prep) from/IN (l_pcomp) producing/VBG (l_dobj) hypertrophy/NN
D007545_D006332 CID isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) hypertrophy/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) hypertrophy/NN -PUNC- isoproterenol/NN (r_dobj) prevent/VB (l_prep) from/IN (l_pcomp) producing/VBG (l_dobj) hypertrophy/NN
D011433_D006984 NONE propranolol/NN (r_csubj) stop/VB (l_dobj) changes/NNS (l_prep) in/IN (l_pobj) pattern/NN (l_prep) of/IN (l_pobj) heart/NN (l_amod) hypertrophied/JJ
7967231
C059447_D020195 NONE S-312/NNP (r_punct) S-312-d/NNP (r_nsubj) showed/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS -PUNC- S-312-d/NNP (r_nsubj) showed/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS
C059447_D012640 NONE S-312-d/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) observed/VBN (l_prep) against/IN (l_pobj) convulsions/NNS -PUNC- S-312-d/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubjpass) observed/VBN (r_advcl) observed/VBN (l_prep) in/IN (l_pobj) convulsions/NNS
C059447_D004827 NONE S-312-d/NN (r_nsubj) be/VB (l_prep) in/IN (l_pobj) therapy/NN (l_prep) of/IN (l_pobj) types/NNS (l_prep) of/IN (l_pobj) epilepsy/NN
D010852_D012640 CID picrotoxin/NN (r_conj) aspartate/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_advcl) observed/VBN (l_prep) against/IN (l_pobj) convulsions/NNS -PUNC- picrotoxin/NN (r_conj) aspartate/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS
D016202_D012640 NONE aspartate/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) in/IN (r_prep) observed/VBN (l_advcl) observed/VBN (l_prep) against/IN (l_pobj) convulsions/NNS -PUNC- aspartate/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS
D010433_D012640 CID pentylenetetrazole/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- pentylenetetrazole/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) against/IN (r_prep) observed/VBN (r_advcl) observed/VBN (l_prep) in/IN (l_pobj) convulsions/NNS
D002118_D020195 NONE calcium/NN (r_compound) channel/NN (r_compound) antagonists/NNS (r_conj) S-312-l/NNP (r_conj) S-312-d/NNP (r_nsubj) showed/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS
-1_D020195 NONE S-312-l/NNP (r_conj) S-312-d/NNP (r_nsubj) showed/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS
D001534_D012640 CID bemegride/NN (r_conj) pentylenetetrazole/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS -PUNC- bemegride/NN (r_conj) pentylenetetrazole/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS (r_pobj) against/IN (r_prep) observed/VBN (r_advcl) observed/VBN (l_prep) in/IN (l_pobj) convulsions/NNS
D005444_D020195 NONE flunarizine/NN (r_pobj) of/IN (r_prep) that/DT (r_nsubj) was/VBD (r_advcl) were/VBD (r_conj) showed/VBD (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) convulsions/NNS
7671401
D000806_D006973 NONE inhibitors/NNS (l_acl) used/VBD (l_xcomp) treat/VB (l_dobj) hypertension/NN
D000806_D000799 CID inhibitor/NN (r_pobj) with/IN (r_prep) therapy/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) oedema/NN -PUNC- inhibitors/NNS (r_pobj) of/IN (r_prep) introduction/NN (r_pobj) after/IN (r_prep) reported/VBN (l_nsubjpass) bouts/NNS (l_prep) of/IN (l_pobj) oedema/NN -PUNC- inhibitors/NNS (r_pobj) to/IN (r_prep) reactions/NNS (l_prep) after/IN (l_conj) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) oedema/NN
D000806_D006333 NONE inhibitors/NNS (l_acl) used/VBD (l_xcomp) treat/VB (l_dobj) hypertension/NN (l_conj) failure/NN
10087562
D004280_D002311 NONE dobutamine/NN (r_compound) treatment/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) failure/NN (l_amod) cardiomyopathy/NN -PUNC- dobutamine/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) arrhythmias/NNS (r_pobj) of/IN (r_prep) absence/NN (r_conj) dilated/VBN (l_advmod) cardiomyopathy/NN
D004280_D016171 CID dobutamine/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) pointes/VBZ -PUNC- dobutamine/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) during/IN (r_prep) developed/VBD (l_dobj) prolongation/NN (l_conj) tachycardia/NN (l_nmod) pointes/FW -PUNC- dobutamine/NN (r_pobj) during/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) tachycardia/NN (l_nmod) pointes/FW
D004280_D001145 NONE dobutamine/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) arrhythmias/NNS -PUNC- dobutamine/NN (r_pobj) during/IN (r_prep) report/NN (r_nsubj) supports/VBZ (l_dobj) hypothesis/NN (l_acl) occur/VB (l_nsubj) arrhythmias/NNS
D004280_D017180 NONE dobutamine/NN (r_compound) treatment/NN (r_pobj) during/IN (r_prep) pointes/VBZ (l_appos) tachycardia/NN -PUNC- dobutamine/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) during/IN (r_prep) developed/VBD (l_dobj) prolongation/NN (l_conj) tachycardia/NN -PUNC- dobutamine/NN (r_pobj) during/IN (r_prep) report/NN (l_prep) of/IN (l_pobj) tachycardia/NN
D004280_D006333 NONE dobutamine/NN (r_compound) treatment/NN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) failure/NN -PUNC- dobutamine/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) during/IN (r_prep) developed/VBD (r_relcl) arrhythmias/NNS (r_pobj) of/IN (r_prep) absence/NN (r_conj) dilated/VBN (r_xcomp) describe/VBP (l_dobj) case/NN (l_prep) of/IN (l_pobj) woman/NN (l_prep) with/IN (l_pobj) failure/NN
D004280_D008133 NONE dobutamine/NN (r_pobj) of/IN (r_prep) cycle/NN (r_pobj) during/IN (r_prep) developed/VBD (l_dobj) prolongation/NN
24614773
D014635_D004660 NONE valproate/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/JJ (l_conj) encephalitis/NN
D016202_D004660 NONE NMDA/NNP (r_nmod) encephalitis/NN
D014635_D020325 NONE valproate/NN (l_prep) for/IN (l_pobj) migraine/NN
D014635_D010291 NONE valproate/NN (r_conj) started/VBN (r_conj) had/VBD (l_dobj) number/NN (l_prep) of/IN (l_pobj) admissions/NNS (l_prep) with/IN (l_pobj) hemiparesis/NN
D016202_D001927 NONE aspartate/NNP (r_nmod) antibodies/NNS (r_conj) encephalopathy/JJ -PUNC- NMDA/NNP (r_nmod) receptor/NN (r_compound) antibodies/NNS (r_conj) encephalopathy/JJ -PUNC- NMDA/NNP (r_nmod) encephalitis/NN (r_conj) encephalopathy/JJ
D014635_D001927 NONE valproate/VBP (r_acl) encephalopathy/NN -PUNC- valproate/NN (r_npadvmod) induced/VBN (r_amod) encephalopathy/JJ
15815446
D010656_D002545 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_pobj) of/IN (r_prep) effect/NN (r_appos) ischemia/NN
D010656_D001930 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (l_prep) on/IN (l_pobj) injury/NN
D010656_D020244 NONE phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) was/VBD (l_prep) After/IN (l_pobj) min/NN (l_prep) of/IN (l_pobj) occlusion/NN
C009591_D001930 NONE chloride/NN (r_dobj) using/VBG (r_advcl) staining/VBG (r_pcomp) by/IN (r_prep) evaluated/VBN (l_prep) for/IN (l_pobj) rats/NNS (l_prep) in/IN (l_pobj) injury/NN
D010656_D006973 CID phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN -PUNC- phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN (r_pobj) of/IN (r_prep) effect/NN (r_nsubj) was/VBD (l_prep) After/IN (l_pobj) min/NN (l_prep) of/IN (l_pobj) occlusion/NN (l_prep) in/IN (l_pobj) rats/NNS (l_amod) hypertensive/JJ -PUNC- phenylephrine/NN (r_npadvmod) induced/VBN (r_amod) hypertension/NN
D005070_D006973 NONE Blue/NNP (r_nsubj) was/VBD (l_acomp) greater/JJR (l_prep) in/IN (l_pobj) group/NN (l_nummod) 90/HTN/CD -PUNC- Blue/NNP (r_nsubj) was/VBD (l_acomp) greater/JJR (l_prep) in/IN (l_pobj) group/NN (l_relcl) was/VBD (l_acomp) greater/JJR (l_prep) than/IN (l_pobj) group/NN (l_compound) 15/HTN/CD
C009591_D004487 NONE chloride/NN (l_conj) edema/NN
25080425
D001622_D020257 NONE betaine/NN (r_pobj) of/IN (r_prep) administration/NN (r_nsubj) reduced/VBD (l_conj) prevented/VBN (l_dobj) remodeling/NN
D007545_D009202 NONE isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) injury/NN
D007545_D017202 CID isoproterenol/NN (r_pobj) of/IN (r_prep) injection/NN (r_pobj) by/IN (r_agent) induced/VBN (l_nsubjpass) injury/NN -PUNC- isoproterenol/NN (r_npadvmod) induced/VBN (r_amod) ischemia/NN
D001622_D017202 NONE betaine/NN (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) ischemia/NN -PUNC- betaine/NN (r_compound) pretreatment/NN (r_nsubj) attenuated/VBD (r_amod) ischemia/NN
D001622_D009202 NONE betaine/NN (r_pobj) by/IN (r_prep) Regulation/NN (r_nsubj) attenuates/VBZ (l_dobj) injury/NN -PUNC- betaine/NN (l_prep) on/IN (l_pobj) damage/NN
6627074
D013390_D020879 NONE succinylcholine/NN (r_pobj) of/IN (r_prep) administration/NN (r_pobj) following/VBG (r_prep) blockade/NN
D013390_D001049 CID Succinylcholine/NN (r_compound) apnoea/NN -PUNC- succinylcholine/NN (r_compound) apnoea/NN
1522360
D012293_D051437 NONE rifampin/NN (r_pobj) of/IN (r_prep) use/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) complication/NN (r_attr) is/VBZ (l_nsubj) failure/NN
D012293_D006461 CID rifampin/NN (r_amod) therapy/NN (r_dobj) following/VBG (r_prep) hemolysis/NN -PUNC- rifampin/NN (r_advmod) is/VBZ (l_nsubj) hemolysis/NN -PUNC- rifampin/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) failure/NN (l_nmod) hemolysis/NN
D012293_D007918 NONE rifampin/NN (r_pobj) following/VBG (r_prep) developed/VBD (r_relcl) patients/NNS (l_prep) with/IN (l_pobj) leprosy/NN
D012293_D058186 CID rifampin/NN (r_amod) therapy/NN (r_dobj) following/VBG (r_prep) hemolysis/NN (l_conj) failure/NN -PUNC- rifampin/NN (r_advmod) is/VBZ (l_nsubj) hemolysis/NN (l_acl) leading/VBG (l_prep) to/IN (l_pobj) failure/NN -PUNC- rifampin/NN (r_pobj) following/VBG (r_prep) developed/VBD (l_dobj) failure/NN
25907210
D010755_D008175 NONE organophosphate/NN (r_compound) insecticide/NN (r_appos) Diazinon/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cancer/NN
D003976_D008175 CID Diazinon/NNP (r_nsubjpass) associated/VBN (l_prep) with/IN (l_pobj) cancer/NN -PUNC- diazinon/NN (r_npadvmod) associated/VBN (r_amod) risk/NN (r_dobj) examined/VBN (l_ccomp) associated/VBN (l_prep) with/IN (l_pobj) cancer/NN -PUNC- diazinon/NN (r_compound) use/NN (r_pobj) of/IN (r_prep) days/NNS (r_conj) Ptrend=0.02/LS (r_appos) CI/NNP (r_npadvmod) observed/VBD (l_dobj) risks/NNS (l_compound) cancer/NN -PUNC- diazinon/NNS (r_pobj) of/IN (r_prep) evaluation/NN (r_nsubj) provides/VBZ (l_dobj) evidence/NN (l_prep) of/IN (l_pobj) association/NN (l_prep) with/IN (l_pobj) risk/NN (l_compound) cancer/NN
D003976_D009369 NONE diazinon/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) applicators/NNS (r_pobj) among/IN (r_prep) tumours/NNS -PUNC- Diazinon/NNP (r_nsubjpass) associated/VBN (r_ccomp) examined/VBN (l_dobj) risk/NN (l_compound) cancer/NN -PUNC- diazinon/NN (r_npadvmod) associated/VBN (r_amod) risk/NN (l_compound) cancer/NN -PUNC- diazinon/NN (r_compound) exposure/NN (l_conj) information/NN (l_compound) cancer/NN -PUNC- diazinon/NN (r_compound) exposure/NN (r_dobj) used/VBD (l_xcomp) evaluate/VB (l_dobj) risk/NN (l_compound) tumour/NN -PUNC- diazinon/NN (r_compound) use/NN (r_dobj) reported/VBD (r_ccomp) assessed/VBN (l_nsubjpass) incidence/NN (l_compound) cancer/NN
D010755_D009369 NONE organophosphate/NN (r_amod) diazinon/NN (r_pobj) to/IN (r_prep) exposed/VBN (r_acl) applicators/NNS (r_pobj) among/IN (r_prep) tumours/NNS -PUNC- organophosphate/NN (r_compound) insecticide/NN (r_appos) Diazinon/NNP (r_nsubjpass) associated/VBN (r_ccomp) examined/VBN (l_dobj) risk/NN (l_compound) cancer/NN
17035713
D013438_D009336 NONE thiols/NNS (r_pobj) in/IN (r_prep) loss/NN (l_conj) increase/NN (l_prep) in/IN (l_pobj) markers/NNS (l_compound) necrosis/NN -PUNC- thiol/JJ (r_compound) donors/NNS (r_pobj) with/IN (r_prep) reaction/NN (r_dobj) slowed/VBD (r_relcl) Acidification/NN (r_nsubj) attenuate/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) markers/NNS (l_compound) necrosis/NN -PUNC- thiol/JJ (r_compound) depletion/NN (r_conj) markers/NNS (l_compound) necrosis/NN
D003545_D009336 NONE cysteine/NN (r_compound) protease/NN (r_compound) inhibition/NN (r_conj) depletion/NN (r_conj) markers/NNS (l_compound) necrosis/NN
D007069_D007674 CID ifosfamide/JJ (r_amod) nephropathy/NN -PUNC- ifosfamide/NN (r_pobj) of/IN (r_prep) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN -PUNC- IFO/NN (r_appos) ifosfamide/NN (r_pobj) of/IN (r_prep) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN -PUNC- IFO/NN (r_pobj) with/IN (r_prep) following/VBG (r_prep) damage/NN -PUNC- IFO/NN (r_compound) nephropathy/NN
D013438_D007674 NONE thiol/JJ (r_compound) groups/NNS (l_prep) in/IN (l_pobj) nephropathy/NN
C004656_D007674 NONE Chloroacetaldehyde/NNP (l_appos) role/NN (l_prep) of/IN (l_pobj) groups/NNS (l_prep) in/IN (l_pobj) nephropathy/NN -PUNC- Chloroacetaldehyde/NNP (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN -PUNC- CAA/NNP (r_appos) Chloroacetaldehyde/NNP (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN
D007069_D009369 NONE ifosfamide/NN (r_pobj) of/IN (r_prep) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN (l_prep) following/VBG (l_pobj) therapy/NN (l_compound) tumor/NN -PUNC- IFO/NN (r_appos) ifosfamide/NN (r_pobj) of/IN (r_prep) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN (l_prep) following/VBG (l_pobj) therapy/NN (l_compound) tumor/NN -PUNC- IFO/NN (r_pobj) with/IN (r_prep) following/VBG (l_pobj) therapy/NN (l_compound) tumor/NN
D013438_D064420 NONE thiols/NNS (r_pobj) with/IN (r_prep) reacts/VBZ (l_advcl) mediating/VBG (l_dobj) toxicity/NN
-1_D007674 NONE sulfhydryl/NN (r_amod) reagent/NN (r_pobj) as/IN (r_prep) Chloroacetaldehyde/NNP (l_appos) role/NN (l_prep) of/IN (l_pobj) groups/NNS (l_prep) in/IN (l_pobj) nephropathy/NN
C004656_D009369 NONE Chloroacetaldehyde/NNP (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN (l_prep) following/VBG (l_pobj) therapy/NN (l_compound) tumor/NN -PUNC- CAA/NNP (r_appos) Chloroacetaldehyde/NNP (r_nsubj) is/VBZ (l_attr) metabolite/NN (l_conj) responsible/JJ (l_prep) for/IN (l_pobj) damage/NN (l_prep) following/VBG (l_pobj) therapy/NN (l_compound) tumor/NN
C004656_D064420 NONE CAA/NNP (r_pobj) of/IN (r_prep) Toxicity/NN -PUNC- CAA/NNP (r_nsubj) reacts/VBZ (l_advcl) mediating/VBG (l_dobj) toxicity/NN
D014343_D064420 NONE blue/JJ (r_amod) exclusion/NN (r_compound) assay/NN (r_dobj) trypan/NN (r_advcl) determined/VBN (l_nsubjpass) Toxicity/NN
C004656_D009336 NONE CAA/NNP (r_nsubj) reduced/VBD (l_conj) induced/VBD (l_dobj) loss/NN (l_conj) increase/NN (l_prep) in/IN (l_pobj) markers/NNS (l_compound) necrosis/NN -PUNC- CAA/NNP (r_pobj) of/IN (r_prep) reaction/NN (r_dobj) slowed/VBD (r_relcl) Acidification/NN (r_nsubj) attenuate/VB (l_dobj) effects/NNS (l_prep) on/IN (l_pobj) markers/NNS (l_compound) necrosis/NN -PUNC- CAA/NNP (r_pobj) of/IN (r_prep) effects/NNS (l_prep) on/IN (l_pobj) markers/NNS (l_compound) necrosis/NN
3083835
D010406_D000707 CID Penicillin/NNP (r_compound) anaphylaxis/NN -PUNC- penicillin/NN (r_compound) anaphylaxis/NN -PUNC- penicillin/NN (r_compound) anaphylaxis/NN (r_pobj) of/IN (r_prep) case/NN (r_nsubjpass) described/VBN (l_conj) reviewed/VBN (l_nsubjpass) terminology/NN (l_conj) occurrence/NN (l_conj) manifestations/NNS (l_conj) pathogenesis/NN (l_conj) prevention/NN (l_conj) treatment/NN (l_prep) of/IN (l_pobj) anaphylaxis/NN -PUNC- penicillin/NN (r_compound) anaphylaxis/NN
12752472
D010862_D004827 CID pilocarpine/NN (r_npadvmod) induced/VBN (r_amod) epilepsy/NN
D010862_D006985 NONE pilocarpine/NN (r_npadvmod) treated/VBN (r_amod) rats/NNS (r_pobj) in/IN (r_prep) ventilation/NN (r_pobj) in/IN (r_prep) decrease/NN (r_dobj) caused/VBD (l_nsubj) maneuver/NN (l_compound) hyperventilation/NN
24234943
D012964_D007177 NONE sodium/NN (r_nsubj) was/VBD (r_ccomp) was/VBD (l_attr) mosmol/NN (l_amod) consistent/JJ (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SIADH/NNP -PUNC- sodium/NN (r_conj) kg/NNS (r_appos) osmolality/NN (r_appos) mosmol/NN (l_amod) consistent/JJ (l_prep) with/IN (l_pobj) diagnosis/NN (l_prep) of/IN (l_pobj) SIADH/NNP
C086816_D001008 CID desvenlafaxine/NN (r_dobj) included/VBD (l_conj) included/VBD (l_dobj) nausea/NN (l_conj) anxiety/NN
C086816_D003221 CID desvenlafaxine/NN (r_dobj) included/VBD (l_conj) included/VBD (l_dobj) nausea/NN (l_conj) anxiety/NN (l_conj) confusion/NN
C086816_D009325 CID desvenlafaxine/NN (r_dobj) included/VBD (l_conj) included/VBD (l_dobj) nausea/NN
C086816_D007177 CID desvenlafaxine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) secretion/NN (l_compound) hormone/NN -PUNC- desvenlafaxine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) secretion/NN (l_nmod) hormone/NN -PUNC- desvenlafaxine/NN (r_pobj) with/IN (r_prep) associated/VBN (r_acl) secretion/NN (l_nmod) SIADH/NNP
C086816_D007010 CID desvenlafaxine/NN (r_nsubj) cause/VB (l_dobj) hyponatremia/NN
19549709
D010984_D002289 NONE platinum/NN (r_nmod) stratum/NN (r_appos) regimens/NNS (r_pobj) with/IN (r_prep) METHODS/NNS (l_appos) IIIb/NNS (l_conj) patients/NNS (l_compound) NSCLC/NNP
D010984_D064420 NONE platinum/NN (r_nmod) stratum/NN (r_appos) regimens/NNS (r_pobj) with/IN (r_prep) METHODS/NNS (r_nsubj) received/VBD (l_prep) until/IN (l_pobj) progression/NN (l_conj) toxicity/NN
C107135_D064420 NONE RAD001/NNP (r_dobj) received/VBD (l_prep) until/IN (l_pobj) progression/NN (l_conj) toxicity/NN
D014443_D064420 NONE tyrosine/NN (r_compound) inhibitors/NNS (r_conj) stratum/NN (r_appos) regimens/NNS (r_pobj) with/IN (r_prep) METHODS/NNS (r_nsubj) received/VBD (l_prep) until/IN (l_pobj) progression/NN (l_conj) toxicity/NN
D020123_D002289 NONE rapamycin/NNS (r_nmod) mTOR/NNP (r_pobj) of/IN (r_prep) target/NN (r_pobj) of/IN (r_prep) inhibitor/NN (r_appos) RAD001/NNP (r_nsubj) shown/VBN (l_dobj) phase/NN (l_prep) in/IN (l_pobj) NSCLC/NNP
D014443_D002289 NONE tyrosine/NN (r_compound) inhibitors/NNS (r_conj) stratum/NN (r_appos) regimens/NNS (r_pobj) with/IN (r_prep) METHODS/NNS (l_appos) IIIb/NNS (l_conj) patients/NNS (l_compound) NSCLC/NNP
C107135_D002289 NONE everolimus/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- RAD001/NNP (r_appos) everolimus/NN (r_pobj) of/IN (r_prep) Efficacy/NN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) NSCLC/NNP -PUNC- RAD001/NNP (r_nsubj) shown/VBN (l_dobj) phase/NN (l_prep) in/IN (l_pobj) NSCLC/NNP -PUNC- RAD001/NNP (r_dobj) received/VBD (l_nsubj) METHODS/NNS (l_appos) IIIb/NNS (l_conj) patients/NNS (l_compound) NSCLC/NNP -PUNC- RAD001/NNP (r_pobj) of/IN (r_prep) Evaluation/NN (r_nsubj) continues/VBZ (l_nsubj) NSCLC/NNP
11105626
D015474_D065817 CID isotretinoin/VB (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) infant/NN (l_prep) with/IN (l_pobj) anomalies/NNS (l_appos) anotia/NN
D015474_D004310 CID isotretinoin/VB (r_pobj) to/IN (r_prep) exposure/NN (r_pobj) due/IN (r_prep) report/VBP (l_dobj) infant/NN (l_prep) with/IN (l_pobj) anomalies/NNS (l_appos) anotia/NN (l_conj) malformation/NN
1361574
D002243_D012640 NONE carboline/NN (r_pobj) of/IN (r_prep) mg/kg/NNS (r_nsubj) reduced/VBD (l_conj) convulsions/NNS
D007538_D012640 CID isoniazid/NN (r_pobj) by/IN (r_agent) induced/VBN (r_acl) convulsions/NNS
C037476_D012640 NONE 35S]TBPS/NNP (r_nummod) binding/NN (r_pobj) of/IN (r_prep) increase/NN (r_dobj) reduced/VBD (l_conj) convulsions/NNS
15265979
D000638_D056486 CID Amiodarone/NNP (r_nsubjpass) reported/VBN (l_xcomp) cause/VB (l_dobj) hepatotoxicity/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) effects/NNS (r_pobj) regarding/VBG (r_prep) information/NN (r_dobj) provide/VBP (l_conj) indicate/VBP (l_ccomp) protects/VBZ (l_prep) against/IN (l_pobj) hepatotoxicity/NN -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN (r_pobj) against/IN (r_prep) protects/VBZ (r_ccomp) indicate/VBP (r_conj) provide/VBP (l_dobj) information/NN (l_prep) regarding/VBG (l_pobj) effects/NNS (l_amod) hepatotoxic/JJ -PUNC- amiodarone/NN (r_npadvmod) induced/VBN (r_amod) hepatotoxicity/NN
D005947_D006529 NONE glucose/NN (r_conj) triglycerides/NNS (r_pobj) in/IN (r_prep) decrease/NN (r_conj) induced/VBD (l_dobj) accumulation/NN (l_amod) hepatomegaly/NN
D014280_D006529 NONE triglycerides/NNS (r_pobj) in/IN (r_prep) decrease/NN (r_conj) induced/VBD (l_dobj) accumulation/NN (l_amod) hepatomegaly/NN
D000638_D006528 NONE amiodarone/NN (r_pobj) of/IN (r_prep) inability/NN (r_nsubj) expressed/VBN (l_prep) in/IN (l_pobj) cells/NNS (l_compound) hepatoma/NN -PUNC- amiodarone/NN (r_pobj) of/IN (r_prep) effects/NNS (r_nsubj) were/VBD (r_ccomp) indicates/VBZ (l_csubj) expressed/VBN (l_prep) in/IN (l_pobj) cells/NNS (l_compound) hepatoma/NN
D000638_D006529 CID Amiodarone/NN (r_nsubj) induced/VBD (l_dobj) accumulation/NN (l_amod) hepatomegaly/NN
D000638_D015431 NONE amiodarone/NN (r_pobj) with/IN (r_prep) treatment/NN (r_appos) mice/NNS (r_pobj) to/IN (r_prep) Compared/VBN (r_prep) resulted/VBD (l_prep) in/IN (l_pobj) rate/NN (l_conj) extent/NN (l_prep) of/IN (l_pobj) loss/NN
24132704
C029036_D006949 NONE Crocin/NNS (r_nsubj) reduced/VBD (l_dobj) inhibition/NN (l_prep) of/IN (l_pobj) activation/NN (l_conj) hyperlipemia/NN -PUNC- Crocin/NNS (r_nsubjpass) considered/VBN (l_prep) as/IN (l_pobj) agent/NN (l_prep) in/IN (l_pobj) hyperlipemia/NN
D003976_D006949 CID diazinon/NN (r_npadvmod) induced/VBN (r_amod) hyperlipemia/NN -PUNC- diazinon/NN (r_npadvmod) induced/VBN (r_amod) hyperlipemia/NN
6106951
D005479_D012798 NONE FZP/NNP (r_compound) toxocity/NN (r_pobj) of/IN (r_prep) Signs/NNS (r_nsubj) included/VBD (l_dobj) salivation/NN
D005479_D004827 NONE FZP/NNP (r_pobj) of/IN (r_prep) use/NN (l_prep) in/IN (l_pobj) situations/NNS (l_relcl) is/VBZ (l_attr) excitability/NN (l_prep) as/IN (l_pobj) epilepsy/NN
D005479_D012640 CID FZP/NNP (r_compound) toxocity/NN (r_pobj) of/IN (r_prep) Signs/NNS (r_nsubj) included/VBD (l_advcl) retching/NN (l_dobj) tremors/NNS (l_conj) convulsions/NNS -PUNC- FZP/NNP (r_nsubj) protected/VBD (l_prep) against/IN (l_pobj) convulsions/NNS -PUNC- FZP/NNP (r_pobj) of/IN (r_prep) doses/NNS (r_nsubj) were/VBD (l_prep) cause/VB (l_dobj) convulsions/NNS
D005479_D014202 NONE FZP/NNP (r_compound) toxocity/NN (r_pobj) of/IN (r_prep) Signs/NNS (r_nsubj) included/VBD (l_advcl) retching/NN (l_dobj) tremors/NNS
D005479_D064420 NONE FZP/NNP (r_compound) toxocity/NN
10327032
D005472_D001424 NONE 5-FU/CD (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) seen/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infections/NNS
D005472_D022124 CID 5-fluorouracil/CD (r_punct) with/IN (r_prep) received/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) encephalopathy/NN -PUNC- 5-fluorouracil/CD (r_punct) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) doses/NNS (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) seen/VBN (l_nsubjpass) levels/NNS (l_conj) onset/NN (l_prep) of/IN (l_pobj) hyperammonemia/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occur/VB (l_nsubj) encephalopathy/NN
D000644_D022124 NONE ammonium/NN (r_compound) levels/NNS (l_conj) onset/NN (l_prep) of/IN (l_pobj) hyperammonemia/NN
D005472_D009369 NONE 5-fluorouracil/CD (r_punct) with/IN (r_prep) received/VBD (r_relcl) patients/NNS (l_compound) cancer/NN -PUNC- 5-fluorouracil/CD (r_punct) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN (r_pobj) of/IN (r_prep) episodes/NNS (r_dobj) had/VBD (r_relcl) patients/NNS (l_compound) cancer/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN (r_pobj) of/IN (r_prep) episodes/NNS (r_dobj) had/VBD (r_relcl) patients/NNS (l_compound) cancer/NN
D000644_D001424 NONE ammonium/NN (r_compound) levels/NNS (r_nsubjpass) seen/VBN (l_prep) in/IN (l_pobj) patients/NNS (l_prep) with/IN (l_pobj) infections/NNS
D005472_D001927 CID 5-fluorouracil/CD (r_punct) with/IN (r_prep) received/VBD (r_relcl) patients/NNS (r_pobj) in/IN (r_prep) encephalopathy/NN -PUNC- 5-fluorouracil/CD (r_punct) 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_pobj) to/IN (r_prep) related/VBN (r_acl) encephalopathy/NN -PUNC- 5-FU/CD (r_pobj) of/IN (r_prep) infusion/NN (r_dobj) receiving/VBG (r_acl) patients/NNS (r_pobj) in/IN (r_prep) occur/VB (l_nsubj) encephalopathy/NN
D005472_D007239 NONE 5-fluorouracil/CD (r_punct) with/IN (l_pobj) complication/NN (l_prep) of/IN (l_pobj) dehydration/NN (l_conj) infection/NN
D005472_D003681 NONE 5-fluorouracil/CD (r_punct) with/IN (l_pobj) complication/NN (l_prep) of/IN (l_pobj) dehydration/NN
20169779
D007980_D010302 NONE levodopa/RB (r_npadvmod) treated/VBN (r_amod) marmoset/NN (r_nsubjpass) used/VBN (l_prep) as/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) symptoms/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP -PUNC- levodopa/NN (r_pobj) between/IN (r_prep) interaction/NN (r_attr) are/VBP (l_nsubj) disorders/NNS (l_prep) in/IN (l_pobj) PD/NNP
D007980_D004409 CID levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) hoc/FW (r_prep) evaluated/VBN (l_prep) for/IN (l_pobj) disability/NN (l_conj) dyskinesia/JJ -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) fluctuations/NNS (l_conj) dyskinesia/JJ -PUNC- levodopa/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) duration/NN (r_pobj) with/IN (r_prep) correlated/VBD (r_relcl) increase/NN (l_prep) in/IN (l_pobj) fluctuations/NNS (l_conj) dyskinesia/JJ
D015632_D010302 NONE MPTP/NNP (r_nmod) model/NN (l_prep) of/IN (l_pobj) disease/NN -PUNC- MPTP/NNP (r_npadvmod) lesioned/VBN (r_amod) marmoset/NN (r_nsubjpass) used/VBN (l_prep) as/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) symptoms/NNS (l_prep) in/IN (l_pobj) patients/NNS (l_compound) PD/NNP -PUNC- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/CD (r_oprd) administered/VBN (l_advcl) resulting/VBG (l_prep) in/IN (l_pobj) parkinsonism/NN
D007980_D001523 NONE levodopa/RB (r_npadvmod) treated/VBN (r_amod) marmoset/NN (r_nsubjpass) used/VBN (l_prep) as/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) symptoms/NNS -PUNC- levodopa/NN (r_npadvmod) induced/VBN (r_amod) fluctuations/NNS (l_conj) behaviors/NNS -PUNC- levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) hoc/FW (r_prep) evaluated/VBN (l_prep) for/IN (l_pobj) disability/NN (l_conj) dyskinesia/JJ (l_conj) behaviors/NNS -PUNC- levodopa/RB (r_npadvmod) induced/VBN (r_amod) behaviors/NNS -PUNC- levodopa/JJ (r_compound) treatment/NN (r_pobj) of/IN (r_prep) 1/CD (r_nummod) Day/NN (r_pobj) on/IN (r_prep) present/JJ (r_acomp) were/VBD (l_nsubj) behaviors/NNS -PUNC- levodopa/NN (r_pobj) between/IN (r_prep) interaction/NN (r_attr) are/VBP (l_nsubj) disorders/NNS
D015632_D001523 NONE MPTP/NNP (r_npadvmod) lesioned/VBN (r_amod) marmoset/NN (r_nsubjpass) used/VBN (l_prep) as/IN (l_pobj) model/NN (l_prep) of/IN (l_pobj) symptoms/NNS
D007980_D020734 NONE levodopa/VB (r_pobj) to/IN (r_prep) prior/RB (r_advmod) hoc/FW (r_prep) evaluated/VBN (l_prep) for/IN (l_pobj) disability/NN
7479194
D014295_D012871 NONE trimethoprim/NN (r_dobj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D015662_D007674 NONE sulfamethoxazole/NN (r_compound) SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS -PUNC- SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D015662_D006402 NONE sulfamethoxazole/NN (r_compound) SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS -PUNC- SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D014295_D008107 CID trimethoprim/NN (r_dobj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS -PUNC- trimethoprim/NN (r_conj) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) disease/NN
D014295_D006402 NONE trimethoprim/NN (r_dobj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D014295_D007674 NONE trimethoprim/NN (r_dobj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D015662_D012871 NONE sulfamethoxazole/NN (r_compound) SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS -PUNC- SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D002506_D064420 NONE cephalexin/NN (r_conj) trimethoprim/NN (r_conj) sulfamethoxazole/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) for/IN (l_pobj) toxicity/NN
D015662_D008107 CID sulfamethoxazole/NN (r_compound) SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS -PUNC- SMZ/NNP (r_dobj) prescribed/VBN (r_relcl) people/NNS (r_pobj) of/IN (r_prep) study/NN (r_dobj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS -PUNC- SMZ/NNP (r_nmod) 5.2/100,000/CD (r_dobj) prescribed/VBN (r_acl) persons/NNS (r_pobj) for/IN (r_prep) similar/JJ (r_acomp) was/VBD (l_nsubj) risk/NN (l_prep) of/IN (l_pobj) disease/NN
D015662_D064420 NONE sulfamethoxazole/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) for/IN (l_pobj) toxicity/NN
D015662_D013262 CID SMZ/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_relcl) disorders/NNS (l_prep) of/IN (l_pobj) seven/CD (l_prep) with/IN (l_pobj) multiforme/NNS (l_conj) syndrome/NN -PUNC- SMZ/NNP (r_pobj) to/IN (r_prep) exposed/VBN (l_ccomp) experienced/VBD (l_dobj) disorders/NNS (l_prep) of/IN (l_pobj) seven/CD (l_prep) with/IN (l_pobj) multiforme/NNS (l_conj) syndrome/NN
D002506_D006402 NONE cephalexin/NN (r_conj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D014295_D064420 NONE trimethoprim/NN (r_conj) sulfamethoxazole/NN (r_pobj) of/IN (r_prep) study/NN (l_prep) for/IN (l_pobj) toxicity/NN
D002506_D013262 CID cephalexin/NN (r_dobj) took/VBD (r_relcl) patient/NN (r_pobj) in/IN (r_prep) occurred/VBD (l_nsubj) case/NN (l_prep) of/IN (l_pobj) necrolysis/NN
D002506_D007674 NONE cephalexin/NN (r_conj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D002506_D012871 NONE cephalexin/NN (r_conj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D002506_D008107 CID cephalexin/NN (r_conj) prescribed/VBD (r_conj) conducted/VBD (l_advcl) estimate/VB (l_dobj) risk/NN (l_prep) of/IN (l_pobj) liver/NN (l_conj) blood/NN (l_conj) skin/NN (l_conj) disorders/NNS
D015662_D004892 NONE SMZ/NNP (r_pobj) to/IN (r_prep) exposed/VBN (r_relcl) disorders/NNS (l_prep) of/IN (l_pobj) seven/CD (l_prep) with/IN (l_pobj) multiforme/NNS -PUNC- SMZ/NNP (r_pobj) to/IN (r_prep) exposed/VBN (l_ccomp) experienced/VBD (l_dobj) disorders/NNS (l_prep) of/IN (l_pobj) seven/CD (l_prep) with/IN (l_pobj) multiforme/NNS
2429800
D014403_D007022 CID tubocurarine/NN (r_advmod) induced/VBN (r_amod) hypotension/NN
D006632_D007022 NONE Histamine/NN (r_amod) antagonists/NNS (l_conj) hypotension/NN
17879217
D012293_D013203 NONE Rifampicin/NNS (r_npadvmod) associated/VBN (r_amod) glomerulonephritis/NN (l_prep) in/IN (l_pobj) endocarditis/NN -PUNC- rifampicin/NNS (l_prep) for/IN (l_pobj) infections/NNS -PUNC- rifampicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (r_relcl) IE/NNP -PUNC- rifampicin/NNS (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) regarding/VBG (r_prep) review/VB (r_conj) developed/VBD (r_relcl) IE/NNP
D012293_D005921 CID Rifampicin/NNS (r_npadvmod) associated/VBN (r_amod) glomerulonephritis/NN -PUNC- rifampicin/NNS (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) as/IN (r_prep) reported/VBN (l_nsubjpass) glomerulonephritis/NN -PUNC- rifampicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (l_dobj) failure/NN (l_amod) secondary/JJ (l_prep) to/IN (l_pobj) glomerulonephritis/NN -PUNC- rifampicin/NNS (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) regarding/VBG (r_prep) review/VB (r_conj) developed/VBD (l_dobj) failure/NN (l_amod) secondary/JJ (l_prep) to/IN (l_pobj) glomerulonephritis/NN
D012293_D007239 NONE rifampicin/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) to/IN (r_prep) led/VBN (l_csubj) Changing/VBG (l_dobj) epidemiology/NN (l_prep) of/IN (l_pobj) infections/NNS
D012293_D058186 CID rifampicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (l_dobj) failure/NN -PUNC- rifampicin/NNS (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) regarding/VBG (r_prep) review/VB (r_conj) developed/VBD (l_dobj) failure/NN
D012293_D004696 NONE Rifampicin/NNS (r_npadvmod) associated/VBN (r_amod) glomerulonephritis/NN (l_prep) in/IN (l_pobj) endocarditis/NN -PUNC- rifampicin/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) to/IN (r_prep) led/VBN (l_csubj) Changing/VBG (l_dobj) epidemiology/NN (l_prep) of/IN (l_pobj) infections/NNS (l_prep) as/IN (l_pobj) endocarditis/NN -PUNC- rifampicin/NNS (r_pobj) of/IN (r_prep) use/NN (r_pobj) in/IN (r_prep) increase/NN (r_pobj) to/IN (r_prep) led/VBN (l_csubj) Changing/VBG (l_dobj) epidemiology/NN (l_prep) of/IN (l_pobj) infections/NNS (l_prep) as/IN (l_pobj) endocarditis/NN (l_appos) IE/NNP -PUNC- rifampicin/NNS (r_pobj) with/IN (r_prep) treated/VBN (r_advcl) developed/VBD (r_relcl) IE/NNP -PUNC- rifampicin/NNS (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (r_pobj) regarding/VBG (r_prep) review/VB (r_conj) developed/VBD (r_relcl) IE/NNP
D012293_D014376 NONE rifampicin/NNS (r_compound) therapy/NN (r_pobj) of/IN (r_prep) complication/NN (l_prep) in/IN (l_pobj) patients/NNS (l_acl) receiving/VBG (l_dobj) treatment/NN (l_prep) for/IN (l_pobj) tuberculosis/NN
3289726
D005047_D005910 NONE etoposide/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) glioma/NN -PUNC- etoposide/NN (r_compound) therapy/NN (l_prep) for/IN (l_pobj) glioma/NN
D005047_D019337 NONE Etoposide/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS (l_conj) malignancies/NNS -PUNC- 213/CD (r_punct) )/-RRB- (r_punct) Etoposide/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS (l_conj) malignancies/NNS
D005047_D064420 NONE etoposide/NN (r_compound) therapy/NN (r_pobj) of/IN (r_prep) toxicity/NN
D005047_D009422 NONE etoposide/NN (r_compound) therapy/NN (r_pobj) after/IN (r_prep) dysfunction/NN
D005047_D009369 NONE Etoposide/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS -PUNC- 213/CD (r_punct) )/-RRB- (r_punct) Etoposide/NNP (r_nsubjpass) used/VBN (l_prep) in/IN (l_pobj) treatment/NN (l_prep) of/IN (l_pobj) tumors/NNS
16083708
D019980_D056486 CID clavulanate/NNP (r_nsubj) stands/VBZ (l_prep) as/IN (l_pobj) drug/NN (l_acl) related/VBN (l_prep) to/IN (l_pobj) DILI/NNP
D001663_D017114 NONE bilirubin/NN (r_compound) value/NN (r_conj) .009/CD (r_appos) were/VBD (l_nsubj) Factors/NNS (l_acl) associated/VBN (l_prep) with/IN (l_pobj) development/NN (l_prep) of/IN (l_pobj) failure/NN
1556529
D015215_D000163 NONE zidovudine/NNP (r_pobj) by/IN (r_agent) induced/VBN (l_prep) in/IN (l_pobj) patient/NN (l_prep) with/IN (l_pobj) AIDS/NNP
D015215_D056486 CID Zidovudine/RB (r_npadvmod) induced/VBN (r_amod) hepatitis/NN -PUNC- zidovudine/NNP (r_pobj) by/IN (r_agent) induced/VBN (r_acl) case/NN (l_prep) of/IN (l_pobj) hepatitis/NN
18399341
D004837_D007022 NONE epinephrine/NN (r_amod) infusion/NN (l_relcl) treat/VB (l_dobj) hypotension/NN
